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 Opioids have been used since antiquity for their ability to treat chronic and severe pain. 
However, their potent analgesic activity comes with severe side effects, including dependence, 
abuse, and even death by respiratory depression. Since these opioids are unmatched in their ability 
to treat pain, the development of alternatives without these negative side effects is sorely needed. 
While numerous strategies have been implemented, none yet have been successful. One promising 
new strategy involves targeting multiple different opioid receptors at the same time. More 
specifically, agonism at the µ-opioid receptor (MOR) with simultaneous activity at the δ-opioid 
receptor (DOR) can attenuate these negative side effects without compromising their analgesic 
effects. 
 Previously, our lab has synthesized a peptidomimetic series that expresses a MOR-
agonist/DOR-antagonist profile. Members of this series were found to express antinociception (a 
proxy measure for analgesia) in vivo without producing dependence, drug-seeking behavior, or 
tolerance to the antinociceptive effects. While these effects show great promise, they are only 
active upon intraperitoneal injection. Since chronic pain requires the administration of drug over 
a long period of time, enabling oral bioavailability is an important goal to transform these 
peptidomimetics into nonaddictive analgesics. Unfortunately, these ligands express very poor 
metabolic stability in mouse liver microsomes (MLM), and this instability is a product of the 
tetrahydroquinoline core structure of the peptidomimetic. This structure requires numerous 
synthetic steps to create, and its instability is manifest in several key intermediates. As such, this 
xvi 
 
dissertation describes a series of structure-activity relationship (SAR) campaigns that sought to 
remove this unstable core while preserving our desired bifunctional opioid activity. 
 Initially, we sought to convert the bicyclic tetrahydroquinoline core of our peptidomimetic 
series to a monocyclic aromatic core. This immediately resulted in improvements in metabolic 
stability, and no unstable intermediates were observed. However, the MOR-agonist properties of 
these ligands, necessary for inducing their analgesic properties, was lost in most analogues in this 
series, and while a few were better than morphine in vitro, they were not as potent or efficacious 
as our original peptidomimetics.  
 Using the results of this SAR campaign as a springboard, we next sought to further improve 
their MOR-agonist properties and metabolic stability. To this end, a series of amine pendants were 
incorporated onto our monocyclic core analogues. These pendants managed to further improve the 
metabolic stability of these ligands. It was also discovered that these amines can induce high MOR-
efficacy in our peptidomimetics, and when combined with an aromatic ring on the pendant, can 
induce high MOR-potency. This “aromatic-amine’ pharmacophore was found to produce highly 
potent and efficacious MOR-agonists, independent of the functionalization of the monocyclic 
aromatic core. In fact, MOR-superagonists with efficacy of up to 147% compared to the standard 
MOR-agonist DAMGO were discovered using this pharmacophore, and the pharmacophore even 
enabled elimination of the aromatic core entirely. All this came with consistent DOR-antagonism 
or weak partial DOR-agonism, in line with the opioid profile we sought to maintain. 
 Herein, the SAR campaigns that led to the improvement in metabolic stability of these 
ligands are discussed, as well as the discovery and scope of this aromatic-amine pharmacophore. 
These campaigns significantly simplified the synthesis of the ligands, yielding no unstable 





Chapter 1: On Opioids 
1.1 The Opioid Epidemic 
Incidences of the abuse of opioids and subsequent overdose have been on the rise in the 
United States. This opioid epidemic traces its inception to the late 1990’s, and was in no small part 
fueled by an aggressive marketing campaign by Purdue pharmaceuticals which touted the safety 
of its newly released drug OxyContin.1  An extended release formulation of oxycodone, this drug 
was advertised to have reduced addiction liabilities.  This caused sales of OxyContin to increase 
from $48 million in 1996 to $1.1 billion in 20001 and OxyContin became the most prescribed 
opioid for the treatment of moderate-to-severe pain.2 In reality, OxyContin was addictive, and it 
soon became the most abused prescription opioid by 2004.3  
The prescription rate of other opioids also increased during this time. Medical use by mass 
of fentanyl, hydromorphone, and morphine increased by 227%, 96%, and 73%, and yielded 
increased mentions of abuse of 642%, 342%, and 113% respectively from 1997 to 2002.4 The 
abuse of these opioids has only increased since 2002, with opioid overdose deaths increasing from 
8,048 in 1999 to 47,600 in 2017.5 More specifically, the number of overdoses related to 
prescription opioids has increased from 1.2-1.4 per 100,000 in 1999 to 5.2-10.2 per 100,000 in 
2016.6 These values each year are difficult to determine exactly, largely due to the uncertainty of 
the source of many opioids (such as fentanyl), which are both illicitly and legally available.6 
Ultimately, these overdose deaths are related to the reported 9.9 million of Americans who have 
misused prescription opioids, 1.7 million of which possessed substance use disorders in 2018.7 
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While the wide distribution of these opioids has led to their misuse and overdose, it must 
not be forgotten that these opioids are prescribed for a purpose. A 2016 survey estimated that 
approximately 50 million Americans suffer from chronic pain,8 defined by the National Pain 
Strategy as:  “pain that occurs on at least half the days for six months or more.”9 In the treatment 
of pain, the World Health Organization (WHO) developed what is called an analgesic ladder, a 
general set of guidelines that describes the analgesic to be prescribed in response to different levels 
and durations of pain. In short, mild to moderate and acute pain should be treated with NSAID’s, 
whereas moderate to severe and chronic pain should be treated with opioids.10 Modest updates to 
this model have been proposed, including neurosurgical procedures,11 but the ladder has changed 
little since its inception. Nevertheless, opioids remain the drug of choice for severe and chronic 
pain, despite their negative side-effects. As such, the development of novel analgesics that have 
the analgesic power of opioids without their negative side-effects is sorely needed. 
1.2 The Opioid Receptors and their Effects 
 The opioid analgesics primarily act on a set of G-protein coupled receptors (GPCR’s) found 
in various locations throughout the brain. There are three opioid receptors that are relevant to this 
work: the µ-opioid receptor (MOR), the δ-opioid receptor (DOR), and the κ-opioid receptor 
(KOR). These receptors are all associated with different phenotypic effects, which are summarized 
in Table 1.12,13  
Table 1: The opioid receptors, their location, and phenotypic effects on activation. 
Opioid Receptor Effects on Activation Location in Brain 
µ (MOR) Analgesia, physical dependence, respiratory depression, 
euphoria, abuse potential, constipation, miosis  
Cortex, periaqueductal 
grey, thalamus, ventral 
tegmental area 
δ (DOR) Convulsions, analgesia, physical dependence Amygdala, cortex 




 More specifically, the opioid analgesics operate by acting as MOR-agonists. This produces 
the most potent analgesia, but also yields their addictive effects and death through respiratory 
depression. These effects are mainly driven through the location with which these receptors are 
activated. Briefly, µ-opioid receptors located in the periaqueductal grey are largely responsible for 
regulating pain,14 whereas µ-opioid receptors located in the ventral tegmental area are responsible 
for the opioid’s abuse symptoms.15  
Unfortunately, all these side-effects are the result of on-target effects. As the analgesic 
effects of the opioid drugs are unmatched for relieving pain, current pharmacological research is 
focused on ways to stimulate the opioid receptors such that their analgesic properties may be 
manifest without the negative effects. These include biased agonists that operate solely at MOR 
and activate the G-protein signaling cascade without inducing β-arrestin recruitment.16–18 The G-
protein signaling cascade is responsible for proper signaling of the receptor, while the β-arrestin 
pathway is involved in blocking the interaction between the GPCR and the G protein, producing 
receptor desensitization.19 Thus, activation of the G-protein signaling cascade produces the desired 
analgesia, whereas failure to activate the β-arrestin pathway was believed to reduce adverse side-
effects.19 However, the biased MOR-agonist PZM21 was found to produce tolerance to 
antinociception and induce respiratory depression in a recent report.20 Furthermore, the biased 
MOR-agonist oliceridine was also found to produce constipation and abuse liabilities in 
rodents.21,22 Mouse knock-in studies have also found that opioid receptors with a reduced ability 
to recruit β-arrestin possess enhanced analgesia on activation, but also enhanced or unaltered 
constipation, respiratory depression, and withdrawal symptoms.23 These data, coupled with the 
fact that oliceridine failed to achieve FDA approval due to its safety profile, suggests that 
alternative avenues of opioid development may be needed to reduce side-effects. 
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A growing body of preclinical evidence has emerged suggesting that stimulation of the µ-
opioid receptor (MOR) in conjunction with antagonism at the δ-opioid receptor (DOR) can 
produce the desired analgesic effects without producing analgesic tolerance or dependence. For 
instance, rats given morphine and co-treated with the DOR-antagonists  TIPP[Ψ]24 or naltrindole25-
26 displayed antinociception with significantly diminished chronic antinociceptive tolerance and 
dependence as measured by reduced withdrawal symptoms. These trends are supported by 
experiments whereby DOR knockout mice27 did not develop chronic tolerance to the analgesic 
effects of morphine. Furthermore, mice treated with antisense DOR oligodeoxynucleotide did not 
develop acute dependence or chronic tolerance to the analgesic effects of morphine.28  
Curiously, DOR-agonism instead of antagonism has also been shown to reduce the side-
effect profile of MOR-agonists. Coadministration of DOR-agonists with MOR-agonists has been 
shown to attenuate dependence29 and respiratory depression30 without affecting antinociception. 
These beneficial effects work both ways, as MOR-agonists can attenuate the convulsive effects 
associated with activation of DOR.31 To this end, many MOR-agonist/DOR-agonist ligands have 
been synthesized and were shown to have reduced abuse profiles, including reduced dependence,32 
and tolerance.33–35 
In short, bifunctional opioid ligands may allow for the development of opioid analgesics 
with reduced side-effects. While the mechanisms underlying these data are not yet well 
understood, these data show potential and warrant further investigation.  
1.3 Bifunctional MOR/DOR ligands 
To this end, a substantial number of bifunctional MOR/DOR ligands have been 
developed,36,37 and some small molecule bifunctional MOR-agonist/DOR-antagonists have been 
reported that show reduced side-effect profiles (Figure 1). Some of these are based on the classical 
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morphinan scaffold (Figure 1A), and show attenuated chronic tolerance and dependence.38–40 
Mitragynine pseudoindoxyl (Figure 1B), derived from the kratom alkaloid mitragynine, was found 
to possess reduced withdrawal, reduced respiratory depression, and does not produce conditioned-
place preference.41 Others still are derived from opioid peptides (Figure 1C-D). DIPP[Ψ]-NH2 
(Figure 1C), an endomorphin derivative, produces antinociception in murine models without acute 
tolerance and chronic physical dependence.42  AAH8 (Figure 1D) has also been shown to produce 
antinociception in murine models without developing tolerance to antinociceptive effects, physical 




Figure 1: Notable small molecules that exhibit a MOR-agonist/DOR-antagonist profile. Some of 
these compounds utilize the morphinan scaffold shared by many opioids (A), or are derivative of 




The research presented here will focus more on this last analogue AAH8. AAH8 is a 
peptidomimetic that is derived from the cyclic opioid peptide JOM13. AAH8 possesses a 
tetrahydroquinoline (THQ) core and it along with many other THQ core containing analogues 
were developed in our lab. Since these analogues mimic the endogenous peptides, an 
understanding of the opioid peptides and their SAR will be useful. 
1.4 From the Opioid Peptides to AAH8 
The opioid receptors are acted on by a host of different endogenous ligands. These 
endogenous opioids were found to be peptides, the first of which discovered were the 
enkephalins,44 followed soon by endorphins45 and dynorphins.46 Eventually, this list of naturally 
occurring opioid peptides would expand to include the endomorphins,47 dermorphins,48 and 
deltorphins,49 the latter two of which are derived from the skin of frogs. These discoveries 
prompted great interest in the structure-activity relationship (SAR) of these peptides at each of the 
opioid receptors. Over time, important SAR trends became apparent (Figure 2).50 In general, it 
was found that two key pharmacophore features were responsible for activation of the opioid 
receptors (Figure 2, blue). These included an N-terminal tyrosine residue and a phenylalanine 
residue. These two pharmacophores need to be separated by one or two amino acids (Figure 2, 
purple), and all together compose what is termed the message sequence, which is responsible for 
opioid receptor activation. Amino acids found after the phenylalanine residue vary widely in terms 
of their composition and number, comprising what is called the address sequence (Figure 2, red) 




Figure 2: General SAR of the opioid peptides. The key pharmacophore elements include an N-
terminal tyrosine and a phenylalanine residue (Blue). These are separated by one or two amino 
acids (purple) and together compose the message sequence that activates the opioid receptor. 
Selectivity between each opioid receptor is dictated by the C-terminal address sequence (Red), 
which can vary widely in composition and length. Conventionally, peptides are presented with 
the N-terminus on the left and the C-terminus on the right but will be represented in the reverse 
for the sake of consistency with other structures in this work. 
 The broad SAR campaign that discovered these trends produced many notable peptides. 
For example, the peptides [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO)51 and [D-Pen2,D-
Pen5]enkephalin (DPDPE)52 are now used as standard agonists for the study of MOR and DOR, 
respectively. Eventually, it was found that replacement of the N-terminal tyrosine residue with an 
N-terminal 2’,6’-dimethyltyrosine residue (DMT) can greatly alter and amplify the effects of an 
opioid peptide.53 This DMT pharmacophore is commonly attached to a 1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid (Tic) residue, which is found in a host of synthetic opioid 
peptides. Of note are H-Tyr-TicΨ[CH2NH]Phe-Phe-OH (TIPP[Ψ]) and H-Dmt-
TicΨ[CH2NH]Phe-Phe-NH2 (DIPP-NH2[Ψ]), opioid peptides that were used to demonstrate that 
MOR-agonist activity used in conjunction with DOR-antagonist activity can produce the 
antinociceptive effects of opioids without the abuse liabilities that are commonly associated with 
them.24,42 
 One series of interest was that of cyclic peptides derived from Met-enkephalin. It was 
observed that Met-enkephalin was a largely flexible peptide, and early research was focused on 
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inducing conformational restrictions within the peptide to determine which orientation the peptide 
adopts on binding to DOR. One such analogue involved cyclization of the linear peptide via a 
disulfide bond, followed by steric rigidification through the introduction of two gem dimethyl 
groups, yielding DPDPE.52 As stated above, DPDPE is used as a standard DOR-agonist due to its 
high potency and selectivity for DOR. In a later analogue, the gem dimethyl group on the 2-
position amino acid was removed, and the 3-position glycine residue was eliminated, yielding a 
smaller peptide.54 This peptide is Tyr-c[D-Cys-Phe-D-Pen]-OH (JOM-13), which had similar 
levels of selectivity and potency as DPDPE, albeit in a smaller structure. The structural evolution 
of these peptides is shown in Figure 3A. 
 After the initial characterization of JOM-13, a series of computational studies were 
performed using this peptide and similar analogues.55–59 These were aimed at further probing the 
conformations of the tyrosine and phenylalanine pharmacophores necessary to facilitate DOR 
activation. These studies were then used to computationally design a peptidomimetic that 
possessed a tetrahydroquinoline core structure instead of the cyclic peptide (Figure 3B).60 This 
peptidomimetic, hereafter termed KSKPP1E, uses a benzyl group to mimic the phenylalanine of 
JOM-13, and uses DMT instead of tyrosine to improve potency. Curiously, this peptidomimetic 
was found to be a potent MOR-agonist/DOR-antagonist, a profile very different from the selective 
DOR-agonist upon which it was based. Nevertheless, this conversion had the effect of further 




Figure 3: Structural evolution of the endogenous peptide Met-enkephalin into the lead 
peptidomimetic KSKPP1E. A) Initially, a series of SAR studies yielded the cyclic peptide 
JOM-13. Blue circles represent peptide cyclization through a disulfide bond, while red circles 
indicate the incorporation of gem dimethyl groups to confer additional rigidity. B) JOM-13 was 
then used in a series of computational studies that ultimately yielded KSKPP1E. The key 
pharmacophore elements are in blue, whereas the structures holding these elements together are 
in violet. 
Derivatization of KSKPP1E was inevitable, especially considering the growing interest in 
bifunctional opioid ligands and the fact that KSKPP1E was found to express antinociceptive 
effects in vivo.61 Derivatization here followed one of three strategies (Figure 4A). The bulk of 
these analogues were on the benzyl pharmacophore, and in general found that bicyclic pendants 
here were more potent at MOR and had improved balance in binding affinity between MOR and 
DOR.62–64 Substitutions to the THQ core were found to also enhance binding affinity balance 
between MOR and DOR without drastic changes in the profile.65,66 Here, the N-acetyl modification 
became standard for this series. These two modifications were also combined into a series of SAR 
matrices in a recent report.67 Finally, a few analogues were synthesized that altered the DMT 
pharmacophore. These proved to do more harm than good, and therefore further diversification 
here was not explored.68 Two compounds of note came out of these studies (Figure 4B). AAH8 
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was found to have the beneficial effects in vivo described above, whereas the analogue AMB47 
also expressed in vivo antinociception without tolerance, though still produced dependence and 
constipation.43 The tetrahydroisoquinoline pendant of AMB47 will become important later in this 
work. 
 
Figure 4: A) Diversification strategies employed to explore the SAR of KSKPP1E. Areas 
explored are in blue rings and include exploration of the benzyl pendant, the THQ core, and the 
DMT pharmacophore. B) Notable analogues that were produced from this SAR campaign. 
Shown are AAH8 and AMB47. 
1.5 Project Overview 
The development of these peptidomimetics thus far has produced some promising 
compounds. AAH8 was shown to possess antinociception in vivo with reduced side-effects, albeit 
through intraperitoneal (ip.) administration. However, any drug must possess good 
pharmacokinetic properties and must be able to be synthesized on a large scale. Patient quality of 
life must also be a factor, particularly if drugs are taken over a long period of time (such as when 
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treating chronic pain). As such, enabling oral bioavailability is an important milestone that must 
be met to convert these peptidomimetics into viable nonaddictive opioid analgesics. In this spirit, 
we opted to test these compounds in mouse liver microsomes (MLM) as a proxy for their behavior 
during first-pass metabolism. Unfortunately, these ligands show poor metabolic stability in MLM 
(T1/2~5 min) (Figure 5). A tandem MS-MS analysis of KSKPP1E identified a total of ten 
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Figure 5: Normalized metabolic half-life of peptidomimetics that contain a THQ core or 
similar bicyclic core structure. These analogues were normalized to the positive control 
verapamil (black). None of these bicyclic analogues had a half-life greater than the positive 




Figure 6: Known metabolites of KSKPP1E from MLM. O+ indicates insertion of an oxygen 
atom into the structure, H- indicates loss of a hydrogen atom. Six metabolites involve 
aromatization of the THQ core with subsequent bifurcation of the peptidomimetic. Four 
metabolites involve oxidation of the DMT pharmacophore. 
 In addition to the metabolic stability issues described above, the synthesis of these 
analogues requires multiple steps (Scheme 1). A total of nine steps are involved in the synthesis 
of AAH8, with a few extra needed to enable further diversification of the benzyl pendant if desired. 
Notably, the HCl salt of the primary chiral amine formed before coupling to DMT is unstable at 
room temperature and can aromatize spontaneously if not used quickly. This instability is reflected 
in the MLM studies described above. This long synthesis, of which most steps involve 
manipulations of the THQ core, combined with unstable intermediates, produces a synthetic 
barrier to these peptidomimetics if they are to be made at scale. As such, there is utility in designing 





Scheme 1: Synthesis of AAH8. The synthesis of this analogue requires nine steps and possesses 
unstable intermediates. 
We therefore sought to improve the poor metabolic stability of these ligands, while 
maintaining the desired bifunctional opioid profile and simplify their synthesis. With this goal in 
mind, we sought to identify regions that would be most amenable to modifications aimed at 
improving metabolic stability. Tetrahydroquinolines have been shown to aromatize upon action 
by CYP2A6 enzymes,69 commonly found in mouse liver microsomes, which is supported by our 
analyses of KSKPP1E. Since the THQ core is not one of the two key pharmacophore elements in 
our series, and since most of the steps of our synthesis involve this structure, we opted to focus 










Chapter 2: Breaking the THQ Core 
2.1 Introduction 
Given the role of the THQ core to connect the 2’6’-dimethyltyrosine (DMT) and benzyl 
pharmacophores together, an SAR campaign aimed at transforming this core into a more stable 
form was pursued. Initially, we sought to remove the aliphatic ring of the THQ system, producing 
more conformationally flexible ligands while removing the metabolically labile cycle (Figure 7). 
We were encouraged by other opioids that relied on similar strategies to connect these two 
pharmacophore elements together, such as  a urea,16 piperidine or piperazine,70  pyrazinone,71–74 
alkyl diamine,75,76 or long alkyl chains.77 In this chapter, the initial SAR campaign that eliminates 
the bicyclic system of the THQ core to both produce our desired MOR-agonist/DOR-antagonist 
profile and to improve metabolic stability is discussed. This SAR campaign focused on introducing 




Figure 7: Pharmacophore and linker elements of KSKPP1E and our initial monocyclic core 
series.60,61 The pharmacophore elements include 2’,6’-dimethyltyrosine and benzyl pendants that 
are sensitive to modification, and the linker consists of a tetrahydroquinoline core. Here we 
sought to convert this core to a monocyclic core and pursue derivatives that maintain our desired 
MOR/DOR profile. Included are new compounds synthesized in this chapter. 
2.2 Results 
General Chemistry: All the described monocyclic compounds were synthesized according to 
Scheme 2. Before engaging in the main route of synthesis, the ethers and the anilines were 
diversified. To synthesize functionalized anilines, 2-amino-5-bromobenzaldehyde was subjected 
to acylation using the appropriate neat anhydride at 100 °C, producing the acetyl and propionyl 
anilines 6 and 7 respectively. To produce aromatic ethers, 5-bromo-2-hydroxybenzaldehyde was 
functionalized using an alkyl bromide or iodide, producing the methyl, ethyl, n-propyl, 
cyclopropyl methyl, and benzyl ethers 8, 10-13. The exceptions here are trifluoromethoxy ether 9, 
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which was purchased, and 14, which used 1-(5-bromo-2-hydroxyphenyl)ethan-1-one as starting 
material instead of 5-bromo-2-hydroxybenzaldehyde. The functionalized aromatic bromo ketone 
or aldehydes 1-14 were then reduced through imine formation with an Ellman’s chiral sulfonamide 
and subsequent reduction with sodium borohydride, producing compounds 15-28. The Ellman’s 
chiral sulfonamide both enables enantioselective amine formation (if applicable) as used 
previously,64 and protects the amine during subsequent Suzuki coupling to generate compounds 
29-42.  This was followed by Ellman deprotection using concentrated HCl and dioxane to produce 
43-47, 49, 51-58. The exception here being the synthesis of the 6-phenol (48) which utilized BBr3 
to both remove the Ellman’s chiral sulfonamide and cleave the 6-position ether 38. The ethyl 
aniline analogue 50 was synthesized by reduction of the acetyl aniline 49 with borane-
dimethylsulfide complex (BH3*Me2S). Finally, Boc-protected DMT was coupled to the free 
primary amine of structures 43-58 using PyBOP, followed by removal of the Boc groups using 
trifluoroacetic acid to yield the final peptidomimetics 59-74. It should be noted that this synthetic 
scheme can yield peptidomimetics in six to seven steps as opposed to nine for the bicyclic 
analogues. 
Scheme 2: Synthesis of Substituted Monocyclic Core Analogues 59-74.
A) 1. (R)-(+)-2-methyl-propane-2-sulfinamide, Ti(OEt)4, THF, 75 °C 2. NaBH4. B) BnBPin, 
K2CO3, Pd(dppf)Cl2, 3:1 Acetone:Water, 80-100 °C. C) HCl conc., Dioxane. D) 1. DiBocDMT, 
DIEA, PyBOP, 6-Cl-HOBt, DMF. 2. TFA, DCM. E) Neat acyl anhydride, 100 °C. F) MeI or 
Alk-Br, K2CO3, DMF. G) BBr3, DCM. H) BH3*Me2S, THF, 75 °C. 
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SAR: Our studies began by first probing the structural components of the aliphatic ring of the THQ 
core. These studies focused on binding affinity, efficacy, and potency at MOR and DOR, though 
the κ-opioid receptor (KOR) was also examined to determine compound selectivity. The binding 
affinity data can be found in Table 2, whereas the efficacy and potency data can be found in Table 
3 (see footnotes of each table for how these values were measured). Initially, all substituents and 
functional groups comprising this aliphatic ring were removed, yielding 59. This conversion had 
little effect on binding affinity compared to the original lead KSKPP1E but had a significant effect 
on relative efficacy. Indeed, 59 did not stimulate any of the three classical opioid receptors. 
We then began to restore different portions of the original aliphatic ring to elucidate the 
importance of each component. The incorporation of short linear alkyl chains (60-61) on the 
benzylic position (R1) connecting the aromatic core to the DMT pharmacophore partially restored 
MOR agonism (41 % stimulation for compound 60). In this case, the methyl group (60) was 
superior to an ethyl group (61), however MOR efficacy was less than that of morphine (57 % 
stimulation), which serves here as a benchmark for MOR activity. It should be noted that 
morphine’s intrinsic activity of 57 % should not be interpreted as poor MOR efficacy, only that 
the standard agonist DAMGO in this assay has exceptional efficacy. DOR affinity was found to 
decrease when these alkyl chains are incorporated, though these compounds still did not stimulate 
DOR. KOR binding improved with increasing chain size, and weak KOR agonism was observed 
with both alkyl groups. 
 In parallel with the analogues described above, an assortment of compounds was made 
with functional groups at the 6-position, matching that of the THQ nitrogen. Initially, a few simple 
substituents were incorporated at this position. These included methyl, chloro, and hydroxy groups 
(62-64). Each of these managed to restore MOR agonism to between 17 % and 39 %, but still fell 
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short of our goal.  None of these ligands produced agonism at DOR, though the hydroxyl group 
(64) significantly reduced the binding at DOR compared to 59. 
 A small number of nitrogen containing substituents were also incorporated at the 6-
position, resulting in ethyl, acetyl, and propionyl anilines (65-67). These were made to mimic the 
substituents of the original THQ core without ring cyclization, or to mimic some N-acyl 
compounds that had utility in our previously reported THQ series.65 These ligands were all weak 
partial MOR agonists and had reduced binding affinity at DOR compared to 59. The ethyl aniline 
also displayed reduced affinity at MOR. 
Several ethers were examined due to their synthetic accessibility, their ability to be rapidly 
diversified, and to probe the effect of hydrogen bond acceptors at the 6-position. The alkyl ethers 
included methyl, trifluoromethyl, ethyl, n-propyl, cyclopropyl methyl (CPM), and benzyl (68-73). 
Here, an activity maximum was observed between the ethyl ether (70), and the n-propyl ether (71). 
Both ethers proved to be more potent than morphine and displayed similar levels of efficacy to 
morphine at MOR. This, in combination with the high DOR affinity and the lack of DOR efficacy 
of these two compounds, demonstrates that these monocyclic core compounds can retain our 
desired in vitro profile.  
A final compound was synthesized to determine if a combination of R1 and R2 substituents 
could yield additive effects. To this end, 74 was synthesized, in which R1=-Me and R2=-OMe. 
These substituents were selected as they have the same number of large atoms as the original THQ 
core, while also utilizing the more desirable ethers. When compared to 60, this compound appears 
to have reduced binding affinity, efficacy, and potency at MOR. DOR binding, however, shows a 




Binding Affinity, Ki (nM) Selectivity 
Name -R1 -R2 MOR DOR KOR MOR:DOR:KOR 
KSKPP1E -CH2CH2NH- 0.22±0.02a 9.4±0.8a 68±2a 1:43:309 
Morphine - - 6.3±2.5b 171±19b 61±17b 1:27:9.7 
59 H H 1.0±0.2 14.7±0.6 410±47 1:15:410 
60 Me H 1.1±0.3 46±10 201±36 1:42:180 
61 Et H 3.2±0.6 61±10 49.5±1.7 1:19:15 
62 H Me 5.2±0.9 33.9±4.9 360±60 1:6.5:69 
63 H Cl 5.6±0.8 38.1±3.9 528±49 1:6.8:94 
64 H OH 9.5±0.5 175±26 307±34 1:18:32 
65 H NHAc 7.9±1.1 387±31 1550±130 1:49:200 
66 H NHEt 23.5±6.5 63.8±5.2 408±54 1:2.7:17 
67 H NHCOEt 4.2±1.1 108±27 1090±290 1:26:260 
68 H OMe 3.6±0.1 21.5±4.5 610±100 1:6.0:170 
69 H OCF3 1.4±0.5 7.3±0.5 370±83 1:5.2:260 
70 H OEt 2.8±0.5 23.8±3.3 1180±120 1:8.5:420 
71 H OnPr 0.91±0.06 5.3±1.0 390±150 1:5.8:430 
72 H OCPM 2.7±0.6 13.9±1.8 319±51 1:5.1:120 
73 H OBn 8.0±1.5 70.4±5.4 575±80 1:8.8:71 
74 Me OMe 8.0±0.8 6.8±1.1 330±150 1:0.85:41 
Table 2: Binding affinity of the benzylic core compounds at MOR, DOR, and KOR. Binding 
affinities (Ki) were obtained by competitive displacement of radiolabeled [
3H] diprenorphine in 
membrane preparations. Included are morphine and the original lead peptidomimetic 
(KSKPP1E) for comparison. All data were from three separate experiments, performed in 
duplicate. These data are reported as the average ± standard error of the mean. Selectivity was 
calculated by dividing the Ki of each receptor by the Ki at MOR for a given compound. 
DNS=Does Not Stimulate. aFrom Reference60. bFrom Reference78. 
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Table 3: Potency and efficacy of benzylic core compounds at MOR, DOR, and KOR. These data 
were obtained using agonist induced stimulation of [35S] GTPγS binding. Potency is represented 
as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO 
(MOR), DPDPE (DOR), or U69,593 (KOR) at 10 μM. Included are morphine and the original 
lead peptidomimetic (KSKPP1E) for comparison. All data were from three separate 
experiments, performed in duplicate. These data are reported as the average ± standard error of 
 Potency, EC50 (nM) Efficacy, (% Stimulation) 
Name -R1 -R2 MOR DOR KOR MOR DOR KOR 
KSKPP1E -CH2CH2NH- 1.6±0.3a 110±6a 540±72a 81±2a 16±2a 22±2a 
Morphine - - 194±21b >593c DNS 57±5b >30c DNS 
59 H H DNS DNS DNS DNS DNS DNS 
60 Me H 44.4±7.5 DNS >1700 41±12 DNS >40 
61 Et H 158±17 DNS 2200±500 15.0±2.6 DNS 26.6±3.0 
62 H Me 111±29 DNS DNS 21.9±5.3 DNS DNS 
63 H Cl 250±24 DNS DNS 39.2±1.0 DNS DNS 
64 H OH 552±90 DNS DNS 17.0±1.1 DNS DNS 
65 H NHAc 117±13 DNS DNS 32.5±2.6 DNS DNS 
66 H NHEt 156±20 DNS >2440 25.9±5.8 DNS >40 
67 H NHCOEt 84±26 DNS >4000 28.7±7.1 DNS >35 
68 H OMe 264±21 DNS DNS 37.2±1.7 DNS DNS 
69 H OCF3 342±80 DNS DNS 45.0±6.1 DNS DNS 
70 H OEt 77±10 DNS DNS 65.9±5.2 DNS DNS 
71 H OnPr 68±10 DNS DNS 54.9±4.0 DNS DNS 
72 H OCPM 71±13 DNS DNS 37.5±1.3 DNS DNS 
73 H OBn 107±19 DNS DNS 34.7±3.8 DNS DNS 
74 Me OMe 296±69 DNS DNS 20.2±1.4 DNS DNS 
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the mean. DNS=Does Not Stimulate. aFrom Reference61. bFrom Reference79. cTested against 
human DOR. 
With regards to KOR, most of the ligands express a reduced binding affinity at this receptor 
compared to KSKPP1E, with the exception of 61. Similarly, only 61, 66, and 67 were shown to 
have weak KOR efficacy; the rest have no efficacy at this receptor. Since we were interested in 
balancing the binding affinity between MOR and DOR, and since we were screening KOR for 
selectivity, we calculated binding ratios between MOR, DOR, and KOR normalized to MOR. Most 
of these ligands synthesized here show an improved balance between MOR and DOR than that of 
the lead compound KSKPP1E, the exception being 65. The greatest balance can be found with 
various functional groups at the R2-position, namely the methyl (62), chloro (63), ethyl aniline 
(66), and all the ethers (68-74). When comparing MOR and KOR for selectivity, only the 
unfunctionalized compound 59, and the ethyl (70) and n-propyl (71) ethers exhibited greater 
selectivity than KSKPP1E.  
Antagonist Potency of Representative Analogues: Finally, while analogues displaying reasonably 
high DOR affinity (~20 nM or less) and no DOR efficacy are presumptive DOR antagonists, this 
was tested explicitly for 70, 71, and 72. DOR antagonism was confirmed for all three analogues, 
which induced rightward shifts in the EC50 of the standard DOR agonist DPDPE that equated to 
Ke values of 20.2 nM, 7.4 nM, and 20.5 nM, respectively (calculated as described in Methods). 
These values are very similar to the Ki’s of these ligands shown in Table 2. The only exception 
here is analogue 72, which has a Ki approximately half of the Ke at a value of 13.9 nM. 
Metabolic Stability: In tandem with the opioid SAR aquired above, the metabolic stability of these 
monocyclic core compounds was characterized in mouse liver microsomes (MLM) (Table 4) 
using verapamil as the positive control. Because of the variability between the measures of 
metabolic half-life for verapamil (from 13.8 to 22.6 min) in the different assay preparations, the 
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ratio of T1/2 for the compound and verapamil was calculated as a stability ratio. This was to ensure 
consistent comparisons between different analogues.  
Name R1 R2 T1/2 (min) Verapamil T1/2 (min) Stability Ratio  cLogP 
KSKPP1E CH2CH2NH 3.1±0.1 14.7±2.0 0.21±0.03 3.74 
59 H H 13.0±2.6 14.6±1.0 0.89±0.19 4.30 
60 Me H 8.5±0.8 22.6±1.4 0.38±0.04 4.61 
61 Et H 4.1±0.2 13.8±1.6 0.29±0.04 5.14 
62 H Me 12.2±0.0 22.6±1.4 0.54±0.03 4.75 
63 H Cl 16.3±2.5 22.6±1.4 0.72±0.12 5.01 
64 H OH 15.4±1.3 14.4±1.0 1.1±0.1 3.58 
65 H NHAc 10.2±0.4 14.4±1.0 0.71±0.06 2.45 
66 H NHEt 12.1±1.5 22.6±1.4 0.54±0.07 4.33 
68 H OMe 19.7±2.0 13.8±1.6 1.4±0.2 4.22 
69 H OCF3 5.7±0.0 14.6±1.0 0.39±0.03 5.33 
70 H OEt 23.7±5.9 14.6±1.0 1.6±0.4 4.75 
71 H OnPr 33.1±2.8 19.6±2.3 1.7±0.2 5.28 
72 H OCPM 56±10 22.6±1.4 2.5±0.5 5.19 
73 H OBn 15.6±0.1 22.6±1.4 0.69±0.04 5.99 
74 Me OMe 4.3±0.0 14.6±1.0 0.30±0.02 4.53 
 Table 4: Metabolic stability of benzylic core compounds in MLM. Included are the 
compound half-life (T1/2), the half-life of the positive control verapamil, and the stability ratio 
between the compound and the positive control. The stability ratio was calculated by dividing the 
half-life of the analogue of interest by the half-life of the positive control in that assay. Individual 
compounds were tested once, with errors representing the SE in the decay curve regressed onto 
the data collected in 15-minute intervals. Finally, the cLogP of these analogues are included and 
were calculated using PerkinElmer’s ChemDraw® Professional Software. 
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To evaluate the improvement in stability of these compounds, the original lead compound 
KSKPP1E is included in Table 4. This compound displays the poorest metabolic stability, with a 
ratio of 0.21 compared to verapamil and is characteristic of the other THQ containing analogues 
in our previously reported series. Stripping away the substituents that make up the aliphatic portion 
of the tetrahydroquinoline ring (59) improves the ratio 4-fold to 0.89. However, introducing alkyl 
chains off this benzylic position (R1, 60-61) reduces the stability of these compounds back to that 
of KSKPP1E.  
 Next, we examined our analogues at the 6-position (R2). The small substituents at this 
position (62-64) did not improve the stability of these compounds, even though some of these 
modifications are polar (which would reduce cLogP80) or are electron withdrawing groups (which 
would inhibit free radical formation during the CYP catalytic cycle). This also extends to the acetyl 
and ethyl anilines (65-66), in which no improvements were observed. 
 The ethers (68-73), generally produced significant improvements in metabolic stability. 
This is particularly true for cyclopropyl methyl ether (72), which was x2.5 more stable than 
verapamil, reflecting a half-life of 56 minutes. This was not true of all the ethers however, as the 
trifluoromethyl ether (69) showed lower stability levels than 59. Finally, the hybrid analogue 74 
had low stability, similar to compound 60. 
Molecular Modeling: To complement the in vitro data acquired thus far, molecular modeling 
studies were performed to dock compound 70 to MOR (Figure 8) with the goal of explaining the 
acquired MOR-agonism in this ligand. Instead of the ethyl ether orienting itself to mimic the 
structure of the original THQ core, it instead appears to wedge itself between His54 and Tyr148 
in the active state of MOR. Here the ethyl group of the ether appears to interact with the imidazole 




Figure 8: Molecular modeling of analogue 70 at MOR. His54, Tyr148 are labelled and their 
distance from the ethyl group is shown. 
2.3 Discussion and Conclusions 
SAR: Using KSKPP1E as a baseline, it appears that moving to 59 causes a loss in MOR-agonism 
and affinity. This can in part be explained by increased conformational flexibility that occurs upon 
elimination of the aliphatic portion of the tetrahydroquinoline ring. This activity can be restored 
through the introduction of small alkyl chains at the benzylic position (60-61), likely due to steric 
interactions with the receptor that KSKPP1E would also possess. 
 Introducing the methyl, chloro, or hydroxy group to the 6-position of the benzylic core (62-
64) produced partial MOR-agonism compared to 59. The hydroxyl group (64) was the least potent 
and efficacious of the three, suggesting that either an electron donating group on the benzylic core 
or a hydrogen bond donor at the 6-position interferes with the ability of substituents at this position 
to activate MOR.  This trend is also seen with binding affinity at DOR, as the hydroxy substituent 
possesses the lowest affinity. The chloro substituent (63) is similar to the methyl (62) substituent 
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in its activity at the three receptors, and differed only from 62 in that it had twice the efficacy at 
MOR. This reinforces the electronics argument, as the chloro group is more electron withdrawing 
than the methyl group due to induction. 
 The 6-position ethers produced some of the most promising ligands in this series. These 
ligands generally had high MOR and DOR affinity, except for the benzyl ether at DOR (73). 
However, the potency and efficacy of these compounds at MOR vary greatly. The optimum here 
appears to be with the ethyl (70) and n-propyl (71) ethers, which proved comparable to morphine 
in efficacy and potency. This is particularly interesting when these data are compared to the 6-
anilines (65-67) and the 6-hydroxyl (64), as they suggest that the hydrogen bond donor present in 
these latter compounds is detrimental for MOR efficacy, rather than the presence of electron 
donating groups. The orientation of the hydrogen bond donor may be important, as the lead 
compound KSKPP1E displays high MOR efficacy. From the data illustrated in compounds 65-
67, it appears that orientating the hydrogen bond donor toward the DMT pendant is detrimental to 
MOR agonism. Since these ethers also antagonize DPDPE, these data suggest that the small chain 
ethers are best for producing our desired MOR-agonist/DOR-antagonist profile.  
It should be noted that the ethers 70 and 71 do not possess the level of potency or efficacy 
at MOR as the original lead compound KSKPP1E. Since we are ultimately interested in 
determining if MOR-agonist/DOR-antagonist ligands are suitable for use as opioid analgesics 
without abuse liabilities, the stability improvements of 70 and 71 represents a necessary 
developmental step toward this end. This is particularly true considering the instability of the THQ 
core compounds such as KSKPP1E. However, 70 and 71 have improved potency and similar 
efficacy at MOR compared to morphine, which is the classic opioid analgesic. As such, sacrificing 
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some potency and efficacy at MOR to improve some pharmacokinetic parameters is worthwhile, 
especially if they still perform better than morphine in vitro.  
 The hybrid compound 74 is also notable due to its poor MOR efficacy and potency. While 
the potency of this compound was akin to the simple 6-OMe precursor (68), the efficacy here was 
less than either precursor analogue 60 and 68. This suggests that steric effects within the ligand 
may be detrimental to activation of MOR, a problem that vanishes when these two groups are tied 
together in the bicyclic ring of the original THQ core. 
 With regards to selectivity, two notable trends can be observed. Selectivity for MOR over 
KOR can be reduced compared to our original lead KSKPP1E through two different means. 
Extending alkyl chains off the benzylic position (R1, 60-61) do this largely through improving 
KOR binding and max out with the ethyl group (61) in this series, whereas some substituents 
containing a hydrogen bond donor off the 6-position (R2), namely the hydroxyl (64) and ethyl 
aniline (66) do this through reduced MOR binding. Conversely, the ethyl and n-propyl ethers (70, 
71) show the best selectivity over KOR, largely due to reduced KOR binding compared to 
KSKPP1E. While almost all of our compounds show improved MOR/DOR affinity balance, 
possibly due to elimination of the bicyclic ring system, all of our ethers (68-74) are among those 
that have the best balance. Overall, the ethers 70 and 71 show the best selectivity over KOR, and 
are among the best compounds that balance MOR and DOR.  
Metabolic Stability: Stripping away all the components of the THQ core (59) produced a 4-fold 
improvement in metabolic stability over KSKPP1E. When incorporating alkyl chains onto the 
benzylic position (60-61, and 74), this improvement is lost, suggesting that this benzylic position 
in both this series and in the original THQ series is a metabolic hot spot. This is consistent with 
the mechanism of CYP metabolism, namely that the benzylic methyne present in compounds 60-
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61, and 74 can greater stabilize the radical formed upon interaction with the enzyme than can the 
methylene alone. Simple chloro (63) and hydroxyl (64) functional groups at the 6-position were 
no different than the unfunctionalized system (59). The ethers (68-73), apart from the trifluoro (69) 
and benzyl (73) ethers, displayed the greatest levels of stability, reaching stability ratios of 2.5 and 
half-lives near an hour, as determined for 72.  
Interestingly, these ethers were more stable than the functionalized anilines, despite their 
greater cLogP, which is commonly associated with reduced stability.80 Nitrogen is a better electron 
donating substituent than oxygen. As such, these nitrogens may further stabilize metabolism at the 
adjacent benzylic positions on the aromatic ring than would the oxygens of the ethers. Notably, 
the most stable ether contained a cyclopropyl moiety. This can likely be attributed to a combination 
of steric effects, and ring strain, as the cyclopropyl group can both block metabolism at adjacent 
positions (which is also possible with most of the other ethers) and the ring strain destabilizes free 
radical formation on the cyclopropyl group itself.  
Fortunately, the SAR regarding the restoration of our MOR-agonist/DOR-antagonist 
profile overlapped with the SAR aimed at improving metabolic stability. This suggests that these 
6-position ethers are a promising new direction for the development of these peptidomimetics. As 
such, our future derivatization of these analogues will follow the lead provided by these promising 
ethers. 
Molecular Modeling: The ethyl ether of analogue 70 wedges itself between His54 and Tyr148. 
This may force the ligand to adopt a conformation within the receptor that enables activation of 
MOR. However, it is the alkyl chain that is interacting with these two residues in the receptor, not 
the ether itself. This may explain the reduced potency of this analogue compared to KSKPP1E, 
as the lipophilic alkyl chain does not produce an ideal interaction with the polar imidazole of His 
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54 and the polar hydroxyl of Tyr148. As such, replacement of the ethyl group with substituents 
that are more polar may be of value. Regardless, the potency of this ligand is still better than 
morphine, and it may be better to keep pursuing stability instead of exploring this position.  
It should be noted that the oxygen of the ether does not appear to interact with MOR, yet 
when replaced with a nitrogen as in analogue 66, a 40 % loss in efficacy is observed. While docked 
structures of 66 to MOR are not available, presumably the ethyl group in 66 would orient itself in 
the same manner as the ethyl group of 70. This would leave the hydrogen bond donor of the aniline 
pointing toward the aromatic ring of the DMT residue instead of a hydrogen bond acceptor in the 
ether. This could produce and intramolecular polar-π interaction within 66 that prevents the ligand 
from assuming a conformation that can activate MOR. 
Conclusion: The results presented here show that the metabolically labile THQ core can be 
changed to a monocyclic core to improve metabolic stability. Initial modification of the simplified 
benzyl core yielded analogues (70 and 71) which display similar potency and efficacy as morphine 
at MOR, are antagonists at DOR, possess a more balanced affinity between MOR and DOR, are 
more selective over KOR, and show improved metabolic stability in mouse liver microsome assays 
compared to our original THQ core ligands. These monocyclic compounds represent an attractive 
new direction through which more stable MOR-agonist/DOR-antagonist ligands may be 









General Methods: All reagents and solvents were obtained commercially and were used 
without further purification. Intermediates were purified by flash chromatography using a Biotage 
Isolera One instrument. Most purification methods utilized a hexanes/ethyl acetate solvent system 
in a Biotage SNAP KP-Sil column, with a linear gradient between 0 and 100% ethyl acetate. 
Reverse phase column chromatography using a linear gradient of 0 % to 100 % solvent B (0.1 % 
TFA in acetonitrile) in solvent A (0.1 % TFA in water) using a Biotage SNAP Ultra C18 column 
was utilized for some intermediate amine salts. Purification of final compounds was performed 
using a Waters semipreparative HPLC with a Vydac protein and peptide C18 reverse phase 
column, using a linear gradient of 0 % to 100 % solvent B in solvent A at a rate 1 % per minute, 
monitoring UV absorbance at 230 nm. The purity of final compounds was assessed using a Waters 
Alliance 2690 analytical HPLC instrument with a Vydac protein and peptide C18 reverse phase 
column. A linear gradient (gradient A) of 0 % to 70 % solvent B in solvent A in 70 min, measuring 
UV absorbance at 230 nm was used to determine purity. All final compounds used for testing were 
≥95 % pure, as determined by analytical HPLC. 1H NMR and 13C NMR data were obtained on a 
500 or 400 MHz Varian spectrometer using CDCl3 or CD3OD solvents. The identities of final 
compounds were verified by mass spectrometry using an Agilent 6130 LC–MS mass spectrometer 
in the positive ion mode, or an Agilent 6230 TOF HPLC-MS in the positive ion mode. Suzuki 
couplings using microwave irradiation were performed on a Discover S-class (CEM) microwave 
in a closed vessel with maximum power input of 300 W and temperature set to 100 °C for 30 min 
under the standard method using their Synergy software.  
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General Procedure for Ellman Reductions (Procedure A): A flamed-dried round bottom 
flask containing 1 equivalent of aldehyde or ketone and 3 equivalents of (R)-(+)-2-methyl-
propane-2-sulfinamide was attached to a reflux condenser and flushed with argon. 4 mL of THF 
was added and cooled to 0 °C. 6 or 7.5 equivalents of titanium (IV) ethoxide was added, followed 
by an additional 4 mL of THF. The solution was stirred and heated to 75 °C overnight with TLC 
monitoring until all ketone or aldehyde was consumed. A separate flame-dried flask containing 6 
equivalents of sodium borohydride was flushed with argon. 4 mL of THF was added, at which 
point the solution was cooled to -78 °C. The solution containing Ellman adduct was cooled to room 
temperature and slowly transferred to the sodium borohydride solution via syringe. This final 
solution was then allowed to warm to room temperature and stirred for 2 hours, at which point the 
reaction mixture was quenched with methanol to consume the sodium borohydride, followed by 
DI water to precipitate the titanium. The solution was vacuum filtered, and the precipitate was 
washed with ethyl acetate. The filtrate was then concentrated in vacuo and purified via column 
chromatography (0-100 % EtOAc in Hexanes). 
General Procedure for Suzuki Couplings Using Microwave Irradiation (Procedure Ba): 
To a microwave vessel containing the protected amine was added 2 equivalents of benzylboronic 
acid pinacol ester, 3 equivalents of potassium carbonate, and 0.1 equivalents of 1,1′-
Bis(diphenylphosphino)ferrocene] dichloropalladium. The vessel was purged with argon and 2.5 
mL of degassed 3:1 acetone:water was added. The vessel was then subject to microwave irradiation 
to a temperature of 100 °C for 30 min. The solution was cooled, partitioned between brine and 
ethyl acetate, and extracted with ethyl acetate. The organic layer was then dried with magnesium 
sulfate, filtered, and concentrated in vacuo. Column chromatography was then performed (0-100 
% ethyl acetate in hexanes), yielding the desired Suzuki coupled derivatives. 
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General Procedure for Suzuki Couplings without Microwave Irradiation (Procedure Bb): 
To a round bottom flask containing protected amine, 2 equivalents of potassium carbonate, and 
0.1 equivalents of 1,1′-Bis(diphenylphosphino)ferrocene] dichloropalladium was added 2.5 
equivalents of benzylboronic acid pinacol ester. The flask was equipped with a reflux condenser, 
purged with argon, and 5 mL of degassed 3:1 acetone:water was added. The vessel was then heated 
to a temperature of 80 °C overnight. The solution was cooled, partitioned between brine and ethyl 
acetate, and extracted with ethyl acetate. The organic layer was then dried with magnesium sulfate, 
filtered, and concentrated in vacuo. Column chromatography was then performed (0-100 % ethyl 
acetate in hexanes), yielding the desired Suzuki coupled derivatives. 
General Procedure for Removal of Ellman’s chiral sulfonamide (Procedure C): To a flask 
containing Ellman protected amine was added 2 mL of Dioxane and 0.2 mL concentrated HCl. 
The solution was stirred at room temperature for 1 minute and concentrated in vacuo. The ensuing 
salt was then purified via one of two methods. If the product is insoluble in diethyl ether, it was 
triturated with diethyl ether, and the precipitate was concentrated in vacuo to dryness, yielding the 
product as an HCl salt. If the product was soluble in diethyl ether, it was purified using a reverse 
phase chromatography (0-100% B in A), yielding the product as a TFA salt.  
General Procedure for the Coupling of 2’,6’-Dimethyltyrosine to Functionalized Amine 
Salt (Procedure D): To a dried flask containing the amine salt under argon was added 3 mL of 
DMF and 10 equivalents of Hunig’s base. 1 equivalent of PyBOP and 1 equivalent of 6-Cl-HOBt 
was added, followed by 1 equivalent of N-Boc-O-Boc-2’,6’-dimethyl-L-tyrosine in 1.5 mL DMF. 
The solution was stirred overnight at room temperature and concentrated in vacuo. 2 mL of TFA 
and 2 mL of DCM were then added, and the solution was stirred for an additional hour. The 
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reaction mixture was concentrated in vacuo and purified via semipreparative reverse phase HPLC 
(0.1% TFA in water: 0.1% TFA in acetonitrile). The product was concentrated in vacuo and 
lyophilized overnight to yield the final peptidomimetic. 
General procedure for the acylation of 2-amino-5-bromobenzaldehyde (Procedure E): To 
a dried flask containing 2-amino-5-bromobenzaldehyde under argon was added neat acyl 
anhydride. The reaction was stirred overnight at 100 °C and concentrated in vacuo. The product 
was then partitioned between sat. NaHCO3 and DCM. The compound was extracted with DCM, 
filtered, and concentrated in vacuo yielding the desired acylated compound.  
General Procedure for the Synthesis of 6-position Ethers (Procedure F): To a flame dried 
flask containing phenolic aldehyde or ketone was added 3 equivalents of potassium carbonate. The 
flask was purged with argon and 4 mL of DMF was added. 3 equivalents of an alkyl iodide or 
bromide was then added, and the solution was stirred at room temperature overnight. The solution 
was then concentrated in vacuo, partitioned between ethyl acetate and saturated sodium 
bicarbonate, and extracted with ethyl acetate. The organic layers were combined, dried with 
magnesium sulfate, filtered, and concentrated in vacuo, yielding the desired ether. 
General procedure for the Cleavage of Phenolic Ethers (Procedure G): To a flame dried 
flask containing 1 equivalent of phenolic ether under argon was added 5 mL DCM and 3.0 
equivalents of 1M BBr3 in DCM was added dropwise. The solution was stirred at room temperature 
for 4 hours and quenched with methanol. The solution was concentrated in vacuo, suspended in 
diethyl ether, and filtered. The precipitate was then dissolved in methanol and filtered. The product 
in methanol was then concentrated in vacuo, yielding the desired phenol. 
33 
 
General procedure for the Reduction of Acyl Anilines (Procedure H): To a dried flask 
containing the desired acyl aniline under argon was added 2M BH3*Me2S in THF and additional 
THF. The solution was heated to 75 °C for 3 hours, at which point the solution was quenched with 
methanol and stirred an additional 15 minutes at 75 °C. The solution was cooled, concentrated in 
vacuo, yielding the reduced alkyl aniline.  
N-(4-bromo-2-formylphenyl)acetamide (6): See Procedure E: 74 mg (0.37 mmol) of 2-
amino-5-bromobenzaldehyde, and 3 mL of acetic anhydride. The compound was purified after 
aqueous workup via column chromatography (0-10% ethyl acetate in hexanes) to produce 
compound 6 (59 mg, 65.9 % yield) which was isolated as an orange solid. 1H NMR (500 MHz, 
Chloroform-d) δ 11.00 (br s, 1H), 9.84 (s, 1H), 8.65 (d, J = 8.9 Hz, 1H), 7.76 (d, J = 2.4 Hz, 1H), 
7.67 (dd, J = 9.0, 2.4 Hz, 1H), 2.24 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 194.22, 169.53, 
139.84, 138.80, 137.98, 122.78, 121.70, 114.91, 25.38. 
N-(4-bromo-2-formylphenyl)propionamide (7): See Procedure E: 98 mg (0.49 mmol) of 
2-amino-5-bromobenzaldehyde, and 3 mL of propionic anhydride. Compound 7 (113 mg, 90.1 
% yield) was isolated as an orange solid. 1H NMR (500 MHz, Chloroform-d) δ 11.00 (s, 1H), 9.81 
(s, 1H), 8.65 (d, J = 9.0 Hz, 1H), 7.72 (d, J = 2.5 Hz, 1H), 7.64 (dd, J = 9.0, 2.4 Hz, 1H), 2.46 (q, 
J = 7.6 Hz, 2H), 1.24 (t, J = 7.6 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 194.21, 173.28, 
139.94, 138.75, 137.95, 122.83, 121.70, 114.71, 31.48, 9.33. 
 5-bromo-2-methoxybenzaldehyde (8): See Procedure F: 157 mg (0.78 mmol) of 5-
bromosalicylaldehyde, 320 mg (2.3 mmol, 3.0 eq.) of K2CO3, 150 µL (342 mg, 2.4 mmol, 3.1 
eq) of MeI, 3 mL of DMF. Compound 8 (170 mg, Quantitative Yield) was isolated as a yellow 
solid. 1H-NMR (400MHz, CDCl3) δ 10.34 (s, 1H), 7.86 (d, J=2.3 Hz, 1H), 7.58 (dd, J=8.9, 2.3 Hz, 
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1H), 6.86 (d, J=8.9 Hz, 1H) 3.89 (s, 3H); 13C-NMR (101 MHz, CDCl3) δ 183.3, 169.7, 138.3, 
130.9, 126.0, 113.7, 113.4, 56.0. 
 5-bromo-2-ethoxybenzaldehyde (10): See Procedure F: 451 mg (1.5 mmol) of 5-
bromosalicylaldehyde, 608 mg (4.4 mmol, 3.0 eq.) of K2CO3, 330 µL (482 mg, 4.4 mmol, 3.0 
eq.) of EtBr, 4 mL of DMF. Compound 10 (495 mg, 96.3 % yield) was isolated as a white solid. 
1H NMR (400 MHz, Chloroform-d) δ 10.36 (s, 1H), 7.85 (d, J = 2.6 Hz, 1H), 7.55 (dd, J = 8.8, 2.6 
Hz, 1H), 6.83 (d, J = 8.9 Hz, 1H), 4.10 (q, J = 7.0 Hz, 2H), 1.44 (t, J = 7.0 Hz, 3H). 13C NMR (101 
MHz, Chloroform-d) δ 188.4, 160.2, 138.2, 130.7, 126.0, 114.5, 113.2, 64.6, 14.5. 
 5-bromo-2-propoxybenzaldehyde (11): See Procedure F: 123 mg (0.61 mmol) of 5-
bromosalicylaldehyde, 251 mg (1.8 mmol, 3.0 eq.) of K2CO3, 160 µL (217 mg, 1.8 mmol, 2.9 
eq.) of nPrBr, 4 mL of DMF. Compound 11 (155 mg, Quantitative Yield) was isolated as a white 
waxy solid. 1H NMR (400 MHz, Chloroform-d) δ 10.41 (s, 1H), 7.89 (d, J = 2.6 Hz, 1H), 7.58 (dd, 
J = 8.9, 2.6 Hz, 1H), 6.86 (d, J = 8.9 Hz, 1H), 4.01 (t, J = 6.4 Hz, 2H), 1.86 (h, J = 7.3 Hz, 2H), 
1.06 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 188.4, 160.4, 138.2, 130.7, 126.1, 
114.5, 113.2, 70.4, 22.4, 10.5. 
 5-bromo-2-(cyclopropylmethoxy)benzaldehyde (12): See Procedure F: 99 mg (0.49 
mmol) of 5-bromosalicylaldehyde, 204 mg (1.5 mmol, 3.0 eq.) of K2CO3, 140 µL (195 mg, 1.4 
mmol, 2.9 eq.) of (bromomethyl)cyclopropane, 3 mL of DMF. Compound 12 (128 mg, 
Quantitative Yield) was isolated as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 10.42 (s, 
1H), 7.87 (s, 1H), 7.55 (d, J = 8.9 Hz, 1H), 6.82 (d, J = 8.7 Hz, 1H), 3.89 (d, J = 6.6 Hz, 2H), 1.27 
(m, 1H), 0.65 (m, 2H), 0.36 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 188.5, 160.3, 138.2, 
130.7, 126.3, 114.9, 113.3, 73.7, 10.0, 3.2. 
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 2-(benzyloxy)-5-bromobenzaldehyde (13): See Procedure F: 401 mg (2.0 mmol) of 5-
bromosalicylaldehyde, 828 mg (6.0 mmol, 3.0 eq.) of K2CO3, 710 µL (1021 mg, 6.0 mmol, 3.0 
eq.) of BnBr, 5 mL of DMF. Compound 13 (569 mg, 97.9 % yield) was isolated as a white solid. 
1H NMR (500 MHz, Chloroform-d) δ 10.46 (s, 1H), 7.94 (d, J = 2.6 Hz, 1H), 7.60 (dd, J = 8.9, 2.6 
Hz, 1H), 7.45 – 7.33 (m, 5H), 6.95 (d, J = 8.9 Hz, 1H), 5.18 (s, 2H). 13C NMR (126 MHz, 
Chloroform-d) δ 188.2, 159.9, 138.2, 135.5, 131.0, 128.8, 128.5, 127.3, 126.5, 115.2, 113.8, 70.9. 
 1-(5-bromo-2-methoxyphenyl)ethan-1-one (14): See Procedure F: 198 mg (0.92 mmol) 
of 1-(5-bromo-2-hydroxyphenyl)ethan-1-one, 380 mg (2.8 mmol, 3.0 eq.) of K2CO3, 0.170 mL 
(388 mg, 2.7 mmol, 3.0 eq.) of MeI, 3 mL of DMF. Compound 14 (205 mg, 97.2 % yield) was 
isolated as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.77 (d, J = 2.7 Hz, 1H), 7.48 (dd, 
J = 8.8, 2.6 Hz, 1H), 6.81 (d, J = 8.9 Hz, 1H), 3.86 (s, 3H), 2.55 (s, 3H). 13C NMR (126 MHz, 
Chloroform-d) δ 198.1, 157.9, 136.0, 132.8, 129.5, 113.6, 113.0, 55.8, 31.7. 
 (R)-N-(3-bromobenzyl)-2-methylpropane-2-sulfinamide (15): See Procedure A: Step 1: 
90 mg (0.49 mmol) of 3-bromobenzaldehyde (1), 179 mg (1.5 mmol, 3.0 eq.) of (R)-(+)-2-
methyl-propane-2-sulfinamide, 600 µL (653 mg, 2.9 mmol, 5.9 eq.) of Ti(OEt)4, and 4+4 mL THF. 
Step 2: 115 mg (3.0 mmol, 6.3 eq.) of sodium borohydride in 4 mL THF. Compound 15 (111 mg, 
78.6 % yield) was isolated as a white solid. 1H NMR (500 MHz, Chloroform-d) δ7.47 (s, 1H), 7.40 
(d, J = 8.0 Hz, 1H), 7.26 (d, J = 7.1 Hz, 1H), 7.19 (t, J = 7.7 Hz, 1H), 4.30 (dd, J = 14.2, 5.1 Hz, 
1H), 4.22 (dd, J = 14.2, 7.5 Hz, 1H), 3.56 (t, J = 6.3 Hz, 1H), 1.23 (s, 9H). 13C NMR (126 MHz, 
Chloroform-d) δ 140.8, 131.1, 130.7, 130.2, 126.6, 122.6, 56.0, 48.7, 22.7. 
 (R)-N-((R)-1-(3-bromophenyl)ethyl)-2-methylpropane-2-sulfinamide (16): See 
Procedure A: Step 1: 155 mg (0.78 mmol) of 3’-bromoacetophenone (2), 261 mg (2.2 mmol, 2.8 
eq.) of (R)-(+)-2-methyl-propane-2-sulfinamide, 1.00 mL (1.09 g, 4.8 mmol, 6.1 eq.) of Ti(OEt)4, 
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and 4+4 mL THF. Step 2: 179 mg (4.7 mmol, 6.1 eq.) of sodium borohydride in 4 mL THF. 
Compound 16 (125 mg, 62.5 % yield) was isolated as a white solid. 1H NMR (400 MHz, 
Chloroform-d) δ 7.46 (t, J = 1.8 Hz, 1H), 7.39 (ddd, J = 7.8, 2.0, 1.2 Hz, 1H), 7.26 (dt, J = 7.8, 1.4 
Hz, 1H), 7.19 (t, J = 7.7 Hz, 1H), 4.48 (qd, J = 6.6, 3.1 Hz, 1H), 3.41 (d, J = 3.2 Hz, 1H), 1.48 (d, 
J = 6.6 Hz, 3H), 1.21 (s, 9H). 13C NMR (101 MHz, Chloroform-d) δ 146.3, 130.9, 130.4, 129.6, 
125.4, 122.7, 55.6, 53.6, 22.8, 22.6. 
 (R)-N-((R)-1-(3-bromophenyl)propyl)-2-methylpropane-2-sulfinamide (17): See 
Procedure A: Step 1: 106 mg (0.50 mmol) of 1-(3-bromophenyl)propan-1-one (3), 185 mg (1.5 
mmol, 3.1 eq.) of (R)-(+)-2-methyl-propane-2-sulfinamide, 800 µL (870 mg, 3.8 mmol, 7.7 eq.) 
of Ti(OEt)4, and 4+4 mL THF. Step 2: 111 mg (2.9 mmol, 5.9 eq.) of sodium borohydride in 4 mL 
THF. Compound 17 (125 mg, 78.9 % yield) was isolated as a white solid. 1H NMR (500 MHz, 
Chloroform-d) δ 7.43 (t, J = 1.8 Hz, 1H), 7.39 (dt, J = 7.6, 1.7 Hz, 1H), 7.25 – 7.16 (m, 2H), 4.21 
(ddd, J = 8.9, 5.4, 4.1 Hz, 1H), 3.40 (d, J = 4.0 Hz, 1H), 2.01 (dtd, J = 14.7, 7.4, 5.5 Hz, 1H), 1.77 
– 1.65 (m, 1H), 1.21 (s, 9H), 0.79 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 144.7, 
130.9, 130.20, 130.15, 126.1, 122.7, 60.1, 55.8, 29.4, 22.6, 10.0. 
 (R)-N-(5-bromo-2-methylbenzyl)-2-methylpropane-2-sulfinamide (18): See Procedure 
A: Step 1: 77 mg (0.39 mmol) of 5-bromo-2-methylbenzaldehyde (4), 143 mg (1.2 mmol, 3.1 
eq.) of (R)-(+)-2-methyl-propane-2-sulfinamide, 490 µL (533 mg, 2.3 mmol, 6.0 eq.) of Ti(OEt)4, 
and 4+4 mL THF. Step 2: 89 mg (2.4 mmol, 6.1 eq.) of sodium borohydride in 4 mL THF. 
Compound 18 (108 mg, 91.8 % yield) was isolated as a colorless oil that solidified on standing. 
1H NMR (500 MHz, Chloroform-d) δ 7.43 (s, 1H), 7.30 (d, J = 8.0 Hz, 1H), 7.02 (d, J = 8.0 Hz, 
1H), 4.27 (dd, J = 13.9, 3.7 Hz, 1H), 4.16 (dd, J = 13.7, 8.4 Hz, 1H), 3.43 (dt, J = 8.4, 3.7 Hz, 1H), 
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2.26 (s, 3H), 1.22 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 138.4, 135.5, 132.1, 131.4, 130.7, 
119.5, 56.0, 46.7, 22.7, 18.6. 
 (R)-N-(5-bromo-2-chlorobenzyl)-2-methylpropane-2-sulfinamide (19): See Procedure 
A: Step 1: 104 mg (0.47 mmol) of 5-bromo-2-chlorobenzaldehyde (5), 162 mg (1.3 mmol, 2.8 eq.) 
of (R)-(+)-2-methyl-propane-2-sulfinamide, 600 µL (653 mg, 2.9 mmol, 6.0 eq.) of Ti(OEt)4, and 
4+4 mL THF. Step 2: 107 mg (2.8 mmol, 6.0 eq.) of sodium borohydride in 4 mL THF. Compound 
19 (134 mg, 87.1 % yield) was isolated as a white solid. 1H NMR (400 MHz, Chloroform-d) δ 
7.54 (d, J = 2.3 Hz, 1H), 7.33 (dd, J = 8.5, 2.4 Hz, 1H), 7.21 (d, J = 8.5 Hz, 1H), 4.40 (dd, J = 
15.0, 5.8 Hz, 1H), 4.28 (dd, J = 15.0, 7.5 Hz, 1H), 3.68 (t, J = 6.7 Hz, 1H), 1.22 (s, 9H). 13C NMR 
(126 MHz, Chloroform-d) δ 138.3, 132.7, 132.6, 131.9, 131.0, 120.6, 56.2, 46.9, 22.6. 
 (R)-N-(4-bromo-2-(((tert-butylsulfinyl)amino)methyl)phenyl)acetamide (20): See 
Procedure A: Step 1: 93 (0.38 mmol) of 6, 144 mg (1.2 mmol, 3.1 eq.) of (R)-(+)-2-methyl-
propane-2-sulfinamide, 600 µL (653 mg, 2.9 mmol, 7.5 eq.) of Ti(OEt)4, and 4+4 mL THF. Step 
2: 87 mg (2.3 mmol, 6.0 eq.) of sodium borohydride in 3 mL THF. This compound was purified 
using 0-10 % methanol in DCM as the mobile phase during column chromatography. Compound 
20 (130 mg, 97.5 % yield) was isolated as a colorless oil. 1H NMR (400 MHz, Chloroform-d) δ 
8.89 (s, 1H), 7.80 (d, J = 8.7 Hz, 1H), 7.41 (dd, J = 8.7, 2.4 Hz, 1H), 7.37 (d, J = 2.4 Hz, 1H), 4.22 
(dd, J = 13.5, 5.8 Hz, 1H), 4.11 (dd, J = 13.5, 4.5 Hz, 1H), 3.72 (t, J = 5.1 Hz, 1H), 2.19 (s, 3H), 
1.23 (s, 9H). 13C NMR (101 MHz, Chloroform-d) δ 169.53, 135.72, 133.03, 132.03, 130.51, 
126.03, 117.34, 56.50, 44.54, 24.08, 22.85. 
(R)-N-(4-bromo-2-(((tert-butylsulfinyl)amino)methyl)phenyl)propionamide (21): See 
Procedure A: Step 1: 84 (0.33 mmol) of 7, 123 mg (1.0 mmol, 3.1 eq.) of (R)-(+)-2-methyl-
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propane-2-sulfinamide, 410 µL (446 mg, 2.0 mmol, 6.0 eq.) of Ti(OEt)4, and 4+4 mL THF. Step 
2: 76 mg (2.0 mmol, 6.1 eq.) of sodium borohydride in 4 mL THF. Compound 21 (78 mg, 65.8 % 
yield) was isolated as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 8.70 (s, 1H), 7.83 (d, 
J = 8.7 Hz, 1H), 7.41 (dd, J = 8.7, 2.2 Hz, 1H), 7.36 (d, J = 2.4 Hz, 1H), 4.20 (dd, J = 13.4, 5.9 
Hz, 1H), 4.08 (dd, J = 13.1, 4.5 Hz, 1H), 3.67 (t, J = 5.1 Hz, 1H), 2.44 (q, J = 7.6 Hz, 2H), 1.22 
(m, 12H). 13C NMR (126 MHz, Chloroform-d) δ 173.14, 135.81, 133.02, 132.07, 130.19, 125.87, 
117.15, 56.47, 44.52, 30.22, 22.82, 9.69. 
 (R)-N-(5-bromo-2-methoxybenzyl)-2-methylpropane-2-sulfinamide (22): See 
Procedure A: Step 1: 142 mg (0.66 mmol) of 8, 240 mg (2.0 mmol, 3.0 eq.) of (R)-(+)-2-methyl-
propane-2-sulfinamide, 1.00 mL (1.09 g, 4.8 mmol, 7.2 eq.) of Ti(OEt)4, and 4+4 mL THF. Step 
2: 152 mg (4.0 mmol, 6.1 eq.) of sodium borohydride in 4 mL THF. Compound 22 (159 mg, 75.2 
% yield) was isolated as a colorless oil. 1H NMR (400 MHz, Chloroform-d) δ 7.36 (d, J = 2.5 Hz, 
1H), 7.33 (dd, J = 8.6, 2.5 Hz, 1H), 6.72 (d, J = 8.6 Hz, 1H), 4.34 (dd, J = 14.4, 5.6 Hz, 1H), 4.11 
(dd, J = 14.5, 7.6 Hz, 1H), 3.80 (s, 3H), 3.66 (t, J = 6.9 Hz, 1H), 1.19 (s, 9H). 13C NMR (101 MHz, 
Chloroform-d) δ 156.4, 131.9, 131.4, 129.3, 112.6, 112.0, 55.9, 44.8, 22.6. 
 (R)-N-(5-bromo-2-(trifluoromethoxy)benzyl)-2-methylpropane-2-sulfinamide (23): 
See Procedure A: Step 1: 70 µL (119 mg, 0.44 mmol) of 5-bromo-2-
(trifluoromethoxy)benzaldehyde (9), 163 mg (1.3 mmol, 3.0 eq.) of (R)-(+)-2-methyl-propane-
2-sulfinamide, 700 µL (762 mg, 3.3 mmol, 7.5 eq.) of Ti(OEt)4, and 4+4 mL THF. Step 2: 103 mg 
(2.7 mmol, 6.1 eq.) of sodium borohydride in 4 mL THF. Compound 23 (128 mg, 77.1 % yield) 
was isolated as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.61 (d, J = 2.4 Hz, 1H), 7.43 
(dd, J = 8.7, 2.5 Hz, 1H), 7.11 (dd, J = 8.7, 1.6 Hz, 1H), 4.38 (dd, J = 15.1, 5.8 Hz, 1H), 4.27 (dd, 
J = 15.1, 7.4 Hz, 1H), 3.61 (t, J = 6.6 Hz, 1H), 1.22 (s, 9H). 13C NMR (126 MHz, Chloroform-d) 
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δ 146.2 (q, J = 1.7 Hz), 133.5, 133.0, 132.0, 122.2 (q, J = 1.7 Hz), 121.4, 120.2, 119.3, 56.2, 43.7, 
22.6. 
 (R)-N-(5-bromo-2-ethoxybenzyl)-2-methylpropane-2-sulfinamide (24): See Procedure 
A: Step 1: 73 mg (0.32 mmol) of 10, 116 mg (0.96 mmol, 3.0 eq.) of (R)-(+)-2-methyl-propane-
2-sulfinamide, 500 µL (544 mg, 2.4 mmol, 7.5 eq.) of Ti(OEt)4, and 4+4 mL THF. Step 2: 74 mg 
(2.0 mmol, 6.1 eq.) of sodium borohydride in 3 mL THF. Compound 24 (97 mg, 91.1 % yield) 
was isolated as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.36 (d, J = 2.5 Hz, 1H), 7.30 
(dd, J = 8.7, 2.5 Hz, 1H), 6.70 (d, J = 8.7 Hz, 1H), 4.35 (dd, J = 14.3, 5.6 Hz, 1H), 4.12 (dd, J = 
14.4, 7.9 Hz, 1H), 4.00 (q, J = 7.0 Hz, 2H), 3.72 (t, J = 6.8 Hz, 1H,), 1.40 (t, J = 7.0 Hz, 3H), 1.20 
(s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 155.8, 131.8, 131.3, 129.4, 112.8, 112.5, 63.9, 55.9, 
45.0, 22.6, 14.8. 
 (R)-N-(5-bromo-2-propoxybenzyl)-2-methylpropane-2-sulfinamide (25): See 
Procedure A: Step 1: 133 mg (0.55 mmol) of 11, 98 mg (0.81 mmol, 1.5 eq.) of (R)-(+)-2-methyl-
propane-2-sulfinamide, 420 µL (457 mg, 2.0 mmol, 3.7 eq.) of Ti(OEt)4, and 3+3 mL THF. Step 
2: 121 mg (3.2 mmol, 5.9 eq.) of sodium borohydride in 3 mL THF. Compound 25 (169 mg, 88.7 
% yield) was isolated as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.35 (d, J = 2.5 Hz, 
1H), 7.28 (dd, J = 8.7, 2.5 Hz, 1H), 6.68 (d, J = 8.7 Hz, 1H), 4.33 (dd, J = 14.4, 5.6 Hz, 1H), 4.11 
(dd, J = 14.4, 7.8 Hz, 1H), 3.88 (t, J = 6.5 Hz, 2H), 3.72 (dd, J = 7.8, 5.6 Hz, 1H), 1.78 (h, J = 7.4 
Hz, 2H), 1.18 (s, 9H), 1.01 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 155.8, 131.8, 
131.3, 129.4, 112.8, 112.4, 69.8, 55.9, 44.9, 22.6, 22.5, 10.6. 
 (R)-N-(5-bromo-2-(cyclopropylmethoxy)benzyl)-2-methylpropane-2-sulfinamide 
(26): See Procedure A: Step 1: 135 mg (0.53 mmol) of 12, 197 mg (1.6 mmol, 3.1 eq.) of (R)-(+)-
2-methyl-propane-2-sulfinamide, 840 µL (914 mg, 4.0 mmol, 7.6 eq.) of Ti(OEt)4, and 4+4 mL 
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THF. Step 2: 115 mg (3.0 mmol, 5.8 eq.) of sodium borohydride in 3 mL THF. Compound 26 (165 
mg, 86.5 % yield) was isolated as a colorless oil that solidifies to a white solid on standing. 1H 
NMR (500 MHz, Chloroform-d) δ 7.36 (d, J = 2.5 Hz, 1H), 7.30 (dd, J = 8.7, 2.5 Hz, 1H), 6.67 
(d, J = 8.7 Hz, 1H), 4.39 (dd, J = 14.4, 5.7 Hz, 1H), 4.14 (dd, J = 14.4, 7.9 Hz, 1H), 3.88 – 3.75 
(m, 3H), 1.21 (s, 9H), 0.62 (dt, J = 8.9, 3.2 Hz, 2H), 0.32 (dd, J = 4.7, 2.1 Hz, 2H). 13C NMR (126 
MHz, Chloroform-d) δ 155.9, 131.8, 131.3, 129.6, 113.0, 112.5, 73.1, 55.9, 45.3, 22.6, 10.2, 3.24, 
3.18. 
 (R)-N-(2-(benzyloxy)-5-bromobenzyl)-2-methylpropane-2-sulfinamide (27): See 
Procedure A: Step 1: 440 mg (1.5 mmol) of 13, 558 mg (4.6 mmol, 3.1 eq.) of (R)-(+)-2-methyl-
propane-2-sulfinamide, 2.4 mL (2.6 g, 11.4 mmol, 7.6 eq.) of Ti(OEt)4, and 5+5 mL THF. Step 2: 
341 mg (9.0 mmol, 6.0 eq.) of sodium borohydride in 4 mL THF. Compound 27 (582 mg, 97.2 % 
yield) was isolated as a white solid. 1H NMR (400 MHz, Chloroform-d) δ 7.29 (d, J = 2.5 Hz, 1H), 
7.27 – 7.18 (m, 4H), 7.18 – 7.11 (m, 2H), 6.62 (d, J = 8.7 Hz, 1H), 4.98 (s, 2H), 4.32 (dd, J = 14.6, 
5.7 Hz, 1H), 4.18 (dd, J = 14.6, 7.2 Hz, 1H), 4.12 (dd, J = 7.2, 5.8 Hz, 1H), 1.14 (s, 9H). 13C NMR 
(101 MHz, Chloroform-d) δ 155.3, 136.2, 131.7, 131.0, 129.9, 128.5, 128.1, 128.0, 127.2, 126.7, 
113.3, 112.8, 70.0, 55.7, 44.5, 22.5. 
 (R)-N-((R)-1-(5-bromo-2-methoxyphenyl)ethyl)-2-methylpropane-2-sulfinamide 
(28): See Procedure A: Step 1: 129 mg (0.59 mmol) of 14, 193 mg (1.6 mmol, 2.7 eq.) of (R)-(+)-
2-methyl-propane-2-sulfinamide, 720 µL (783 mg, 3.4 mmol, 5.8 eq.) of Ti(OEt)4, 4+4 mL THF, 
Step 2: 137 mg (3.6 mmol, 6.1 eq.) of sodium borohydride in 4 mL THF. Compound 28 (173 mg, 
91.9 % yield) was isolated as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.33 (d, J = 2.5 
Hz, 1H), 7.26 (dd, J = 8.7, 2.5 Hz, 1H), 6.69 (d, J = 8.7 Hz, 1H), 4.69 (p, J = 6.5 Hz, 1H), 3.77 (s, 
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3H), 3.75 (d, J = 5.8 Hz, 1H), 1.40 (d, J = 6.7 Hz, 3H), 1.16 (s, 9H). 13C NMR (126 MHz, 
Chloroform-d) δ 155.6, 134.5, 131.1, 129.7, 113.0, 112.6, 55.6, 49.6, 23.6, 22.6, 21.0. 
 (R)-N-(3-benzylbenzyl)-2-methylpropane-2-sulfinamide (29): See Procedure Bb: 55 mg 
(0.19 mmol) of 15, 120 µL (118 mg, 0.54 mmol, 2.8 eq.) of benzyl boronic acid pinacol ester, 54 
mg (0.39 mmol, 2.1 eq.) of potassium carbonate, 17 mg (0.023 mmol, 0.12 eq.) of 1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium, 4 mL of 3:1 acetone:water. Compound 29 
(38 mg, 66.5% yield) was isolated as a colorless oil that solidified to a white solid on standing. 1H 
NMR (400 MHz, Chloroform-d) δ 7.32 – 7.24 (m, 3H), 7.23 – 7.10 (m, 6H), 4.31 (dd, J = 13.8, 
4.6 Hz, 1H), 4.21 (dd, J = 13.8, 7.8 Hz, 1H), 3.98 (s, 2H), 3.45 (dd, J = 7.6, 4.6 Hz, 1H), 1.22 (s, 
9H). 13C NMR (101 MHz, Chloroform-d) δ 141.6, 140.8, 138.7, 128.9, 128.7, 128.6, 128.5, 128.3, 
126.2, 125.8, 55.9, 49.3, 41.8, 22.7. 
 (R)-N-((R)-1-(3-benzylphenyl)ethyl)-2-methylpropane-2-sulfinamide (30): See 
Procedure Bb: 98 mg (0.32 mmol) of 16, 180 µL (176 mg, 0.81 mmol, 2.5 eq.) of benzyl boronic 
acid pinacol ester, 86 mg (0.62 mmol, 1.9 eq.) of potassium carbonate, 21 mg (0.029 mmol, 0.089 
eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 5 mL of 3:1 acetone:water. 
Compound 30 (58 mg, 57.1 % yield) was isolated as a colorless oil. 1H NMR (500 MHz, 
Chloroform-d) δ 7.33 – 7.23 (m, 3H), 7.24 – 7.14 (m, 5H), 7.11 (dt, J = 7.7, 1.4 Hz, 1H), 4.51 (qd, 
J = 6.5, 2.6 Hz, 1H), 3.99 (s, 2H), 3.39 (d, J = 2.6 Hz, 1H), 1.49 (d, J = 6.5 Hz, 3H), 1.22 (s, 9H). 
13C NMR (126 MHz, Chloroform-d) δ 144.3, 141.7, 140.8, 128.91, 128.87, 128.5, 128.3, 127.2, 
126.1, 124.2, 55.4, 53.8, 41.9, 22.8, 22.6. 
 (R)-N-((R)-1-(3-benzylphenyl)propyl)-2-methylpropane-2-sulfinamide (31): See 
Procedure Ba: 83 mg (0.28 mmol) of 17, 130 µL (127 mg, 0.58 mmol, 2.1 eq.) of benzyl boronic 
acid pinacol ester, 116 mg (0.84 mmol, 3.0 eq.) of potassium carbonate, 20 mg (0.027 mmol, 0.098 
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eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 2.5 mL of 3:1 acetone:water. 
Compound 31 (81 mg, 94.3 % yield) was isolated as a colorless oil. 1H NMR (500 MHz, 
Chloroform-d) δ 7.30 – 7.23 (m, 3H), 7.21 – 7.07 (m, 6H), 4.23 (dt, J = 8.5, 4.6 Hz, 1H), 3.98 (s, 
2H), 2.02 (dp, J = 13.2, 7.4 Hz, 1H), 1.73 (dq, J = 21.7, 7.3 Hz, 1H), 1.20 (s, 9H), 0.77 (t, J = 7.5 
Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 142.4, 141.4, 140.9, 128.9, 128.7, 128.5, 128.4, 
127.9, 126.1, 124.9, 60.2, 55.7, 41.8, 29.3, 22.6, 10.0. 
 (R)-N-(5-benzyl-2-methylbenzyl)-2-methylpropane-2-sulfinamide (32): See Procedure 
Bb: 89 mg (0.29 mmol) of 18, 200 µL (196 mg, 0.90 mmol, 3.1 eq.) of benzyl boronic acid pinacol 
ester, 82 mg (0.59 mmol, 2.0 eq.) of potassium carbonate, 22 mg (0.030 mmol, 0.10 eq.) of 1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium, 4 mL of 3:1 acetone:water. Compound 32 
(65 mg, 70.4 % yield) was isolated as a tan solid. 1H NMR (500 MHz, Chloroform-d) δ 7.30 – 
7.26 (m, 2H), 7.19 (t, J = 8.7 Hz, 3H), 7.12 – 7.07 (m, 2H), 7.05 (dd, J = 7.8, 1.9 Hz, 1H), 4.30 
(dd, J = 13.3, 3.9 Hz, 1H), 4.18 (dd, J = 13.3, 8.8 Hz, 1H), 3.94 (s, 2H), 3.27 (dd, J = 9.1, 3.9 Hz, 
1H), 2.31 (s, 3H), 1.20 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 141.0, 139.0, 136.2, 134.4, 
130.6, 129.4, 128.9, 128.5, 128.3, 126.1, 55.9, 47.4, 41.5, 22.7, 18.6. 
 (R)-N-(5-benzyl-2-chlorobenzyl)-2-methylpropane-2-sulfinamide (33): See Procedure 
Bb: 59 mg (0.18 mmol) of 19, 100 µL (98 mg, 0.45 mmol, 2.5 eq.) of benzyl boronic acid pinacol 
ester, 47 mg (0.34 mmol, 1.9 eq.) of potassium carbonate, 13 mg (0.018 mmol, 0.098 eq.) of 1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium, 4 mL of 3:1 acetone:water. Compound 33 
(45 mg, 73.7 % yield) was isolated as a colorless oil that solidifies to a white solid on standing. 1H 
NMR (500 MHz, Chloroform-d) δ 7.30 – 7.24 (m, 3H), 7.21-7.18 (m, 2H), 7.15 (d, J = 7.5 Hz, 
2H), 7.05 (d, J = 8.1 Hz, 1H), 4.40 (dd, J = 14.4, 5.1 Hz, 1H), 4.27 (dd, J = 14.3, 7.8 Hz, 1H), 3.93 
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(s, 2H), 3.60 (t, J = 6.8 Hz, 1H), 1.18 (d, J = 1.4 Hz, 9H). 13C NMR (126 MHz, Chloroform-d) δ 
140.3, 136.0, 131.4, 130.5, 129.6, 129.5, 128.9, 128.6, 126.3, 56.1, 47.3, 41.2, 22.6. 
 (R)-N-(4-benzyl-2-(((tert-butylsulfinyl)amino)methyl)phenyl)acetamide (34): See 
Procedure Ba: 125 mg (0.36 mmol) of 20, 140 µL (137 mg, 0.63 mmol, 1.8 eq.) of benzyl boronic 
acid pinacol ester, 136 mg (0.98 mmol, 2.7 eq.) of potassium carbonate, 29 mg (0.040 mmol, 0.11 
eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 3.2 mL of 3:1 acetone:water. 
Compound 34 (94 mg, 72.8 % yield) was isolated as a yellow oil 1H NMR (500 MHz, Chloroform-
d) δ 8.72 (s, 1H), 7.79 (d, J = 8.3 Hz, 1H), 7.29 – 7.22 (m, 2H), 7.20 – 7.12 (m, 4H), 7.04 (d, J = 
2.1 Hz, 1H), 4.20 (dd, J = 13.2, 6.0 Hz, 1H), 4.12 (dd, J = 13.3, 4.4 Hz, 1H), 3.90 (s, 2H), 3.65 (t, 
J = 5.3 Hz, 1H), 2.18 (s, 3H), 1.21 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 169.48, 140.67, 
137.91, 134.64, 130.73, 129.71, 128.89, 128.74, 128.51, 126.19, 124.72, 56.34, 45.48, 41.28, 
24.05, 22.84. 
 (R)-N-(4-benzyl-2-(((tert-butylsulfinyl)amino)methyl)phenyl)propionamide (35): See 
Procedure Bb: 76 mg (0.21 mmol) of 21, 120 µL (118 mg, 0.54 mmol, 2.6 eq.) of benzyl boronic 
acid pinacol ester, 59 mg (0.43 mmol, 2.0 eq.) of potassium carbonate, 15 mg (0.020 mmol, 0.098 
eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 5 mL of 3:1 acetone:water. 
Compound 35 (68 mg, 86.8 % yield) was isolated as a yellow oil. 1H NMR (500 MHz, Chloroform-
d) δ 8.56 (s, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.27 (t, J = 7.3 Hz, 2H), 7.23 – 7.11 (m, 4H), 7.05 (s, 
1H), 4.19 (dd, J = 13.1, 6.2 Hz, 1H), 4.11 (dd, J = 13.1, 4.3 Hz, 1H), 3.92 (s, 2H), 3.55 (t, J = 5.2 
Hz, 1H), 2.44 (q, J = 7.6 Hz, 2H), 1.25 – 1.21 (m, 12H). 13C NMR (126 MHz, Chloroform-d) δ 
173.06, 140.73, 137.67, 134.78, 130.73, 129.71, 128.88, 128.50, 128.46, 126.18, 124.49, 56.27, 
45.47, 41.28, 30.28, 22.83, 9.87. 
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 (R)-N-(5-benzyl-2-methoxybenzyl)-2-methylpropane-2-sulfinamide (36): See 
Procedure Bb: 149 mg (0.47 mmol) of 22, 200 µL (196 mg, 0.90 mmol, 1.9 eq.) of benzyl boronic 
acid pinacol ester, 193 mg (1.4 mmol, 3.0 eq.) of potassium carbonate, 33 mg (0.045 mmol, 0.096 
eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 3 mL of 3:1 acetone:water. 
Compound 36 (98 mg, 63.5 % yield) was isolated. 1H NMR (400 MHz, Chloroform-d) δ 7.26 (ddd, 
J = 7.6, 6.3, 1.3 Hz, 2H), 7.20 – 7.13 (m, 3H), 7.09 – 7.04 (m, 2H), 6.77 (d, J = 9.0 Hz, 1H), 4.36 
(dd, J = 13.8, 5.1 Hz, 1H), 4.10 (dd, J = 13.8, 8.0 Hz, 1H), 3.90 (s, 2H), 3.79 (s, 3H), 3.76 (dd, J = 
8.0, 5.3 Hz, 1H), 1.17 (s, 9H). 13C NMR (101 MHz, Chloroform-d) δ 155.8, 141.3, 133.2, 129.9, 
129.0, 128.8, 128.4, 126.9, 126.0, 110.4, 55.9, 55.4, 45.5, 41.0, 22.6. 
 (R)-N-(5-benzyl-2-(trifluoromethoxy)benzyl)-2-methylpropane-2-sulfinamide (37): 
See Procedure Bb: 141 mg (0.38 mmol) of 23, 110 µL (108 mg, 0.49 mmol, 1.3 eq.) of benzyl 
boronic acid pinacol ester, 94 mg (0.68 mmol, 1.8 eq.) of potassium carbonate, 28 mg (0.038 
mmol, 0.10 eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 5 mL of 3:1 
acetone:water. Compound 37 (105 mg, 72.3 % yield) was isolated as a tan solid. 1H NMR (500 
MHz, Chloroform-d) δ 7.33 – 7.27 (m, 2H), 7.26 (s, 1H), 7.25 – 7.11 (m, 5H), 4.39 (dd, J = 14.5, 
5.4 Hz, 1H), 4.26 (dd, J = 14.5, 7.7 Hz, 1H), 3.97 (s, 2H), 3.53 (dd, J = 7.7, 5.4 Hz, 1H), 1.19 (s, 
9H). 13C NMR (126 MHz, Chloroform-d) δ 145.6 (q, J = 1.5 Hz), 140.2, 140.1, 131.1, 130.5, 
129.3, 128.9, 128.6, 126.4, 121.6, 120.6 (q, J = 1.4 Hz), 119.5, 56.03, 44.1, 41.2, 22.5. 
 (R)-N-(5-benzyl-2-ethoxybenzyl)-2-methylpropane-2-sulfinamide (38): See Procedure 
Ba: 119 mg (0.36 mmol) of 24, 160 µL (157 mg, 0.72 mmol, 2.0 eq.) of benzyl boronic acid pinacol 
ester, 151 mg (1.1 mmol, 3.1 eq.) of potassium carbonate, 29 mg (0.040 mmol, 0.11 eq.) of 1,1′-
bis(diphenylphosphino)ferrocene] dichloropalladium, 2.5 mL of 3:1 acetone:water. Compound 38 
(87 mg, 70.7 % yield) was isolated as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.29 – 
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7.24 (m, 2H), 7.20 – 7.15 (m, 3H), 7.07 (d, J = 2.3 Hz, 1H), 7.05 (dd, J = 8.2, 2.3 Hz, 1H), 6.76 
(d, J = 8.3 Hz, 1H), 4.39 (dd, J = 13.8, 5.1 Hz, 1H), 4.11 (dd, J = 13.8, 8.1 Hz, 1H), 4.02 (qd, J = 
7.0, 1.1 Hz, 2H), 3.91 (s, 2H), 3.76 (dd, J = 8.3, 5.2 Hz, 1H), 1.40 (t, J = 7.0 Hz, 3H), 1.18 (s, 9H). 
13C NMR (126 MHz, Chloroform-d) δ 155.2, 141.4, 133.0, 129.9, 129.0, 128.8, 128.4, 127.1, 
126.0, 111.2, 63.6, 55.8, 45.6, 41.0, 22.6, 15.0. 
(R)-N-(5-benzyl-2-propoxybenzyl)-2-methylpropane-2-sulfinamide (39): See 
Procedure Ba: 122 mg (0.35 mmol) of 25, 130 µL (127 mg, 0.58 mmol, 1.7 eq.) of benzyl boronic 
acid pinacol ester, 135 mg (0.98 mmol, 2.8 eq.) of potassium carbonate, 25 mg (0.034 mmol, 0.098 
eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 2.5 mL of 3:1 acetone:water. 
Compound 39 (92 mg, 73.1 % yield) was isolated as a yellow oil. 1H NMR (500 MHz, Chloroform-
d) δ 7.26 (dd, J = 8.1, 6.9 Hz, 2H), 7.20 – 7.14 (m, 3H), 7.08 (d, J = 2.3 Hz, 1H), 7.05 (dd, J = 8.3, 
2.3 Hz, 1H), 6.76 (d, J = 8.3 Hz, 1H), 4.39 (dd, J = 13.8, 5.2 Hz, 1H), 4.12 (dd, J = 13.8, 8.2 Hz, 
1H), 3.91 (t, J = 6.5 Hz, 2H), 3.90 (s, 2H) 3.76 (dd, J = 8.2, 5.2 Hz, 1H), 1.80 (h, J = 7.2 Hz, 2H), 
1.17 (s, 9H), 1.04 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 155.3, 141.4, 133.0, 
129.9, 129.0, 128.8, 128.4, 127.1, 126.0, 111.2, 69.6, 55.8, 45.6, 41.0, 22.7, 22.6, 10.7. 
 (R)-N-(5-benzyl-2-(cyclopropylmethoxy)benzyl)-2-methylpropane-2-sulfinamide 
(40): See Procedure Ba: 48 mg (0.13 mmol) of 26, 60 µL (59 mg, 0.27 mmol, 2.0 eq.) of benzyl 
boronic acid pinacol ester, 56 mg (0.41 mmol, 3.1 eq.) of potassium carbonate, 10 mg (0.014 
mmol, 0.10 eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 3.25 mL of 3:1 
acetone:water. Compound 40 (41 mg, 82.8 % yield) was isolated as a colorless oil. 1H NMR (500 
MHz, Chloroform-d) δ 7.30 – 7.25 (m, 2H), 7.22 – 7.15 (m, 3H), 7.08 (d, J = 2.3 Hz, 1H), 7.04 
(dd, J = 8.3, 2.3 Hz, 1H), 6.74 (d, J = 8.3 Hz, 1H), 4.43 (dd, J = 13.8, 5.1 Hz, 1H), 4.13 (dd, J = 
13.8, 8.1 Hz, 1H), 3.91 (s, 2H), 3.86 (dd, J = 8.0, 5.3 Hz, 1H), 3.80 (qd, J = 9.9, 6.9 Hz, 2H), 1.28 
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– 1.22 (m, 1H), 1.20 (s, 9H), 0.68 – 0.58 (m, 2H), 0.33 (tdd, J = 4.8, 3.3, 2.2 Hz, 2H). 13C NMR 
(126 MHz, Chloroform-d) δ 155.3, 141.4, 133.1, 129.9, 128.9, 128.8, 128.4, 127.3, 126.0, 111.4, 
72.8, 55.7, 45.9, 41.0, 22.6, 10.4, 3.2, 3.1. 
 (R)-N-(5-benzyl-2-(benzyloxy)benzyl)-2-methylpropane-2-sulfinamide (41): See 
Procedure Ba: 500 mg (1.3 mmol) of 27, 590 µL (578 mg, 2.7 mmol, 2.0 eq.) of benzyl boronic 
acid pinacol ester, 564 mg (4.1 mmol, 3.1 eq.) of potassium carbonate, 98 mg (0.13 mmol, 0.10 
eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 2.5 mL of 3:1 acetone:water. 
Compound 41 (363 mg, 70.6 % yield) was isolated as a white solid. 1H NMR (500 MHz, 
Chloroform-d) δ 7.43 – 7.35 (m, 4H), 7.34 – 7.25 (m, 3H), 7.21 – 7.15 (m, 3H), 7.12 (d, J = 2.2 
Hz, 1H), 7.06 (dd, J = 8.3, 2.2 Hz, 1H), 6.85 (d, J = 8.3 Hz, 1H), 5.06 (s, 2H), 4.41 (dd, J = 14.0, 
5.4 Hz, 1H), 4.20 (dd, J = 14.0, 7.8 Hz, 1H), 3.92 (s, 2H), 3.81 (dd, J = 7.8, 5.4 Hz, 1H), 1.13 (s, 
9H). 13C NMR (126 MHz, Chloroform-d) δ 154.9, 141.3, 136.9, 133.6, 130.0, 129.0, 128.9, 128.6, 
128.5, 128.0, 127.32, 127.29, 126.1, 111.7, 70.1, 55.9, 45.6, 41.1, 22.6. 
 (R)-N-((R)-1-(5-benzyl-2-methoxyphenyl)ethyl)-2-methylpropane-2-sulfinamide 
(42): See Procedure Bb: 134 mg (0.40 mmol) of 28, 240 µL (235 mg, 1.1 mmol, 2.7 eq.) of benzyl 
boronic acid pinacol ester, 101 mg (0.73 mmol, 1.8 eq.) of potassium carbonate, 28 mg (0.038 
mmol, 0.096 eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 4 mL of 3:1 
acetone:water. Compound 42 (75 mg, 54.2 % yield) was isolated as a colorless oil. 1H NMR (500 
MHz, Chloroform-d) δ 7.30 – 7.23 (m, 2H), 7.21 – 7.13 (m, 3H), 7.09 (d, J = 2.2 Hz, 1H), 7.02 
(dd, J = 8.4, 2.2 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 4.75 (p, J = 6.5 Hz, 1H), 3.92 (s, 2H), 3.80 (s, 
3H), 3.77 (d, J = 5.0 Hz, 1H), 1.44 (d, J = 6.7 Hz, 3H), 1.17 (s, 9H). 13C NMR (126 MHz, 
Chloroform-d) δ 154.9, 141.4, 133.3, 132.2, 128.9, 128.6, 128.4, 127.4, 126.0, 110.9, 55.40, 55.37, 
49.9, 41.1, 22.6, 21.9. 
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 (3-benzylphenyl)methanaminium chloride (43): See Procedure C: 123 mg (0.41 mmol) 
of 29, 0.4 mL HCl conc., 2 mL dioxane. Compound 43 (85 mg, 89.1 % yield) was isolated as a 
white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.38 – 7.32 (m, 2H), 7.32 – 7.23 (m, 4H), 7.23 – 
7.19 (m, 2H), 7.19 – 7.12 (m, 1H), 4.07 (s, 2H), 4.00 (s, 2H). 13C NMR (126 MHz, Methanol-d4) 
δ 142.6, 140.8, 133.2, 129.4, 129.1, 128.9, 128.5, 128.1, 126.3, 125.8, 42.9, 41.2. 
 (R)-1-(3-benzylphenyl)ethan-1-aminium chloride (44): See Procedure C: 43 mg (0.14 
mmol) of 30, 0.2 mL HCl conc., 2 mL dioxane. Compound 44 (35 mg, Quantitative Yield) was 
isolated as a white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.39 – 7.33 (m, 2H), 7.31 (dt, J = 
7.7, 1.6 Hz, 1H), 7.29 – 7.23 (m, 3H), 7.23 – 7.19 (m, 2H), 7.19 – 7.14 (m, 1H), 4.41 (q, J = 6.9 
Hz, 1H), 4.01 (s, 2H), 1.61 (d, J = 6.8 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 142.6, 140.8, 
138.4, 129.3, 129.0, 128.5, 128.1, 126.8, 125.8, 123.9, 51.0, 41.3, 19.4. 
 (R)-1-(3-benzylphenyl)propan-1-aminium chloride (45): See Procedure C: 81 mg (0.25 
mmol) of 31, 0.4 mL HCl conc., 2 mL dioxane. Compound 45 (26 mg, 40.4 % yield) was isolated 
as a white solid. 1H NMR (400 MHz, Methanol-d4) δ 7.38 (dd, J = 8.2, 6.9 Hz, 1H), 7.31 (t, J = 
1.7 Hz, 1H), 7.29 – 7.23 (m, 4H), 7.23 – 7.14 (m, 3H), 4.11 (dd, J = 9.3, 5.9 Hz, 1H), 4.01 (s, 2H), 
2.09 – 1.85 (m, 2H), 0.86 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, Methanol-d4) δ 142.7, 140.8, 
136.9, 129.4, 129.0, 128.5, 128.1, 127.5, 125.8, 124.5, 56.9, 41.3, 27.3, 9.1. 
 (5-benzyl-2-methylphenyl)methanaminium chloride (46): See Procedure C: 65 mg 
(0.21 mmol) of 32, 0.3 mL HCl conc., 3 mL dioxane. Compound 46 (42 mg, 82.3 % yield) was 
isolated as a white solid.  1H NMR (500 MHz, Methanol-d4) δ 7.29 (d, J = 1.7 Hz, 1H), 7.26 – 
7.22 (m, 2H), 7.21 – 7.10 (m, 5H), 4.11 (s, 2H), 3.94 (s, 2H), 2.36 (s, 3H). 13C NMR (126 MHz, 




(5-benzyl-2-chlorophenyl)methanaminium chloride (47): See Procedure C: 45 mg (0.30 
mmol) of 33, 0.2 mL HCl conc., 2 mL dioxane. Compound 47 (33 mg, 91.8 % yield) was isolated 
as a white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.45 – 7.40 (m, 2H), 7.30 – 7.25 (m, 3H), 
7.24 – 7.16 (m, 3H), 4.22 (s, 2H), 4.00 (s, 2H). 13C NMR (126 MHz, Methanol-d4) δ 141.7, 140.3, 
131.4, 131.1, 130.6, 129.6, 128.5, 128.3, 126.0, 40.6, 40.3. 
(5-benzyl-2-hydroxyphenyl)methanaminium bromide (48): See Procedure G: 103 mg 
(0.298 mmol) of 38, 900 µL 1M BBr3 in DCM (0.90 mmol, 3.02 eq.), 5 mL DCM. Compound 48 
(64 mg, 73.0 % yield) was isolated as a yellow solid as the bromide salt. 1H NMR (400 MHz, 
Methanol-d4) δ 7.27 – 7.21 (m, 2H), 7.20 – 7.11 (m, 4H), 7.09 (dd, J = 8.2, 2.3 Hz, 1H), 6.83 (d, J 
= 8.2 Hz, 1H), 4.04 (s, 2H), 3.88 (s, 2H). 13C NMR (101 MHz, Methanol-d4) δ 154.1, 141.5, 132.8, 
130.8, 130.6, 128.4, 128.0, 125.6, 119.1, 114.8, 40.4, 39.4. 
(2-acetamido-5-benzylphenyl)methanaminium chloride (49): See Procedure C: 94 mg 
(0.26 mmol) of 34, 0.4 mL HCl conc., 2 mL dioxane. Compound 49 (69 mg, 90.6 % yield) was 
isolated as a white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.43 (s, 1H), 7.30 – 7.24 (m, 3H), 
7.24 – 7.20 (m, 2H), 7.20 – 7.15 (m, 2H), 4.00 (s, 2H), 3.99 (s, 2H), 2.20 (s, 3H). 13C NMR (126 
MHz, Methanol-d4) δ 173.9, 142.6, 142.1, 135.3, 132.2, 131.7, 130.2, 130.0, 129.7, 127.9, 127.4, 
42.2, 40.9, 23.2. 
(5-benzyl-2-(ethylamino)phenyl)methanaminium chloride (50): See Procedure H: 21 
mg (0.072 mmol) of 49, 260 µL (0.52 mmol, 7.2 eq.) of 2M BH3*Me2S in THF, and 4 mL of THF. 
Compound 50 continued to the next step without further purification.   
 (5-benzyl-2-propionamidophenyl)methanaminium chloride (51): See Procedure C: 68 
mg (0.18 mmol) of 35, 0.2 mL HCl conc., 2 mL dioxane. Compound 51 (50 mg, 89.9 % yield) 
was isolated as a yellow oil. 1H NMR (500 MHz, Methanol-d4) δ 7.38 (s, 1H), 7.31 – 7.12 (m, 7H), 
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3.99 (s, 2H), 3.94 (s, 2H), 2.46 (q, J = 7.0 Hz, 2H), 1.22 (t, J = 6.6 Hz, 3H). 13C NMR (126 MHz, 
Methanol-d4) δ 176.1, 141.0, 140.5, 133.9, 130.8, 130.4, 128.7, 128.6, 128.2, 126.4, 126.0, 40.9, 
40.0, 29.1, 9.0. 
 (5-benzyl-2-methoxyphenyl)methanaminium chloride (52): See Procedure C: 98 mg 
(0.30 mmol) of 36, 0.3 mL HCl conc., 1 mL dioxane. Compound 52 (44 mg, 56.4 % yield) was 
isolated as a white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.27-7.23 (m, 3H), 7.21 – 7.12 (m, 
4H), 6.99 (d, J = 8.3 Hz, 1H), 4.05 (s, 2H), 3.92 (s, 2H), 3.89 (s, 3H). 13C NMR (126 MHz, 
Methanol-d4) δ 156.2, 141.3, 133.9, 131.0, 130.9, 128.4, 128.1, 125.7, 120.7, 110.5, 54.8, 40.4, 
39.2. 
 (5-benzyl-2-(trifluoromethoxy)phenyl)methanaminium chloride (53): See Procedure 
C: 105 mg (0.27 mmol) of 37, 0.2 mL HCl conc., 2 mL dioxane. Compound 53 (76 mg, 87.8 % 
yield) was isolated as a yellow-white solid. 1H NMR (400 MHz, Methanol-d4) δ 7.50 (d, J = 2.0 
Hz, 1H), 7.39 (dd, J = 8.5, 1.9 Hz, 1H), 7.33 (dq, J = 8.5, 1.8 Hz, 1H), 7.31 – 7.14 (m, 5H), 4.18 
(s, 2H), 4.04 (s, 2H). 13C NMR (101 MHz, Methanol-d4) δ 145.6, 141.6, 140.2, 131.1, 130.9, 128.6, 
128.3, 126.1, 125.4, 121.8, 120.5, 119.2, 40.5, 37.2. 
 (5-benzyl-2-ethoxyphenyl)methanaminium chloride (54): See Procedure C: 70 mg (0.20 
mmol) of 38, 0.4 mL HCl conc., 2 mL dioxane. Compound 54 (37 mg, 65.7 % yield) was isolated 
as a white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.24 (d, J = 7.0 Hz, 3H), 7.21 – 7.12 (m, 4H), 
6.98 (d, J = 8.3 Hz, 1H), 4.13 (q, J = 6.6 Hz, 2H), 4.06 (s, 2H), 3.92 (s, 2H), 1.44 (t, J = 6.8 Hz, 
3H). 13C NMR (126 MHz, Methanol-d4) δ 155.4, 141.3, 133.8, 130.9, 130.7, 128.4, 128.1, 125.7, 
120.8, 111.4, 63.7, 40.4, 39.0, 13.6. 
 (5-benzyl-2-propoxyphenyl)methanaminium chloride (55): See Procedure C: 37 mg 
(0.10 mmol) of 39, 0.4 mL HCl conc., 2 mL dioxane. Compound 55 (27 mg, 71.0 % yield) was 
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purified via reverse phase chromatography and isolated as a colorless oil. 1H NMR (500 MHz, 
Methanol-d4) δ 7.27 – 7.22 (m, 3H), 7.20 – 7.13 (m, 4H), 6.98 (d, J = 8.4 Hz, 1H), 4.06 (s, 2H), 
4.03 (t, J = 6.6 Hz, 2H), 3.92 (s, 2H), 1.86 (h, J = 7.2 Hz, 2H), 1.06 (t, J = 7.4 Hz, 3H). 13C NMR 
(126 MHz, Methanol-d4) δ 155.4, 141.3, 133.8, 130.9, 130.6, 128.4, 128.1, 125.7, 120.8, 111.4, 
69.6, 40.4, 38.8, 22.0, 9.4. 
 (5-benzyl-2-(cyclopropylmethoxy)phenyl)methanaminium chloride (56): See 
Procedure D: 43 mg (0.12 mmol) of 40, 0.2 mL HCl conc., 2 mL dioxane. Compound 56 (20 mg, 
56.9 % yield) was isolated as a white solid.  1H NMR (500 MHz, Methanol-d4) δ 7.27 – 7.21 (m, 
3H), 7.21 – 7.13 (m, 4H), 6.97 (d, J = 8.4 Hz, 1H), 4.09 (s, 2H), 3.94 – 3.90 (m, 4H), 1.36 – 1.27 
(m, 1H), 0.66 – 0.60 (m, 2H), 0.38 (dt, J = 6.1, 4.5 Hz, 2H). 13C NMR (126 MHz, Methanol-d4) δ 
155.5, 141.3, 133.9, 130.9, 130.6, 128.4, 128.1, 125.7, 120.9, 111.8, 73.0, 40.4, 38.9, 9.7, 2.2. 
 (5-benzyl-2-(benzyloxy)phenyl)methanaminium chloride (57): See Procedure D: 57 mg 
(0.14 mmol) of 41, 0.3 mL HCl conc., 2 mL dioxane. Compound 57 (31 mg, 65.3 % yield) was 
isolated as a white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.50 – 7.45 (m, 2H), 7.41 – 7.36 (m, 
2H), 7.35 – 7.30 (m, 1H), 7.28 – 7.21 (m, 4H), 7.21 – 7.14 (m, 3H), 7.07 – 7.01 (m, 1H), 5.19 (s, 
2H), 4.10 (s, 2H), 3.92 (s, 2H). 13C NMR (126 MHz, Methanol-d4) δ 155.1, 141.2, 136.8, 134.3, 
130.9, 130.7, 128.4, 128.3, 128.1, 127.7, 127.3, 125.7, 121.1, 112.2, 70.0, 40.4, 38.8. 
 (R)-1-(5-benzyl-2-methoxyphenyl)ethan-1-aminium chloride (58): See Procedure D: 
29 mg (0.084 mmol) of 42, 0.4 mL HCl conc., 2 mL dioxane. Compound 58 (20 mg, 85.8 % yield) 
was isolated as an off-yellow colorless oil (insoluble in diethyl ether). 1H NMR (500 MHz, 
Methanol-d4) δ 7.27 – 7.22 (m, 3H), 7.21 – 7.13 (m, 4H), 7.01 (d, J = 8.4 Hz, 1H), 4.59 (q, J = 6.6 
Hz, 1H), 3.93 (s, 2H), 3.89 (s, 3H), 1.59 (d, J = 6.8 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 




aminium trifluoroacetate (59): See Procedure D: Step 1: 16 mg (0.068 mmol) of 43, 120 µL (89 
mg, 0.69 mmol, 10.1 eq.) of N,N-diisopropylethylamine, 39 mg (0.075 mmol, 1.1 eq.) of PyBOP, 
12 mg (0.071 mmol, 1.0 eq.) of 6-Cl-HOBt, 28 mg (0.068 mmol, 1.0 eq.) of Boc-O-Boc-L-2’,6’-
dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. Compound 59 (10 mg, 
29.1 % yield) was isolated as a white solid. 1H NMR (400 MHz, Methanol-d4) δ 7.25-7.21 (m, 
2H), 7.18-7.12 (m, 4H), 7.06 (d, J = 7.7 Hz, 1H), 6.93 (s, 1H), 6.78 (d, J = 7.8 Hz, 1H), 6.46 (s, 
2H), 4.30 (d, J = 14.7 Hz, 1H), 4.11 (d, J = 14.7 Hz, 1H), 3.92 (s, 2H), 3.83 (dd, J = 11.3, 4.8 Hz, 
1H), 3.19 (dd, J = 13.6, 11.5 Hz, 1H), 2.96 (dd, J = 13.8, 4.8 Hz, 1H), 2.18 (s, 6H). No 13C Data 
Acquired. ESI-MS: 389.3 [M + H]+, HPLC (gradient A): Retention Time: 36.25 min. 
 (S)-1-(((R)-1-(3-benzylphenyl)ethyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-
oxopropan-2-aminium trifluoroacetate (60): See Procedure D: Step 1: 14 mg (0.057 mmol) of 
44, 100 µL (74 mg, 0.57 mmol, 10.2 eq.) of N,N-diisopropylethylamine, 31 mg (0.060 mmol, 1.1 
eq.) of PyBOP, 11 mg (0.065 mmol, 1.2 eq.) of 6-Cl-HOBt, 26 mg (0.063 mmol, 1.1 eq.) of Boc-
O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. 
Compound 60 (14.4 mg, 49.3 % yield) was isolated as a white solid.  1H NMR (500 MHz, 
Methanol-d4) δ 7.27 – 7.20 (m, 2H), 7.21 – 7.11 (m, 4H), 7.11 (s, 1H), 7.07 (d, J = 7.8 Hz, 1H), 
7.03 (d, J = 7.5 Hz, 1H), 6.54 (s, 2H), 4.79 (q, J = 6.7 Hz, 1H), 3.91 (s, 2H), 3.79 (dd, J = 11.5, 
4.6 Hz, 1H), 3.21 (dd, J = 13.7, 11.6 Hz, 1H), 3.01 (dd, J = 13.8, 4.7 Hz, 1H), 2.28 (s, 6H), 1.10 
(d, J = 7.0 Hz, 3H). No 13C Data Acquired. ESI-MS: 403.2 [M + H]+, HPLC (gradient A): 
Retention Time: 38.26 min. 
 (S)-1-(((R)-1-(3-benzylphenyl)propyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-
oxopropan-2-aminium trifluoroacetate (61): See Procedure D: Step 1: 18 mg (0.069 mmol) of 
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45, 140 µL (103 mg, 0.80 mmol, 11.7 eq.) of N,N-diisopropylethylamine, 45 mg (0.086 mmol, 1.3 
eq.) of PyBOP, 14 mg (0.083 mmol, 1.2 eq.) of 6-Cl-HOBt, 30 mg (0.073 mmol, 1.1 eq.) of Boc-
O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. 
Compound 61 (10 mg, 27.4 % yield) was isolated as a white solid.  1H NMR (500 MHz, Methanol-
d4) δ 8.12 (d, J = 8.0 Hz, 1H), 7.25 – 7.11 (m, 6H), 7.10 (s, 1H), 7.09 – 7.00 (m, 2H), 6.52 (s, 2H), 
4.51 (dd, J = 8.8, 6.5 Hz, 1H), 3.92 (s, 2H), 3.83 (dd, J = 11.5, 4.6 Hz, 1H), 3.23 (dd, J = 13.8, 
11.5 Hz, 1H), 2.98 (dd, J = 13.8, 4.6 Hz, 1H), 2.29 (s, 6H), 1.47 (tt, J = 9.2, 4.6 Hz, 2H), 0.56 (t, J 
= 7.4 Hz, 3H). No 13C Data Acquired. ESI-MS: 417.3 [M + H]+, HPLC (gradient A): Retention 
Time: 40.94 min. 
 (S)-1-((5-benzyl-2-methylbenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-
oxopropan-2-aminium trifluoroacetate (62): See Procedure D: Step 1: 20 mg (0.081 mmol) of 
46, 170 µL (126 mg, 0.98 mmol, 12.1 eq.) of N,N-diisopropylethylamine, 54 mg (0.10 mmol, 1.3 
eq.) of PyBOP, 20 mg (0.12 mmol, 1.5 eq.) of 6-Cl-HOBt, 39 mg (0.095 mmol, 1.3 eq.) of Boc-
O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. 
Compound 62 (6 mg, 14.4 % yield) was isolated as a white solid.   1H NMR (500 MHz, Methanol-
d4) δ 7.99 (s, 1H), 7.23 (t, J = 7.5 Hz, 2H), 7.14 (dd, J = 15.9, 7.6 Hz, 3H), 7.03 (d, J = 7.8 Hz, 
1H), 6.99 (d, J = 7.6 Hz, 1H), 6.94 (s, 1H), 6.41 (s, 2H), 4.25 (dd, J = 14.7, 4.7 Hz, 1H), 4.16 (dd, 
J = 14.5, 5.0 Hz, 1H), 3.88 (s, 2H), 3.82 (dd, J = 11.3, 4.7 Hz, 1H), 3.15 (dd, J = 13.5, 11.5 Hz, 
1H), 2.93 (dd, J = 13.7, 4.7 Hz, 1H), 2.10 (s, 6H), 2.03 (s, 3H). No 13C Data Acquired. ESI-MS: 
403.3 [M + H]+, HPLC (gradient A): Retention Time: 38.13 min. 
(S)-1-((5-benzyl-2-chlorobenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-
oxopropan-2-aminium trifluoroacetate (63): See Procedure D: Step 1: 20 mg (0.075 mmol) of 
47, 150 µL (111 mg, 0.86 mmol, 11.5 eq.) of N,N-diisopropylethylamine, 47 mg (0.090 mmol, 1.2 
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eq.) of PyBOP, 16 mg (0.094 mmol, 1.3 eq.) of 6-Cl-HOBt, 39 mg (0.095 mmol, 1.3 eq.) of Boc-
O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. 
Compound 63 (18 mg, 44.9 % yield) was isolated as a white solid. 1H NMR (400 MHz, Methanol-
d4) δ 7.69-7.66 (m, 3H), 7.61-7.58 (m, 3H), 7.53 – 7.44 (m, 2H), 6.81 (s, 2H), 4.82 (d, J = 14.9 
Hz, 1H), 4.67 (d, J = 14.8 Hz, 1H), 4.35 (s, 2H), 4.30 (dd, J = 11.4, 4.8 Hz, 1H), 3.57 (dd, J = 13.4, 
11.6 Hz, 1H), 3.36 (dd, J = 13.9, 5.0 Hz, 1H), 2.53 (s, 6H). No 13C Data Acquired. ESI-MS: 423.2 
[M + H]+, HPLC (gradient A): Retention Time: 38.05 min. 
(S)-1-((5-benzyl-2-hydroxybenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-
oxopropan-2-aminium trifluoroacetate (64): See Procedure D: Step 1: 12 mg (0.041 mmol) of 
48, 90 µL (67 mg, 0.52 mmol, 12.7 eq.) of N,N-diisopropylethylamine, 26 mg (0.050 mmol, 1.2 
eq.) of PyBOP, 9 mg (0.053 mmol, 1.3 eq.) of 6-Cl-HOBt, 20 mg (0.049 mmol, 1.2 eq.) of Boc-
O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. 
Compound 64 (7 mg, 28.1 % yield) was isolated as a white solid.     1H NMR (500 MHz, Methanol-
d4) δ 7.88 (t, J = 5.7 Hz, 1H), 7.23 (t, J = 7.5 Hz, 2H), 7.18 – 7.07 (m, 3H), 6.92 (dd, J = 8.2, 2.2 
Hz, 1H), 6.80 (d, J = 2.2 Hz, 1H), 6.66 (d, J = 8.2 Hz, 1H), 6.39 (s, 2H), 4.20 (d, J = 3.8 Hz, 2H), 
3.89 – 3.81 (m, 3H), 3.14 (dd, J = 14.0, 11.2 Hz, 1H), 2.94 (dd, J = 13.9, 4.8 Hz, 1H), 2.12 (s, 6H). 
No 13C Data Acquired. ESI-MS: 405.3 [M + H]+, HPLC (gradient A): Retention Time: 33.69 min. 
(S)-1-((2-acetamido-5-benzylbenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-
oxopropan-2-aminium trifluoroacetate (65): See Procedure D: Step 1: 31 mg (0.11 mmol) of 
49, 190 µL (141 mg, 1.1 mmol, 10.2 eq.) of N,N-diisopropylethylamine, 58 mg (0.11 mmol, 1.0 
eq.) of PyBOP, 19 mg (0.11 mmol, 1.1 eq.) of 6-Cl-HOBt, 44 mg (0.11 mmol, 1.0 eq.) of Boc-O-
Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. Compound 
65 (12 mg, 20.1 % yield) was isolated as a white solid.  1H NMR (500 MHz, Methanol-d4) δ 7.42 
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(d, J = 8.2 Hz, 1H), 7.27 – 7.20 (m, 2H), 7.20 – 7.09 (m, 4H), 6.89 (d, J = 2.0 Hz, 1H), 6.42 (s, 
2H), 4.14 (d, J = 2.8 Hz, 2H), 3.93 (d, J = 2.9 Hz, 2H), 3.80 (dd, J = 11.2, 4.9 Hz, 1H), 3.15 (dd, 
J = 13.9, 11.2 Hz, 1H), 2.96 (dd, J = 13.9, 5.0 Hz, 1H), 2.16 (s, 3H), 2.13 (s, 6H). No 13C Data 
Acquired. ESI-MS: 446.3 [M + H]+, HPLC (gradient A): Retention Time: 31.27 min. 
(S)-1-((5-benzyl-2-(ethylamino)benzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-
oxopropan-2-aminium trifluoroacetate (66): See Procedure D: Step 1: 0.072 mmol of 50, 130 
µL (96 mg, 0.75 mmol, 10.3 eq.) of N,N-diisopropylethylamine, 40 mg (0.077 mmol, 1.1 eq.) of 
PyBOP, 14 mg (0.083 mmol, 1.1 eq.) of 6-Cl-HOBt, 30 mg (0.073 mmol, 1.0 eq.) of Boc-O-Boc-
L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. Compound 66 
(15.9 mg, 40.4 % yield) was isolated as a white solid.   1H NMR (400 MHz, Methanol-d4) δ 7.42 
– 7.32 (m, 2H), 7.31 – 7.22 (m, 2H), 7.23 – 7.14 (m, 3H), 7.00 (d, J = 1.8 Hz, 1H), 6.35 (s, 2H), 
4.22 (d, J = 15.0 Hz, 1H), 4.12 (d, J = 15.0 Hz, 1H), 4.03 (d, J = 3.4 Hz, 2H), 3.88 (dd, J = 11.4, 
4.9 Hz, 1H), 3.48 (qd, J = 7.2, 1.7 Hz, 2H), 3.12 (dd, J = 13.9, 11.5 Hz, 1H), 2.99 (dd, J = 13.9, 
5.0 Hz, 1H), 2.03 (s, 6H), 1.45 (t, J = 7.2 Hz, 3H). No 13C Data Acquired. ESI-MS: 432.3 [M + 
H]+, HPLC (gradient A): Retention Time: 28.11 min. 
 (S)-1-((5-benzyl-2-propionamidobenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-
oxopropan-2-aminium trifluoroacetate (67): See Procedure D: Step 1: 6 mg (0.020 mmol) of 
51, 40 µL (30 mg, 0.23 mmol, 11.3 eq.) of N,N-diisopropylethylamine, 12 mg (0.023 mmol, 1.1 
eq.) of PyBOP, 11 mg (0.065 mmol, 3.2 eq.) of 6-Cl-HOBt, 11 mg (0.027 mmol, 1.3 eq.) of Boc-
O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. 
Compound 67 (6.4 mg, 56.7 % yield) was isolated as a white solid.  1H NMR (500 MHz, Methanol-
d4) δ 8.20 (t, J = 6.1 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.24 (t, J = 7.6 Hz, 2H), 7.18 – 7.11 (m, 
4H), 6.87 (d, J = 2.0 Hz, 1H), 6.41 (s, 2H), 4.12 (d, J = 3.1 Hz, 2H), 3.93 (d, J = 3.1 Hz, 2H), 3.80 
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(dd, J = 11.2, 4.9 Hz, 1H), 3.15 (dd, J = 13.9, 11.3 Hz, 1H), 2.96 (dd, J = 13.9, 4.9 Hz, 1H), 2.44 
(q, J = 7.6 Hz, 2H), 2.11 (s, 6H), 1.23 (t, J = 7.6 Hz, 3H). No 13C Data Acquired. ESI-MS: 460.3 
[M + H]+, HPLC (gradient A): Retention Time: 32.89 min. 
 (S)-1-((5-benzyl-2-methoxybenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-
oxopropan-2-aminium trifluoroacetate (68): See Procedure D: Step 1: 22 mg (0.083 mmol) of 
52, 170 µL (126 mg, 0.98 mmol, 11.8 eq.) of N,N-diisopropylethylamine, 51 mg (0.098 mmol, 1.2 
eq.) of PyBOP, 19 mg (0.11 mmol, 1.4 eq.) of 6-Cl-HOBt, 43 mg (0.11 mmol, 1.3 eq.) of Boc-O-
Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. Compound 
68 (18 mg, 40.5 % yield) was isolated as a white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.63 
(t, J = 5.9 Hz, 1H), 7.25 (t, J = 7.6 Hz, 2H), 7.21 – 7.17 (m, 2H), 7.15 (tt, J = 7.2, 1.3 Hz, 1H), 
7.10 (dd, J = 8.4, 2.3 Hz, 1H), 6.96 (d, J = 2.2 Hz, 1H), 6.81 (d, J = 8.4 Hz, 1H), 6.31 (s, 2H), 4.37 
– 4.26 (m, 1H), 4.12 (dd, J = 14.2, 4.6 Hz, 1H), 3.89 – 3.83 (m, 3H), 3.67 (s, 3H), 3.10 (dd, J = 
13.8, 11.6 Hz, 1H), 2.92 (dd, J = 13.8, 4.5 Hz, 1H), 2.03 (s, 6H). No 13C Data Acquired. ESI-MS: 
419.3 [M + H]+, HPLC (gradient A): Retention Time: 37.07 min. 
(S)-1-((5-benzyl-2-(trifluoromethoxy)benzyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (69): See Procedure D: Step 1: 19 
mg (0.060 mmol) of 53, 110 µL (82 mg, 0.63 mmol, 10.5 eq.) of N,N-diisopropylethylamine, 32 
mg (0.061 mmol, 1.0 eq.) of PyBOP, 11 mg (0.065 mmol, 1.1 eq.) of 6-Cl-HOBt, 29 mg (0.071 
mmol, 1.2 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 
2 mL DCM. Compound 69 (19 mg, 54.2 % yield) was isolated as a white solid.   1H NMR (500 
MHz, Methanol-d4) δ 8.10 (t, J = 5.7 Hz, 1H), 7.29 – 7.22 (m, 2H), 7.20 – 7.12 (m, 5H), 7.01 (s, 
1H), 6.43 (s, 2H), 4.39 (dd, J = 15.1, 6.4 Hz, 1H), 4.23 (dd, J = 15.2, 4.7 Hz, 1H), 3.95 (d, J = 3.7 
Hz, 2H), 3.89 (dd, J = 11.1, 5.0 Hz, 1H), 3.16 (dd, J = 13.9, 11.1 Hz, 1H), 2.97 (dd, J = 13.9, 5.0 
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Hz, 1H), 2.15 (s, 6H). No 13C Data Acquired. ESI-MS: 473.3 [M + H]+, HPLC (gradient A): 
Retention Time: 42.11 min. 
 (S)-1-((5-benzyl-2-ethoxybenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-
oxopropan-2-aminium trifluoroacetate (70): See Procedure D: Step 1: 18 mg (0.065 mmol) of 
54, 120 µL (89 mg, 0.69 mmol, 10.6 eq.) of N,N-diisopropylethylamine, 38 mg (0.073 mmol, 1.1 
eq.) of PyBOP, 13 mg (0.077 mmol, 1.2 eq.) of 6-Cl-HOBt, 26 mg (0.063 mmol, 0.98 eq.) of Boc-
O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. 
Compound 70 (15 mg, 42.4 % yield) was isolated as a white solid.  1H NMR (500 MHz, Methanol-
d4) δ 7.35 (t, J = 5.7 Hz, 1H), 7.23 (t, J = 7.5 Hz, 2H), 7.21 – 7.16 (m, 2H), 7.13 (t, J = 7.2 Hz, 
1H), 7.07 (dd, J = 8.4, 2.3 Hz, 1H), 6.93 (d, J = 2.2 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 6.30 (s, 2H), 
4.33 (dd, J = 14.3, 7.0 Hz, 1H), 4.14 (dd, J = 14.3, 4.6 Hz, 1H), 3.93 – 3.84 (m, 5H), 3.08 (dd, J = 
13.8, 11.6 Hz, 1H), 2.91 (dd, J = 13.8, 4.6 Hz, 1H), 2.01 (s, 6H), 1.27 (t, J = 7.0 Hz, 3H). No 13C 
Data Acquired. ESI-MS: 433.3 [M + H]+, HPLC (gradient A): Retention Time: 39.20 min. 
 (S)-1-((5-benzyl-2-propoxybenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-
oxopropan-2-aminium trifluoroacetate (71): See Procedure D: Step 1: 24 mg (0.065 mmol) of 
55, 110 µL (82 mg, 0.63 mmol, 9.7 eq.) of N,N-diisopropylethylamine, 37 mg (0.071 mmol, 1.1 
eq.) of PyBOP, 14 mg (0.083 mmol, 1.3 eq.) of 6-Cl-HOBt, 30 mg (0.073 mmol, 1.1 eq.) of Boc-
O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. 
Compound 71 (17 mg, 46.7 % yield) was isolated as a white solid.  1H NMR (500 MHz, Methanol-
d4) δ 7.31 (t, J = 5.8 Hz, 1H), 7.25-7.22 (m, 2H), 7.20 – 7.16 (m, 2H), 7.13 (t, J = 7.1 Hz, 1H), 
7.06 (dd, J = 8.4, 2.2 Hz, 1H), 6.92 (d, J = 2.2 Hz, 1H), 6.78 (d, J = 8.3 Hz, 1H), 6.30 (s, 2H), 4.36 
(dd, J = 14.4, 7.0 Hz, 1H), 4.15 (dd, J = 14.4, 4.4 Hz, 1H), 3.89 – 3.85 (m, 3H), 3.80 (td, J = 6.6, 
4.5 Hz, 2H), 3.08 (dd, J = 13.8, 11.6 Hz, 1H), 2.92 (dd, J = 13.8, 4.6 Hz, 1H), 2.02 (s, 6H), 1.67 
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(h, J = 7.1 Hz, 2H), 0.99 (t, J = 7.4 Hz, 3H). No 13C Data Acquired. ESI-MS: 447.3 [M + H]+, 
HPLC (gradient A): Retention Time: 42.13 min. 
 (S)-1-((5-benzyl-2-(cyclopropylmethoxy)benzyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (72): See Procedure D: Step 1: 17 
mg (0.045 mmol) of 56, 140 µL (104 mg, 0.80 mmol, 18.0 eq.) of N,N-diisopropylethylamine, 35 
mg (0.067 mmol, 1.5 eq.) of PyBOP, 13 mg (0.077 mmol, 1.7 eq.) of 6-Cl-HOBt, 28 mg (0.068 
mmol, 1.5 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 
2 mL DCM. Compound 72 (4 mg, 12.5 % yield) was isolated as a white solid.   1H NMR (500 
MHz, Methanol-d4) δ 7.23 (t, J = 7.6 Hz, 2H), 7.20 – 7.16 (m, 2H), 7.13 (t, J = 7.3 Hz, 1H), 7.06 
(dd, J = 8.4, 2.2 Hz, 1H), 6.92 (d, J = 2.2 Hz, 1H), 6.76 (d, J = 8.4 Hz, 1H), 6.29 (s, 2H), 4.37 (d, 
J = 14.4 Hz, 1H), 4.18 (d, J = 14.4 Hz, 1H), 3.87 (s, 2H), 3.84 (dd, J = 11.7, 4.8 Hz, 1H), 3.74 – 
3.61 (m, 2H), 3.08 (dd, J = 13.8, 11.5 Hz, 1H), 2.90 (dd, J = 13.8, 4.6 Hz, 1H), 2.03 (s, 6H), 1.12 
(ddd, J = 12.7, 8.0, 5.6 Hz, 1H), 0.56 (d, J = 7.5 Hz, 2H), 0.27 (dd, J = 7.1, 5.0 Hz, 2H). No 13C 
Data Acquired. ESI-MS: 459.3 [M + H]+, HPLC (gradient A): Retention Time: 42.68 min. 
 (S)-1-((5-benzyl-2-(benzyloxy)benzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-
oxopropan-2-aminium trifluoroacetate (73): See Procedure D: Step 1: 17 mg (0.050 mmol) of 
57, 100 µL (74 mg, 0.57 mmol, 11.5 eq.) of N,N-diisopropylethylamine, 31 mg (0.060 mmol, 1.2 
eq.) of PyBOP, 10 mg (0.059 mmol, 1.2 eq.) of 6-Cl-HOBt, 24 mg (0.059 mmol, 1.2 eq.) of Boc-
O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. 
Compound 73 (11 mg, 36.1 % yield) was isolated as a white solid.  1H NMR (400 MHz, Methanol-
d4) δ 7.44 – 7.38 (m, 1H), 7.36 (d, J = 4.4 Hz, 4H), 7.32 – 7.27 (m, 1H), 7.26 – 7.21 (m, 2H), 7.21 
– 7.16 (m, 2H), 7.13 (t, J = 7.2 Hz, 1H), 7.08 (dd, J = 8.3, 2.2 Hz, 1H), 6.95 (d, J = 2.2 Hz, 1H), 
6.87 (d, J = 8.4 Hz, 1H), 6.29 (s, 2H), 4.95 (d, J = 4.3 Hz, 2H), 4.40 (dd, J = 14.4, 7.0 Hz, 1H), 
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4.17 (dd, J = 14.4, 4.3 Hz, 1H), 3.88 (s, 2H), 3.80 (dd, J = 11.4, 4.6 Hz, 1H), 3.06 (dd, J = 13.4, 
11.8 Hz, 1H), 2.89 (dd, J = 13.8, 4.7 Hz, 1H), 1.98 (s, 6H). No 13C Data Acquired.  ESI-MS: 495.3 
[M + H]+, HPLC (gradient A): Retention Time: 44.98 min. 
 (S)-1-(((R)-1-(5-benzyl-2-methoxyphenyl)ethyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (74): See Procedure D: Step 1:12 
mg (0.043 mmol) of 58, 76 µL (56 mg, 0.44 mmol, 10.1 eq.) of N,N-diisopropylethylamine, 24 
mg (0.046 mmol, 1.1 eq.) of PyBOP, 8 mg (0.047 mmol, 1.1 eq.) of 6-Cl-HOBt, 19 mg (0.046 
mmol, 1.1 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 
2 mL DCM. Compound 74 (7 mg, 29.6 % yield) was isolated as a white solid.  1H NMR (500 
MHz, Methanol-d4) δ 7.52 (d, J = 8.0 Hz, 1H), 7.22 (dd, J = 8.2, 7.0 Hz, 2H), 7.16 – 7.09 (m, 3H), 
7.02 – 6.94 (m, 2H), 6.82 (d, J = 8.3 Hz, 1H), 6.55 (s, 2H), 5.08 (p, J = 6.9 Hz, 1H), 3.87 (dd, J = 
11.6, 4.7 Hz, 1H), 3.84 (s, 2H), 3.76 (s, 3H), 3.20 (dd, J = 13.7, 11.7 Hz, 1H), 3.02 (dd, J = 13.8, 
4.8 Hz, 1H), 2.29 (s, 6H), 1.06 (d, J = 6.9 Hz, 3H). No 13C Data Acquired. ESI-MS: 433.4 [M + 
H]+, HPLC (gradient A): Retention Time: 40.43 min. 
In Vitro Pharmacology 
Cell Lines and Membrane Preparations.  
All opioid in vitro assays were performed by Nicholas Griggs, Thomas Fernandez, and 
Jessica Anand. Tissue culture reagents were purchased from Gibco Life Sciences (Grand Island, 
NY, U.S.) unless otherwise noted. C6-rat glioma cells stably expressing rat MOR (C6-MOR) or 
rat DOR (C6-DOR) and Chinese hamster ovary (CHO) cells stably expressing human DOR (CHO-
DOR) or human KOR (CHO-KOR) were used for all in vitro assays. Cells were grown to 
confluence at 37 °C in 5 % CO2 in Dulbecco’s modified Eagle medium (DMEM) containing 10 % 
fetal bovine serum and 5 % penicillin/streptomycin. Membranes were prepared by washing 
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confluent cells three times with ice cold phosphate buffered saline (0.9 % NaCl, 0.61 mM 
Na2HPO4, 0.38 mM KH2PO4, pH 7.4). Cells were detached from the plates by incubation in warm 
harvesting buffer (20 mM HEPES, 150 mM NaCl, 0.68 mM EDTA, pH 7.4) and pelleted by 
centrifugation at 1600 rpm for 3 min. The cell pellet was suspended in ice-cold 50 mM Tris- HCl 
buffer, pH 7.4, and homogenized with a Tissue Tearor (Biospec Products, Inc., Bartlesville, OK, 
U.S.) for 20 s. The homogenate was centrifuged at 15,000 rpm for 20 min at 4 °C. The pellet was 
rehomogenized in 50 mM Tris-HCl with a Tissue Tearor for 10 s, followed by recentrifugation. 
The final pellet was resuspended in 50 mM Tris-HCl and frozen in aliquots at -80 °C. Protein 
concentration was determined via a BCA protein assay (Thermo Scientific Pierce, Waltham, MA, 
U.S.) using bovine serum albumin as the standard.  
Radioligand Competition Binding Assays.  
Radiolabeled compounds were purchased from Perkin-Elmer (Waltham, MA, U.S.). 
Opioid ligand binding assays were performed by competitive displacement of 0.2 nM [3H]-
diprenorphine (250 μCi, 1.85 TBq/mmol) by the peptidomimetic from membrane preparations 
containing opioid receptors as described above. The assay mixture, containing membranes (20 μg 
protein/tube) in 50 mM Tris-HCl buffer (pH 7.4), 0.2 nM [3H]-diprenorphine, and various 
concentrations of test peptidomimetic, was incubated at room temperature on a shaker for 1 h to 
allow binding to reach equilibrium. The samples were rapidly filtered through Whatman GF/C 
filters using a Brandel harvester (Brandel, Gaithersburg, MD, U.S.) and washed three times with 
50 mM Tris-HCl buffer, pH 7.4. Bound radioactivity on dried filters was determined by liquid 
scintillation counting, after saturation with EcoLume liquid scintillation cocktail, in a Wallac 1450 
MicroBeta (Perkin-Elmer, Waltham, MA, U.S.). Nonspecific binding was determined using 10 
μM naloxone. The results presented are the mean ± standard error (S.E.M.) from at least three 
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separate assays performed in duplicate. Ki (nM) values were calculated using nonlinear regression 
analysis to fit a logistic equation to the competition data using GraphPad Prism, version 6.0c, 
(GraphPad Software Inc., La Jolla, CA).  
[35S]-GTPγS Binding Assays.  
Agonist stimulation of [35S]guanosine 5′-O-[γ- thio]triphosphate ([35S]-GTPγS, 1250 Ci, 
46.2 TBq/mmol) binding to G protein was measured as described previously.82 Briefly, membranes 
(10 μg of protein/well) were incubated for 1 h at 25°C in GTPγS buffer (50 mM Tris-HCl, 100 
mM NaCl, 5 mM MgCl2, 1 mM EDTA, pH 7.4) containing 0.1 nM [
35S]-GTPγS, 30 μM guanosine 
diphosphate (GDP), and varying concentrations of test peptidomimetic. G protein activation 
following receptor activation by peptidomimetic was compared with 10 μM of the standard 
compounds [D-Ala2,N-MePhe4,Gly-ol]enkephalin (DAMGO) at MOR, D-Pen2,5- enkephalin 
(DPDPE) at DOR, or U69,593 at KOR. The reaction was terminated by vacuum filtration through 
GF/C filters that were washed 5 times with GTPγS buffer. Bound radioactivity was measured as 
described above. The results are presented as the mean ± standard error (S.E.M.) from at least three 
separate assays performed in duplicate; potency (EC50 (nM)) and percent stimulation were 
determined using nonlinear regression analysis with GraphPad Prism 6, as above.  
Ke Determination.  
Agonist stimulation of [35S]GTPγS binding by the known standard agonist DPDPE at delta 
opioid receptor was measured as described above. This was then compared to [35S]GTPγS binding 
stimulated by DPDPE in the presence of test compound. Both conditions produced 100% 
stimulation relative to DPDPE. The fold difference between the EC50 of DPDPE alone and in the 
presence of test compound is defined as the shift in dose response. The Ke was then calculated as 
Ke = (concentration of test compound)/ (Dose response shift – 1). The results presented are the 
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mean ± SEM from three individual assays performed in duplicate and then averaged. The data 
were fitted to a non-linear regression curve (sigmoidal dose response curve for agonist stimulation) 
using GraphPad Prism v8.01. 
Mouse Liver Microsome Stability Assays 
All liver microsome assays were performed by Quintara Biosciences. Metabolic stability 
of testing compounds was evaluated using mouse liver microsomes to predict intrinsic clearance. 
Mouse liver microsome tissue fractions were obtained from Corning or BioreclamationIVT. The 
assay was carried out in 96-well microtiter plates at 37 °C. Reaction mixtures (25 μL) contained a 
final concentration of 1 μM test compound, 0.1 mg/mL liver microsome protein, and 1 mM 
NADPH in 100 mM potassium phosphate, pH 7.4 buffer with 3 mM MgCl2. At each of the time 
points (0, 15, 30, and 60 minutes), 150 μL of quench solution (acetonitrile with 0.1% formic acid) 
with internal standard (bucetin) was transferred to each well. Verapamil was included as a positive 
control to verify assay performance. Plates were sealed, vortexed, and centrifuged at 4 °C for 15 
minutes at 4000 rpm. The supernatant was transferred to fresh plates for LC/MS/MS analysis. All 
samples were analyzed on LC/MS/MS using an AB Sciex API 4000 instrument, coupled to a 
Shimadzu LC-20AD LC Pump system. Analytical samples were separated using a Waters Atlantis 
T3 dC18 reverse phase HPLC column (20 mm x 2.1 mm) at a flow rate of 0.5 mL/min. The mobile 
phase consists of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile 
(solvent B). The extent of metabolism was calculated as the disappearance of the test compound, 
compared to the 0-min time incubation. Initial rates were calculated for the compound 






All in silico studies were performed by Irina Pogozheva. Modeling of three-dimensional 
(3D) structures of receptor-ligand complexes was based on available X-ray structures of the mouse 
MOR (PDB ID: 5c1m).83 Structures of peptidomimetic ligands were generated using the 3D-
Builder Application of QUANTA (Accelrys, Inc) followed by Conformational Search included in 
the program package. Low-energy ligand conformations (within 2 kcal/mol) that demonstrated the 
best superposition of aromatic substituents of the ligand core with the pharmacophore elements 
(DMT and benzyl pendant) of receptor-bound conformations of peptidomimetics were selected for 
docking into the receptor binding pocket. Ligands were positioned inside the receptor binding 
cavity to reproduce the binding modes of peptidomimetics and co-crystalized ligands in MOR X-
ray structures. The docking pose of each ligand was subsequently refined using the solid docking 














Chapter 3: Further Derivatization of the Aromatic Core  
3.1 Introduction 
 The conversion to the monocyclic core described in the previous chapter was an important 
first step in improving the metabolic stability of our MOR-agonist/DOR-antagonist 
peptidomimetic series. However, there exists a lot of room for improvement both in terms of their 
metabolic stability and in their ability to activate MOR. We therefore opted to introduce small 
modifications aimed at blocking sites of CYP metabolism and observe their effects on our MOR-
agonist/DOR-antagonist profile (Figure 9). Two different ligands from the previous studies were 
selected for these purposes. These ligands were selected as they possessed the best MOR-efficacy 
of the two different modifications types, namely the best benzylic position analogue (Compound 
60), and the best aromatic position analogue (Compound 70).  
 Diversification here consisted of small changes on each respective analogue. For 
derivatives of 60, these modifications consisted of inversion of stereochemistry of the benzylic 
position aimed at determining if this can block binding to the active site of the CYP enzyme. This 
was also followed by similar analogues containing a methyl ether, or those containing a nitrogen 
within the aromatic ring system aimed at decreasing the cLogP of these ligands and reducing the 
electron density of the aromatic ring. Finally, the benzylic methyl group was converted to a 
trifluoromethyl group to probe the effect of electronics on the stability of the benzylic position. 
Derivative of 70 followed a similar design philosophy as those of 60, with the focus here being 
solely on the aromatic ring. This included the addition of simple fluoro groups to block potential 
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sites of metabolism on the core aromatic ring. For the purposes of this chapter, the data will be 
grouped based on these two different lead analogues. 
 
Figure 9: Further derivatization of compounds 60 and 70. These analogues were selected as they 
were the best in their respective sites of functionalization. New substituents were selected on the 
grounds that they either block metabolism sterically through manipulation of appropriate 
stereocenters, or electronically using fluorine and nitrogen atoms. 
3.2 Results 
General Chemistry: The bulk of the benzylic core modifications are described in Scheme 3. They 
largely use the same synthetic steps, though the order of the steps varies to enable diversification 
in later stages of the synthesis. Scheme 3A is concerned with the synthesis of the trifluoromethyl 
analogue 101. This was synthesized by first subjecting the trifluoromethyl ketone to Ellman’s 
chiral auxiliary, followed by sodium borohydride, yielding the reduced and protected amine. It 
should be noted that this stereochemistry is inverted when using the R-enantiomer of Ellman’s 
chiral auxiliary. It is hypothesized that this is a result of electrostatic repulsion between the lone 
pair of the sulfinimide and the trifluromethyl group,84 which results in an inversion of the more 
stable transition state when compared to the simple ketones in the previous chapter.85 It should be 
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noted that this intermediate is poorly UV active, so care must be taken during purification by 
chromatography. This was followed by Suzuki coupling with benzyl boronic acid pinacol ester, 
and deprotection of the Ellman auxiliary with concentrated HCl and dioxane. Finally, the liberated 
amine was coupled to Boc-protected DMT, of which, the Boc groups were removed using TFA 
and DCM.  
 The simple methyl analogues 102-104 described in Scheme 3B were synthesized using 
similar methods as the trifluoromethyl analogue 101 described above. However, the order of the 
Suzuki coupling, and the introduction of the chiral amine was inverted. This was to allow for the 
diversification of these analogues to occur later in the synthesis, reducing the total number of steps 
and thus time needed to synthesize each analogue. This diversification consisted of the use of either 
the S or R enantiomer of Ellman’s chiral auxiliary, yielding either the R or S stereocenter on the 
chiral amine. 
Scheme 3: Synthesis of Analogues 101-104. 
 
A) 1. (R)-(+)-2-methyl-propane-2-sulfinamide or (S)-(-)-2-methyl-propane-2-sulfinamide, 
Ti(OEt)4, THF, 75 °C 2. NaBH4. B) BnBPin, K2CO3, Pd(dppf)Cl2, 3:1 Acetone:Water, 
80-100 °C. C) HCl conc., Dioxane. D) 1. DiBocDMT, DIEA, PyBOP, 6-Cl-HOBt, DMF. 
2. TFA, DCM.  
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Finally, we were interested in synthesizing analogue 105, which is a diastereomer of 74. 
This is described in Scheme 4 and used the same synthetic steps as those described in Scheme 3. 
The only difference here is the use of the S isomer of Ellman’s chiral auxiliary. 
Scheme 4: Synthesis of Analogue 105. 
 
A) 1. (S)-(-)-2-methyl-propane-2-sulfinamide, Ti(OEt)4, THF, 75 °C 2. NaBH4. B) BnBPin, 
K2CO3, Pd(dppf)Cl2, 3:1 Acetone:Water, 80-100 °C. C) HCl conc., Dioxane. D) 1. 
DiBocDMT, DIEA, PyBOP, 6-Cl-HOBt, DMF. 2. TFA, DCM.  
In addition to the benzylic analogues described above, we also opted to look at 
modifications focusing only on the aromatic core. The synthesis of the fluorinated analogues is 
described in Scheme 5. These analogues also used the same synthetic steps described above; 
however, they included an initial alkylation step to incorporate the ethyl ether, akin to that 
described in the previous chapter. 
Scheme 5: Synthesis of Analogues 106-107. 
 
A) 1. (R)-(+)-2-methyl-propane-2-sulfinamide, Ti(OEt)4, THF, 75 °C 2. NaBH4. B) BnBPin, 
K2CO3, Pd(dppf)Cl2, 3:1 Acetone:Water, 80-100 °C. C) HCl conc., Dioxane. D) 1. 
DiBocDMT, DIEA, PyBOP, 6-Cl-HOBt, DMF. 2. TFA, DCM. E) EtBr, K2CO3, DMF. 
Finally, the conversion of the core benzene ring of 70 into the pyridine ring of 114 was not 
as straight forward as the other analogues. As similar starting materials were unavailable, this 
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required the alternative synthesis as describe in Scheme 6. 2-ethoxynicotinic acid was first 
converted to 2-ethoxynicotinamide using PyBOP and NH4Cl. This primary amide was then subject 
to reduction using BH3*Me2S at 75 °C, and the subsequent amine was then protected with a Boc 
group. This was in preparation for aromatic bromination using NBS, though the yields here were 
low. This can be explained both by how electron poor the pyridine ring is, and by competition with 
benzylic bromination on the position adjacent to the protected amine. The brominated intermediate 
was then subject to similar chemistry as described above, namely, Suzuki coupling, Boc-
deprotection with concentrated HCl and dioxane, and peptide coupling to Boc-protected DMT and 
subsequent deprotection with TFA. 
Scheme 6: Synthesis of Analogue 114.  
 
B) BnBPin, K2CO3, Pd(dppf)Cl2, 3:1 Acetone:Water, 80-100 °C. C) HCl conc., Dioxane. D) 1. 
DiBocDMT, DIEA, PyBOP, 6-Cl-HOBt, DMF. 2. TFA, DCM. F) NH4Cl, PyBOP, NMM, DMF. 
G) 1. BH3*Me2S, THF, 75 °C. 2. Boc2O, TEA, THF. H) NBS, MeCN, 80 °C 
SAR: Our analyses started with the benzylic analogues 101-105, the binding affinity of which at 
MOR, DOR, and KOR are described in Table 5. Included are the previously described analogues 
60 and 74 for comparison. As a technical note, some of these analogues were tested against human 
MOR and DOR as well as rat MOR and DOR. These analogues were screened during a transition 
period within our laboratory where we moved away from rat MOR and DOR to human MOR and 
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DOR to better model the performance of these analogues in human patients. These distinctions are 
thus made where necessary in the following data tables.  If the stereochemistry of the methyl group 
of 60 is inverted to that of 102, then approximately a single log unit loss in binding affinity is 
observed at each receptor. Notably, the MOR selectivity of 60 is lost in 102. Attachment of fluoro 
groups to this methyl as in 101 resulted in further 6-fold loss in binding affinity at MOR and a 
further 2-fold loss in binding at DOR compared to 101.  
 
Binding Affinity, Ki (nM) Selectivity 
Name Structure MOR DOR KOR MOR:DOR:KOR 
60 
 
1.1±0.3 46±10 201±36 1:42:180 
101 
 
560±120 279±83 ND 1:0.50:- 
102 
 
96±37 122±46 1133±83* 1:1.3:11.8 
103 
 
0.53±0.03a 8.0±1.9a 143±60 1:15.1:270 
104 
 
238±16*a 540±120*a >975 1:2.3:4.1 
105 
 
580±360 6.5±0.9* 1380** 1:0.011:2.4 
74 
 
8.0±0.8 6.8±1.1 330±150 1:0.85:41 
Table 5: Binding affinity of 2nd generation benzylic derivatives at MOR, DOR, and KOR. 
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3H] 
diprenorphine in membrane preparations. Included are analogues 60 and 74 for comparison. All 
data were from three separate experiments, performed in duplicate unless otherwise noted. These 
data are reported as the average ± standard error of the mean. Selectivity was calculated by 
dividing the Ki of each receptor by the Ki at MOR for a given compound. DNS=Does Not 
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Stimulate. ND =No Data. * N=2, ** N=1. aData are from assays using human MOR and DOR 
instead of rat MOR and DOR. 
Conversion to the pyridine core structure appears to have divergent effects. Analogue 103, with 
the same stereochemistry as 60, appears to have improved binding affinity at each of the three 
receptors, whereas 104 had a 2-fold loss compared to 102. Finally, the diastereomer of 74 (105) 
had significantly reduced binding affinity at MOR and KOR. Curiously, the binding affinity at 
DOR was not affected upon this conversion. 
Table 6: Potency and efficacy of 2nd generation benzylic derivatives at MOR, DOR, and KOR. 
Potency and efficacy data were obtained using agonist induced stimulation of [35S] GTPγS 
binding. Potency is represented as EC50 (nM) and efficacy as percent maximal stimulation 
relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 μM. 
Included are analogues 60 and 74 for comparison. All data were from three separate experiments, 
performed in duplicate unless otherwise noted. These data are reported as the average ± standard 
 
Potency, EC50 (nM) Efficacy, (% Stimulation) 
Name Structure MOR DOR KOR MOR DOR KOR 
60 
 
44.4±7.5 DNS >1700 41±12 DNS >40 
101 
 
DNS** DNS* DNS** DNS** DNS* DNS** 
102 
 
333** DNS >6720* 30.7** DNS >65.9* 
103 
 
38±19a DNS*a DNS 55.6±6.3a DNS*a DNS 
104 
 
DNS**a DNSa DNS DNS**a DNSa DNS 
105 
 
DNS DNS** DNS** DNS DNS** DNS** 
74 
 
296±69 DNS DNS 20.2±1.4 DNS DNS 
70 
 
error of the mean. DNS=Does Not Stimulate. * N=2, ** N=1. aData are from assays using human 
MOR and DOR instead of rat MOR and DOR. 
The efficacy and potency of analogues 101-105 were also examined, with analogues 60 
and 74 shown for comparison and are shown in Table 6. The trifluoromethyl analogue 101 did not 
stimulate any of the three opioid receptors. Furthermore, inverting the stereochemistry of 60 
reduced potency at MOR and KOR. The pyridine analogue 103 produced no significant change 
compared to 60, but the inverted stereocenter of 104 eliminated any agonism that may have been 
present in 102. A similar trend was observed upon the inversion of 74 to 105, namely that the 
ligand’s ability to stimulate MOR is lost.  
 
Binding Affinity, Ki (nM) Selectivity 
Name Structure MOR DOR KOR MOR:DOR:KOR 
70 
 
2.8±0.5 23.8±3.3 1180±120 1:8.4:415 
106 
 
0.32±0.14 1.7±0.7 ND 1:5.3:- 
107 
 
5.5±2.2 4.4±0.2 234** 1:0.80:43 
114 
 
13.8±1.0a 1.8±0.4a >393 1:0.16:>28 
Table 7: Binding affinity of 2nd generation aromatic derivatives at MOR, DOR, and KOR. 
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3H] 
diprenorphine in membrane preparations. All data were from three separate experiments, 
performed in duplicate unless otherwise noted. Included is analogue 70 for comparison. These 
data are reported as the average ± standard error of the mean. Selectivity was calculated by 
dividing the Ki of each receptor by the Ki at MOR for a given compound. DNS=Does Not 
Stimulate. ND =No Data. ** N=1. aData are from assays using human MOR and DOR instead of 
rat MOR and DOR. 
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 Table 7 describes the binding affinity of the aromatic derivatives of analogue 70. 
Here, the ortho-fluoro analogue 106 possessed improved binding affinity at MOR and DOR by a 
log unit as compared to 70. Similarly, the meta-fluoro analogue 107 had improved binding affinity 
at DOR and KOR, but not MOR, and was therefore less selective for MOR over DOR and KOR. 
Interestingly, the pyridine analogue 114 improved binding affinity at DOR only, and reduced 
affinity at MOR compared to 70. 
Table 8: Potency and efficacy of 2nd generation aromatic derivatives at MOR, DOR, and KOR. 
Potency and efficacy data were obtained using agonist induced stimulation of [35S] GTPγS 
binding. Potency is represented as EC50 (nM) and efficacy as percent maximal stimulation 
relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 μM. 
Included is analogue 70 for comparison. All data were from three separate experiments, 
performed in duplicate unless otherwise noted. These data are reported as the average ± standard 
error of the mean. DNS=Does Not Stimulate. ND =No Data. ** N=1. aData are from assays 
using human MOR and DOR instead of rat MOR and DOR. 
These aromatic modifications also yielded interesting changes in potency and efficacy at 
MOR and DOR as illustrated in Table 8. The best appears to be the ortho-fluoro analogue 106, 
which yielded a 7-fold improvement in potency at MOR compared to 70 without stimulating DOR. 
Interestingly, moving the fluoro group to the meta-position in 107 had the reverse effect, yielding 
 
Potency, EC50 (nM) Efficacy, (% Stimulation) 
Name Structure MOR DOR KOR MOR DOR KOR 
70 
 
77±10 DNS DNS 65.9±5.2 DNS DNS 
106 
 
10.9±3.0 DNS DNS** 74.8±2.8 DNS DNS** 
107 
 
340±140 1.87** ND 64±11 13.0** ND 
114 
 
216±87a 43±20a DNS 80.5±9.4a 54.6±3.4a DNS 
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a 5-fold loss in potency compared to 70 with some residual DOR agonism. The pyridine analogue 
114 behaved similarly to the meta-fluoro analogue 107 at MOR. However, this analogue had a 
much greater efficacy at DOR. None of these new analogues were able to stimulate KOR.  
Metabolic Stability: A few benzylic modifications were then subjected to stability analyses in 
MLM. These were the trifluoromethyl analogue 101 and the diastereomer of 74 (105) and are 
found in Table 9. The conversion from the methyl group of 60 to the trifluoromethyl of 101 and 
inverting this stereochemistry managed to improve the metabolic stability by a factor of 3, despite 
increasing the cLogP of this ligand by a quarter unit. Furthermore, inverting the benzylic 
stereochemistry of 74 produced a 6-fold improvement in metabolic stability as illustrated by 
compound 105. 
Name Structure T1/2 (min) Verapamil T1/2 (min) Stability Ratio  cLogP 
60 
 
8.5± 0.8 22.6±1.4 0.38±0.04 4.75 
101 
 
29.0±2.2 19.6±1.3 1.4±0.2 5.07 
105 
 
26.4±0.3 14.6±1.0 1.8±0.1 4.53 
74 
 
4.3±0.0 14.6±1.0 0.30±0.02 4.53 
Table 9: Metabolic stability of 2nd generation benzylic derivatives in MLM. Included are the 
compound half-life (T1/2), the half-life of the positive control verapamil, and the stability ratio 
between the compound and the positive control. The stability ratio was calculated by dividing the 
half-life of the analogue of interest by the half-life of the positive control in that assay. Individual 
compounds were tested once, with errors representing the SE in the decay curve regressed onto 
the data collected in 15-minute intervals. Finally, the cLogP of these analogues are included and 
were calculated using PerkinElmer’s ChemDraw® Professional Software. 
 Likewise, the simple aromatic core modifications of 70 were examined for their effects on 
the metabolic stability of our ligands (Table 10). Curiously, the ortho-fluoro modification in 106 
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and its pyridine counterpart 114 managed to cut the stability of these ligands in half. The meta-
fluoro analogue 107 yielded no significant improvements in stability. 
 
Name Structure T1/2 (min) Verapamil T1/2 (min) Stability Ratio  cLogP 
70 
 
23.7±5.9 14.6±1.0 1.6±0.4 4.75 
106 
 
17.5±0.9 19.6±1.3 0.89±0.07 4.83 
107 
 
23.9±1.6 19.6±1.3 1.2±0.1 5.03 
114 
 
20.3±2.6 29.9±4.7 0.7±0.1 4.15 
 Table 10: Metabolic stability of 2nd generation aromatic derivatives in MLM. Included 
are the compound half-life (T1/2), the half-life of the positive control verapamil, and the stability 
ratio between the compound and the positive control. The stability ratio was calculated by 
dividing the half-life of the analogue of interest by the half-life of the positive control in that 
assay. Individual compounds were tested once, with errors representing the SE in the decay 
curve regressed onto the data collected in 15-minute intervals. Finally, the cLogP of these 
analogues are included and were calculated using PerkinElmer’s ChemDraw® Professional 
Software. 
3.3 Discussion and Conclusion 
SAR: Modest modifications to analogue 60 had profound effects on our opioid profile. A simple 
inversion in stereochemistry from 60 to 102 yielded significant losses in binding at all three 
receptors. Given the size of the methyl substituent, this suggests that significant steric factors are 
coming into play and the inversion of this stereocenter is causing the ligand to enter a much less 
favorable conformation that impedes receptor binding. This trend is reflected in the change in 
potency upon this conversion, as the ligand’s ability to induce the receptor’s active state is also 
impaired. The incorporation of fluoro groups (101) onto this methyl group only exacerbates this 
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problem, as its larger size amplifies steric effects and no electronic effects are present to 
compensate and recover the lost binding affinity and potency.  
Curiously, the conversion to a pyridine ring in the core had varying effects on these ligands. 
Comparisons here, however, should be made with caution, as the pyridine analogues 103 and 104 
were tested against human MOR and DOR, whereas their phenyl analogues were tested against rat 
MOR and DOR. Nevertheless, conversion from 60 to 103 resulted in improvements in DOR 
binding and in selectivity of MOR and DOR over KOR. This may be attributed to electronic 
interactions between the pyridine ring of the ligand and DOR. This interaction may translate to the 
improved efficacy of this ligand at MOR, as this pyridine ring can enable MOR to assume a more 
active state. In DOR, this has the reverse effect, enabling binding, but still preventing the adoption 
of the active state. Inversion of the methyl group to 104 has a disruptive effect, possibly due to the 
ligands inability to adopt a conformation that can both accommodate the negative steric effects of 
the new stereocenter and the electronic effects of the pyridine ring. As such, these two factors 
instead work against each other, causing losses in binding affinity across at DOR, and converting 
104 into a MOR antagonist. 
Finally, this loss in binding affinity and potency was further illustrated by the inversion of 
74 to 105. This is true for binding affinity at MOR and KOR, as well as what little potency was 
present in MOR. However, no difference in binding affinity at DOR was observed between these 
two ligands. In fact, 105 is a very selective DOR antagonist. This may be attributed to the methoxy 
group, which may interact with the receptor in a manner that can counteract the effect of the 
inverted stereocenter. It should be noted that within those other analogues that were tested against 
rat DOR (60, 101, and 102), DOR binding was the least affected upon these structural 
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transformations where data is available. Thus, only modest interactions between DOR and the 
methoxy group may be necessary to prevent losses in binding affinity. 
The aromatic core modifications also yielded some interesting effects on the binding 
affinity of these ligands. The ortho-fluoro analogue 106 produced a log improvement in binding 
affinity at MOR and DOR over the unfunctionalized analogue 70. This contrasts with the meta-
fluoro analogue 107 and the ortho pyridine analogue 114, which improved DOR binding, but not 
MOR binding. The large differences in affinity between the ortho- and meta-fluoro analogues at 
MOR suggests that the ortho-analogue is picking up a specific interaction with this receptor rather 
than a more general interaction mediated by lipophilicity or the electronics of the core aromatic 
ring. This contrasts with the binding of these two analogues at DOR, which are more similar to 
each other than to analogue 70, suggesting that the improvement in binding at DOR is a product 
of electronics or lipophilicity. 
The pyridine analogue 114 clarifies whether electronics or lipophilicity is responsible for 
binding at DOR. Since the pyridine analogue is more polar than the two fluoro analogues, 
differences in binding affinity would be expected if lipophilicity is the dominate force. This is not 
the case, as the fluoro analogues and the pyridine analogue have very similar binding affinity to 
each other at DOR. However, since both pyridine rings and fluoro groups make the aromatic core 
more electron poor, it appears that these differences in binding affinity at DOR are driven by 
electronics.  
Many of these trends that are observed at MOR for these ethyl ether analogues are also 
reflected in the efficacy and potency of these ligands. The ortho-fluoro analogue (106) possesses 
a near 8-fold improvement in potency and a 10 % improvement in efficacy compared to 70. When 
compared to the meta-fluoro (107) and pyridine analogues (114), these data suggest that 106 is 
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picking up a specific interaction with the receptor rather than manipulating the electronics or 
polarity of the core aromatic ring. Indeed, fluorine is highly electronegative, and therefore is 
capable of engaging in dipole-dipole interactions.86  
DOR stimulation with the fluoro analogues is practically nonexistent, whereas substantial 
DOR agonism is acquired in the pyridine analogue. This could be a product of the different DOR 
homologs, or the pyridine ring may be picking up a specific interaction with DOR needed to 
activate the receptor. Under this hypothesis, the ortho-fluoro analogue (106) would not be able to 
interact with this receptor in the same way as the pyridine analogue (114) due to the position of 
these groups in space. 
Metabolic Stability: The ligands within this brief series that were subject to metabolism studies 
yielded some surprising results. Regarding the benzylic analogues, metabolism appears to be 
sensitive to the stereochemistry of the benzylic modification. This is illustrated in the difference 
in stability of analogues 74 and 105, which only differ in the stereochemistry of the benzylic 
methyl group. Here, inversion of the stereocenter yields a 6-fold improvement in metabolic 
stability as measured by the stability ratio. This trend is reinforced with the metabolism of 
analogues 60 and 101, which contain different stereocenters. The presence of the trifluoromethyl 
group in 101 does not appear to be a factor in stability in this specific case. These data suggest that 
the methyl group can block metabolism by cytochrome P450 enzymes due to steric effects if it has 
the appropriate stereochemistry. Conversely, when the stereocenter is inverted, the steric effect is 
removed, and the methyl group instead facilitates metabolism through stabilization of the free 
radical intermediate. 
 Curiously, the aromatic core analogues did not yield the stability improvements we 
anticipated. Blocking possible metabolic sites with fluoro groups in 106 and 107 appeared to 
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instead reduce stability as compared to 70. This suggests that the aromatic core is not a site of 
further metabolism and that losses in stability may be a product of increased cLogP. However, this 
is inconsistent with the reduced stability of the pyridine analogue 114, which possesses a lower 
cLogP than 70. The reduced stability here may instead be explained by electronic effects on the 
adjacent ethyl ether. In the previous chapter, we postulated that the ethers improved stability in 
part by sterically blocking metabolism on the benzylic position linking the dimethyltyrosine 
residue to the rest of the peptidomimetic. This did not mean that the ether itself was not labile, as 
metabolism here could be mitigated through the incorporation of a cyclopropyl methyl group 
(analogue 72). If the ethyl ether then is still metabolically labile, it is possible that the fluoro and 
pyridine groups are facilitating metabolism of the adjacent ether through stabilization of the phenol 
as illustrated in Figure 10. 
 
Figure 10: Proposed CYP450 reaction mechanism on both A) 70 and B) analogues that possess 
an electron-withdrawing group (106, 107, 114). 
Conclusion: The exploration of these simple modifications to analogues 60 and 70 yielded new 
insights into the opioid SAR of this series, in addition to their metabolic stability. We further 
confirmed that the benzylic position is a metabolic hotspot, and that metabolism at this position 
differs based on the stereochemistry of substituents at this position as illustrated by analogues 74 
and 105. However, any improvements in stability through modulation of this stereochemistry are 
associated with losses in the capability of these ligands to stimulate MOR. The introduction of 
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electron withdrawing groups into the core aromatic ring proved to be tolerated in terms of 
maintaining the ability to stimulate MOR. This is particularly true for the ortho-fluoro analogue 
106, which produced a near log improvement in MOR-potency and affinity over analogue 70. 
However, these electron withdrawing groups surprisingly reduced the metabolic stability of these 
ligands where tested, likely through facilitation of cleavage of the adjacent ethyl ether. 
 While the derivatives presented here provided some valuable insights into SAR profile both 
in terms of improving stability or improving MOR stimulation, these two effects did not occur 
simultaneously. Improvements in stability here resulted in losses in MOR stimulation, and 
improvements in MOR stimulation resulted in losses in stability. These data suggest that further 
modifications to the aromatic core of these peptidomimetics are unlikely to be fruitful for both 
improving MOR stimulation and metabolic stability. As such, we sought instead to pursue further 
derivatization elsewhere in our peptidomimetics in the next chapter. 
3.4 Experimental 
Chemistry 
General Methods: All reagents and solvents were obtained commercially and were used 
without further purification. Intermediates were purified by flash chromatography using a Biotage 
Isolera One instrument. Most purification methods utilized a hexanes/ethyl acetate solvent system 
in a Biotage SNAP KP-Sil column, with a linear gradient between 0 and 100% ethyl acetate. 
Reverse phase column chromatography using a linear gradient of 0 % to 100 % solvent B (0.1 % 
TFA in acetonitrile) in solvent A (0.1 % TFA in water) using a Biotage SNAP Ultra C18 column 
was utilized for some intermediate amine salts. Purification of final compounds was performed 
using a Waters semipreparative HPLC with a Vydac protein and peptide C18 reverse phase 
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column, using a linear gradient of 0 % to 100 % solvent B in solvent A at a rate 1 % per minute, 
monitoring UV absorbance at 230 nm. The purity of final compounds was assessed using a Waters 
Alliance 2690 analytical HPLC instrument with a Vydac protein and peptide C18 reverse phase 
column. A linear gradient (gradient A) of 0 % to 70 % solvent B in solvent A in 70 min, measuring 
UV absorbance at 230 nm was used to determine purity. All final compounds used for testing were 
≥95 % pure, as determined by analytical HPLC. 1H NMR and 13C NMR data were obtained on a 
500 or 400 MHz Varian spectrometer using CDCl3 or CD3OD solvents. The identities of final 
compounds were verified by mass spectrometry using an Agilent 6130 LC–MS mass spectrometer 
in the positive ion mode, or an Agilent 6230 TOF HPLC-MS in the positive ion mode. Suzuki 
couplings using microwave irradiation were performed on a Discover S-class (CEM) microwave 
in a closed vessel with maximum power input of 300 W and temperature set to 100 °C for 30 min 
under the standard method using their Synergy software.  
General Procedure for Ellman Reductions (Procedure A): A flamed-dried round bottom 
flask containing 1 equivalent of aldehyde or ketone and 1.5 or 3 equivalents of (R)-(+)-2-methyl-
propane-2-sulfinamide was attached to a reflux condenser and flushed with argon. 4 mL of THF 
was added and cooled to 0 °C. 3.8, 6, or 7.5 equivalents of titanium (IV) ethoxide was added, 
followed by an additional 4 mL of THF. The solution was stirred and heated to 75 °C overnight 
with TLC monitoring until all ketone or aldehyde was consumed. A separate flame-dried flask 
containing 6 or 6.5 equivalents of sodium borohydride was flushed with argon. 4 mL of THF was 
added, at which point the solution was cooled to -78 °C. The solution containing Ellman adduct 
was cooled to room temperature and slowly transferred to the sodium borohydride solution via 
syringe. This final solution was then allowed to warm to room temperature and stirred for 2 hours, 
at which point the reaction mixture was quenched with methanol to consume the sodium 
80 
 
borohydride, followed by DI water to precipitate the titanium. The solution was vacuum filtered, 
and the precipitate was washed with ethyl acetate. The filtrate was then concentrated in vacuo and 
purified via column chromatography (0-100 % EtOAc in Hexanes). 
General Procedure for Suzuki Couplings Using Microwave Irradiation (Procedure Ba): 
To a microwave vessel containing the protected amine was added 1.7 equivalents of benzylboronic 
acid pinacol ester, 2.8 equivalents of potassium carbonate, and 0.11 equivalents of 1,1′-
bis(diphenylphosphino)ferrocene] dichloropalladium. The vessel was purged with argon and 2.5 
mL of degassed 3:1 acetone:water was added. The vessel was then subject to microwave irradiation 
to a temperature of 100 °C for 30 min. The solution was cooled, partitioned between brine and 
ethyl acetate, and extracted with ethyl acetate. The organic layer was then dried with magnesium 
sulfate, filtered, and concentrated in vacuo. Column chromatography was then performed (0-100 
% ethyl acetate in hexanes), yielding the desired Suzuki coupled derivatives. 
General Procedure for Suzuki Couplings without Microwave Irradiation (Procedure Bb): 
To a round bottom flask containing protected amine, 1.8 equivalents of potassium carbonate, and 
0.1 equivalents of 1,1′-bis(diphenylphosphino)ferrocene] dichloropalladium was added 1.3 
equivalents of benzylboronic acid pinacol ester. The flask was equipped with a reflux condenser, 
purged with argon, and 5 mL of degassed 3:1 acetone:water was added. The vessel was then heated 
to a temperature of 80 °C overnight. The solution was cooled, partitioned between brine and ethyl 
acetate, and extracted with ethyl acetate. The organic layer was then dried with magnesium sulfate, 
filtered, and concentrated in vacuo. Column chromatography was then performed (0-100 % ethyl 
acetate in hexanes), yielding the desired Suzuki coupled derivatives. 
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General Procedure for Removal of Ellman’s chiral sulfonamide or Boc groups (Procedure 
C): To a flask containing Ellman or Boc protected amine was added 2 mL of Dioxane and 0.2 mL 
concentrated HCl. The solution was stirred at room temperature for 1 minute and concentrated in 
vacuo. The ensuing salt was then purified via one of two methods. If the product is insoluble in 
diethyl ether, it was triturated with diethyl ether, and the precipitate was concentrated in vacuo to 
dryness, yielding the product as an HCl salt. 
General Procedure for the Coupling of 2’,6’-Dimethyltyrosine to Functionalized Amine 
Salt (Procedure D): To a dried flask containing the amine salt under argon was added 3 mL of 
DMF and 10 equivalents of Hunig’s base. 1 equivalent of PyBOP and 1 equivalent of 6-Cl-HOBt 
was added, followed by 1 equivalent of N-Boc-O-Boc-2’,6’-dimethyl-L-tyrosine in 1.5 mL DMF. 
The solution was stirred overnight at room temperature and concentrated in vacuo. 2 mL of TFA 
and 2 mL of DCM were then added, and the solution was stirred for an additional hour. The 
reaction mixture was concentrated in vacuo and purified via semipreparative reverse phase HPLC 
(0.1% TFA in water: 0.1% TFA in acetonitrile). The product was concentrated in vacuo and 
lyophilized overnight to yield the final peptidomimetic. 
General Procedure for the Synthesis of 6-position Ethers (Procedure E): To a flame dried 
flask containing phenolic aldehyde or ketone was added 2 or 3 equivalents of potassium carbonate. 
The flask was purged with argon and 4 mL of DMF was added. 3 or 4 equivalents of an alkyl 
iodide or bromide was then added, and the solution was stirred at room temperature overnight. The 
solution was then concentrated in vacuo, partitioned between ethyl acetate and saturated sodium 
bicarbonate, and extracted with ethyl acetate. The organic layers were combined, dried with 
magnesium sulfate, filtered, and concentrated in vacuo, yielding the desired ether. 
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General Procedure for the Synthesis of 2-ethoxynicotinamide (Procedure F): To a flame 
dried flask containing 2-ethoxynicotinic acid was added 1.2 equivalents of PyBOP and 1.1 
equivalents of NH4Cl. The flask was flushed with argon, at which point 4.1 mL of DMF and 9.9 
equivalents of NMM were added. The reaction was allowed to stir overnight and was concentrated 
in vacuo. The residue was then partitioned between sat. NaHCO3 and EtOAc and extracted with 
EtOAc. The organic layers were combined, dried with MgSO4, filtered and concentrated in vacuo. 
The residue was then purified via column chromatography (0 to 100 % EtOAc in Hexanes) 
yielding the desired amide. 
 General Procedure for the Synthesis of tert-butyl ((2-ethoxypyridin-3-
yl)methyl)carbamate (Procedure G): To a flame dried flask under argon equipped with a reflux 
condenser containing 2-ethoxynicotinamide was added 7 equivalents of 2 M BH3*Me2S in THF 
and 4 mL of THF. The solution was heated to 75 °C for 3 hours, at which point the reaction was 
quenched with methanol and heated for an additional 15 minutes. The solution was concentrated 
in vacuo, acidified using 1 M HCl, and concentrated in vacuo again. The residue was dried in the 
same pot in a vacuum desiccator, at which point 1.2 equivalents of Boc2O was added and the flask 
was purged with argon. 3.3 equivalents of TEA and 4 mL of THF were added and the reaction was 
stirred overnight. An additional 2.4 equivalents of Boc2O were added and the reaction was stirred 
for an additional day. The solution was then partitioned between sat. NaHCO3 and EtOAc and 
extracted with EtOAc. The organic layers were then collected, dried with MgSO4, filtered, and 
concentrated in vacuo. The residue was then purified yielding column chromatography (2:1 
Hexanes:EtOAc), yielding the Boc-protected amine. 
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 General Procedure for the Synthesis of tert-butyl ((5-bromo-2-ethoxypyridin-3-
yl)methyl)carbamate (Procedure H): To a flame dried flask equipped with tert-butyl ((2-
ethoxypyridin-3-yl)methyl)carbamate was added 1 equivalent of NBS. The flask was equipped 
with a condenser and purged under argon. 5 mL of MeCN was added and the solution was heated 
to 80 °C overnight. The solution was cooled and concentrated in vacuo. The residue was then 
purified using column chromatography (2:1 Hexanes:EtOAc), yielding the brominated compound. 
5-bromo-2-ethoxy-3-fluorobenzaldehyde (79): See Procedure E: 106 mg (0.48 mmol) 5-
bromo-3-fluoro-2-hydroxybenzaldehyde (77), 271 mg (2.0 mmol, 4.1 eq.) of K2CO3, 0.11 mL 
(161 mg, 1.5 mmol, 3.0 eq.) of EtBr, 4 mL of DMF. Compound 79 (107 mg, 86 % yield) was 
isolated as a light brown oil. 1H NMR (500 MHz, Chloroform-d) δ 10.32 (s, 1H), 7.70 (dd, J = 2.5, 
1.5 Hz, 1H), 7.45 (dd, J = 10.9, 2.5 Hz, 1H), 4.31 (qd, J = 7.1, 1.8 Hz, 2H), 1.42 (td, J = 7.0, 0.8 
Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 187.55, 187.52, 156.11, 154.08, 148.68, 148.60, 
130.99, 130.97, 126.16, 126.13, 125.79, 125.62, 115.17, 115.10, 71.08, 71.03, 15.37, 15.36. 
5-bromo-2-ethoxy-4-fluorobenzaldehyde (80): See Procedure E: 150 mg (0.68 mmol) 5-
bromo-4-fluoro-2-hydroxybenzaldehyde (78), 289 mg (2.1 mmol, 3.1 eq.) of K2CO3, 0.15 mL 
(219 mg, mmol, 2.0 eq.) of EtBr, 4 mL of DMF. Compound 80 (136 mg, 80 % yield) was isolated 
as a white solid. 1H NMR (400 MHz, Chloroform-d) δ 10.31 (s, 1H), 8.00 (d, J = 8.1 Hz, 1H), 6.75 
(d, J = 10.2 Hz, 1H), 4.12 (q, J = 7.0 Hz, 2H), 1.49 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, 
Chloroform-d) δ 187.17, 187.16, 187.15, 187.14, 164.65, 162.10, 161.90, 161.81, 133.25, 133.23, 
133.21, 133.20, 101.81, 101.79, 101.54, 101.52, 100.55, 100.32, 65.08, 65.07, 14.39. 
 (R)-N-((R)-1-(3-bromophenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfinamide 
(81): See Procedure A: Step 1: 60 µL (98 mg, 0.39 mmol) of 1-(3-bromophenyl)-2,2,2-
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trifluoroethan-1-one (75), 78 mg (0.64 mmol, 1.7 eq.) of (R)-(+)-2-methyl-propane-2-
sulfinamide, 310 µL (337 mg, 1.5 mmol, 3.8 eq.) of Ti(OEt)4, and 3+3 mL THF. Step 2: 94 mg 
(2.5 mmol, 6.4 eq.) of sodium borohydride in 3 mL THF. Compound 81 (69 mg) was isolated as 
a colorless oil and continued without further purification.  
 (S)-N-((S)-1-(3-benzylphenyl)ethyl)-2-methylpropane-2-sulfinamide (88): See 
Procedure A: Step 1: 63 mg (0.30 mmol) of 82, 114 mg (0.94 mmol, 3.1 eq.) of (S)-(-)-2-methyl-
propane-2-sulfinamide, 380 µL (413 mg, 1.8 mmol, 6.0 eq.) of Ti(OEt)4, and 3+3 mL THF. Step 
2: 68 mg (1.8 mmol, 6.0 eq.) of sodium borohydride in 3 mL THF. Compound 88 (76 mg, 80 % 
yield) was isolated as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.32 – 7.25 (m, 3H), 
7.23 – 7.16 (m, 5H), 7.12 (d, J = 7.6 Hz, 1H), 4.52 (qd, J = 6.5, 2.6 Hz, 1H), 3.99 (s, 2H), 3.41 (d, 
J = 2.6 Hz, 1H), 1.50 (d, J = 6.5 Hz, 3H), 1.22 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 
144.31, 141.68, 140.77, 128.93, 128.88, 128.50, 128.35, 127.23, 126.15, 124.22, 55.43, 53.79, 
41.88, 22.79, 22.63. 
(S)-N-((S)-1-(5-benzylpyridin-3-yl)ethyl)-2-methylpropane-2-sulfinamide (89): See 
Procedure A: Step 1: 61 mg (0.29 mmol) of 83, 111 mg (0.92 mmol, 3.2 eq.) of (S)-(-)-2-methyl-
propane-2-sulfinamide, 370 µL (403 mg, 1.8 mmol, 6.1 eq.) of Ti(OEt)4, and 3+3 mL THF. Step 
2: 68 mg (1.8 mmol, 6.2 eq.) of sodium borohydride in 3 mL THF. Compound 89 (52 mg, 57 % 
yield) was isolated as a yellow oil. 1H NMR (500 MHz, Chloroform-d) δ 8.43 (s, 1H), 8.38 (s, 1H), 
7.70 (s, 1H), 7.37 – 7.30 (m, 2H), 7.30 – 7.24 (m, 1H), 7.19 – 7.12 (m, 2H), 4.55 (qd, J = 6.7, 4.8 
Hz, 1H), 4.02 (s, 2H), 3.49 (d, J = 4.3 Hz, 1H), 1.53 (d, J = 6.7 Hz, 3H), 1.20 (s, 9H). 13C NMR 
(126 MHz, Chloroform-d) δ 146.76, 143.83, 141.85, 139.53, 138.06, 137.57, 129.11, 128.87, 
127.24, 56.03, 51.93, 38.73, 22.59, 22.50. 
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(R)-N-((R)-1-(5-benzylpyridin-3-yl)ethyl)-2-methylpropane-2-sulfinamide (90): See 
Procedure A: Step 1: 38 mg (0.18 mmol) of 83, 67 mg (0.55 mmol, 3.1 eq.) of (R)-(+)-2-methyl-
propane-2-sulfinamide, 230 µL (250 mg, 1.1 mmol, 6.1 eq.) of Ti(OEt)4, and 3+3 mL THF. Step 
2: 44 mg (1.2 mmol, 6.5 eq.) of sodium borohydride in 3 mL THF. Compound 90 (10 mg, 17 % 
yield) was isolated as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 8.44 (s, 1H), 8.39 (s, 
1H), 7.70 (s, 1H), 7.37 – 7.32 (m, 2H), 7.30 – 7.27 (m, 1H), 7.19 – 7.13 (m, 2H), 4.56 (qd, J = 6.6, 
4.4 Hz, 1H), 4.03 (s, 2H), 3.42 (d, J = 4.2 Hz, 1H), 1.54 (d, J = 6.7 Hz, 3H), 1.21 (s, 9H). 13C 
NMR (126 MHz, Chloroform-d) δ 146.80, 143.83, 141.83, 139.54, 138.04, 137.53, 129.12, 
128.87, 127.27, 56.02, 51.90, 38.74, 22.58, 22.49. 
(S)-N-((S)-1-(5-bromo-2-methoxyphenyl)ethyl)-2-methylpropane-2-sulfinamide (84): 
See Procedure A: Step 1: 208 mg (0.91 mmol) of 14, 336 mg (2.8 mmol, 3.1 eq.) of (S)-(-)-2-
methyl-propane-2-sulfinamide, 1450 µL (1578 mg, 6.9 mmol, 7.6 eq.) of Ti(OEt)4, 4+4 mL THF. 
Step 2: 206 mg (5.4 mmol, 6.0 eq.) of sodium borohydride in 4 mL THF. Compound 84 (242 mg, 
80 % yield) was isolated as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.34 (d, J = 2.4 
Hz, 1H), 7.28 (dd, J = 8.7, 2.5 Hz, 1H), 6.71 (d, J = 8.7 Hz, 1H), 4.71 (p, J = 6.5 Hz, 1H), 3.78 (s, 
3H), 1.41 (d, J = 6.7 Hz, 3H), 1.17 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 155.55, 134.51, 
131.05, 129.70, 113.02, 112.60, 55.58, 49.54, 23.62, 22.55, 21.73. 
(R)-N-(5-bromo-2-ethoxy-3-fluorobenzyl)-2-methylpropane-2-sulfinamide (85): See 
Procedure A: Step 1: 105 mg (0.43 mmol) of 77, 156 mg (1.3 mmol, 3.0 eq.) of (R)-(+)-2-methyl-
propane-2-sulfinamide, 670 µL (729 mg, 3.2 mmol, 7.5 eq.) of Ti(OEt)4, and 3+3 mL THF. Step 
2: 97 mg (2.6 mmol, 6.0 eq.) of sodium borohydride in mL 3 THF. Compound 85 (91 mg, 60 % 
yield) was isolated as a white solid on standing. 1H NMR (400 MHz, Chloroform-d) δ 7.23 (td, J 
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= 1.6, 0.7 Hz, 1H), 7.18 (dd, J = 10.8, 2.4 Hz, 1H), 4.37 (dd, J = 14.4, 5.5 Hz, 1H), 4.23 – 4.13 (m, 
3H), 3.64 (t, J = 6.7 Hz, 1H), 1.38 (td, J = 7.0, 0.8 Hz, 3H), 1.23 (s, 9H). 13C NMR (101 MHz, 
Chloroform-d) δ 156.21, 153.71, 143.75, 134.92, 134.89, 127.49, 127.46, 119.86, 119.63, 114.65, 
114.56, 69.73, 56.05, 44.43, 44.40, 22.61, 15.70. 
(R)-N-(5-bromo-2-ethoxy-4-fluorobenzyl)-2-methylpropane-2-sulfinamide (86): See 
Procedure A: Step 1: 122 mg (0.50 mmol) of 78, 89 mg (0.73 mmol, 1.5 eq.) of (R)-(+)-2-methyl-
propane-2-sulfinamide, 390 µL (424 mg, 1.9 mmol, 3.8 eq.) of Ti(OEt)4, and 3+3 mL THF. Step 
2: 112 mg (3.0 mmol, 6.0 eq.) of sodium borohydride in 3 mL THF. Compound 86 (111 mg, 64 % 
yield) was isolated as a waxy white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.39 (d, J = 7.8 
Hz, 1H), 6.63 (d, J = 10.2 Hz, 1H), 4.30 (dd, J = 14.4, 5.7 Hz, 1H), 4.12 (dd, J = 14.3, 7.4 Hz, 1H), 
4.00 (q, J = 6.9 Hz, 2H), 3.70 (t, J = 6.8 Hz, 1H), 1.42 (t, J = 6.8 Hz, 3H), 1.21 (s, 9H). 13C NMR 
(126 MHz, Chloroform-d) δ 159.96, 158.00, 156.97, 156.90, 132.88, 132.87, 124.76, 124.73, 
100.84, 100.63, 98.35, 98.19, 64.34, 55.94, 44.54, 22.58, 14.61. 
(R)-N-((R)-1-(3-benzylphenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfinamide 
(87): See Procedure Ba: 67 mg (0.19 mmol) of 81, 70 µL (69 mg, 0.31 mmol, 1.7 eq.) of benzyl 
boronic acid pinacol ester, 74 mg (0.54 mmol, 2.9 eq.) of potassium carbonate, 14 mg (0.019 
mmol, 0.10 eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 1.8 mL of acetone, 
and 0.6 mL of water. Compound 87 (32 mg, 46 % yield) was isolated as a yellow oil. 1H NMR 
(500 MHz, Chloroform-d) δ 7.38 – 7.13 (m, 9H), 4.82 (qd, J = 7.3, 3.8 Hz, 1H), 4.00 (s, 2H), 1.23 
(s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 141.77, 140.40, 131.70, 130.35, 129.77, 128.94, 
128.83, 128.52, 128.51, 127.14, 126.24, 60.81, 60.57, 60.32, 60.08, 56.36, 53.79, 41.67, 22.30. 
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1-(3-benzylphenyl)ethan-1-one (82): See Procedure Bb: 150 µL (226 mg, 1.1 mmol) of 
1-(3-bromophenyl)ethan-1-one  (2), 320 µL (314 mg, 1.4 mmol, 1.3 eq.) of benzyl boronic acid 
pinacol ester, 280 mg (2.0 mmol, 1.8 eq.) of potassium carbonate, 77 mg (0.11 mmol, 0.093 eq.) 
of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 4 mL of 3:1 Acetone:Water. 
Compound 82 (176 mg, 74 % yield) was isolated as a colorless oil. 1H NMR (500 MHz, 
Chloroform-d) δ 7.86 (s, 1H), 7.82 (dt, J = 6.8, 1.9 Hz, 1H), 7.43 – 7.37 (m, 2H), 7.32 (dd, J = 8.2, 
6.9 Hz, 2H), 7.26 – 7.20 (m, 3H), 4.06 (s, 2H), 2.59 (s, 3H). 13C NMR (126 MHz, Chloroform-d) 
δ 198.17, 141.74, 140.45, 137.41, 133.74, 128.91, 128.76, 128.67, 128.65, 126.38, 126.37, 41.80, 
26.69. 
1-(5-benzylpyridin-3-yl)ethan-1-one (83): See Procedure Bb: 146 mg (0.73 mmol) of 1-
(5-bromopyridin-3-yl)ethan-1-one (76), 210 µL (206 mg, 0.94 mmol, 1.3 eq.) of benzyl boronic 
acid pinacol ester, 179 mg (1.3 mmol, 1.8 eq.) of potassium carbonate, 50 mg (0.068 mmol, 0.094 
eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 5 mL of 3:1 acetone:water. 
Compound 83 (141 mg, 91 % yield) was isolated as an orange oil. 1H NMR (500 MHz, 
Chloroform-d) δ 8.96 (d, J = 2.1 Hz, 1H), 8.62 (d, J = 2.2 Hz, 1H), 8.00 (t, J = 2.2 Hz, 1H), 7.26 
(dd, J = 8.1, 6.7 Hz, 2H), 7.19 (tt, J = 7.1, 1.4 Hz, 1H), 7.17 – 7.11 (m, 2H), 4.00 (s, 2H), 2.55 (s, 
3H). 13C NMR (126 MHz, Chloroform-d) δ 196.79, 153.84, 147.75, 138.99, 136.89, 135.55, 
132.14, 128.82, 128.76, 126.74, 38.84, 26.78. 
(S)-N-((S)-1-(5-benzyl-2-methoxyphenyl)ethyl)-2-methylpropane-2-sulfinamide (91): 
See Procedure Ba: 142 mg (0.43 mmol) of 84, 160 µL (157 mg, 0.72 mmol, 1.7 eq.) of benzyl 
boronic acid pinacol ester, 160 mg (1.2 mmol, 2.7 eq.) of potassium carbonate, 31 mg (0.042 
mmol, 0.10 eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 2.4 mL of 3:1 
88 
 
acetone:water. Compound 91 (87 mg, 59 % yield) was isolated as a colorless oil. 1H NMR (500 
MHz, Chloroform-d) δ 7.30 – 7.25 (m, 2H), 7.20 – 7.15 (m, 3H), 7.10 (d, J = 2.2 Hz, 1H), 7.03 
(dd, J = 8.2, 2.2 Hz, 1H), 6.79 (d, J = 8.4 Hz, 1H), 4.77 (p, J = 6.3 Hz, 1H), 3.93 (s, 2H), 3.81 (s, 
3H), 3.79 (d, J = 5.2 Hz, 1H), 1.45 (d, J = 6.7 Hz, 3H), 1.19 (s, 9H). 13C NMR (126 MHz, 
Chloroform-d) δ 154.88, 141.34, 133.29, 132.20, 128.96, 128.59, 128.40, 127.36, 125.97, 110.85, 
55.44, 55.39, 49.85, 41.09, 22.60, 21.81. 
(R)-N-(5-benzyl-2-ethoxy-3-fluorobenzyl)-2-methylpropane-2-sulfinamide (92): See 
Procedure Bb: 67 mg (0.20 mmol) of 85, 60 µL (59 mg, 0.27 mmol, 1.3 eq.) of benzyl boronic 
acid pinacol ester, 52 mg (0.38 mmol, 1.9 eq.) of potassium carbonate, 14 mg (0.019 mmol, 0.095 
eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 5 mL of 3:1 acetone:water. 
Compound 92 (42 mg, 61 % yield) was isolated as a white solid on standing. 1H NMR (500 MHz, 
Chloroform-d) δ 7.29 (t, J = 7.4 Hz, 2H), 7.21 (tt, J = 6.5, 1.4 Hz, 1H), 7.17 (d, J = 6.9 Hz, 2H), 6.90 (s, 
1H), 6.83 (dd, J = 12.2, 2.1 Hz, 1H), 4.38 (dd, J = 13.9, 5.1 Hz, 1H), 4.21 – 4.07 (m, 3H), 3.90 (s, 2H), 3.65 
(dd, J = 8.0, 5.1 Hz, 1H), 1.38 (t, J = 7.1 Hz, 3H), 1.19 (s, 10H). 13C NMR (126 MHz, Chloroform-d) δ 
156.08, 154.11, 142.78, 142.69, 140.25, 136.91, 136.86, 133.05, 133.03, 128.89, 128.57, 126.34, 124.77, 
124.75, 116.61, 116.46, 69.62, 69.57, 55.88, 44.83, 44.80, 41.14, 41.12, 22.60, 15.74. 
(R)-N-(5-benzyl-2-ethoxy-4-fluorobenzyl)-2-methylpropane-2-sulfinamide (93): See 
Procedure Ba: 65 mg (0.19 mmol) of 86, 70 µL (69 mg, 0.31 mmol, 1.7 eq.) of benzyl boronic 
acid pinacol ester, 72 mg (0.52 mmol, 2.8 eq.) of potassium carbonate, 15 mg (0.021 mmol, 0.11 
eq.) of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 2.5 mL of 3:1 acetone:water. 
Compound 93 (49 mg, 73 % yield) was isolated as a yellow oil. 1H NMR (500 MHz, Chloroform-
d) δ 7.29 – 7.26 (m, 2H), 7.22 – 7.16 (m, 3H), 7.01 (d, J = 8.6 Hz, 1H), 6.57 (d, J = 11.6 Hz, 1H), 
4.32 (dd, J = 13.9, 5.4 Hz, 1H), 4.08 (dd, J = 13.9, 7.9 Hz, 1H), 4.00 (q, J = 7.0 Hz, 2H), 3.91 (s, 
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2H), 3.62 (dd, J = 8.0, 5.4 Hz, 1H), 1.42 (t, J = 7.0 Hz, 3H), 1.17 (s, 9H). 13C NMR (126 MHz, 
Chloroform-d) δ 161.66, 159.70, 156.23, 156.15, 140.17, 131.25, 131.19, 128.66, 128.47, 126.13, 
122.81, 119.10, 118.97, 99.73, 99.52, 63.99, 55.76, 44.96, 34.08, 34.06, 22.57, 14.75. 
(R)-1-(3-benzylphenyl)-2,2,2-trifluoroethan-1-aminium chloride (94): See Procedure 
C: 32 mg (0.087 mmol) of 87, 0.4 mL HCl conc., 2 mL dioxane. Compound 94 (21 mg, 80 % 
yield) was isolated as a white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.48 – 7.39 (m, 4H), 7.30 
– 7.25 (m, 2H), 7.23 – 7.16 (m, 3H), 5.32 (q, J = 7.5 Hz, 1H), 4.05 (s, 2H). 13C NMR (126 MHz, 
Methanol-d4) δ 143.20, 140.40, 131.19, 129.29, 128.72, 128.48, 128.21, 125.97, 125.80, 55.37, 
55.11, 48.43, 41.11. 
(S)-1-(3-benzylphenyl)ethan-1-aminium chloride (95): See Procedure C: 76 mg (0.24 
mmol) of 88, 0.2 mL HCl conc., 2 mL dioxane. Compound 95 (56 mg, 94 % yield) was isolated 
as a white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.39 – 7.34 (m, 2H), 7.31 (dt, J = 7.7, 1.5 
Hz, 1H), 7.28 – 7.20 (m, 5H), 7.19 – 7.14 (m, 1H), 4.42 (q, J = 6.9 Hz, 1H), 4.01 (s, 2H), 1.61 (d, 
J = 7.1 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 142.63, 140.82, 138.44, 129.29, 129.01, 
128.51, 128.14, 126.84, 125.82, 123.91, 50.96, 41.30, 19.43. 
(S)-3-(1-ammonioethyl)-5-benzylpyridin-1-ium chloride (96): See Procedure C: 52 mg 
(0.16 mmol) of 89, 0.2 mL HCl conc., 2 mL dioxane. Compound 96 was isolated as a tan oil and 
used without further purification. 1H NMR (500 MHz, Methanol-d4) δ 8.98 (s, 1H), 8.84 (s, 1H), 
8.77 (s, 1H), 7.38 – 7.26 (m, 5H), 4.84 (s, 1H), 4.32 (s, 2H), 1.75 (d, J = 5.4 Hz, 3H). 13C NMR 
(126 MHz, Methanol-d4) δ 145.64, 143.10, 141.48, 138.76, 138.26, 137.54, 128.98, 128.87, 
127.02, 37.86, 20.11, 18.48. 
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(R)-3-(1-ammonioethyl)-5-benzylpyridin-1-ium chloride (97): See Procedure C: 10 mg 
(0.18 mmol) of 90, 0.2 mL HCl conc., 2 mL dioxane. Compound 97 (6 mg, 67 % yield) was 
isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 8.92 (s, 1H), 8.84 (s, 1H), 8.66 (s, 
1H), 7.42 – 7.32 (m, 4H), 7.32 – 7.22 (m, 1H), 4.80 (q, J = 6.9 Hz, 1H), 4.30 (s, 2H), 1.72 (d, J = 
6.9 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 146.66, 145.01, 143.01, 141.76, 138.84, 137.48, 
128.85, 128.83, 127.04, 37.74, 20.04, 18.27. 
(S)-1-(5-benzyl-2-methoxyphenyl)ethan-1-aminium chloride (98): See Procedure D: 87 
mg (0.25 mmol) of 91, 0.4 mL HCl conc., 2 mL dioxane. Compound 98 was continued without 
further purification.  
 (5-benzyl-2-ethoxy-3-fluorophenyl)methanaminium chloride (99): See 
Procedure C: 42 mg (mmol) of 92, 0.2 mL HCl conc., 2 mL dioxane. Compound 99 (30 mg, 88 % 
yield) was isolated as a white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.30 – 7.26 (m, 2H), 7.23 
– 7.17 (m, 3H), 7.09 – 7.04 (m, 2H), 4.24 (qd, J = 7.1, 1.6 Hz, 2H), 4.11 (s, 2H), 3.94 (s, 2H), 1.40 
(td, J = 7.0, 0.7 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 155.56, 153.59, 140.31, 138.02, 
137.96, 128.46, 128.23, 126.01, 125.50, 125.48, 118.12, 117.97, 69.60, 69.54, 40.36, 40.35, 38.24, 
38.22, 14.52. 
 (5-benzyl-2-ethoxy-4-fluorophenyl)methanaminium chloride (100): See 
Procedure C: 49 mg (mmol) of 93, 0.4 mL HCl conc., 2 mL dioxane. Compound 100 (36 mg, 90 
% yield) was isolated as an off white solid. 1H NMR (500 MHz, .-d4) δ 7.28 – 7.22 (m, 3H), 7.20 
(d, J = 7.5 Hz, 2H), 7.16 (t, J = 7.1 Hz, 1H), 6.86 (d, J = 11.7 Hz, 1H), 4.13 (q, J = 6.9 Hz, 2H), 
4.04 (s, 2H), 3.93 (s, 2H), 1.45 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 162.93, 
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160.97, 156.91, 156.82, 140.02, 132.76, 132.70, 128.22, 128.11, 125.85, 119.90, 119.76, 116.87, 
116.85, 99.85, 99.63, 64.34, 38.23, 33.39, 33.37, 13.42. 
 (S)-1-(((R)-1-(3-benzylphenyl)-2,2,2-trifluoroethyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (101): See Procedure D: Step 1: 20 
mg (0.066 mmol) of 94, 140 µL (104 mg, 0.80 mmol, 12 eq.) of N,N-diisopropylethylamine, 42 
mg (0.081 mmol, 1.2 eq.) of PyBOP, 15 mg (0.088 mmol, 1.3 eq.) of 6-Cl-HOBt, 34 mg (0.083 
mmol, 1.3 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 
2 mL DCM. Compound 101 (4 mg, 11 % yield) was isolated as a white solid. 1H NMR (500 MHz, 
Methanol-d4) δ 7.29 – 7.22 (m, 4H), 7.21 – 7.14 (m, 3H), 6.98 (s, 1H), 6.85 – 6.79 (m, 1H), 6.13 
(s, 2H), 5.59 (q, J = 8.3, 7.4 Hz, 1H), 4.05 – 3.93 (m, 4H), 3.09 (dd, J = 13.8, 11.7 Hz, 1H), 2.93 
(dd, J = 13.8, 4.2 Hz, 1H), 1.94 (s, 6H). No 13C Data Acquired.  ESI-MS: 457.3 [M + H]+, HPLC 
(gradient A): Retention Time: 40.42 min. 
 (S)-1-(((S)-1-(3-benzylphenyl)ethyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-
oxopropan-2-aminium trifluoroacetate (102): See Procedure D: Step 1: 27 mg (0.11 mmol) of 
95, 190 µL (141 mg, 1.1 mmol, 10 eq.) of N,N-diisopropylethylamine, 61 mg (0.12 mmol, 1.1 eq.) 
of PyBOP, 20 mg (0.12 mmol, 1.1 eq.) of 6-Cl-HOBt, 47 mg (0.11 mmol, 1.1 eq.) of Boc-O-Boc-
L-2’,6’-dimethyltyrosine, 3+1 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. Compound 102 
(mg, % yield) was isolated as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (s, 1H), 8.43 
(d, J = 8.1 Hz, 1H), 8.32 (br s, 3H), 7.29 – 7.22 (m, 2H), 7.21 – 7.13 (m, 3H), 7.10 (t, J = 7.6 Hz, 
1H), 7.02 (d, J = 7.6 Hz, 1H), 6.90 (s, 1H), 6.51 (d, J = 7.5 Hz, 1H), 6.34 (s, 2H), 4.85 (p, J = 6.7 
Hz, 1H), 3.91 (d, J = 14.6 Hz, 1H), 3.85 (d, J = 14.6 Hz, 1H), 3.72 (br s, 1H), 3.15 (s, 1H), 2.97 
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(dd, J = 13.5, 11.1 Hz, 1H), 2.76 (dd, J = 13.8, 4.2 Hz, 1H), 2.01 (s, 6H), 1.26 (d, J = 6.9 Hz, 3H). 
No 13C Data Acquired.  ESI-MS: 457.3 [M + H]+, HPLC (gradient A): Retention Time: 37.48 min. 
 (S)-1-(((S)-1-(5-benzylpyridin-3-yl)ethyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-
1-oxopropan-2-aminium trifluoroacetate (103): See Procedure D: Step 1: 24 mg (0.084 mmol) 
of 96, 150 µL (111 mg, 0.86 mmol, 10 eq.) of N,N-diisopropylethylamine, 47 mg (0.090 mmol, 
1.1 eq.) of PyBOP, 17 mg (0.10 mmol, 1.2 eq.) of 6-Cl-HOBt, 35 mg (0.085 mmol, 1.0 eq.) of 
Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. 
Compound 103 (9.5 mg, 19 % yield) was isolated as a white solid. 1H NMR (500 MHz, Methanol-
d4) δ 8.62 (s, 1H), 8.38 (s, 1H), 7.99 (s, 1H), 7.38 – 7.33 (m, 2H), 7.32 – 7.24 (m, 3H), 6.22 (s, 
2H), 5.15 (q, J = 6.9 Hz, 1H), 4.26 (d, J = 15.5 Hz, 1H), 4.20 (d, J = 15.5 Hz, 1H), 3.88 (dd, J = 
11.5, 5.1 Hz, 1H), 3.08 (dd, J = 13.7, 11.5 Hz, 1H), 2.92 (dd, J = 13.8, 5.2 Hz, 1H), 2.02 (s, 6H), 
1.39 (d, J = 7.1 Hz, 3H). No 13C Data Acquired.  ESI-MS: 403.2 [M + H]+, HPLC (gradient A): 
Retention Time: 20.45 min. 
 (S)-1-(((R)-1-(5-benzylpyridin-3-yl)ethyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-
1-oxopropan-2-aminium trifluoroacetate (104): See Procedure D: Step 1: 5 mg (0.018 mmol) 
of 97, µL (30 mg, 0.23 mmol, 13 eq.) of N,N-diisopropylethylamine, 12 mg (0.023 mmol, 1.3 eq.) 
of PyBOP, 5 mg (0.029 mmol, 1.7 eq.) of 6-Cl-HOBt, 7 mg (0.017 mmol, 0.98 eq.) of Boc-O-Boc-
L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. Compound 104 
(5.6 mg, 54 % yield) was isolated as a white solid. 1H NMR (500 MHz, Methanol-d4) δ 8.60 (s, 
1H), 8.56 (s, 1H), 8.33 (s, 1H), 7.37 – 7.30 (m, 2H), 7.29 – 7.23 (m, 3H), 6.54 (s, 2H), 4.96 (q, J 
= 7.1 Hz, 1H), 4.19 (s, 2H), 3.84 (dd, J = 11.6, 4.8 Hz, 1H), 3.20 (dd, J = 13.8, 11.6 Hz, 1H), 3.06 
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(dd, J = 13.8, 4.9 Hz, 1H), 2.27 (s, 6H), 1.18 (d, J = 7.1 Hz, 3H). No 13C Data Acquired.  ESI-MS: 
404.2 [M + H]+, HPLC (gradient A): Retention Time: 21.64 min. 
(S)-1-(((S)-1-(5-benzyl-2-methoxyphenyl)ethyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (105): See Procedure D: Step 1: 27 
mg (0.097 mmol) of 98, 170 µL (126 mg, 0.98 mmol, 10 eq.) of N,N-diisopropylethylamine, 54 
mg (0.10 mmol, 1.1 eq.) of PyBOP, 18 mg (0.11 mmol, 1.1 eq.) of 6-Cl-HOBt, 40 mg (0.098 
mmol, 1.0 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 
2 mL DCM. Compound 105 (6 mg, 11 % yield) was isolated as a white solid. 1H NMR (500 MHz, 
Methanol-d4) δ 7.63 (d, J = 9.1 Hz, 1H), 7.29 – 7.16 (m, 4H), 7.15 – 7.07 (m, 2H), 6.79 (dd, J = 
5.3, 3.1 Hz, 2H), 6.14 (s, 2H), 5.19 – 5.11 (m, 1H), 3.87 (dd, J = 9.3, 4.6 Hz, 3H), 3.63 (s, 3H), 
3.01 (dd, J = 13.8, 11.5 Hz, 1H), 2.84 (dd, J = 13.9, 4.4 Hz, 1H), 1.92 (s, 6H), 1.31 (d, J = 7.0 Hz, 
3H).
 




1-oxopropan-2-aminium trifluoroacetate (106): See Procedure D: Step 1: 13 mg (0.044 mmol) 
of 99, 80 µL (59 mg, 0.46 mmol, 10 eq.) of N,N-diisopropylethylamine, 25 mg (0.048 mmol, 1.1 
eq.) of PyBOP, 8 mg (0.047 mmol, 1.1 eq.) of 6-Cl-HOBt, 18 mg (0.044 mmol, 1.0 eq.) of Boc-
O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. 
Compound 106 (20.1 mg, 81 % yield) was isolated as a white solid. 1H NMR (400 MHz, Methanol-
d4) δ 7.80 (t, J = 5.7 Hz, 1H), 7.30 – 7.21 (m, 2H), 7.19 – 7.11 (m, 3H), 6.81 (dd, J = 12.5, 2.1 Hz, 
1H), 6.70 (s, 1H), 6.42 (s, 2H), 4.41 – 4.15 (m, 2H), 4.07 – 3.92 (m, 2H), 3.91 – 3.80 (m, 3H), 3.15 
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(dd, J = 13.8, 11.2 Hz, 1H), 2.95 (dd, J = 13.9, 4.8 Hz, 1H), 2.14 (s, 6H), 1.27 (t, J = 7.0 Hz, 3H). 
No 13C Data Acquired.  ESI-MS: 451.3 [M + H]+, HPLC (gradient A): Retention Time: 40.46 min. 
 (S)-1-((5-benzyl-2-ethoxy-4-fluorobenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-
1-oxopropan-2-aminium trifluoroacetate (107): See Procedure D: Step 1: 18 mg (0.061 mmol) 
of 100, 130 µL (96 mg, 0.75 mmol, 12 eq.) of N,N-diisopropylethylamine, 39 mg (0.075 mmol, 
1.2 eq.) of PyBOP, 14 mg (0.083 mmol, 1.4 eq.) of 6-Cl-HOBt, 30 mg (0.073 mmol, 1.2 eq.) of 
Boc-O-Boc-L-2’,6’-dimethyltyrosine, 2.5+2 mL of DMF. Step 2: 2 mL TFA and 2 mL DCM. 
Compound 107 (15 mg, 44 % yield) was isolated as a white solid. 1H NMR (400 MHz, Methanol-
d4) δ 7.41 (t, J = 5.8 Hz, 1H), 7.27 – 7.17 (m, 4H), 7.13 (tt, J = 6.1, 1.7 Hz, 1H), 6.97 (d, J = 8.7 
Hz, 1H), 6.64 (d, J = 11.9 Hz, 1H), 6.29 (s, 2H), 4.35 – 4.25 (m, 1H), 4.05 (dd, J = 14.3, 4.3 Hz, 
1H), 3.95 – 3.78 (m, 5H), 3.06 (dd, J = 13.7, 11.6 Hz, 1H), 2.90 (dd, J = 13.8, 4.6 Hz, 1H), 1.98 
(s, 6H), 1.27 (t, J = 7.0 Hz, 3H). No 13C Data Acquired.  ESI-MS: 451.2 [M + H]+, HPLC (gradient 
A): Retention Time: 40.24 min. 
 2-ethoxynicotinamide (109): See Procedure F: 117 mg (0.70 mmol) of 2-ethoxynicotinic 
acid (108), 426 mg (0.82 mmol, 1.2 eq.) of PyBOP, 41 mg (0.77 mmol, 1.1 eq.) of ammonium 
chloride, 760 µL (699 mg, 6.9 mol, 9.9 eq.) of NMM, and 4.1 mL of DMF. Compound 109 (85 
mg, 73 % yield) was isolated as a white solid. 1H NMR (400 MHz, Chloroform-d) δ 8.44 (dd, J = 
7.5, 2.1 Hz, 1H), 8.20 (dd, J = 4.9, 2.1 Hz, 1H), 7.83 (br s, 1H), 7.16 (br s, 1H), 6.97 (dd, J = 7.6, 
4.9 Hz, 1H), 4.48 (q, J = 7.1 Hz, 2H), 1.40 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Chloroform-
d) δ 166.33, 160.74, 150.06, 141.62, 117.45, 115.25, 62.87, 14.58. 
 tert-butyl ((2-ethoxypyridin-3-yl)methyl)carbamate (110): See Procedure G: 84 mg 
(0.51 mmol) of 109, 3.5 mL of 2M BH3*Me2S in THF (7.0 mmol, 14 eq.) and 4 mL THF. 132 mg 
95 
 
(0.60 mmol, 1.2 eq.) of Boc2O, 230 µL (167 mg, 1.6 mmol, 3.3 eq.) of triethylamine and 4 mL of 
THF. An additional 261 mg (1.2 mmol, 2.4 eq.) of Boc2O was added. Compound 110 (32 mg, 25 
% yield) was isolated a yellow oil that solidified on standing. 1H NMR (500 MHz, Chloroform-d) 
δ 8.04 (dd, J = 5.1, 1.9 Hz, 1H), 7.52 (d, J = 7.2 Hz, 1H), 6.82 (dd, J = 7.2, 5.0 Hz, 1H), 5.04 (br 
s, 1H), 4.40 (q, J = 7.1 Hz, 2H), 4.25 (d, J = 6.3 Hz, 2H), 1.44 (s, 9H), 1.40 (t, J = 7.0 Hz, 3H). 13C 
NMR (126 MHz, Chloroform-d) δ 161.57, 155.85, 145.58, 137.10, 121.33, 116.56, 79.45, 61.62, 
39.92, 28.39, 14.71. 
 tert-butyl ((5-bromo-2-ethoxypyridin-3-yl)methyl)carbamate (111): See Procedure H: 
42 mg (0.17 mmol) of 109, 31 mg (0.17 mmol, 1.0 eq.) of NBS, and 5 mL of MeCN. Compound 
111 (13 mg, 24 % yield) was isolated as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 8.07 
(d, J = 2.4 Hz, 1H), 7.61 (s, 1H), 5.00 (br s, 1H), 4.36 (q, J = 7.1 Hz, 2H), 4.23 (d, J = 6.4 Hz, 2H), 
1.45 (s, 9H), 1.38 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 160.25, 152.28, 
145.94, 139.12, 123.36, 117.00, 62.19, 39.42, 28.37, 14.58. 
tert-butyl ((5-benzyl-2-ethoxypyridin-3-yl)methyl)carbamate (112): See Procedure Bb: 
22 mg (0.066 mmol) of 111, 30 µL (29 mg, 0.13 mmol, 2.0 eq.) of benzyl boronic acid pinacol 
ester, 20 mg (0.14 mmol, 2.2 eq.) of potassium carbonate, 12 mg (0.016 mmol, 0.25 eq.) of 1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium, 4 mL of 3:1 acetone:water. Compound 112  
(13 mg, 57 % yield) was isolated as a colorless oil and used without further purification. 
3-(ammoniomethyl)-5-benzyl-2-ethoxypyridin-1-ium chloride (113): See Procedure C: 
13 mg (mmol) of 112, 0.2 mL HCl conc., 2 mL dioxane. No trituration was performed. Compound 
113 (12 mg, Quantitative yield) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) 
δ 8.10 (d, J = 2.3 Hz, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.32 – 7.26 (m, 2H), 7.26 – 7.17 (m, 3H), 4.49 
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(q, J = 7.0 Hz, 2H), 4.08 (s, 2H), 3.98 (s, 2H), 1.46 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, 
Methanol-d4) δ 159.54, 144.71, 141.70, 139.91, 130.84, 128.44, 128.36, 126.18, 63.46, 37.91, 
37.13, 13.33. 
(S)-1-(((5-benzyl-2-ethoxypyridin-3-yl)methyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (114): See Procedure D: Step 1: 5 
mg (0.016 mmol) of 113, 40 µL (30 mg, 0.23 mmol, 14 eq.) of N,N-diisopropylethylamine, 11 mg 
(0.021 mmol, 1.3 eq.) of PyBOP, 5 mg (0.029 mmol, 1.9 eq.) of 6-Cl-HOBt, 11 mg (0.027 mmol, 
1.7 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA and 2 mL 
DCM. Compound 114 (3.8 mg, 39 % yield) was isolated as a white solid. 1H NMR (500 MHz, 
Methanol-d4) δ 7.89 (d, J = 2.3 Hz, 1H), 7.68 (t, J = 6.0 Hz, 1H), 7.30 – 7.23 (m, 3H), 7.24 – 7.19 
(m, 2H), 7.16 (t, J = 7.3 Hz, 1H), 6.31 (s, 2H), 4.37 – 4.30 (m, 1H), 4.23 (qq, J = 10.3, 7.0 Hz, 
2H), 4.03 (dd, J = 14.8, 4.5 Hz, 1H), 3.89 (s, 2H), 3.86 (dd, J = 11.5, 4.7 Hz, 1H), 3.07 (dd, J = 
13.8, 11.5 Hz, 1H), 2.91 (dd, J = 13.8, 4.7 Hz, 1H), 2.00 (s, 6H), 1.27 (t, J = 7.0 Hz, 3H). No 13C 
Data Acquired.  ESI-MS: 434.3 [M + H]+, HPLC (gradient A): Retention Time: 31.87 min. 
In Vitro Pharmacology 
Cell Lines and Membrane Preparations.  
All opioid in vitro assays were performed by Nicholas Griggs, Thomas Fernandez, and 
Jessica Anand. Tissue culture reagents were purchased from Gibco Life Sciences (Grand Island, 
NY, U.S.) unless otherwise noted. C6-rat glioma cells stably expressing rat MOR, Chinese hamster 
ovary cells human (CHO) stably expressing human MOR, C6 for rat DOR, CHO for human DOR 
and CHO for human KOR were used for all in vitro assays. Cells were grown to confluence at 37 
°C in 5 % CO2 in Dulbecco’s modified Eagle medium (DMEM) containing 10 % fetal bovine 
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serum and 5 % penicillin/streptomycin. Membranes were prepared by washing confluent cells 
three times with ice cold phosphate buffered saline (0.9 % NaCl, 0.61 mM Na2HPO4, 0.38 mM 
KH2PO4, pH 7.4). Cells were detached from the plates by incubation in warm harvesting buffer 
(20 mM HEPES, 150 mM NaCl, 0.68 mM EDTA, pH 7.4) and pelleted by centrifugation at 1600 
rpm for 3 min. The cell pellet was suspended in ice-cold 50 mM Tris- HCl buffer, pH 7.4, and 
homogenized with a Tissue Tearor (Biospec Products, Inc., Bartlesville, OK, U.S.) for 20 s. The 
homogenate was centrifuged at 15,000 rpm for 20 min at 4 °C. The pellet was rehomogenized in 
50 mM Tris-HCl with a Tissue Tearor for 10 s, followed by recentrifugation. The final pellet was 
resuspended in 50 mM Tris-HCl and frozen in aliquots at -80 °C. Protein concentration was 
determined via a BCA protein assay (Thermo Scientific Pierce, Waltham, MA, U.S.) using bovine 
serum albumin as the standard.  
Radioligand Competition Binding Assays.  
Radiolabeled compounds were purchased from Perkin-Elmer (Waltham, MA, U.S.). 
Opioid ligand binding assays were performed by competitive displacement of 0.2 nM [3H]-
diprenorphine (250 μCi, 1.85 TBq/mmol) by the peptidomimetic from membrane preparations 
containing opioid receptors as described above. The assay mixture, containing membranes (20 μg 
protein/tube) in 50 mM Tris-HCl buffer (pH 7.4), 0.2 nM [3H]-diprenorphine, and various 
concentrations of test peptidomimetic, was incubated at room temperature on a shaker for 1 h to 
allow binding to reach equilibrium. The samples were rapidly filtered through Whatman GF/C 
filters using a Brandel harvester (Brandel, Gaithersburg, MD, U.S.) and washed three times with 
50 mM Tris-HCl buffer, pH 7.4. Bound radioactivity on dried filters was determined by liquid 
scintillation counting, after saturation with EcoLume liquid scintillation cocktail, in a Wallac 1450 
MicroBeta (Perkin-Elmer, Waltham, MA, U.S.). Nonspecific binding was determined using 10 
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μM naloxone. The results presented are the mean ± standard error (S.E.M.) from at least three 
separate assays performed in duplicate. Ki (nM) values were calculated using nonlinear regression 
analysis to fit a logistic equation to the competition data using GraphPad Prism, version 6.0c, 
(GraphPad Software Inc., La Jolla, CA).  
[35S]-GTPγS Binding Assays.  
Agonist stimulation of [35S]guanosine 5′-O-[γ- thio]triphosphate ([35S]-GTPγS, 1250 Ci, 
46.2 TBq/mmol) binding to G protein was measured as described previously.82 Briefly, membranes 
(10 μg of protein/well) were incubated for 1 h at 25°C in GTPγS buffer (50 mM Tris-HCl, 100 
mM NaCl, 5 mM MgCl2, 1 mM EDTA, pH 7.4) containing 0.1 nM [
35S]-GTPγS, 30 μM guanosine 
diphosphate (GDP), and varying concentrations of test peptidomimetic. G protein activation 
following receptor activation by peptidomimetic was compared with 10 μM of the standard 
compounds [D-Ala2,N-MePhe4,Gly-ol]enkephalin (DAMGO) at MOR, D-Pen2,5- enkephalin 
(DPDPE) at DOR, or U69,593 at KOR. The reaction was terminated by vacuum filtration through 
GF/C filters that were washed 5 times with GTPγS buffer. Bound radioactivity was measured as 
described above. The results are presented as the mean ± standard error (S.E.M.) from at least three 
separate assays performed in duplicate; potency (EC50 (nM)) and percent stimulation were 
determined using nonlinear regression analysis with GraphPad Prism 6, as above.  
Mouse Liver Microsome Stability Assays 
All liver microsome assays were performed by Quintara Biosciences. Metabolic stability 
of testing compounds was evaluated using mouse liver microsomes to predict intrinsic clearance. 
Mouse liver microsome tissue fractions were obtained from Corning or BioreclamationIVT. The 
assay was carried out in 96-well microtiter plates at 37°C. Reaction mixtures (25 μL) contained a 
final concentration of 1 μM test compound, 0.1 mg/mL liver microsome protein, and 1 mM 
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NADPH in 100 mM potassium phosphate, pH 7.4 buffer with 3 mM MgCl2. At each of the time 
points (0, 15, 30, and 60 minutes), 150 μL of quench solution (acetonitrile with 0.1% formic acid) 
with internal standard (bucetin) was transferred to each well. Verapamil was included as a positive 
control to verify assay performance. Plates were sealed, vortexed, and centrifuged at 4°C for 15 
minutes at 4000 rpm. The supernatant was transferred to fresh plates for LC/MS/MS analysis. All 
samples were analyzed on LC/MS/MS using an AB Sciex API 4000 instrument, coupled to a 
Shimadzu LC-20AD LC Pump system. Analytical samples were separated using a Waters Atlantis 
T3 dC18 reverse phase HPLC column (20 mm x 2.1 mm) at a flow rate of 0.5 mL/min. The mobile 
phase consists of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile 
(solvent B). The extent of metabolism was calculated as the disappearance of the test compound, 
compared to the 0-min time incubation. Initial rates were calculated for the compound 
























Chapter 4: Amine Pendants as MOR Pharmacophores with Improved Stability  
4.1 Introduction 
The conversion from a bicyclic core to a monocyclic core structure as described in Chapter 
2 yielded MOR-agonist/DOR-antagonists with improved metabolic stability. While this was a 
useful first step, there was room for improvement on both fronts. Unfortunately, further core 
modifications described in Chapter 3 did not yield simultaneous improvements in both parameters. 
Therefore, we opted to shift our focus onto different areas of our peptidomimetic that may be more 
amenable to further derivatization. DMT is very sensitive to modification, and typically is optimal 
for affinity and potency at all three opioid receptors.53 As such, we decided to ignore this region 
and focus instead on the benzyl pendant, which is more amenable to modification as illustrated by 
our previous bicyclic core series. Here, successful derivatives in this bicyclic series were used to 
help guide the design of our new analogues. 
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 The monocyclic ligands that possess MOR-agonism while improving metabolic stability 
thus far have a cLogP of 4.75 or higher. Therefore, we sought to make analogues that would reduce 
cLogP in order to reduce their liability to CYP metabolism.80 In our original tetrahydroquinoline 
core peptidomimetics, we reported that cyclic amine pendants are either tolerated or show 
improved efficacy and potency at MOR (Figure 11).64 These amine pendants also have a lower 
cLogP than their benzyl pendant precursor. As such, we opted to introduce these polar amine 
pendants into our previously described monocyclic core system. This was hypothesized to retain 
or improve already established opioid activity while further improving metabolic stability through 
reduced cLogP. Herein, the results of an SAR campaign aimed at combining these two structural 
elements will be discussed. 
 
Figure 11: Design path leading to more stable peptidomimetics with amine pendants. Blue 




General Chemistry: In order to incorporate basic amine pendants into our series, we first opted to 
introduce the ethyl ether into the scaffold using Scheme 7. This was done by taking commercially 
available methyl 3-formyl-4-hydroxybenzoate and alkylating the phenol with ethyl bromide and 
potassium carbonate. The aldehyde was then subject to a reductive amination using an Ellman 
auxiliary as an amine source. The auxiliary was left on the scaffold, as it served as a protecting 
group for the subsequent LiOH mediated saponification and attachment of the amine pendant using 
PyBOP. The carboxylate was not reduced before the pendant attachment because we were 
interested in producing analogues that tested the effect an amide would have on our SAR. This 
amide was then deprotected with conc. HCl and reduced with borane at elevated temperatures if 
desired. Finally, the intermediate was coupled to Boc-protected DMT and the Boc groups were 
removed with TFA. 




A) EtBr, K2CO3, DMF. B) 1. (R)-(+)-2-methyl-2-propanesulfinamide, Ti(OEt)4, THF 2. NaBH4. 
C) LiOH, THF, EtOH, H2O D) 1. NHR
1R2, NMM, PyBOP, DMF. 2. conc. HCl, Dioxane. E) 
BH3*Me2S, THF, 75 C° F) 1. DiBocDMT, DIEA, PyBOP, 6-Cl-HOBt, DMF. 2. TFA, DCM. 
SAR: Our studies began by selecting the monocyclic analogue from the previous series with the 
best MOR/DOR profile, namely that containing the ethyl ether (70). We were further encouraged 
by the stability of this analogue, as this was one of the most stable derivatives synthesized thus far. 
We proceeded by replacing the benzyl pendant with various cyclic amines, some of which were 
previously reported in our THQ series.64 These included piperidine (128), morpholine (130), 
isoindoline (131), and tetrahydroisoquinoline (THIQ) (132) pendants. A few novel pendants for 
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this series were also synthesized and screened, namely the pyrrolidine (127) and 3-
azabicyclo[3.1.0]hexane (129) heterocycles, and two analogues that possessed conformationally 
flexible benzyl amines (133 and 134). Finally, these derivatives were complemented with the 
amide analogues of the pyrrolidine (135) and isoindoline (136) pendants.  
Conversion to the monocyclic amine analogues (127, 129-130) generally came with a loss 
in MOR binding, in contrast to the bicyclic amine analogues (131-132) which showed 
improvements in binding affinity at this receptor (Table 11). The monocyclic amines also caused 
losses in DOR binding affinity, whereas the bicyclic amines produced no change in affinity at this 
receptor. Neither the benzyl amines (133-134) nor the amides (135-136) were significantly 
different from their bicyclic amine counterparts at MOR or DOR. KOR affinity was generally 
higher with each of these amine pendant analogues, the only exception here being the morpholine 
pendant (130). The highest binding affinity at KOR comes from the benzyl amine pendant 
analogues (133-134), with binding affinity in the low double-digit nanomolar range. The 
selectivity ratio was also determined for each of these analogues. In general, good binding affinity 
balance was maintained between MOR and DOR, the only exceptions being the THIQ analogue 
132 and the isoindoline amide analogue 136. Selectivity of MOR over KOR was reduced for most 
analogues, though good selectivity was maintained with the bicyclic analogues 131, 132, and 136. 
 
 
Binding Affinity, Ki (nM) Selectivity 
Name R MOR DOR KOR MOR:DOR:KOR 
70 
 





15.0±1.8 44.4±7.9 430±16 1:3.0:29 
128 
 
5.0±1.5 15.7±4.3 101±14 1:3.1:20 
129 
 
19.6±6.1 50±10 247±51 1:2.6:13 
130 
 
38.0±9.9 76.0±4.5 >1870 1:2.0:>49 
131 
 
0.80±0.22 2.7±0.6 243±53 1:3.4:304 
132 
 
0.23±0.04 2.4±0.5 44.2±4.6 1:10:192 
133 
 
0.45±0.13 0.82±0.27 23.2±7.6 1:1.2:52 
134 
 
0.48±0.13 1.9±0.4 12.4±0.5 1:4.0:26 
135 
 
33±11 74±23 760±100 1:2.2:23 
136 
 
0.29±0.05 5.9±2.0 261±12 1:20:900 
Table 11: Binding affinity of amine or amide pendant analogues at MOR, DOR, and KOR. 
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3H] 
diprenorphine in membrane preparations. Included is 70 for comparison. Selectivity was 
calculated by dividing the Ki of each receptor by the Ki at MOR for a given compound. All data 
were from three separate experiments, performed in duplicate unless otherwise noted. These data 
are reported as the average ± standard error of the mean. * N=2. aData are from assays using 
human MOR and DOR instead of rat MOR and DOR as reported in Chapter 2. 
With regards to potency at MOR, a variety of effects were observed (Table 12). The 
pyrrolidine (127) and piperidine (128) had potency lower than 70. Incorporation of a cyclopropyl 
group (129) onto the pyrrolidine, or conversion from a piperidine to a morpholine pendant (130) 
only reduced this potency further. Analogues that reincorporated an aromatic ring (131-134) 
showed improvements in potency, which was especially true if the ring was locked in a bicyclic 
structure (131-132). Variable levels of DOR activity were observed in these amine pendants. Some 
were partial DOR agonists, having either weak potency and 40-50 % efficacy (127-129), or were 
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moderately potent (131). The morpholine (130), THIQ (132), N-methyl benzyl amine (134), and 
the amides (135-136) did not stimulate DOR. Finally, none of these compounds had any 
appreciable potency at KOR up to 1.3 µM. 
 The most interesting data that came from this series was the efficacy of these ligands at 
MOR. Notably, every analogue discussed thus far had the same or greater efficacy compared to 
70, apart from the amides (135-136). This high efficacy was true regardless of the size or presence 
of a cyclic amine ring. The greatest improvements in efficacy were with the bicyclic amine 









  Potency, EC50 (nM) Efficacy (% Stimulation) 





DNSa DNS 75.5±5.8a DNSa DNS 
127 
 





585±73 129±20 DNS 77.5±5.8 36.8±6.7 DNS 
129 
 
990±160 460±100 >10000 88±16 52.1±7.0 >36.4 
130 
 
1020±290 DNS DNS 72.2±8.3 DNS DNS 
131 
 
8.4±1.2 43±13 Not Tested 98.1±6.7 35.7±2.8 Not Tested 
132 
 
1.9±0.5 DNS DNS 94.6±3.9 DNS DNS 
133 
 
16.7±4.8 4.8±2.0 >1000 77.9±3.0 26.1±2.0 >20 
134 
 
33.9±4.3 DNS DNS 72.2±6.2 DNS DNS 
135 
 
DNS DNS Not Tested DNS DNS Not Tested 
136 
 
15.0±3.3 DNS DNS 27.8±0.7 DNS DNS 
Table 12: Potency and efficacy of amine or amide pendant analogues at MOR, DOR, and KOR. 
Potency and efficacy data were obtained using agonist induced stimulation of [35S] GTPγS 
binding. Potency is represented as EC50 (nM) and efficacy as percent maximal stimulation 
relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 μM. 
Included is 70 for comparison. All data were from three separate experiments, performed in 
duplicate unless otherwise noted. These data are reported as the average ± standard error of the 
mean. DNS=Does Not Stimulate. * N=2, ** N=1. aData are from assays using human MOR and 
DOR instead of rat MOR and DOR as reported in Chapter 2. 
Metabolic Stability: Since improving metabolic stability is one of our goals, most of the ligands 
described above were examined for stability in MLM (Table 13). For comparison, our previously 
reported benzyl pendant (70) is again included, as well as the ratio in stability between each  
Name R1 T1/2 (min) Verapamil T1/2 (min) Stability Ratio  cLogP 
70 
 
23.7±5.9 14.6±1.0 1.6±0.4 4.75 
127 
 





99.2±4.3 29.9±4.7 3.3±0.5 3.71 
131 
 
70.4±7.5 25.7±1.7 2.7±0.3 4.11 
132 
 















25.7±1.7 5.3±1.9 2.08 
136 
 
97±12 29.9±4.7 3.3±0.6 3.56 
Table 13: Metabolic stability of amine or amide pendant analogues in MLM. Included are the 
compound half-life (T1/2), the half-life of the positive control verapamil, and the stability ratio 
between the compound and the positive control. The stability ratio was calculated by dividing the 
half-life of the analogue of interest by the half-life of the positive control in that assay. Included 
is compound 70 for comparison. Individual compounds were tested once, with errors 
representing the SE in the decay curve regressed onto the data collected in 15-minute intervals. 
Finally, the cLogP of these analogues are included and were calculated using PerkinElmer’s 
ChemDraw® Professional Software. 
compound and the positive control verapamil. Immediate conversion to the simple pyrrolidine 
(127) or piperidine (128) pendants produced a significant boost in metabolic stability, providing 
half-lives of 199 and 99 min respectively. The attachment of aromatic rings to form the isoindoline 
(131) and THIQ (132) pendants attenuates these stability improvements, however their stability is 
greater than or equal to that of the original benzyl pendant. Breaking the THIQ pendant of 132 
produces differential effects, as the benzylamine analogue (133) shows no change in stability, 
while the N-methyl benzylamine (134) causes stability loss. Finally, the amide analogues of 127 
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and 131 either produce a minor loss, or a minor gain in stability compared to their amine 
counterparts. 
Antinociceptive Activity: The analogues presented in this work were also screened for in vivo 
antinociceptive activity using the acetic acid stretch assay (AASA). Analogues 127-128 and 131-
134 were tested for their antinociceptive activity and are described in Figure 12A-C. Morphine 
was used as a positive control. Additional details for this assay are found in the experimental 
section. Two analogues were inactive in this assay, namely the pyrrolidine analogue 127 and the 
N-methylbenzyl amine analogue 134. Three analogues showed antinociception at 10 mg/kg (70, 
132, and 133) when administered sc. Finally, the piperidine (128) and isoindoline (131) analogues 
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Figure 12: Antinociceptive activity of 70 and analogues 127-128, and 131-134 using the AASA. 
Included is morphine as positive control. Panels A-C represent dose-response curves with the 
ligands: A) 70 and monocyclic amine analogues 127 and 128, B) bicyclic amine analogues 131 
and 132 C) benzyl amine analogues 133 and 134. * P<0.05 compared to vehicle. ** P<0.01 
compared to vehicle. ***P<0.001 compared to vehicle. **** P<0.0001 compared to vehicle. D) 
Competition assays between each analogue active at 10 mg/kg and the opioid antagonist 
naloxone in the AASA. ## P<0.01 (drug - nlx) vs (vehicle - nlx). ### P<0.001 (drug - nlx) vs 
(vehicle - nlx). #### P<0.0001 (drug - nlx) vs (vehicle - nlx). * P<0.05 (drug - nlx) vs (drug + 
nlx). ** P<0.01 (drug - nlx) vs (drug + nlx). 
 We next sought to confirm that antinociception was mediated through the opioid receptors. 
Each mouse was pretreated with a 10 mg/kg dose of the nonselective opioid receptor antagonist 
naloxone (NLX) (Figure 12D) before treatment with 10 mg/kg of an active ligand from above. If 
the antinociception here is opioid mediated, it will be attenuated. For each analogue tested, the 
administration of naloxone inhibited the antinociceptive response induced in the AASA, 
confirming that the antinociception observed for these analogues is opioid receptor mediated.  
 Next, we opted to test these analogues in another assay for antinociception, namely the 
warm water tail withdrawal assay (WWTW). Unfortunately, none of the analogues that showed 
activity in the AASA were active at doses up to 32 mg/kg in the WWTW.  
4.3 Discussion and Conclusion 
SAR: Within the analogues found in Table 11, it appears that most of the monocyclic amine 




Those that contain an aromatic ring (131-134, 136) instead show improved binding at MOR. 
Conversion of the amine to an amide (127 to 135, 131 to 136) produced no significant difference 
in this binding affinity. This suggests that the aromatic ring is an important component for MOR 
binding, whereas the amine is not. Similar trends can be observed for DOR binding as well. 
 In general, increases in binding affinity to KOR were observed for these analogues. This 
is possibly a result of polarity around the attachment point of the pendant to the rest of the 
molecule, as conversion between the amine and the amides of the pyrrolidine (127 and 135) and 
the isoindoline (131 and 136) produce similar affinities. The greatest binding affinity comes with 
the benzyl amine analogues (133-134), and suggests that additional conformational flexibility 
enables higher binding as compared to their conformationally restricted counterparts (131-132) 
 Consistent with the binding affinity at MOR is the potency. Aromatic rings appear to be 
important in these new pendants for potency, whereas the amine does not appear to be vital (as 
exemplified by 131 and 136). Concerning efficacy at MOR, every compound containing an amine 
group had at least 72 % stimulation compared to DAMGO. Converting the amine into an amide 
drastically reduces this efficacy, but had little effect on potency, as evidenced by 131 and 136. 
This suggests either that this amine is an important pharmacophore element for activation of MOR, 
or that the conjugation of the amide with the aromatic ring prevents the pendant from adopting an 
orientation necessary to activate MOR. While these amines may provide efficacy at MOR, alone 
they reduce potency. However, attachment of an aromatic ring greatly improves this potency, and 
in most cases, improves potency compared to the original benzyl pendant. It then appears that the 
amine in these pendants is important for maintaining high efficacy, whereas the aromatic ring is 
important for high potency. This combination may therefore be a useful pharmacophore for 
producing future MOR-agonists. 
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Interestingly, half of these amine compounds produced some residual agonism at DOR. As 
with MOR, this residual agonism at DOR is abolished upon conversion to the amide, suggesting 
the amine is contributing to this activity. The incorporation of an aromatic ring also appears to 
improve the potency of these compounds at DOR (when applicable), namely through comparison 
between 127 and 131. However, it should be noted that the efficacy here decreases with these 
aromatic rings, and the only MOR-agonist/DOR-antagonists in this series possess an aromatic ring. 
As such, it appears that the additional aromatic ring can reduce the efficacy at DOR of these 
compounds. Finally, none of these compounds had any appreciable ability to activate KOR, though 
the N-methyl benzylamine analogue (134) was a weak partial agonist at 1.3 µM. 
Metabolic Stability: The conversion from the benzyl pendant to the pyrrolidine and piperidine 
pendants produced a marked improvement in metabolic stability. This can be attributed to the 
reduced cLogP of these two pendants, which is known to reduce binding affinity to cytochrome 
P450 enzymes.80 In fact, regression analyses of the stability ratio of the cyclic amines (127-132) 
against their cLogP follows a linear relationship with an R2 value of 0.89 as shown in Figure 13 
(blue). Two different groups of exceptions exist. The first are the benzyl amine analogues 133 and 
134 (Figure 13, orange), which have lower stability than predicted by their cLogP. This could be 
attributed to their increased conformational flexibility in relation to the amine and the aromatic 
ring, allowing for more binding orientations within the CYP enzyme. Furthermore, the amides 135 
and 136 also have reduced stability than predicted by their cLogP (Figure 13, grey). These amides 
are conjugated to the ethyl ether through the aromatic core and could facilitate elimination of the 
ethyl group at the end of the CYP catalytic cycle akin to analogues described in Chapter 3. Overall, 
the stability improvements of this series are primarily inversely related to their cLogP, and 




Figure 13: Stability ratio of analogues 127-128 and 131-136 against their cLogP. These ligands 
are divided into group based on their structure, with cyclic amines in blue, benzyl amines in 
orange, and amides in grey. The cyclic amines were also subject to linear regression. 
Antinociceptive Activity: Of the analogues synthesized that possess high MOR agonism, only the 
pyrrolidine (127) and the N-methylbenzyl (134) amine pendants did not express antinociceptive 
activity. In fact, the piperidine (128) and the isoindoline (131) analogues were active at 1 mg/kg. 
Within this set of analogues, there appear to be no obvious trends that dictate what would be active. 
In vitro MOR potency does not appear to be a driving force, as the piperidine 128 has a potency 
value of 585 nM. The presence of an aromatic ring also does not appear to be a factor from these 
analogues, as the piperidine analogue 128 is active and the N-methylbenzyl analogue 134 is 
inactive. More analogues would need to be synthesized in order to allow trends in in vivo activity 
to emerge. 
 Unlike in the acetic acid stretch assay, none of these analogues were active in the warm 
water tail withdrawal assay. This difference in activity may be a result of both the type of 
nociception and the location upon which the opioids are operating. Abdominal writhing in the 


























AASA can be inhibited by the action of opioids in the periphery, whereas the tail flick in the 
WWTW is centrally mediated.87 This suggests that these molecules are having trouble crossing 
the blood-brain barrier (BBB) and their action may be peripherally mediated.  
Fortunately, the nociception in the AASA is presumed to be a result of inflammation,88 and 
opioid receptor agonists have been found to induce stronger antinociceptive responses in inflamed 
tissue.89 This inflammation can appear in many different disease syndromes, including cancer, 
arthritis, and chronic injuries.89 Given the long duration of these health conditions, the use of 
peripheral opioids may be beneficial for treating various forms of chronic pain. This can be of 
great benefit, as drug-seeking behavior is a centrally mediated effect and other side-effects can be 
bypassed through peripheral action. An example of this peripheral activity in action is a series of 
fluorinated fentanyl derivatives designed to be active in the low pH of inflamed tissue. Analogues 
in this series were found to produce antinociception without respiratory depression, constipation, 
or addiction.90 
Conclusion: In comparison to Chapter 3, the analogues synthesized in this chapter represent a more 
promising direction for further derivatization. It appears thus far that the amine in the pendant can 
induce high levels of efficacy at MOR, whereas the incorporation of an aromatic ring back into 
the pendant can induce high levels of potency at MOR. This is largely insensitive to flexibility in 
the pendant, as illustrated by the two benzyl amine analogues. For the purposes of our initial goals, 
the metabolic stability of these ligands was much greater than those of previous chapters. This is 
noteworthy, as the isoindoline analogue produced improved stability with improved MOR-
agonism. The only drawback  in the SAR thus far appears to be a lurking partial DOR-agonism 
that appears in some analogues. This may not be a huge problem, as bifunctional MOR-
agonist/DOR-agonist ligands have been shown to display reduced opioid side effect profiles as 
115 
 
described in Chapter 1. Finally, we can also show that these compounds can express 
antinociceptive activity in vivo through the acetic acid stretch assay and that this antinociception 
is mediated through opioid receptors. Though not active in the warm water tail withdrawal assay, 
the fact that these analogues may only be active peripherally may help us eliminate some negative 
side-effects associated with opioids. Given the progress that these pendants have provided us, 
future analogues will use these as a key element in their design. 
4.4 Experimental 
Chemistry 
General Methods: All reagents and solvents were obtained commercially and were used 
without further purification. Intermediates were purified by flash chromatography using a Biotage 
Isolera One instrument. Most purification methods utilized a hexanes/ethyl acetate solvent system 
in a Biotage SNAP KP-Sil column, with a linear gradient between 0 and 100% ethyl acetate. 
Reverse phase column chromatography using a linear gradient of 0 % to 100 % solvent B (0.1 % 
TFA in acetonitrile) in solvent A (0.1 % TFA in water) using a Biotage SNAP Ultra C18 column 
was utilized for some intermediate amine salts. Purification of final compounds was performed 
using a Waters semipreparative HPLC with a Vydac protein and peptide C18 reverse phase 
column, using a linear gradient of 0 % to 100 % solvent B in solvent A at a rate 1 % per minute, 
monitoring UV absorbance at 230 nm. The purity of final compounds was assessed using a Waters 
Alliance 2690 analytical HPLC instrument with a Vydac protein and peptide C18 reverse phase 
column. A linear gradient (gradient A) of 0 % to 70 % solvent B in solvent A in 70 min, measuring 
UV absorbance at 230 nm was used to determine purity. All final compounds used for testing were 
≥95 % pure, as determined by analytical HPLC. 1H NMR and 13C NMR data were obtained on a 
500 or 400 MHz Varian spectrometer using CDCl3, CD3OD, DMSO-d6, or D2O as solvents. The 
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identities of final compounds were verified by mass spectrometry using an Agilent 6130 LC–MS 
mass spectrometer in the positive ion mode, or an Agilent 6230 TOF HPLC-MS in the positive ion 
mode.  
General Procedure for the Synthesis of 6-position Ethyl Ethers (Procedure A): To a flame 
dried flask containing methyl 3-formyl-4-hydroxybenzoate (115) was added 3 equivalents of 
potassium carbonate. The flask was purged with argon and 4 mL of DMF was added. 3 equivalents 
of an alkyl iodide or bromide was then added, and the solution was stirred at room temperature 
overnight. The solution was then concentrated in vacuo, partitioned between ethyl acetate and 
saturated sodium carbonate, and extracted with ethyl acetate. The organic layers were combined, 
dried with magnesium sulfate, filtered, and concentrated in vacuo, yielding the desired ethyl ether 
(116). 
General Procedure for Ellman Reductions (Procedure B): A flamed-dried round bottom 
flask containing 1 equivalent of aldehyde (116) and 3 equivalents of (R)-(+)-2-methyl-2-
propanesulfinamide was attached to a reflux condenser and flushed with argon. 4 mL of THF was 
added and cooled to 0 °C. 6 equivalents of titanium (IV) ethoxide was added, followed by an 
additional 4 mL of THF. The solution was stirred and heated to 75 °C overnight with TLC 
monitoring until all ketone or aldehyde was consumed. A separate flame-dried flask containing 6 
equivalents of sodium borohydride was flushed with argon. 4 mL of THF was added, at which 
point the solution was cooled to -78 °C. The solution containing Ellman adduct was cooled to room 
temperature and slowly transferred to the sodium borohydride solution via syringe. This final 
solution was then allowed to warm to room temperature and stirred for 2 hours, at which point the 
reaction mixture was quenched with methanol to consume the sodium borohydride, followed by 
DI water to precipitate the titanium. The solution was vacuum filtered, and the precipitate was 
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washed with ethyl acetate. The filtrate was the concentrated in vacuo and purified via column 
chromatography (0-100% EtOAc in Hexanes), yielding the desired sulfonamide (117). 
General Procedure for the Saponification of Esters (Procedure C): To a flask containing 
1 equivalent of the ester (117) was added 7 equivalents of LiOH, 2 mL of THF, 2 mL of EtOH, 
and 2 mL of H2O. The reaction was stirred overnight under ambient atmosphere and temperature. 
Upon completion, the solvent was concentrated in vacuo, suspended in acetone, and filtered. The 
precipitate was washed with additional acetone, and the filtrate was concentrated in vacuo, yielding 
the saponified product as a lithium carboxylate (118).  
General Procedure for Amine Pendant Attachment and Cleavage of Ellman Auxiliaries 
(Procedure D): To a flask containing 1 equivalent of the lithium carboxylate (118) was added 1 
equivalent of PyBOP and 1 equivalent of the desired amine. The flask was flushed with argon, 
DMF was added as solvent, and 10 equivalents of N-methylmorpholine was added. The reaction 
was stirred overnight, at which point it was concentrated in vacuo and purified via column 
chromatography (0-10% methanol in DCM). To the protected amine was immediately added 2 mL 
of Dioxane and 0.2 mL concentrated HCl. The solution was stirred at room temperature for 1 
minute and concentrated in vacuo. The ensuing salt was triturated with diethyl ether, and then was 
purified using a reverse phase chromatography (0-100% B in A), yielding the product as a TFA 
salt. 
General Procedure for the Reduction of Pendant Amides (Procedure E): To a dried flask 
containing 1 equivalent of the desired amide under argon was added THF and 7 equivalents of 2 
M BH3*Me2S complex in THF. The reaction was heated at 75 °C for 3 hours, at which point the 
reaction was quenched with MeOH and heated for an additional 15 minutes. The reaction was then 
cooled, concentrated in vacuo, and was used in Procedure F without further purification. 
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General Procedure for the Coupling of 2’,6’-Dimethyltyrosine to Functionalized Amine 
Salt (Procedure F): To a dried flask containing the amine under argon was added 3 mL of DMF 
and 10 equivalents of Hunig’s base. 1 equivalent of PyBOP and 1 equivalent of 6-Cl-HOBt was 
added, followed by a 1 equivalent of doubly Boc protected 2’,6’-Dimethyltyrosine in 1.5 mL DMF. 
The solution was stirred overnight at room temperature, concentrated in vacuo, and purified via 
semipreparative reverse phase HPLC (0.1% TFA in water: 0.1% TFA in acetonitrile). 2 mL of 
TFA and 2 mL of DCM were then added, and the solution was stirred for an additional hour. The 
reaction mixture was concentrated in vacuo and purified via an additional semipreparative reverse 
phase HPLC (0.1% TFA in water: 0.1% TFA in acetonitrile). The product was concentrated in 
vacuo and lyophilized overnight to yield the final peptidomimetic. 
Methyl 4-ethoxy-3-formylbenzoate (116): See Procedure A: 149 mg (0.83 mmol) of 
methyl 3-formyl-4-hydroxybenzoate (115), 342 mg (2.47 mmol, 2.99 eq.) of K2CO3, 190 µL 
(277 mg, 2.55 mmol, 3.08 eq) of EtBr, 4 mL of DMF. Compound 116 (162 mg, Yield=94 %) was 
isolated as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 10.46 (s, 1H), 8.47 (d, J = 2.3 Hz, 
1H), 8.19 (dd, J = 8.8, 2.3 Hz, 1H), 7.00 (d, J = 8.8 Hz, 1H), 4.21 (q, J = 7.0 Hz, 2H), 3.88 (s, 3H), 
1.50 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 188.93, 166.00, 164.25, 137.01, 
130.35, 124.33, 122.63, 112.22, 64.68, 52.07, 14.49. 
 Ethyl (R)-3-(((tert-butylsulfinyl)amino)methyl)-4-ethoxybenzoate (117): See 
Procedure B: Step 1: 149 mg (0.72 mmol) of 116, 262 mg (2.16 mmol, 3.02 eq.) of (R)-(+)-2-
methyl-2-propanesulfinamide, 900 µL (979 mg, 4.3 mmol, 6.0 eq.) of Ti(OEt)4, 4+4 mL THF. 
Step 2: 165 mg (4.4 mmol, 6.1 eq.) of sodium borohydride in 4 mL THF. Compound 117 (232 mg, 
Yield= 99 %) was isolated as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.95 (m, 2H), 
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6.85 (d, J = 9.1 Hz, 1H), 4.41 (dd, J = 14.3, 5.5 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 4.20 (dd, J = 
14.3, 7.8 Hz, 1H), 4.11 (q, J = 7.0 Hz, 2H), 3.74 (dd, J = 7.8, 5.6 Hz, 1H), 1.44 (t, J = 7.0 Hz, 3H), 
1.36 (t, J = 7.1 Hz, 3H), 1.21 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 166.26, 160.35, 
131.05, 130.61, 127.10, 122.49, 110.50, 63.94, 60.67, 55.87, 45.18, 22.60, 14.73, 14.34. 
 Lithium (R)-3-(((tert-butylsulfinyl)amino)methyl)-4-ethoxybenzoate (118): See 
Procedure C: 208 mg (0.64 mmol) of 117, 198 mg (8.27 mmol, 12.9 eq.) of LiOH, 2 mL of THF, 
2 mL of EtOH, and 2 mL of H2O. Compound 118 (172 mg, Yield= 89 %) was isolated as a white 
solid. 1H NMR (500 MHz, Methanol-d4) δ 7.91 (d, J = 2.2 Hz, 1H), 7.88 (dd, J = 8.5, 2.2 Hz, 1H), 
6.91 (d, J = 8.5 Hz, 1H), 4.34 (d, J = 14.3 Hz, 1H), 4.23 (d, J = 14.3 Hz, 1H), 4.12 (q, J = 7.0 Hz, 
2H), 1.44 (t, J = 7.0 Hz, 3H), 1.22 (s, 9H). 13C NMR (126 MHz, Methanol-d4) δ 173.90, 158.48, 
130.37, 130.12, 129.54, 125.96, 109.79, 63.44, 55.64, 44.31, 21.73, 13.81. 
 (2-ethoxy-5-(pyrrolidine-1-carbonyl)phenyl)methanaminium trifluoroacetate (119): 
See Procedure D: Step 1: 28 mg (0.092 mmol) of 118, 49 mg (0.094 mmol, 1.0 eq.) of PyBOP, 
20 µL (17 mg, 0.24 mmol, 2.7 eq.) of pyrrolidine, 100 µL (92 mg, 0.91 mmol, 9.9 eq.) of NMM, 
and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 118 (33 mg, Quant 
Yield) was isolated as a yellow oil. 1H NMR (500 MHz, Methanol-d4) δ 7.61 (dd, J = 8.6, 2.2 Hz, 
1H), 7.54 (d, J = 2.3 Hz, 1H), 7.13 (d, J = 8.6 Hz, 1H), 4.22 (q, J = 6.9 Hz, 2H), 4.15 (s, 2H), 3.57 
(t, J = 7.0 Hz, 2H), 3.51 (t, J = 6.7 Hz, 2H), 1.99 (p, J = 6.8 Hz, 2H), 1.89 (p, J = 6.2 Hz, 2H), 1.47 
(t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 169.75, 158.69, 130.16, 129.66, 128.32, 
126.99, 111.15, 64.29, 49.81, 46.41, 38.49, 25.88, 23.92, 13.52. 
(2-ethoxy-5-(piperidine-1-carbonyl)phenyl)methanaminium trifluoroacetate (120): 
See Procedure D: Step 1: 27 mg (0.088 mmol) of 118, 46 mg (0.088 mmol, 1.0 eq.) of PyBOP, 
120 
 
20 µL (17 mg, 0.20 mmol, 2.3 eq.) of piperidine, 100 µL (92 mg, 0.91 mmol, 10.3 eq.) of NMM, 
and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 120 (28 mg, Yield= 
84 %) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.47 (dd, J = 8.5, 2.2 
Hz, 1H), 7.41 (d, J = 2.2 Hz, 1H), 7.14 (d, J = 8.4 Hz, 1H), 4.22 (q, J = 7.0 Hz, 2H), 4.14 (s, 2H), 
3.68 (br s, 2H), 3.44 (br s, 2H), 1.76 – 1.68 (m, 2H), 1.64 (br s, 2H), 1.57 (br s, 2H), 1.48 (t, J = 
7.0 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 170.20, 158.22, 129.74, 129.42, 127.91, 121.26, 
111.19, 64.17, 38.48, 24.02, 20.05, 13.41. 
(5-(3-azabicyclo[3.1.0]hexane-3-carbonyl)-2-ethoxyphenyl)methanaminium 
trifluoroacetate (121): See Procedure D: Step 1: 25 mg (0.082 mmol) of 118, 41 mg (0.079 mmol, 
0.96 eq.) of PyBOP, 12 mg, (0.10 mmol, 1.2 eq.) of 3-azabicyclo[3.1.0]hexane hydrochloride, 90 
µL (83 mg, 0.82 mmol, 10.0 eq.) of NMM, and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 
mL conc. HCl. Compound 121 (21 mg, Yield=69 %) was isolated as a colorless oil. 1H NMR (500 
MHz, Methanol-d4) δ 7.54 (dd, J = 8.6, 2.3 Hz, 1H), 7.47 (d, J = 2.2 Hz, 1H), 7.12 (d, J = 8.6 Hz, 
1H), 4.22 (q, J = 7.0 Hz, 2H), 4.14 (s, 2H), 4.07 (d, J = 12.0 Hz, 1H), 3.75 (dd, J = 10.9, 4.1 Hz, 
1H), 3.51 – 3.42 (m, 2H), 1.60 (ddt, J = 20.4, 7.1, 3.6 Hz, 2H), 1.48 (t, J = 7.0 Hz, 3H), 0.72 (td, J 
= 7.7, 5.2 Hz, 1H), 0.10 (q, J = 4.3 Hz, 1H). 13C NMR (126 MHz, Methanol-d4) δ 170.61, 158.46, 
130.07, 129.60, 128.61, 126.97, 111.01, 64.19, 51.35, 38.45, 20.05, 15.41, 13.73, 13.41, 7.57. 
(2-ethoxy-5-(morpholine-4-carbonyl)phenyl)methanaminium trifluoroacetate (122): 
See Procedure D: Step 1: 29 mg (0.095 mmol) of 118, 50 mg (0.096 mmol, 1.0 eq.) of PyBOP, 
20 µL (20 mg, 0.23 mmol, 2.4 eq.) of morpholine, 110 µL (101 mg, 1.0 mmol, 10.5 eq.) of NMM, 
and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 122 (28 mg, Yield= 
78 %) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.51 (dd, J = 8.5, 2.2 
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Hz, 1H), 7.45 (d, J = 2.1 Hz, 1H), 7.15 (d, J = 8.5 Hz, 1H), 4.23 (q, J = 7.0 Hz, 2H), 4.15 (s, 2H), 
3.78 – 3.50 (m, 8H), 1.48 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 170.37, 158.48, 
130.22, 129.77, 126.97, 121.33, 111.27, 66.35, 64.21, 38.44, 20.05, 13.40. 
(2-ethoxy-5-(isoindoline-2-carbonyl)phenyl)methanaminium trifluoroacetate (123): 
See Procedure D: Step 1: 40 mg (0.13 mmol) of 118, 70 mg (0.13 mmol, 1.0 eq.) of PyBOP, 22 
mg (0.14 mmol, 1.1 eq.) of isoindoline hydrochloride, 150 µL (138 mg, 1.4 mol, 10.4 eq.) of 
NMM, and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 123 (39 
mg, Yield=73 %) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.74 (dd, J 
= 8.5, 2.2 Hz, 1H), 7.64 (d, J = 2.2 Hz, 1H), 7.37 (d, J = 7.3 Hz, 1H), 7.35 – 7.25 (m, 2H), 7.23 (d, 
J = 7.4 Hz, 1H), 7.19 (d, J = 8.5 Hz, 1H), 4.96 (s, 2H), 4.88 (s, 5H), 4.26 (q, J = 7.0 Hz, 2H), 4.18 
(s, 2H), 1.50 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 170.15, 158.61, 136.31, 
135.58, 130.08, 129.61, 128.19, 127.51, 127.33, 122.44, 122.15, 121.20, 111.20, 64.24, 54.70, 
52.29, 38.49, 13.43. 
(2-ethoxy-5-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)phenyl)methanaminium 
trifluoroacetate (124): Step 1: See Procedure D: 26 mg (0.085 mmol) of 118, 44 mg (0.085 mmol, 
0.99 eq.) of PyBOP, 20 µL (21 mg, 0.16 mmol, 1.9 eq.) of 1,2,3,4-tetrahydroquinoline, 90 µL (83 
mg, 0.82 mmol, 9.6 eq.) of NMM, and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. 
HCl. Compound 124 (22 mg, Yield=61 %) was isolated as a colorless oil. 1H NMR (400 MHz, 50 
°C, Methanol-d4) δ 7.54 (dd, J = 8.5, 2.2 Hz, 1H), 7.48 (d, J = 2.1 Hz, 1H), 7.16 (d, J = 8.2 Hz, 
4H), 7.07 (s, 1H), 4.74 (s, 2H), 4.25 (q, J = 7.0 Hz, 2H), 4.17 (s, 2H), 3.81 (s, 2H), 2.93 (t, J = 6.0 
Hz, 2H), 1.49 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, 50 °C, Methanol-d4) δ 158.48, 134.19, 
132.61, 129.93, 129.54, 128.32, 127.96, 126.54, 126.15, 121.39, 111.44, 64.33, 38.61, 13.38. 
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(5-(benzylcarbamoyl)-2-ethoxyphenyl)methanaminium trifluoroacetate (125): See 
Procedure D: Step 1: 30 mg (0.098 mmol) of 118, 52 mg (0.10 mmol, 1.02 eq.) of PyBOP, 20 µL 
(20 mg, 0.183 mmol, 1.86 eq.) of benzylamine, 110 µL (101 mg, 1.00 mmol, 10.2 eq.) of NMM, 
and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 125 (27 mg, 
Yield=69 %) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.94 (dd, J = 8.6, 
2.3 Hz, 1H), 7.89 (d, J = 2.3 Hz, 1H), 7.35 – 7.22 (m, 5H), 7.14 (d, J = 8.7 Hz, 1H), 4.57 (s, 2H), 
4.23 (q, J = 7.0 Hz, 2H), 4.15 (s, 2H), 1.48 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) 
δ 167.60, 159.69, 138.80, 130.02, 129.99, 128.10, 127.15, 127.09, 126.78, 126.77, 126.40, 121.10, 
111.07, 64.29, 43.12, 38.63, 13.40. 
(5-(benzyl(methyl)carbamoyl)-2-ethoxyphenyl)methanaminium trifluoroacetate 
(126): See Procedure D: Step 1: 30 mg (0.098 mmol) of 118, 52 mg (0.10 mmol, 1.02 eq.) of 
PyBOP, 20 µL (19 mg, 0.155 mmol, 1.58 eq.) of N-methylbenzylamine, 110 µL (101 mg, 1.00 
mmol, 10.2 eq.) of NMM, and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. 
Compound 126 (28 mg, Yield=69 %) was isolated as a colorless oil. 1H NMR (400 MHz, 50 °C, 
Methanol-d4) δ 7.53 (dd, J = 8.5, 2.2 Hz, 1H), 7.49 (d, J = 2.1 Hz, 1H), 7.39 – 7.19 (m, 5H), 7.12 
(d, J = 8.5 Hz, 1H), 4.68 (s, 2H), 4.23 (q, J = 7.0 Hz, 2H), 4.15 (s, 2H), 2.97 (s, 3H), 1.47 (t, J = 
7.0 Hz, 3H). 13C NMR (101 MHz, 50 °C, Methanol-d4) δ 158.31, 136.67, 129.84, 129.54, 129.48, 
128.41, 128.12, 127.27, 121.29, 111.39, 64.31, 38.63, 13.38. 
(S)-1-((2-ethoxy-5-(pyrrolidin-1-ylmethyl)benzyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (127): See Procedure E and F: 32 
mg (0.088 mmol) of 119, 320 µL (0.64 mmol, 7.25 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of F: 155 µL (115 mg, 0.89 mmol, 10.1 eq.) of N,N-diisopropylethylamine, 52 mg 
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(0.10 mmol, 1.13 eq.) of PyBOP, 17 mg (0.10 mmol, 1.14 eq.) of 6-Cl-HOBt, 36 mg (0.088 mmol, 
1.00 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL TFA and 
2 mL DCM. Compound 127 (12.4 mg, Yield= 26 %) was isolated as a white solid. 1H NMR (500 
MHz, Methanol-d4) δ 7.67 (t, J = 5.8 Hz, 1H), 7.40 (dd, J = 8.6, 2.3 Hz, 1H), 7.14 (d, J = 2.3 Hz, 
1H), 6.98 (d, J = 8.4 Hz, 1H), 6.34 (s, 2H), 4.39 (dd, J = 14.7, 6.3 Hz, 1H), 4.26 (q, J = 13.0 Hz, 
2H), 4.15 (dd, J = 14.5, 4.7 Hz, 1H), 3.98 (p, J = 7.1 Hz, 2H), 3.91 (dd, J = 11.8, 4.4 Hz, 1H), 3.53 
– 3.38 (m, 2H), 3.22 – 3.06 (m, 3H), 2.94 (dd, J = 13.8, 4.4 Hz, 1H), 2.18 (br s, 2H), 2.03 (s, 8H), 
1.30 (t, J = 6.9 Hz, 3H). No 13C Data Acquired. ESI-MS: 426.3 [M + H]+, HPLC (gradient A): 
Retention Time: 17.62 min. 
(S)-1-((2-ethoxy-5-(piperidin-1-ylmethyl)benzyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (128): See Procedure E and F: 30 
mg (0.080 mmol) of 120, 280 µL (0.56 mmol, 7.03 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of F: 140 µL (104 mg, 0.80 mmol, 10.1 eq.) of N,N-diisopropylethylamine, 44 mg 
(0.085 mmol, 1.1 eq.) of PyBOP, 14 mg (0.083 mmol, 1.0 eq.) of 6-Cl-HOBt, 34 mg (0.083 mmol, 
1.0 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL TFA and 
2 mL DCM. Compound 128 (11 mg, Yield= 25 %) was isolated as a white solid. 1H NMR (500 
MHz, Methanol-d4) δ 7.73 (t, J = 5.8 Hz, 1H), 7.38 (dd, J = 8.4, 2.2 Hz, 1H), 7.13 (d, J = 2.2 Hz, 
1H), 6.98 (d, J = 8.4 Hz, 1H), 6.35 (s, 2H), 4.36 (dd, J = 14.7, 6.8 Hz, 1H), 4.21-4.15 (m, 3H), 
4.04 – 3.94 (m, 2H), 3.92 (dd, J = 11.8, 4.4 Hz, 1H), 3.42 (t, J = 11.9 Hz, 2H), 3.12 (dd, J = 13.7, 
11.8 Hz, 1H), 3.00 – 2.90 (m, 2H), 2.87 (td, J = 13.2, 12.4, 2.8 Hz, 1H), 2.04 (s, 6H), 1.93 (d, J = 
13.8 Hz, 2H), 1.83 (d, J = 13.8 Hz, 1H), 1.79 – 1.63 (m, 2H), 1.50 (qt, J = 12.8, 3.3 Hz, 1H), 1.31 
(t, J = 7.0 Hz, 3H). No 13C Data Acquired. ESI-MS: 440.3 [M + H]+, HPLC (gradient A): Retention 




hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (129): See Procedure 
E and F: 9 mg (0.024 mmol) of 121, 220 µL (0.44 mmol, 18.3 eq.) of 2 M BH3*Me2S in THF, and 
3 mL of THF. Step 1 of F: 60 µL (44 mg, 0.34 mmol, 14.3 eq.) of N,N-diisopropylethylamine, 17 
mg (0.033 mmol, 1.36 eq.) of PyBOP, 6 mg (0.035 mmol, 1.47 eq.) of 6-Cl-HOBt, 14 mg (0.034 
mmol, 1.42 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL 
TFA and 2 mL DCM. Compound 129 (1.0 mg, Yield=8 %) was isolated as a white solid. 1H NMR 
(500 MHz, Methanol-d4) δ 7.38 (dd, J = 8.4, 2.4 Hz, 1H), 7.15 (d, J = 2.2 Hz, 1H), 6.97 (d, J = 8.4 
Hz, 1H), 6.34 (s, 2H), 4.39 (dd, J = 14.5, 4.4 Hz, 1H), 4.28 (d, J = 12.6 Hz, 1H), 4.24 (d, J = 12.8 
Hz, 1H), 4.15 (dd, J = 14.6, 4.3 Hz, 1H), 3.98 (qd, J = 9.4, 7.3 Hz, 2H), 3.90 (dd, J = 11.8, 4.4 Hz, 
1H), 3.51 – 3.38 (m, 4H), 3.11 (dd, J = 13.8, 11.9 Hz, 1H), 2.94 (dd, J = 13.8, 4.5 Hz, 1H), 2.03 
(s, 6H), 1.86 (s, 2H), 1.30 (t, J = 6.9 Hz, 3H), 0.85 (q, J = 7.7 Hz, 1H), 0.65 (q, J = 4.9 Hz, 1H). 
No 13C Data Acquired. ESI-MS: 438.3 [M + H]+, HPLC (gradient A): Retention Time: 18.41 min. 
(S)-1-((2-ethoxy-5-(morpholinomethyl)benzyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (130): See Procedure E and F: 27 
mg (0.071 mmol) of 122, 250 µL (0.50 mmol, 7.0 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of F: 130 µL (96 mg, 0.75 mmol, 10.5 eq.) of N,N-diisopropylethylamine, 38 mg 
(0.073 mmol, 1.0 eq.) of PyBOP, 13 mg (0.077 mmol, 1.1 eq.) of 6-Cl-HOBt, 29 mg (0.071 mmol, 
0.99 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL TFA and 
2 mL DCM. Compound 130 (12.9 mg, Yield= 33 %) was isolated as a white solid. 1H NMR (500 
MHz, Methanol-d4) δ 7.72 (t, J = 5.7 Hz, 1H), 7.40 (dd, J = 8.4, 2.3 Hz, 1H), 7.15 (d, J = 2.2 Hz, 
1H), 6.99 (d, J = 8.4 Hz, 1H), 6.35 (s, 2H), 4.38 (dd, J = 14.8, 4.6 Hz, 1H), 4.28 (d, J = 13.1 Hz, 
1H), 4.24 (d, J = 13.0 Hz, 1H), 4.17 (dd, J = 14.7, 4.6 Hz, 1H), 4.08 – 3.95 (m, 4H), 3.92 (dd, J = 
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11.8, 4.4 Hz, 1H), 3.73 (t, J = 12.6 Hz, 2H), 3.38 – 3.32 (m, 2H), 3.21 – 3.07 (m, 3H), 2.95 (dd, J 
= 13.8, 4.5 Hz, 1H), 2.05 (s, 6H), 1.31 (t, J = 6.9 Hz, 3H). No 13C Data Acquired. ESI-MS: 442.3 
[M + H]+, HPLC (gradient A): Retention Time: 15.94 min. 
(S)-1-((2-ethoxy-5-(isoindolin-2-ylmethyl)benzyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (131): See Procedure E and F: 16 
mg (0.039 mmol) of 123, 140 µL (0.28 mmol, 7.18 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of F: 80 µL (59 mg, 0.46 mmol, 11.8 eq.) of N,N-diisopropylethylamine, 22 mg (0.042 
mmol, 1.08 eq.) of PyBOP, 9 mg (0.053 mmol, 1.36 eq.) of 6-Cl-HOBt, 17 mg (0.042 mmol, 1.06 
eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL TFA and 2 mL 
DCM. Compound 131 (6.1 mg, Yield=27 %) was isolated as a white solid. 1H NMR (500 MHz, 
Methanol-d4) δ 7.74 – 7.62 (m, 1H), 7.46 (dd, J = 8.5, 2.3 Hz, 1H), 7.44 – 7.37 (m, 4H), 7.22 (d, J 
= 2.3 Hz, 1H), 7.02 (d, J = 8.5 Hz, 1H), 6.32 (s, 2H), 4.66 (s, 2H), 4.64 (s, 2H), 4.52 (d, J = 3.2 
Hz, 2H), 4.45 – 4.35 (m, 1H), 4.17 (dd, J = 14.5, 4.6 Hz, 1H), 4.07 – 3.94 (m, 2H), 3.91 (dd, J = 
11.7, 4.4 Hz, 1H), 3.11 (dd, J = 13.5, 12.2 Hz, 1H), 2.94 (dd, J = 13.8, 4.4 Hz, 1H), 2.02 (s, 6H), 
1.31 (t, J = 7.0 Hz, 3H). No 13C Data Acquired. ESI-MS: 474.2 [M + H]+, HPLC (gradient A): 
Retention Time: 22.43 min. 
(S)-1-((5-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-2-ethoxybenzyl)amino)-3-(4-
hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (132): See Procedure 
E and F: 32 mg (0.075 mmol) of 124, 270 µL (0.54 mmol, 7.16 eq.) of 2 M BH3*Me2S in THF, 
and 4 mL of THF. Step 1 of F: 140 µL (103 mg, 0.80 mmol, 10.6 eq.) of N,N-
diisopropylethylamine, 41 mg (0.079 mmol, 1.04 eq.) of PyBOP, 15 mg (0.088 mmol, 1.17 eq.) of 
6-Cl-HOBt, 33 mg (0.081 mmol, 1.07 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of 
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DMF. Step 2 of F: 2 mL TFA and 2 mL DCM. Compound 132 (6.3 mg, Yield=14 %) was isolated 
as a white solid. 1H NMR (400 MHz, Methanol-d4) δ 7.78 (t, J = 5.7 Hz, 1H), 7.46 (dd, J = 8.4, 
2.3 Hz, 1H), 7.36 – 7.20 (m, 4H), 7.18 (d, J = 7.4 Hz, 1H), 7.02 (d, J = 8.5 Hz, 1H), 6.33 (s, 2H), 
4.38 (d, J = 12.8 Hz, 5H), 4.17 (dd, J = 14.5, 4.3 Hz, 1H), 4.00 (p, J = 7.4 Hz, 2H), 3.91 (dd, J = 
11.8, 4.4 Hz, 1H), 3.77 (br s, 1H), 3.39 (br s, 1H), 3.24 – 3.15 (m, 2H), 3.10 (t, J = 12.7 Hz, 1H), 
2.94 (dd, J = 13.8, 4.3 Hz, 1H), 2.01 (s, 6H), 1.30 (t, J = 6.9 Hz, 3H). No 13C Data Acquired. ESI-
MS: 488.3 [M + H]+, HPLC (gradient A): Retention Time: 23.36 min. 
(S)-1-((5-((benzylamino)methyl)-2-ethoxybenzyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (133): See Procedure E and F: 26 
mg (0.065 mmol) of 125, 230 µL (0.46 mmol, 7.04 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of F: 120 µL (89 mg, 0.69 mmol, 10.5 eq.) of N,N-diisopropylethylamine, 34 mg 
(0.065 mmol, 1.00 eq.) of PyBOP, 11 mg (0.065 mmol, 0.99 eq.) of 6-Cl-HOBt, 30 mg (0.073 
mmol, 1.12 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL 
TFA and 2 mL DCM. Compound 133 (13.5 mg, Yield= 36%) was isolated as a white solid. 1H 
NMR (500 MHz, Methanol-d4) δ 7.69 (t, J = 5.9 Hz, 1H), 7.54 – 7.42 (m, 5H), 7.38 (dd, J = 8.4, 
2.4 Hz, 1H), 7.18 (d, J = 2.3 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.34 (s, 2H), 4.35 (dd, J = 14.5, 4.8 
Hz, 1H), 4.24 – 4.12 (m, 5H), 3.97 (dddd, J = 16.3, 9.3, 7.0, 2.4 Hz, 3H), 3.92 (dd, J = 11.8, 4.4 
Hz, 1H), 3.10 (dd, J = 13.8, 11.7 Hz, 1H), 2.95 (dd, J = 13.8, 4.5 Hz, 1H), 2.03 (s, 6H), 1.30 (t, J 
= 6.9 Hz, 3H). No 13C Data Acquired. ESI-MS: 462.3 [M + H]+, HPLC (gradient A): Retention 
Time: 22.58 min. 
(S)-1-((5-((benzyl(methyl)amino)methyl)-2-ethoxybenzyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (134): See Procedure E and F: 26 
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mg (0.063 mmol) of 126, 220 µL (0.44 mmol, 7.18 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of F: 110 µL (82 mg, 0.63 mmol, 10.0 eq.) of N,N-diisopropylethylamine, 37 mg 
(0.071 mmol, 1.13 eq.) of PyBOP, 11 mg (0.065 mmol, 1.03 eq.) of 6-Cl-HOBt, 28 mg (0.068 
mmol, 1.09 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL 
TFA and 2 mL DCM. Compound 134 (14.4 mg, Yield= 39%) was isolated as a white solid. 1H 
NMR (400 MHz, Methanol-d4) δ 7.50 (s, 5H), 7.39 (dd, J = 8.4, 2.3 Hz, 1H), 7.18 (s, 1H), 7.00 (d, 
J = 8.5 Hz, 1H), 6.35 (s, 2H), 4.53 – 4.29 (m, 3H), 4.29 – 4.11 (m, 3H), 4.05 – 3.95 (m, 2H), 3.92 
(dd, J = 11.7, 4.4 Hz, 1H), 3.10 (dd, J = 13.6, 12.0 Hz, 1H), 2.94 (dd, J = 13.8, 4.4 Hz, 1H), 2.67 
(s, 3H), 2.03 (s, 6H), 1.31 (t, J = 7.0 Hz, 3H). No 13C Data Acquired. ESI-MS: 476.3 [M + H]+, 
HPLC (gradient A): Retention Time: 23.30 min. 
(S)-1-((2-ethoxy-5-(pyrrolidine-1-carbonyl)benzyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (135): See Procedure F: Step 1: 36 
mg (0.099 mmol) of 119, 180 µL (133 mg, 1.03 mmol, 10.4 eq.) of N,N-diisopropylethylamine, 
55 mg (0.11 mmol, 1.06 eq.) of PyBOP, 17 mg (0.10 mmol, 1.01 eq.) of 6-Cl-HOBt, 41 mg (0.10 
mmol, 1.01 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2: 2 mL TFA 
and 2 mL DCM. Compound 135 (9.7 mg, Yield=18 %) was isolated as a yellow solid. 1H NMR 
(500 MHz, Methanol-d4) δ 7.63 (t, J = 5.9 Hz, 1H), 7.48 (dd, J = 8.5, 2.2 Hz, 1H), 7.35 (d, J = 2.2 
Hz, 1H), 6.94 (d, J = 8.5 Hz, 1H), 6.33 (s, 2H), 4.31 (dd, J = 14.6, 5.0 Hz, 1H), 4.21 (dd, J = 14.6, 
4.7 Hz, 1H), 4.01 (dtt, J = 16.3, 8.9, 6.9 Hz, 2H), 3.89 (dd, J = 11.6, 4.5 Hz, 1H), 3.59 (t, J = 7.0 
Hz, 2H), 3.52 (t, J = 6.7 Hz, 2H), 3.11 (dd, J = 13.7, 11.7 Hz, 1H), 2.94 (dd, J = 13.8, 4.5 Hz, 1H), 
2.06 (s, 6H), 1.99 (p, J = 6.7 Hz, 2H), 1.90 (p, J = 6.4 Hz, 2H), 1.32 (t, J = 6.3 Hz, 3H). No 13C 




dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (136): See Procedure F: Step 1: 7 
mg (0.021 mmol) of 123 as HCl salt, 40 µL (30 mg, 0.23 mmol, 10.9 eq.) of N,N-
diisopropylethylamine, 14 mg (0.027 mmol, 1.28 eq.) of PyBOP, 4 mg (0.024 mmol, 1.12 eq.) of 
6-Cl-HOBt, 11 mg (0.027 mmol, 1.28 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of 
DMF. Step 2: 2 mL TFA and 2 mL DCM. Compound 136 (4.2 mg, Yield=41 %) was isolated as 
a white solid. 1H NMR (500 MHz, DMSO-d6) δ 8.99 (s, 1H), 8.29 (d, J = 5.4 Hz, 3H), 8.10 (t, J = 
5.9 Hz, 1H), 7.52 (dd, J = 8.5, 2.2 Hz, 1H), 7.38 (d, J = 6.9 Hz, 1H), 7.35 – 7.21 (m, 4H), 6.98 (d, 
J = 8.6 Hz, 1H), 6.31 (s, 2H), 4.85 (s, 2H), 4.73 (d, J = 8.4 Hz, 2H), 4.29 (dd, J = 15.3, 6.1 Hz, 
1H), 4.11 – 3.99 (m, 3H), 3.82 – 3.73 (m, 1H), 2.96 (dd, J = 13.9, 11.0 Hz, 1H), 2.81 (dd, J = 14.0, 
4.6 Hz, 1H), 2.07 (s, 6H), 1.30 (t, J = 6.9 Hz, 3H). No 13C Data Acquired. ESI-MS: 488.3 [M + 
H]+, HPLC (gradient A): Retention Time: 32.75 min. 
In Vitro Pharmacology 
Cell Lines and Membrane Preparations.  
All opioid in vitro assays were performed by Ashley Brinkel, Jack Twarozynski, and 
Jessica Anand. Tissue culture reagents were purchased from Gibco Life Sciences (Grand Island, 
NY, U.S.) unless otherwise noted. C6-rat glioma cells stably expressing rat MOR (C6-MOR) or 
rat DOR (C6-DOR) and Chinese hamster ovary (CHO) cells stably expressing human KOR (CHO-
KOR) were used for all in vitro assays. Cells were grown to confluence at 37 °C in 5 % CO2 in 
Dulbecco’s modified Eagle medium (DMEM) containing 10 % fetal bovine serum and 5 % 
penicillin/streptomycin. Membranes were prepared by washing confluent cells three times with ice 
cold phosphate buffered saline (0.9 % NaCl, 0.61 mM Na2HPO4, 0.38 mM KH2PO4, pH 7.4). Cells 
were detached from the plates by incubation in warm harvesting buffer (20 mM HEPES, 150 mM 
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NaCl, 0.68 mM EDTA, pH 7.4) and pelleted by centrifugation at 1600 rpm for 3 min. The cell 
pellet was suspended in ice-cold 50 mM Tris- HCl buffer, pH 7.4, and homogenized with a Tissue 
Tearor (Biospec Products, Inc., Bartlesville, OK, U.S.) for 20 s. The homogenate was centrifuged 
at 15,000 rpm for 20 min at 4 °C. The pellet was rehomogenized in 50 mM Tris-HCl with a Tissue 
Tearor for 10 s, followed by recentrifugation. The final pellet was resuspended in 50 mM Tris-
HCl and frozen in aliquots at -80 °C. Protein concentration was determined via a BCA protein 
assay (Thermo Scientific Pierce, Waltham, MA, U.S.) using bovine serum albumin as the standard.  
Radioligand Competition Binding Assays.  
Radiolabeled compounds were purchased from Perkin-Elmer (Waltham, MA, U.S.). 
Opioid ligand binding assays were performed by competitive displacement of 0.2 nM [3H]-
diprenorphine (250 μCi, 1.85 TBq/mmol) by the peptidomimetic from membrane preparations 
containing opioid receptors as described above. The assay mixture, containing membranes (20 μg 
protein/tube) in 50 mM Tris-HCl buffer (pH 7.4), 0.2 nM [3H]-diprenorphine, and various 
concentrations of test peptidomimetic, was incubated at room temperature on a shaker for 1 h to 
allow binding to reach equilibrium. The samples were rapidly filtered through Whatman GF/C 
filters using a Brandel harvester (Brandel, Gaithersburg, MD, U.S.) and washed three times with 
50 mM Tris-HCl buffer, pH 7.4. Bound radioactivity on dried filters was determined by liquid 
scintillation counting, after saturation with EcoLume liquid scintillation cocktail, in a Wallac 1450 
MicroBeta (Perkin-Elmer, Waltham, MA, U.S.). Nonspecific binding was determined using 10 
μM naloxone. The results presented are the mean ± standard error (S.E.M.) from at least three 
separate assays performed in duplicate. Ki (nM) values were calculated using nonlinear regression 
analysis to fit a logistic equation to the competition data using GraphPad Prism, version 6.0c, 
(GraphPad Software Inc., La Jolla, CA).  
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[35S]-GTPγS Binding Assays.  
Agonist stimulation of [35S]guanosine 5′-O-[γ- thio]triphosphate ([35S]-GTPγS, 1250 Ci, 
46.2 TBq/mmol) binding to G protein was measured as described previously.82 Briefly, membranes 
(10 μg of protein/well) were incubated for 1 h at 25°C in GTPγS buffer (50 mM Tris-HCl, 100 
mM NaCl, 5 mM MgCl2, 1 mM EDTA, pH 7.4) containing 0.1 nM [
35S]-GTPγS, 30 μM guanosine 
diphosphate (GDP), and varying concentrations of test peptidomimetic. G protein activation 
following receptor activation by peptidomimetic was compared with 10 μM of the standard 
compounds [D-Ala2,N-MePhe4,Gly-ol]enkephalin (DAMGO) at MOR, D-Pen2,5- enkephalin 
(DPDPE) at DOR, or U69,593 at KOR. The reaction was terminated by vacuum filtration through 
GF/C filters that were washed 5 times with GTPγS buffer. Bound radioactivity was measured as 
described above. The results are presented as the mean ± standard error (S.E.M.) from at least three 
separate assays performed in duplicate; potency (EC50 (nM)) and percent stimulation were 
determined using nonlinear regression analysis with GraphPad Prism 6, as above.  
Mouse Liver Microsome Stability Assays 
All liver microsome assays were performed by Quintara Biosciences. Metabolic stability 
of testing compounds was evaluated using mouse liver microsomes to predict intrinsic clearance. 
Mouse liver microsome tissue fractions were obtained from Corning or BioreclamationIVT. The 
assay was carried out in 96-well microtiter plates at 37 °C. Reaction mixtures (25 μL) contained a 
final concentration of 1 μM test compound, 0.1 mg/mL liver microsome protein, and 1 mM 
NADPH in 100 mM potassium phosphate, pH 7.4 buffer with 3 mM MgCl2. At each of the time 
points (0, 15, 30, and 60 minutes), 150 μL of quench solution (acetonitrile with 0.1% formic acid) 
with internal standard (bucetin) was transferred to each well. Verapamil was included as a positive 
control to verify assay performance. Plates were sealed, vortexed, and centrifuged at 4°C for 15 
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minutes at 4000 rpm. The supernatant was transferred to fresh plates for LC/MS/MS analysis. All 
samples were analyzed on LC/MS/MS using an AB Sciex API 4000 instrument, coupled to a 
Shimadzu LC-20AD LC Pump system. Analytical samples were separated using a Waters Atlantis 
T3 dC18 reverse phase HPLC column (20 mm x 2.1 mm) at a flow rate of 0.5 mL/min. The mobile 
phase consists of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile 
(solvent B). The extent of metabolism was calculated as the disappearance of the test compound, 
compared to the 0-min time incubation. Initial rates were calculated for the compound 
concentration and used to determine T1/2 values. 
Animals and In Vivo Solutions 
All in vivo opioid assays were performed by Bryan Sears. Animal care and experimental 
procedures complied with the US National Research Council's Guide for the Care and Use of 
Laboratory Animals.91 Animal studies are reported in compliance with the ARRIVE 
guidelines.92,93 Mice were group‐housed with a maximum of five animals per cage in clear 
polypropylene cages with corn cob bedding and nestlets as enrichment. Mice had free access to 
food and water at all times. Animals were housed in pathogen‐free rooms maintained between 68 
and 79 °F and humidity between 30 and 70 % humidity with a 12 h light/dark cycle with lights on 
at 07:00 h. Experiments were conducted in the housing room during the light cycle. All studies 
utilize male C57BL/6 mice from Envigo laboratories. Wild type mice weighing between 20-30 g 
at 7-15 weeks old, were used for behavioral experiments. All drug solutions were injected at a 
volume of 10 ml/kg. All drugs were dissolved in 9:1 DMSO/saline solution except for morphine 
sulphate and 0.6 % acetic acid which were dissolved in saline and water, respectively. All drugs 
were given sc. except for 0.6 % acetic acid which was given ip. 
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Acetic Acid Stretch Assay (AASA) 
Antinociceptive effects were evaluated in the mouse acetic acid stretch assay in which a 
noxious stimulus is administered ip. that induces a stretching behavior characterized by 
constriction of the abdomen followed by extension of the hind limbs. Mice received an injection 
of 0.6 % acetic acid, placed individually in clear plastic observation cages (10 x 6 x 8 in) with 
bedding, and the number of stretches were recorded for 20 min. Antinociceptive effects were 
determined with a 30 min pretreatment dose of compound sc. followed by 0.6 % acetic acid ip. A 
5 min latency period after acetic acid injection was establish and total number of stretches were 
recorded for the following 20 min. For the competition assays, a dose of 10 mg/kg naloxone was 
administered ip. 15 min. before administration of test drug. The assay was resumed as described 
above. Statistical comparison of the number of stretches recorded were assessed using a two-way 
ANOVA. 
 
Warm Water Tail Withdrawal Assay (WWTW) 
Antinociceptive effects were evaluated in the mouse warm water tail withdrawal (WWTW) 
assay. Mice were placed in cylindrical plastic restrainers and 2-3 cm of their tail were immersed 
in a water bath maintained at 50 C. Latency to a tail withdrawal or a rapid flick of the tail from 
the water bath was recorded for a maximum cut-off time of 20 s. Acute antinociceptive effects 
were determined by a single bolus injection. Each mouse received an injection of saline ip. and 
then 30 min later their baseline withdrawal latencies were recorded. Mice were then administered 
















Chapter 5: Discovery of Aromatic-Amine Pharmacophore 
5.1 Introduction 
 In the previous chapter, we had determined that replacing the benzyl pendant with an 
aromatic-amine pendant was capable of greatly improving MOR affinity, efficacy, and potency, 
while providing improvements in metabolic stability. These improvements in MOR effects occur 
regardless of whether the amine is attached to the aromatic group through a simple methylene 
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group (such as the benzyl amines), or through an aromatic-aliphatic bicyclic system (such as with 
an isoindoline or tetrahydroisoquinoline pendant). Furthermore, the amine alone was capable of 
greatly improving metabolic stability while stimulating MOR, though at the cost of reduced MOR 
potency. 
 These amine pendant analogues therefore show promise in our new series, and we were 
interested in exploring the scope with which these pendants can yield MOR-agonists. While it was 
feasible to begin to introduce additional functional groups around both the aromatic core and these 
amine pendants, we instead opted for a tighter SAR campaign that sought to combine these new 
pendants with elements from Chapter 2 that improved stability. This allowed us to ask multiple 
questions simultaneously in our series, opens the door for structural simplification rather than 
complication, and uses the same chemistry developed in Chapter 4.  
 Four structural elements from Chapter 2 were selected to complement the ethyl ether 
derivatives described in Chapter 4. These include the methyl, n-propyl and cyclopropyl methyl 
ethers, as well as the unfunctionalized aromatic core. The ethers were selected due to their capacity 
to improve stability and due to the range of MOR efficacy they elicit with modest differences in 
alkyl chain length and structure. The unfunctionalized core was also selected because it was the 
simplest structure and because it produced no stimulation at MOR. This provided a wide range of 
MOR efficacy and metabolic stability values through very simple structural changes upon which 
the introduction of amine pendants can reveal the degree to which the pendants can improve these 
parameters. These modifications can thus allow us to determine the scope of MOR-agonism and 
stability the amine pendants can provide in our series. 
 Regarding the amine pendants, four were selected. The bicyclic aromatic-amine pendants 
(isoindoline and tetrahydroisoquinoline) were selected due to their ability to greatly improve MOR 
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efficacy and potency, with the possibility of improving stability. Two monocyclic amine pendants 
(pyrrolidine and piperidine) were selected due to their capacity to greatly improve metabolic 
stability and MOR efficacy. 
 The overall design of these ligands is summarized in Figure 14. These four amine pendants 
and the additional four aromatic core structural elements were used to construct an SAR matrix 
pairing each amine pendant with each core element. This resulted in sixteen additional analogues 
that were combined with their respective ethyl ether analogues described in Chapter 4 and used to 
ask the several questions. To what degree can these new amine pendants stimulate MOR? How 
dependent is this activity on their respective aromatic core modifications? Do the stability gains 
described thus far with the amine pendants translate across different core modifications?  
 
Figure 14: Design of amine pendant analogues with different aromatic core modifications. 
Pendants were selected based on their improved metabolic stability, MOR-efficacy, and MOR-
potency. Core modifications were selected based on their improved stability and variability in 
MOR-agonism with minor changes in structure. 
 The answers to these questions can give us valuable insight into the SAR of these 
structures, allowing us to determine the ability and degree to which these pharmacophore elements 
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can produce our desired MOR-agonist/DOR-antagonist profile. This will also enable more 
efficient design of future analogues by reducing the number of ligands synthesized that do not 
stimulate MOR, as opposed to exploring moieties that produce unknown results. 
5.2 Results 
General Chemistry: The synthesis of these new analogues followed the same synthetic pathway 
described in Chapter 4 and are described in Scheme 8A. Here, the different ethers were introduced 
by alkylating methyl 3-formyl-4-hydroxybenzoate (115) using different alkyl iodides or bromides. 
These ethers, in addition to methyl 3-formylbenzoate (137), were then treated with Ellman’s chiral 
auxiliary to introduce a protected amine onto the aldehyde. The subsequent ethyl ester was then 
cleaved using LiOH and used as a common intermediate for incorporation of the amine analogues 
to construct our desired matrix (Scheme 8B). Pyrrolidine, piperidine, isoindoline, and 
tetrahydroisoquinoline pendants were incorporated into each aromatic core scaffold using PyBOP,  
Scheme 8: A) Synthesis of aromatic core analogues containing amine pendants to produce SAR 
matrices. B) Analogue codes for the intermediate amides and final compounds for each aromatic 




A) MeI or Alk-Br, K2CO3, DMF. B) 1. (R)-(+)-2-methyl-2-propanesulfinamide, Ti(OEt)4, THF 
2. NaBH4. C) LiOH, THF, EtOH, H2O D) 1. Cyclic amine, NMM, PyBOP, DMF. 2. conc. HCl, 
Dioxane. E) BH3*Me2S, THF, 75 C° F) 1. DiBocDMT, DIEA, PyBOP, 6-Cl-HOBt, DMF. 2. 
TFA, DCM. 
 
and the Ellman auxiliary was removed with conc. HCl and purified by reverse phase, yielding the 
intermediate as a TFA salt. The subsequent tertiary amide was then reduced with BH3*Me2S at 75 
°C and the primary amine was coupled to Boc-protected 2’,6’-dimethyltyrosine. The synthesis was 
completed by deprotection of the Boc group using TFA. 
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SAR: The analogues synthesized using Scheme 8 were sorted into matrices based on their affinity, 
selectivity, potency, and efficacy at MOR, DOR, and KOR respectively. The binding affinity 
matrix for MOR and DOR are described in Table 14, and for the sake of space, the binding affinity 
at KOR and selectivity are described in Table 15. These matrices will be used to describe the 
general effects of each pendant and core modification on our SAR. 
With regards to MOR-binding affinity (Table 14), several noteworthy trends are revealed 
from these matrices. The monocyclic amines possess low double-digit to single-digit nanomolar 
binding affinity depending on the presence and size of the ether chain. The pyrrolidine achieves 
an affinity maximum at the methyl ether (169) and gets close to but does not achieve similar levels 
of binding affinity as their benzyl pendant counterparts. The piperidine pendant in general, 
possesses higher levels of binding affinity than the pyrrolidine pendant and is in the single-digit 
nanomolar range independent of ether chain size. These piperidine analogues are often similar to 
their benzyl pendant counterparts. 
The binding affinity of the aromatic-amine analogues at MOR produce very flat SAR 
landscapes. These affinity values are similar and consistently sub-nanomolar, with the greatest 
affinity found with the cyclopropyl methyl ethers (179-180). These analogues generally possess a 
log improvement in binding affinity over the benzyl and piperidine analogues and upwards of a 2-
fold log improvement over the pyrrolidine depending on the core modification.  
The trends observed in DOR binding affinity (Table 14) with these analogues are similar 
to those observed in MOR. Conversion to the pyrrolidine ring consistently yielded a log loss in 
binding affinity compared to the benzyl pendant and was optimized at the ethyl (127) and n-propyl 
ethers (173). The piperidine pendant had a near 2 log range in binding affinity, which improves 
with increasing size of the ether. The isoindoline and tetrahydroquinoline pendants were also 
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insensitive to changes to the aromatic core, and in contrast to MOR binding affinity, DOR binding 
affinity rested in the low single-digit nanomolar range. 
 
59, 165-168 68, 169-172 70, 127-128, 
131-132 
71, 173-176 72, 177-180 





















































































































































































































4.8±1.0 1.85** 2.4±0.5 1.4±0.3 2.33** 
Table 14: Binding affinity matrix (Ki (nM)) of amine analogues of benzylic core structures from 
Chapter 2 at MOR and DOR. Included are the original benzylic core structures containing the 
benzyl pendant. Binding affinities were obtained by competitive displacement of radiolabeled 
[3H] diprenorphine in membrane preparations. All data were from three separate experiments, 
performed in duplicate unless otherwise noted. These data are reported as the average ± standard 
error of the mean. aData are from assays using rat MOR and DOR instead of human MOR and 
DOR used for all other assays. ** N=1, * N=2. 
 KOR binding affinity (Table 15) was subject to a greater variety of trends within these 
structural matrices. In general, each of the amine pendants yielded higher binding affinity 
compared to the original benzyl pendant. The exception exists when the pyrrolidine pendant is 
combined with the n-propyl ether (173), which had the lowest KOR affinity in the amine series 
and was the affinity minimum for the pyrrolidine pendant. The piperidine pendant had its affinity 




affinity minimum with the n-propyl ether (175), which was instead located with the ethyl ether 
(131). Conversely, affinity maximums, if anywhere, appear to occur consistently with the methyl 
ether across all four pendants (169-172). Finally, the aromatic-amine pendants generally had mid 
double-digit nanomolar affinity at KOR, a trend which broke with the ethyl ether and isoindoline 
pendant analogue (131), and with the n-propyl ether with both aromatic-amine pendants. 
 In general, the amine pendants yielded reduced selectivity of MOR over KOR, and variable 
affinity balance between MOR and DOR. The monocyclic analogues possessing smaller 
modifications (165-166, 169-170) had very poor selectivity for MOR over KOR.  For the 
piperidine and isoindoline pendants, MOR-selectivity over KOR was at its highest with the larger 
cyclopropyl methyl ethers (178-179). For the pyrrolidine, the greatest selectivity was with the ethyl 
ether (127), and for the THIQ pendant, the greatest selectivity was with the n-propyl ether (176). 
MOR binding affinity was most balanced with DOR binding affinity at different ethers within each 
pendant type. The pyrrolidine and piperidine pendants possessed the most affinity balance ranging 
from the ethyl ether to the cyclopropyl methyl ether. The aromatic-amine analogues generally had 
their affinity balance between MOR and DOR ranging from the methyl to n-propyl ethers. 
Interestingly, a loss of MOR/DOR balance was observed on the aromatic-amine pendants with the 
cyclopropyl methyl ethers (179-180). This, in conjunction with the improved selectivity of MOR 
over KOR, is likely a product of the improved binding affinity at MOR with these two analogues. 
 
59, 165-168 68, 169-172 70, 127-128, 
131-132 
71, 173-176 72, 177-180 

























































































































































































































1:21:201 1:8.8:178 1:10:192 1:6.4:918 1:47:520 
Table 15: Binding affinity (Ki (nM)) matrices of amine analogues of benzylic core structures 
from Chapter 2 at KOR and the selectivity of each analogue across all three receptors 
standardized to MOR. Included are the original benzylic core structures containing the benzyl 
pendant. Binding affinities were obtained by competitive displacement of radiolabeled [3H] 
diprenorphine in membrane preparations. All data were from three separate experiments, 
performed in duplicate unless otherwise noted. These data are reported as the average ± standard 
error of the mean. ** N=1, * N=2. 
 The potency matrices across MOR, DOR, and KOR are described in Table 16. The 
pyrrolidine analogues in general had micromolar potency at MOR, the only exception here is with 
the ethyl ether (70), which was in the low triple-digit nanomolar range. The piperidine also 
possessed poor MOR potency, with the maximum being with the n-propyl ether (174). In general, 
these monocyclic amines were less potent than their benzyl pendant counterparts. Interestingly, 
the aromatic-amine pendant analogues possessed improved potency at MOR across all core 
modifications as compared to their benzyl pendant precursors. Like MOR-binding affinity, 
potency here varied little and was in the single-digit nanomolar range, the only exception being 
the isoindoline pendant with no ether on the core (167). 
 
59, 165-168 68, 169-172 70, 127-128, 
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DNS >1000 DNS** DNS DNS 
Table 16: Potency matrices of amine and analogues of previously reported benzylic core 
structures from Chapter 2 at MOR, DOR, and KOR. Included are the original benzylic core 
structures containing the benzyl pendant. Potency data were obtained using agonist induced 
stimulation of [35S] GTPγS binding assay. Potency is represented as EC50 (nM). All data were 
from three separate experiments, performed in duplicate unless otherwise noted. ** N=1, * N=2 
These data are reported as the average ± standard error of the mean. DNS=Does Not Stimulate. 
aData are from assays using rat MOR and DOR instead of human MOR and DOR used for all 
other assays. 
 
In this series, a mixture of DOR effects was observed. Whereas the benzyl pendant 
consistently did not stimulate DOR, regions of DOR-agonism were found in the matrices. In fact, 
it is simpler to describe which regions did not have any DOR-agonism in this series. No agonism 
was observed for analogues that possessed no ether modification on the core except with the 
tetrahydroisoquinoline pendant (168). The tetrahydroquinoline pendant did not yield DOR-
agonism when combined with the ethyl or larger ethers. Finally, the pyrrolidine combined with the 
methyl ether also did not stimulate DOR (169). KOR-agonism in this series appears to be 
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consistently very low. In most cases, no observed KOR-stimulation was observed over the assay 
concentrations, and when efficacy was present, the potency was weak at values no less than 474 
nM. 
Efficacy matrices were also produced across MOR, DOR, and KOR and are shown in 
Table 17. The efficacy data collected at MOR revealed some promising trends. In the benzyl 
pendant series from Chapter 2, the efficacy at MOR ranged from no stimulation to 75.6 % 
stimulation. Here, across nearly all the amine pendant analogues, high levels of efficacy were 
observed. The exceptions here were with the monocyclic pendants with the unmodified core (165-
166), which may be a result of the poor potency of these analogues, and the pyrrolidine with the 
cyclopropyl methyl ether (177), which still had double the efficacy of its benzyl pendant 
counterpart (72). More importantly, most of these analogues were full agonists compared to 
DAMGO, and two analogues were superagonists compared to DAMGO, namely 168 and 175. 
With regard to DOR-efficacy when present, efficacy decreased with increasing size of the 
ether and efficacy also dropped with increasing amine pendant size. None of these analogues 
produced more than 55 % efficacy as compared to DPDPE. KOR-efficacy was largely poor when 
present. Of those that activated KOR, only one analogue produced efficacy greater than 40 % over 
the assay range (127).  
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DNS >15 DNS** DNS DNS 
Table 17: Efficacy matrices of amine analogues of previously reported benzylic core structures 
from Chapter 2 at MOR, DOR, and KOR. Included are the original benzylic core structures 
containing the benzyl pendant. Efficacy data were obtained using agonist induced stimulation of 
[35S] GTPγS binding assay. Efficacy was measured as percent maximal stimulation relative to 
standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 μM. All data were 
from three separate experiments, performed in duplicate unless otherwise noted. These data are 
reported as the average ± standard error of the mean. ** N=1, * N=2. DNS=Does Not Stimulate. 
aData are from assays using rat MOR and DOR instead of human MOR and DOR used for all 
other assays. 
Metabolic Stability: In keeping with our goals of maintaining improved metabolic stability, these 
stability values were determined for many of these analogues and compiled into a matrix found in 
Table 18. Many of these analogues possessed enhanced stability compared to their respective 
benzyl pendant counterparts. Where tested, the monocyclic amines still showed the greatest 
stability, which improved significantly when the ether on the core was removed. The stability here 
reached half-lives upwards of 5 hours in this assay. Curiously, the aromatic-amine pendants 
followed a different trend than that of the benzyl or monocyclic amine pendants. Here, they 
expressed stability optima at the ethyl ether, and stability dropped on either side of the ether chain 
length. The least stable molecule was analogue 167, which possessed an isoindoline pendant and 
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Table 18: Metabolic stability matrix of amine analogues of previously reported benzylic core 
structures from Chapter 2. Included are the original benzylic core structures containing the 
benzyl pendant for comparison. The compound half-life (T1/2) is in bold, the half-life of the 
positive control verapamil is in parentheses, and the stability ratio between the compound and 
the positive control is in brackets. The stability ratio was calculated by dividing the half-life of 
the analogue of interest by the half-life of the positive control in that assay. Individual 
compounds were tested once, with errors representing the SE in the decay curve regressed onto 
the data collected in 15-minute intervals. ND= No Data 
 
Molecular Modeling: To elucidate how the aromatic-amine pharmacophore is producing the in 
vitro effects described above, molecular docking studies of superagonist 168 were performed at 
MOR, DOR, and KOR (Figure 15). At MOR, a couple of notable interactions can be observed. It 
appears that the aromatic ring is interacting with Trp133, and while at a distance, Asn127 may be 
interacting with the tertiary amine. At DOR, another tryptophan residue (Trp114) interacts with 






Figure 15: Molecular docking of superagonist 168 at the three opioid receptors. Shown are 
interactions of the tetrahydroisoquinoline pendant with A) MOR in the active state, B) DOR in 
the inactive state, and C) KOR in the inactive state. 
with Lys108. Finally, the tertiary amine may interact with the phenol of Tyr109. Lastly, the 
aromatic ring of the pharmacophore again interacts with the indole of Trp124, and the amine may 
interact with the primary amide of Gln115. 
Antinociceptive Activity: Several of the tetrahydroquinoline pendant analogues were then subject 
to in vivo screening in the AASA (Figure 16). For comparison, the ethyl ether analogue 132 is 
included and morphine was used as the positive control. Since the screening of these analogues is 




produced antinociception at a dose of at least 10 mg/kg, and the n-propyl ether analogue 176 was 
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Figure 16: Antinociceptive activity of 132 and analogues 168, 172, 176, and 180 using the 
AASA. Included is morphine as positive control. Panels A-B represent dose-response curves 
with the ligands: A) 132 and the superagonist 168, B) ether analogues 172, 176, and 180. ** 
P<0.01 compared to vehicle. ***P<0.001 compared to vehicle. **** P<0.0001 compared to 
vehicle. Codes by asterisks in panel B represent P-values for overlapping analogues. N’s are 
between 2 and 6 for each data point. 
5.3 Discussion and Conclusions 
SAR: The data presented in the above matrices reveal some very useful SAR trends, particularly 
in their effects at MOR. Monocyclic amine pendants generally appear to be dependent on their 
aromatic core modifications for binding affinity and potency, but not high efficacy. Conversely, 
the aromatic-amine pendants are largely insensitive to changes on the aromatic core and 
consistently possess very good binding affinity and potency. These data point out two important 
SAR characteristics on the nature of the amine pendants. Amines can produce high MOR-efficacy 
on their own, a trend that is supported by the amide analogues 135 and 136 of the previous chapter, 
which lose all MOR-efficacy. When these amines are combined with an aromatic ring in the 
pendant, then high MOR-binding affinity and potency are achieved independent of changes to the 
aromatic core. In some cases, this aromatic-amine pharmacophore can produce potent 




can be a valuable pharmacophore for producing MOR-agonists, which is a necessary component 
in our desired bifunctional profile. 
 With regard to DOR-binding, aromatic-amine analogues generally possessed between a 
one to two log improvement in binding affinity over their monocyclic amine counterparts. This 
can be attributed to the aromatic ring, as the original benzyl pendant analogues also possessed 
good binding affinity at this receptor. DOR-potency and efficacy occurred frequently and was 
typically weak. If the analogue was relatively potent at DOR compared to the other analogues, 
then it was not as efficacious and vice versa. This points to weak interactions within DOR that 
come from a combination of core and pendant modifications. This is supported by the fact that 
within each amine pendant and core modification, there exist analogues which do not stimulate 
DOR. Ergo no single amine pendant or core modification consistently stimulates DOR. 
KOR-binding was generally improved upon conversion to the amine pendants, and the 
addition of the aromatic ring to the amine pharmacophore either further improved binding affinity 
or had no appreciable effect. This suggests that the aromatic-amine pharmacophore generally 
improves binding compared to the benzyl pendant, though exceptions do exist. This points toward 
the possibility that KOR-binding can be reduced with appropriate core modifications. When 
selectivity is incorporated, the aromatic-amine pendants generally possess greater selectivity for 
MOR over KOR, mostly through improved MOR-binding. The aromatic-amine analogues also 
possessed the best MOR/DOR balance, particularly with the isoindolines. These data suggest that 
the aromatic-amines will be better pharmacophores for our desired opioid profile. Finally, KOR-
agonism was always low, which is consistent with our desired profile. 
Metabolic Stability: The stability data acquired here revealed some interesting trends. Unlike the 
benzyl pendant, the monocyclic amines possess improved stability with no ether on the core (165-
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166). This may be attributed to a combination of two things. The monocyclic amines are more 
polar than the benzyl pendant and are less metabolically labile. Conversion then away from this 
benzyl pendant therefore reduces the cLogP of the entire ligand and removes a metabolically labile 
aromatic ring. Since the ethers increase cLogP and are metabolically labile, removal of these 
structures when the monocyclic amines are present result in further stability improvements. 
 Curiously, the aromatic-amine pendants result in different stability trends compared to the 
benzyl and monocyclic amine pendants. The stability optimum exists in both cases with the ethyl 
ethers, though the tetrahydroisoquinoline pendant with an n-propyl ether was just as stable as the 
ethyl ether. Here, it appears that a balance of cLogP and blocking metabolic sites is important for 
the stability of these ligands. The cyclopropyl group, which may sterically block metabolism at 
the adjacent benzylic position that connects to DMT, also happens to increase cLogP. This increase 
in cLogP can facilitate metabolism on the aromatic-amine pendant, which is more metabolically 
liable than the monocyclic amine or benzyl pendants. The steric effects of these ethers are still 
relevant, as reduction to a methyl ether or removal of the ether entirely enables metabolism at the 
adjacent benzylic position. This is more prevalent in the aromatic-amine series than in the 
monocyclic amine series likely due to their greater cLogP. 
Molecular Modeling: The molecular modeling shown in this chapter may allow us to explain the 
superagonist activity enabled by the pharmacophore at MOR, any residual DOR agonism present, 
and the enhanced binding at KOR. Consistent across all of the opioid receptors is an interaction 
between the aromatic ring of the pharmacophore and the indole of a tryptophan residue. This 
interaction can explain the enhanced binding at MOR and DOR, though the lack of a trend in the 
KOR-binding data with and without the aromatic ring suggests this interaction is not a deciding 
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factor at this receptor. At MOR, the closest residue to the amine is an asparagine residue, which 
may activate the receptor through the formation of a hydrogen bond.  
 At DOR, there appears to be a clear charge-π interaction between the aromatic ring of the 
peptidomimetic and Lys108 and can explain the enhanced binding affinity that occurs with the 
aromatic rings. On either side of this residue is a tyrosine residue (Tyr109), and a tryptophan 
residue (Trp114). The phenol of the tyrosine residue may interact with the tertiary amine of the 
ligand, and thus facilitate activation of this receptor. Receptor activation though, appears to be a 
bit sensitive to both the identity of the pendant and the identity of the ether modification. It is 
feasible that the ligand needs to position this amine in just the right way to interact with this 
tyrosine residue. If this ligand is too big (eg a large ether with a large pendant), the amine may be 
pushed closer to Trp114 and unable to interact with the phenol. If too small (eg no ether and a 
small pendant), the amine is too close to the DMT pharmacophore in space and can’t interact with 
the phenol. This may explain diagonal line of DOR-stimulation that bisects the DOR-efficacy 
matrix. 
 Finally, the amine of analogue 168 may interact with Gln115 at KOR. Though this 
possesses an amide, like Asn127 in MOR, it should be noted that any KOR-stimulation that exists 
is extremely weak, if present at all. In MOR, the residues Trp133 and Asn127 that interact with 
the pharmacophore are only six residues apart. In KOR, Trp124 and Gln115 are nine residues 
apart. This difference in distance may have important implications for receptor activation, as it 
may not be possible for the pharmacophore to adequately interact with both residues such that the 
receptor is activated, especially if the core of the ligand is tied into an aromatic ring. However, 
given the large distance between some of these key residues and the tetrahydroisoquinoline 
pendant, additional in silico studies will be needed to verify these interactions. 
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Antinociceptive Activity: The additional analogues screened for their in vivo activity, while limited, 
allows for a possible trend to emerge. It appears that the ether on the aromatic core may be 
important for activity, as the only analogue without this ether (168) was inactive. It should be noted 
here that 168 is a superagonist at MOR. While this high efficacy did not translate in this case to in 
vivo activity, it is possible that this may be a product of pharmacokinetic factors rather than 
pharmacodynamic ones. Short of synthesizing additional analogues that may yield an in vivo active 
superagonist, it may be more feasible to administer this compound via intracerebral ventricular 
injection. This may allow for the pharmacological effects of a MOR-superagonist to be elucidated 
in future studies. 
Broader Implications: This aromatic-amine pharmacophore appears to have great potential in 
producing bifunctional MOR/DOR ligands. As such, we were curious to determine if a similar 
pharmacophore was utilized in previously described opioids outside of our peptidomimetic series. 
The aromatic activity of this pharmacophore is unsurprising, as it still mimics the phenylalanine 
side chain of the opioid peptides. An overview of the literature of similar peptides and 
peptidomimetics suggests that the most similar analogues rely upon aromatic-amides instead of 
our aromatic-amines (Figure 17A), with the superagonist analogue 168 shown for comparison. 
Most notable are the DMT-Tic pharmacophore series94–101 their structurally related DMT-Aba 
derivatives102,103 and the DMT-Xxx-Aba derivatives,104–110 though a screen of a peptide library 
also produced a cyclic peptides with a similar amide.111,112 Bifunctional ligands connecting the 
DMT-Tic pharmacophore to a fentanyl scaffold have also been reported.113 Finally, a series of 
endomorphin derivatives have also been reported.114–120 
The closest structures that utilize amines possess the amine in a different relative position 
compared to the dimethyl tyrosine residue (Figure 17B). For instance, the MOR-agonist/DOR 
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antagonist DIPP[Ψ]-NH2 in the TIPP series of analogues
121 possesses an amine in the peptide 
chain, albeit at the 3rd heavy atom away from the DMT residue instead of ours which is the 6th 
heavy atom. A few similar ligands have also been described.77,122 
There are a few opioid peptides that express a nitrogen heterocycle at similar positions to 
our newly synthesized peptidomimetics without the aromatic ring (Figure 17C). The nitrogen in 
these systems are noticeably at different distances from the DMT or Tyr residues, and they are 







Figure 17: Literature structures that are close to our discovered aromatic-amine pharmacophore 
outside of our previously reported peptidomimetic series. A) Opioid peptides and 
peptidomimetics that contain the benzyl pharmacophore, but have the amine trapped as an 
amide. B) Opioid peptides and small molecules that contain an amine pharmacophore with 
variability in the distance to the aromatic portion of the pharmacophore and in the distance from 
the dimethyltyrosine residue if applicable. C) Opioid peptides that contain a nitrogen heterocycle 
without the corresponding aromatic ring. 
Notably, each of the unnatural peptides reported previously have a much higher molecular 
weight than our peptidomimetics, and many of these are incapable of stimulating MOR. With this 
aromatic-amine pharmacophore, we believe that this structure can be incorporated into the opioid 
peptides and their analogues to produce potent MOR-agonists. This pharmacophore in turn may 
allow for structural simplification of these peptides, through removal of bulky core elements, such 
as the large ring systems produced through peptide cyclization, or the use of large amino acids, 
such as Tic, Phe, and their other unnatural amino acid counterparts. 
Conclusions: The data collected in this chapter provide valuable information necessary to address 
the questions asked in the beginning of this chapter. Amines in the pendant are capable of 
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consistently stimulating MOR, independent of modifications to the core. The addition of an 
aromatic ring onto the amine pendant consistently improves potency at MOR, also independent of 
modifications to the core. As such, this aromatic-amine pendant pharmacophore may be used in 
future ligands to produce MOR-agonists out of a wide variety of structures. In this series, DOR-
affinity is maintained, and while some residual DOR-agonism may be present in some ligands, 
they may still be used as leads to further develop non-addictive opioids. Finally, the monocyclic 
amines maintain high levels of metabolic stability, whereas the stability of the aromatic-amine 
pendant analogues are dependent on the structures attached to the core. 
 Finally, it should be noted that this series produced two MOR-superagonists (168 and 175). 
Not only does this reinforce the utility of this new pharmacophore, but it may also yield some 
novel pharmacological results, as there are few ligands that possess efficacy at MOR this high. As 
such, further pharmacological studies should be pursued with these analogues, and additional 
derivatives that use this aromatic-amine pendant are likely to be fruitful. 
5.4 Experimental 
Chemistry 
General Methods: All reagents and solvents were obtained commercially and were used 
without further purification. Intermediates were purified by flash chromatography using a Biotage 
Isolera One instrument. Most purification methods utilized a hexanes/ethyl acetate solvent system 
in a Biotage SNAP KP-Sil column, with a linear gradient between 0 and 100% ethyl acetate. 
Reverse phase column chromatography using a linear gradient of 0% to 100% solvent B (0.1% 
TFA in acetonitrile) in solvent A (0.1% TFA in water) using a Biotage SNAP Ultra C18 column 
was utilized for some intermediate amine salts. Purification of final compounds was performed 
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using a Waters semipreparative HPLC with a Vydac protein and peptide C18 reverse phase 
column, using a linear gradient of 0% to 100% solvent B in solvent A at a rate 1% per minute, 
monitoring UV absorbance at 230 nm. The purity of final compounds was assessed using a Waters 
Alliance 2690 analytical HPLC instrument with a Vydac protein and peptide C18 reverse phase 
column. A linear gradient (gradient A) of 0% to70% solvent B in solvent A in 70 min, measuring 
UV absorbance at 230 nm was used to determine purity. All final compounds used for testing were 
≥95% pure, as determined by analytical HPLC. 1H NMR and 13C NMR data were obtained on a 
500 or 400 MHz Varian spectrometer using CDCl3, CD3OD, DMSO-d6, or D2O as solvents. The 
identities of final compounds were verified by mass spectrometry using an Agilent 6130 LC–MS 
mass spectrometer in positive ion mode, or an Agilent 6230 TOF HPLC-MS in the positive ion 
mode. 
General Procedure for the Synthesis of 6-position Ethers (Procedure A): To a flame dried 
flask containing methyl 3-formyl-4-hydroxybenzoate (115) was added 3 equivalents of 
potassium carbonate. The flask was purged with argon and 4 mL of DMF was added. 3 equivalents 
of an alkyl iodide or bromide was then added, and the solution was stirred at room temperature 
overnight. The solution was then concentrated in vacuo, partitioned between ethyl acetate and 
saturated sodium carbonate, and extracted with ethyl acetate. The organic layers were combined, 
dried with magnesium sulfate, filtered, and concentrated in vacuo, yielding the desired ether. 
General Procedure for Ellman Reductions (Procedure B): A flamed-dried round bottom 
flask containing 1 equivalent of aldehyde and 3 equivalents of (R)-(+)-2-methyl-2-
propanesulfinamide was attached to a reflux condenser and flushed with argon. 4 mL of THF was 
added and cooled to 0 °C. 6 equivalents of titanium (IV) ethoxide was added, followed by an 
additional 4 mL of THF. The solution was stirred and heated to 75 °C overnight with TLC 
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monitoring until all ketone or aldehyde was consumed. A separate flame-dried flask containing 6 
equivalents of sodium borohydride was flushed with argon. 4 mL of THF was added, at which 
point the solution was cooled to -78 °C. The solution containing Ellman adduct was cooled to room 
temperature and slowly transferred to the sodium borohydride solution via syringe. This final 
solution was then allowed to warm to room temperature and stirred for 2 hours, at which point the 
reaction mixture was quenched with methanol to consume the sodium borohydride, followed by 
DI water to precipitate the titanium. The solution was vacuum filtered, and the precipitate was 
washed with ethyl acetate. The filtrate was the concentrated in vacuo and purified via column 
chromatography (0-100% EtOAc in Hexanes). 
General Procedure for the Saponification of Esters (Procedure C): To a flask containing 
1 equivalent of the desired ester was added 7 equivalents of LiOH, 2 mL of THF, 2 mL of EtOH, 
and 2 mL of H2O. The reaction was stirred overnight under ambient atmosphere and temperature. 
Upon completion, the solvent was concentrated in vacuo, suspended in acetone, and filtered. The 
precipitate was washed with additional acetone, and the filtrate was concentrated in vacuo, yielding 
the saponified product as a lithium carboxylate.  
General Procedure for Amine Pendant Attachment and Cleavage of Ellman auxiliaries 
(Procedure D): To a flask containing 1 equivalent of the lithium carboxylate was added 1 
equivalent of PyBOP and 1 equivalent of the desired amine. The flask was flushed with argon, 
DMF was added as solvent, and 10 equivalents of N-methylmorpholine was added. The reaction 
was stirred overnight, at which point it was concentrated in vacuo and purified via column 
chromatography (0-10% methanol in DCM). To the protected amine was immediately added 2 mL 
of Dioxane and 0.2 mL concentrated HCl. The solution was stirred at room temperature for 1 
minute and concentrated in vacuo. The ensuing salt was triturated with diethyl ether, and then was 
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purified using a reverse phase chromatography (0-100% B in A), yielding the product as a TFA 
salt. 
General Procedure for the Reduction of Pendant Amides (Procedure E): To a dried flask 
containing 1 equivalent of the desired amide under argon was added THF and 7 equivalents of 2 
M BH3*Me2S complex in THF. The reaction was heated at 75 °C for 3 hours, at which point the 
reaction was quenched with MeOH and heated for an additional 15 minutes. The reaction was then 
cooled, concentrated in vacuo, and was used in Procedure F without further purification. 
General Procedure for the Coupling of 2’,6’-Dimethyltyrosine to Functionalized Amine 
Salts (Procedure F): To a dried flask containing the amine under argon was added 3 mL of DMF 
and 10 equivalents of Hunig’s base. 1 equivalent of PyBOP and 1 equivalent of 6-Cl-HOBt was 
added, followed by a 1 equivalent of doubly Boc protected 2’,6’-Dimethyltyrosine in 1.5 mL DMF. 
The solution was stirred overnight at room temperature, concentrated in vacuo, and purified via 
semipreparative reverse phase HPLC (0.1% TFA in water: 0.1% TFA in acetonitrile). 2 mL of 
TFA and 2 mL of DCM were then added, and the solution was stirred for an additional hour. The 
reaction mixture was concentrated in vacuo and purified via an additional semipreparative reverse 
phase HPLC (0.1% TFA in water: 0.1% TFA in acetonitrile). The product was concentrated in 
vacuo and lyophilized overnight to yield the final peptidomimetic. 
Methyl 4-methoxy-3-formylbenzoate (138): See Procedure A: 160 mg (0.88 mmol) of 
methyl 3-formyl-4-hydroxybenzoate (115), 368 mg (2.66 mmol, 3.00 eq.) of K2CO3, 170 µL 
(388 mg, 2.73 mmol, 3.08 eq) of MeI, 4 mL of DMF. Compound 138 (162 mg, Yield=94 %) was 
isolated as a yellow solid. 1H NMR (500 MHz, Chloroform-d) δ 10.44 (s, 1H), 8.49 (d, J = 2.3 Hz, 
1H), 8.23 (dd, J = 8.8, 2.3 Hz, 1H), 7.04 (d, J = 8.8 Hz, 1H), 4.00 (s, 3H), 3.90 (s, 3H). 13C NMR 
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(126 MHz, Chloroform-d) δ 188.84, 165.96, 164.71, 137.10, 130.67, 124.44, 122.92, 111.54, 
56.06, 52.12. 
Methyl 4-propoxy-3-formylbenzoate (139): See Procedure A: 168 mg (0.93 mmol) of 
methyl 3-formyl-4-hydroxybenzoate (115), 388 mg (2.81 mmol, 3.01 eq.) of K2CO3, 260 µL 
(352 mg, 2.86 mmol, 3.07 eq) of nPrBr, 4 mL of DMF. Compound 139 (188 mg, Yield=91 %) 
was isolated as a colorless oil that turns to a white solid on standing. 1H NMR (500 MHz, 
Chloroform-d) δ 10.44 (s, 1H), 8.43 (d, J = 2.3 Hz, 1H), 8.15 (dd, J = 8.8, 2.3 Hz, 1H), 6.98 (d, J 
= 8.8 Hz, 1H), 4.07 (t, J = 6.4 Hz, 2H), 3.86 (s, 3H), 1.87 (h, J = 7.2 Hz, 2H), 1.05 (t, J = 7.4 Hz, 
3H). 13C NMR (126 MHz, Chloroform-d) δ 188.78, 165.94, 164.41, 136.98, 130.24, 124.36, 
122.56, 112.27, 70.44, 52.03, 22.30, 10.41. 
Methyl 4-(cyclopropylmethoxy)-3-formylbenzoate (140): See Procedure A: See 
Procedure A: 181 mg (1.00 mmol) of methyl 3-formyl-4-hydroxybenzoate (115), 417 g (3.02 
mmol, 3.00 eq.) of K2CO3, 290 µL (404 mg, 2.99 mmol, 2.98 eq) of cyclopropylmethyl bromide, 
4 mL of DMF. Compound 140 (233 mg, Yield=99 %) was isolated as a yellow oil. 1H NMR (500 
MHz, Chloroform-d) δ 10.41 (s, 1H), 8.35 (d, J = 2.3 Hz, 1H), 8.07 (dd, J = 8.8, 2.3 Hz, 1H), 6.90 
(d, J = 8.8 Hz, 1H), 3.91 (d, J = 6.9 Hz, 2H), 3.80 (s, 3H), 1.31 – 1.20 (m, 1H), 0.65 – 0.56 (m, 
2H), 0.32 (dt, J = 6.2, 4.8 Hz, 2H). 13C NMR (126 MHz, Chloroform-d) δ 188.81, 165.84, 164.29, 
136.86, 130.06, 124.34, 122.48, 112.43, 73.58, 51.97, 9.83, 3.18. 
Ethyl (R)-3-(((tert-butylsulfinyl)amino)methyl)benzoate (141): See Procedure B: Step 
1: 220 mg (1.34 mmol) of methyl 3-formylbenzoate (137), 490 mg (4.04 mmol, 3.02 eq.) of (R)-
(+)-2-methyl-2-propanesulfinamide, 1.7 mL (1.8 g, 8.1 mmol, 6.1 eq.) of Ti(OEt)4, 5+5 mL THF. 
Step 2: 331 mg (8.75 mmol, 6.08 eq.) of sodium borohydride in 5 mL THF.  Compound 141 (278 
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mg, Yield= 73 %) was isolated as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.93 (t, J 
= 1.8 Hz, 1H), 7.86 (dt, J = 7.8, 1.5 Hz, 1H), 7.46 (dt, J = 7.7, 1.4 Hz, 1H), 7.32 (td, J = 7.7, 2.5 
Hz, 1H), 4.33 – 4.18 (m, 4H), 3.80 (dd, J = 6.9, 4.6 Hz, 1H), 1.30 (t, J = 7.1 Hz, 3H), 1.17 (d, J = 
1.4 Hz, 9H). 13C NMR (126 MHz, Chloroform-d) δ 166.24, 139.00, 132.41, 130.68, 128.97, 
128.66, 128.57, 60.95, 55.94, 48.79, 22.63, 14.24. 
Ethyl (R)-3-(((tert-butylsulfinyl)amino)methyl)-4-methoxybenzoate (142): See 
Procedure B: Step 1: 234 mg (1.21 mmol) of 138, 441 mg (3.64 mmol, 3.02 eq.) of (R)-(+)-2-
methyl-2-propanesulfinamide, 1.55 mL (1.69 g, 7.39 mmol, 6.14 eq.) of Ti(OEt)4, 4+4 mL THF. 
Step 2: 274 mg (7.24 mmol, 6.01 eq.) of sodium borohydride in 4 mL THF. Compound 142 (374 
mg, Yield=99 %) was isolated as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.96 – 7.90 
(m, 2H), 6.84 (d, J = 9.3 Hz, 1H), 4.36 (dd, J = 14.3, 5.6 Hz, 1H), 4.28 (q, J = 7.1 Hz, 2H), 4.16 
(dd, J = 14.3, 7.6 Hz, 1H), 3.85 (s, 3H), 3.73 (t, J = 6.6 Hz, 1H), 1.32 (t, J = 7.1 Hz, 3H), 1.17 (s, 
9H). 13C NMR (126 MHz, Chloroform-d) δ 166.19, 160.92, 131.07, 130.63, 127.08, 122.66, 
109.83, 60.65, 55.88, 55.58, 44.92, 22.56, 21.94, 14.31. 
Ethyl (R)-3-(((tert-butylsulfinyl)amino)methyl)-4-propoxybenzoate (143): See 
Procedure B: Step 1: 181 mg (0.81 mmol) of 139, 299 mg (2.5 mmol, 3.0 eq.) of (R)-(+)-2-methyl-
2-propanesulfinamide, 1025 µL (1115 mg, 4.9 mmol, 6.0 eq.) of Ti(OEt)4, 4+4 mL THF. Step 2: 
187 mg (4.9 mmol, 6.1 eq.) of sodium borohydride in 4 mL THF. Compound 143 (272 mg, Yield= 
98 %) was isolated as a yellow oil. 1H NMR (500 MHz, Chloroform-d) δ 7.89 (d, J = 2.2 Hz, 1H), 
7.86 (dd, J = 8.5, 2.3 Hz, 1H), 6.77 (d, J = 8.6 Hz, 1H), 4.32 (dd, J = 14.4, 5.5 Hz, 1H), 4.23 (q, J 
= 7.0 Hz, 2H), 4.13 (dd, J = 14.3, 7.7 Hz, 1H), 3.91 (t, J = 6.4 Hz, 2H), 3.76 (t, J = 6.6 Hz, 1H), 
1.75 (h, J = 7.4 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H), 1.13 (s, 9H), 0.97 (t, J = 7.4 Hz, 3H). 13C NMR 
161 
 
(126 MHz, Chloroform-d) δ 166.11, 160.35, 130.90, 130.46, 127.11, 122.34, 110.40, 69.73, 60.20, 
55.74, 44.88, 22.52, 22.40, 14.25, 10.52. 
Ethyl (R)-3-(((tert-butylsulfinyl)amino)methyl)-4-(cyclopropylmethoxy)benzoate 
(144): See Procedure B: Step 1: 230 mg (0.98 mmol) of 140, 359 mg (2.96 mmol, 3.02 eq.) of 
(R)-(+)-2-methyl-2-propanesulfinamide, 1.25 mL (1.36 g, 5.96 mmol, 6.07 eq.) of Ti(OEt)4, 4+4 
mL THF. Step 2: 225 mg (4.26 mmol, 5.95 eq.) of sodium borohydride in 4 mL THF. Compound 
144 (333 mg, Yield= 96 %) was isolated as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 
7.97 – 7.87 (m, 2H), 6.79 (d, J = 8.5 Hz, 1H), 4.42 (dd, J = 14.3, 5.7 Hz, 1H), 4.29 (q, J = 7.1 Hz, 
2H), 4.20 (dd, J = 14.3, 7.8 Hz, 1H), 3.91 – 3.81 (m, 3H), 1.34 (t, J = 7.1 Hz, 4H), 1.29 – 1.20 (m, 
2H), 1.19 (s, 10H), 0.66 – 0.58 (m, 2H), 0.36 – 0.29 (m, 2H). 13C NMR (126 MHz, Chloroform-
d) δ 166.23, 160.41, 131.01, 130.59, 127.24, 122.48, 110.58, 72.99, 60.65, 55.83, 45.46, 22.59, 
14.33, 10.10, 3.24, 3.20. 
Lithium (R)-3-(((tert-butylsulfinyl)amino)methyl)benzoate (145): See Procedure C: 
285 mg (1.01 mmol) of 141, 143 mg (5.97 mmol, 5.94 eq.) of LiOH, 2 mL of THF, 2 mL of EtOH, 
and 2 mL of H2O. The compound was suspended and filtered in EtOH instead of acetone. 
Compound 145 (240 mg, Yield= 91 %) was isolated as a white solid. 1H NMR (400 MHz, 
Methanol-d4) δ 7.92 (d, J = 1.8 Hz, 1H), 7.85 (dt, J = 7.7, 1.5 Hz, 1H), 7.45 – 7.39 (m, 1H), 7.33 
(t, J = 7.6 Hz, 1H), 4.34 (d, J = 14.4 Hz, 1H), 4.26 (d, J = 14.4 Hz, 1H), 1.24 (s, 9H). 13C NMR 
(101 MHz, Methanol-d4) δ 173.83, 138.51, 137.91, 129.60, 128.53, 127.93, 127.48, 55.72, 48.76, 
21.79. 
Lithium (R)-3-(((tert-butylsulfinyl)amino)methyl)-4-methoxybenzoate (146): See 
Procedure C: 181 mg (0.58 mmol) of 142, 86 mg (3.59 mmol, 6.21 eq.) of LiOH, 2 mL of THF, 2 
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mL of EtOH, and 2 mL of H2O. Compound 146 (128 mg, Yield= 76 %) was isolated as a white 
solid. 1H NMR (500 MHz, Methanol-d4) δ 7.95 – 7.88 (m, 2H), 6.93 (d, J = 8.4 Hz, 1H), 4.32 (d, 
J = 14.4 Hz, 1H), 4.22 (d, J = 14.4 Hz, 1H), 3.87 (s, 3H), 1.22 (s, 9H). 13C NMR (126 MHz, 
Methanol-d4) δ 173.83, 159.18, 130.41, 130.20, 129.69, 125.95, 109.03, 55.64, 54.63, 44.23, 
21.74. 
Lithium (R)-3-(((tert-butylsulfinyl)amino)methyl)-4-propoxybenzoate (147): See 
Procedure C: 272 mg (0.80 mmol) of 143, 114 mg (4.76 mmol, 6.0 eq.) of LiOH, 2 mL of THF, 2 
mL of EtOH, and 2 mL of H2O. Compound 147 (226 mg, Yield= 89 %) was isolated as a colorless 
oil. 1H NMR (400 MHz, Methanol-d4) δ 7.92 (d, J = 2.2 Hz, 1H), 7.87 (dd, J = 8.5, 2.2 Hz, 1H), 
6.91 (d, J = 8.6 Hz, 1H), 4.35 (d, J = 14.3 Hz, 1H), 4.23 (d, J = 14.3 Hz, 1H), 4.01 (t, J = 6.4 Hz, 
2H), 1.85 (h, J = 7.4 Hz, 2H), 1.22 (s, 9H), 1.08 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, Methanol-
d4) δ 173.91, 158.57, 130.34, 130.11, 129.48, 125.96, 109.75, 69.35, 55.63, 44.22, 22.32, 21.73, 
9.67. 
Lithium (R)-3-(((tert-butylsulfinyl)amino)methyl)-4-(cyclopropylmethoxy)benzoate 
(148): See Procedure C: 333 mg (0.94 mmol) of 144, 135 mg (5.64 mmol, 5.98 eq.) of LiOH, 2 
mL of THF, 2 mL of EtOH, and 2 mL of H2O. Compound 148 (271 mg, Yield=87 %) was isolated 
as a white amorphous solid. 1H NMR (500 MHz, Methanol-d4) δ 7.93 (d, J = 2.2 Hz, 1H), 7.88 
(dd, J = 8.5, 2.2 Hz, 1H), 6.89 (d, J = 8.6 Hz, 1H), 4.37 (d, J = 14.3 Hz, 1H), 4.25 (d, J = 14.4 Hz, 
1H), 3.90 (d, J = 7.2 Hz, 2H), 1.30 (dddd, J = 11.6, 8.0, 4.7, 1.2 Hz, 2H), 1.23 (s, 12H), 0.67 – 
0.59 (m, 2H), 0.41 – 0.35 (m, 2H). 13C NMR (126 MHz, Methanol-d4) δ 173.84, 158.58, 130.38, 
130.15, 129.60, 126.06, 110.05, 72.54, 55.65, 44.55, 21.77, 9.87, 2.28, 2.27. 
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(3-(pyrrolidine-1-carbonyl)phenyl)methanaminium trifluoroacetate (149): See 
Procedure D: Step 1: 24 mg (0.092 mmol) of 145, 49 mg (0.094 mmol, 1.02 eq.) of PyBOP, 20 
µL (17 mg, 0.24 mmol, 2.6 eq.) of pyrrolidine, 100 µL (92 mg, 0.91 mmol, 9.89 eq.) of NMM, 
and 4 mL of DMF. The compound was suspended in DCM and sat. Na2CO3, extracted with DCM, 
and filtered after column chromatography. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. 
Compound 149 (12 mg, Yield=41 %) was isolated as a colorless oil. 1H NMR (500 MHz, 
Methanol-d4) δ 7.61 – 7.51 (m, 4H), 4.17 (s, 2H), 3.60 (t, J = 7.0 Hz, 2H), 3.45 (t, J = 6.7 Hz, 2H), 
2.00 (p, J = 6.5, 6.1 Hz, 2H), 1.91 (p, J = 6.7 Hz, 2H). 13C NMR (126 MHz, Methanol-d4) δ 169.56, 
137.54, 133.57, 130.29, 129.00, 127.28, 127.15, 49.36, 46.07, 42.52, 25.78, 23.90. 
(3-(piperidine-1-carbonyl)phenyl)methanaminium trifluoroacetate (150): See 
Procedure D: Step 1: 20 mg (0.077 mmol) of 145, 41 mg (0.079 mmol, 1.03 eq.) of PyBOP, 20 
µL (17 mg, 0.20 mmol, 2.6 eq.) of piperidine, 90 µL (83 mg, 0.82 mmol, 10.7 eq.) of NMM, and 
4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 150 (15 mg, Yield=59 
%) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.60 – 7.51 (m, 2H), 7.47 
(d, J = 1.8 Hz, 1H), 7.44 (dt, J = 7.1, 1.6 Hz, 1H), 3.72 (d, J = 5.9 Hz, 2H), 3.37 (t, J = 5.4 Hz, 
2H), 1.76 – 1.63 (m, 4H), 1.54 (s, 2H). 13C NMR (126 MHz, Methanol-d4) δ 170.04, 136.87, 
133.77, 129.94, 129.13, 126.96, 126.91, 48.62, 42.94, 42.53, 26.13, 25.28, 23.97. 
(3-(isoindoline-2-carbonyl)phenyl)methanaminium trifluoroacetate (151): See 
Procedure D: Step 1: 21 mg (0.080 mmol) of 145, 45 mg (0.086 mmol, 1.08 eq.) of PyBOP, 14 
mg (0.090 mmol, 1.12 eq.) of isoindoline hydrochloride, 90 µL (83 mg, 0.82 mmol, 10.2 eq.) of 
NMM, and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 151 (19 
mg, Yield=65 %) was isolated as a colorless oil. 1H NMR (500 MHz, DMSO-d6) δ 8.29 (br s, 3H), 
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7.70 (t, J = 1.6 Hz, 1H), 7.62 (dt, J = 7.4, 1.5 Hz, 1H), 7.57 (dt, J = 7.8, 1.6 Hz, 1H), 7.52 (t, J = 
7.5 Hz, 1H), 7.40 (d, J = 6.5 Hz, 1H), 7.34 – 7.21 (m, 3H), 4.87 (s, 2H), 4.76 (s, 2H), 4.11 (q, J = 
5.8 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ 168.97, 158.86, 158.58, 137.40, 137.21, 136.35, 
134.74, 130.74, 129.20, 127.97, 127.87, 127.84, 127.38, 123.41, 123.12, 54.63, 52.49, 42.47. 
(3-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)phenyl)methanaminium 
trifluoroacetate (152): See Procedure D: Step 1: 16 mg (0.061 mmol) of 145, 36 mg (0.069 mmol, 
1.13 eq.) of PyBOP, 20 µL (21 mg, 0.16 mmol, 2.6 eq.) of 1,2,3,4-tetrahydroisoquinoline, 80 µL 
(74 mg, 0.73 mmol, 11.9 eq.) of NMM, and 5 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL 
conc. HCl. Compound 152 (17 mg, Yield=73 %) was isolated as a colorless oil. 1H NMR (400 
MHz, 50 °C, Methanol-d4) δ 7.62 – 7.41 (m, 5H), 7.17 (s, 3H), 4.77 (br s, 2H), 4.18 (s, 2H), 3.68 
(br s, 2H), 2.92 (br s, 2H). 13C NMR (101 MHz, 50 °C, Methanol-d4) δ 170.64,136.84, 133.78, 
132.44, 130.11, 129.20, 128.32, 127.16, 127.00, 126.57, 126.18, 42.63. 
(2-methoxy-5-(pyrrolidine-1-carbonyl)phenyl)methanaminium trifluoroacetate 
(153): See Procedure D: Step 1: 20 mg (0.069 mmol) of 146, 37 mg (0.071 mmol, 1.03 eq.) of 
PyBOP, 20 µL (17 mg, 0.24 mmol, 3.5 eq.) of pyrrolidine, 80 µL (74 mg, 0.73 mmol, 10.6 eq.) of 
NMM, and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 153 (21 
mg, Yield=88 %) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.65 (dd, J 
= 8.5, 2.2 Hz, 1H), 7.55 (d, J = 2.3 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 4.14 (s, 2H), 3.97 (s, 3H), 
3.58 (t, J = 7.0 Hz, 2H), 3.51 (t, J = 6.6 Hz, 2H), 1.98 (p, J = 6.9 Hz, 2H), 1.91 (p, J = 6.7 Hz, 2H). 
13C NMR (126 MHz, Methanol-d4) δ 169.44, 159.24, 130.20, 129.76, 128.82, 110.28, 55.09, 49.60, 
46.25, 38.67, 25.89, 23.89. 
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(2-methoxy-5-(piperidine-1-carbonyl)phenyl)methanaminium trifluoroacetate (154): 
See Procedure D: Step 1: 23 mg (0.079 mmol) of 146, 42 mg (0.081 mmol, 1.02 eq.) of PyBOP, 
20 µL (17 mg, 0.20 mmol, 2.5 eq.) of piperidine, 90 µL (83 mg, 0.82 mmol, 10.4 eq.) of NMM, 
and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 154 (23 mg, 
Yield=80 %) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.49 (dd, J = 8.5, 
2.2 Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.16 (d, J = 8.5 Hz, 1H), 4.13 (s, 2H), 3.97 (s, 3H), 3.69 (br 
s, 2H), 3.44 (br s, 2H), 1.74 – 1.51 (m, 6H). 13C NMR (126 MHz, Methanol-d4) δ 170.18, 158.97, 
129.82, 129.49, 128.10, 121.24, 110.47, 55.08, 48.43, 38.67, 24.01, 20.05. 
(5-(isoindoline-2-carbonyl)-2-methoxyphenyl)methanaminium trifluoroacetate (155): 
See Procedure D: Step 1: 21 mg (0.072 mmol) of 146, 39 mg (0.075 mmol, 1.04 eq.) of PyBOP, 
12 mg (0.077 mmol, 1.07 eq.) of isoindoline hydrochloride, 80 µL (74 mg, 0.73 mmol, 10.1 eq.) 
of NMM, and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 155 (26 
mg, Yield=91 %) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.76 (dd, J 
= 8.5, 2.2 Hz, 1H), 7.64 (d, J = 2.2 Hz, 1H), 7.37 (d, J = 7.3 Hz, 1H), 7.34 – 7.26 (m, 2H), 7.22 (t, 
J = 7.3 Hz, 2H), 4.96 (s, 2H), 4.88 (s, 2H), 4.17 (s, 2H), 4.00 (s, 3H). 13C NMR (126 MHz, 
Methanol-d4) δ 170.13, 159.36, 136.29, 135.57, 130.16, 129.68, 128.39, 127.51, 127.33, 122.44, 
122.15, 121.19, 110.48, 55.13, 54.69, 52.29, 38.66. 
(2-methoxy-5-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)phenyl)methanaminium 
trifluoroacetate (156): See Procedure D: Step 1: 19 mg (0.065 mmol) of 146, 34 mg (0.065 mmol, 
1.0 eq.) of PyBOP, 40 µL (42 mg, 0.32 mmol, 4.8 eq.) of 1,2,3,4-tetrahydroisoquinoline, 75 µL 
(69 mg, 0.68 mmol, 10.0 eq.) of NMM, and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL 
conc. HCl. Compound 156 (23 mg, Yield=86 %) was isolated as a colorless oil. 1H NMR (400 
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MHz, 50 °C, Methanol-d4) δ 7.56 (dd, J = 8.5, 2.2 Hz, 1H), 7.47 (d, J = 2.1 Hz, 1H), 7.20 – 7.13 
(m, 4H), 7.07 (br s, 1H), 4.74 (br s, 2H), 4.15 (s, 2H), 3.98 (s, 3H), 3.80 (br s, 2H), 2.92 (t, J = 6.1 
Hz, 2H). 13C NMR (101 MHz, 50 °C, Methanol-d4) δ 159.24, 134.20, 132.60, 130.00, 129.60, 
128.31, 128.17, 126.52, 126.14, 121.34, 110.66, 55.13, 38.75. 
(2-propoxy-5-(pyrrolidine-1-carbonyl)phenyl)methanaminium trifluoroacetate 
(157): See Procedure D: Step 1: 20 mg (0.063 mmol) of 147, 33 mg (0.063 mmol, 1.01 eq.) of 
PyBOP, 20 µL (17 mg, 0.24 mmol, 3.8 eq.) of pyrrolidine, 70 µL (64 mg, 0.64 mmol, 10.2 eq.) of 
NMM, and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 157 (15 
mg, Yield=64 %) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.63 (dd, J 
= 8.5, 2.2 Hz, 1H), 7.55 (d, J = 2.2 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 4.15 (s, 2H), 4.12 (t, J = 6.6 
Hz, 2H), 3.58 (t, J = 7.0 Hz, 2H), 3.52 (t, J = 6.5 Hz, 2H), 1.99 (p, J = 6.8 Hz, 2H), 1.94 – 1.87 
(m, 4H), 1.08 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 169.54, 158.57, 130.11, 
129.57, 128.56, 116.57, 111.10, 70.03, 46.29, 38.34, 25.90, 23.90, 21.90, 9.34. 
(5-(piperidine-1-carbonyl)-2-propoxyphenyl)methanaminium trifluoroacetate (158): 
See Procedure D: Step 1: 25 mg (0.078 mmol) of 147, 41 mg (0.079 mmol, 1.0 eq.) of PyBOP, 
20 µL (17 mg, 0.20 mmol, 2.6 eq.) of piperidine, 90 µL (83 mg, 0.82 mmol, 10.5 eq.) of NMM, 
and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 158 (24 mg, 
Yield=79 %) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.46 (dd, J = 8.5, 
2.2 Hz, 1H), 7.41 (d, J = 2.1 Hz, 1H), 7.14 (d, J = 8.5 Hz, 1H), 4.14 (s, 2H), 4.11 (t, J = 6.6 Hz, 
2H), 3.68 (br s, 2H), 3.44 (br s, 2H), 1.89 (h, J = 7.4 Hz, 2H), 1.75 – 1.61 (m, 4H), 1.55 (br s, 2H), 
1.08 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 170.32, 158.30, 129.73, 129.29, 
127.79, 121.27, 111.30, 70.03, 38.34, 23.98, 21.89, 20.07, 9.34. 
167 
 
(5-(isoindoline-2-carbonyl)-2-propoxyphenyl)methanaminium trifluoroacetate (159): 
See Procedure D: Step 1: 23 mg (0.072 mmol) of 147, 39 mg (0.075 mmol, 1.0 eq.) of PyBOP, 
15 mg (0.096 mmol, 1.3 eq.) of isoindoline hydrochloride, 80 µL (74 mg, 0.73 mmol, 10.2 eq.) of 
NMM, and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 159 (23 
mg, Yield=75 %) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.73 (dd, J 
= 8.5, 2.2 Hz, 1H), 7.64 (d, J = 2.2 Hz, 1H), 7.37 (d, J = 7.4 Hz, 1H), 7.30 (dt, J = 15.3, 7.0 Hz, 
2H), 7.22 (d, J = 7.4 Hz, 1H), 7.19 (d, J = 8.6 Hz, 1H), 4.96 (s, 2H), 4.18 (s, 2H), 4.15 (t, J = 6.6 
Hz, 2H), 1.92 (h, J = 7.4 Hz, 2H), 1.10 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 
170.17, 158.67, 136.29, 135.57, 130.06, 129.48, 128.17, 127.51, 127.33, 122.44, 122.15, 121.24, 
111.27, 70.06, 54.70, 52.30, 38.32, 21.92, 9.32. 
(2-propoxy-5-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)phenyl)methanaminium 
trifluoroacetate (160): See Procedure D: Step 1: 30 mg (0.094 mmol) of 147, 49 mg (0.094 mmol, 
1.0 eq.) of PyBOP, 20 µL (21 mg, 0.16 mmol, 1.7 eq.) of 1,2,3,4-tetrahydroisoquinoline, 110 µL 
(101 mg, 1.0 mmol, 10.7 eq.) of NMM, and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL 
conc. HCl. Compound 160 (33 mg, Yield=80 %) was isolated as a colorless oil. 1H NMR (400 
MHz, 50 °C, Methanol-d4) δ 7.53 (dd, J = 8.5, 2.2 Hz, 1H), 7.48 (d, J = 2.1 Hz, 1H), 7.21 – 7.12 
(m, 4H), 7.07 (br s, 1H), 4.73 (br s, 2H), 4.17 (s, 2H), 4.14 (t, J = 6.6 Hz, 2H), 3.80 (br s, 2H), 2.92 
(br t, J = 6.1 Hz, 2H), 1.90 (h, J = 7.2 Hz, 2H), 1.08 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, 50 
°C, Methanol-d4) δ 158.55, 134.20, 132.61, 129.88, 129.46, 128.31, 127.98, 126.53, 126.14, 
121.42, 111.50, 70.23, 38.43, 21.90, 9.22. 
(2-(cyclopropylmethoxy)-5-(pyrrolidine-1-carbonyl)phenyl)methanaminium 
trifluoroacetate (161): See Procedure D: Step 1: 31 mg (0.094 mmol) of 148, 49 mg (0.094 mmol, 
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1.01 eq.) of PyBOP, 20 µL (17 mg, 0.24 mmol, 2.6 eq.) of pyrrolidine, 100 µL (92 mg, 0.91 mmol, 
9.7 eq.) of NMM, and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 
161 (32 mg, Yield=88 %) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.61 
(dd, J = 8.5, 2.2 Hz, 1H), 7.56 (d, J = 2.2 Hz, 1H), 7.11 (d, J = 8.6 Hz, 1H), 4.17 (s, 2H), 4.01 (d, 
J = 7.0 Hz, 2H), 3.58 (t, J = 7.0 Hz, 2H), 3.51 (t, J = 6.7 Hz, 2H), 1.99 (p, J = 6.7 Hz, 2H), 1.90 
(p, J = 6.5 Hz, 2H), 1.39 – 1.31 (m, 1H), 0.69 – 0.63 (m, 2H), 0.44 – 0.38 (m, 2H). 13C NMR (126 
MHz, Methanol-d4) δ 169.45, 158.58, 130.06, 129.56, 128.67, 121.12, 111.31, 73.29, 49.59, 46.24, 
38.45, 25.89, 23.89, 20.05, 9.50, 2.24. 
(2-(cyclopropylmethoxy)-5-(piperidine-1-carbonyl)phenyl)methanaminium 
trifluoroacetate (162): See Procedure D: Step 1: 31 mg (0.094 mmol) of 148, 49 mg (0.094 mmol, 
1.01 eq.) of PyBOP, 20 µL (17 mg, 0.20 mmol, 2.2 eq.) of piperidine, 100 µL (92 mg, 0.91 mmol, 
9.7 eq.) of NMM, and 4.5 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 
162 (25 mg, Yield=69 %) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.45 
(d, J = 8.4 Hz, 1H), 7.42 (s, 1H), 7.12 (d, J = 8.4 Hz, 1H), 4.17 (s, 2H), 4.00 (d, J = 6.9 Hz, 2H), 
3.68 (br s, 2H), 3.44 (br s, 2H), 1.72 (br s, 2H), 1.64 (br s, 2H), 1.56 (br s, 2H), 1.42 – 1.30 (m, 
1H), 0.71 – 0.61 (m, 2H), 0.48 – 0.35 (m, 2H). 13C NMR (126 MHz, Methanol-d4) δ 170.20, 
158.30, 129.68, 129.29, 127.96, 121.38, 111.51, 73.30, 38.45, 24.01, 9.50, 2.24. 
(2-(cyclopropylmethoxy)-5-(isoindoline-2-carbonyl)phenyl)methanaminium 
trifluoroacetate (163): See Procedure D: Step 1: 24 mg (0.072 mmol) of 148, 39 mg (0.075 mmol, 
1.04 eq.) of PyBOP, 11 mg (0.071 mmol, 0.98 eq.) of isoindoline hydrochloride, 80 µL (74 mg, 
0.73 mmol, 10.1 eq.) of NMM, and 4 mL of DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. 
HCl. Compound 163 (26 mg, Yield=82 %) was isolated as a colorless oil. 1H NMR (500 MHz, 
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Methanol-d4) δ 7.72 (dd, J = 8.5, 2.2 Hz, 1H), 7.64 (d, J = 2.2 Hz, 1H), 7.37 (d, J = 7.4 Hz, 1H), 
7.30 (dt, J = 15.3, 7.0 Hz, 2H), 7.22 (d, J = 7.3 Hz, 1H), 7.18 (d, J = 8.6 Hz, 1H), 4.96 (s, 2H), 
4.88 (s, 2H), 4.21 (s, 2H), 4.04 (d, J = 7.0 Hz, 2H), 1.37 (dddd, J = 12.1, 9.9, 7.2, 3.4 Hz, 1H), 0.71 
– 0.64 (m, 2H), 0.43 (dt, J = 6.2, 4.6 Hz, 2H). 13C NMR (126 MHz, Methanol-d4) δ 170.15, 158.70, 
136.30, 135.57, 130.02, 129.47, 128.22, 127.51, 127.32, 122.44, 122.15, 121.32, 111.51, 73.34, 
54.69, 52.29, 38.45, 9.52, 2.27. 
(2-(cyclopropylmethoxy)-5-(1,2,3,4-tetrahydroisoquinoline-2-
carbonyl)phenyl)methanaminium trifluoroacetate (164): See Procedure D: Step 1: 28 mg 
(0.085 mmol) of 148, 46 mg (0.089 mmol, 1.0 eq.) of PyBOP, 20 µL (21 mg, 0.16 mmol, 1.9 eq.) 
of 1,2,3,4-tetrahydroisoquinoline, 100 µL (92 mg, 0.91 mmol, 10.8 eq.) of NMM, and 4 mL of 
DMF. Step 2: 2 mL of dioxane and 0.2 mL conc. HCl. Compound 164 (30 mg, Yield=79 %) was 
isolated as a colorless oil. 1H NMR (400 MHz, 50 °C, Methanol-d4) δ 7.52 (dd, J = 8.5, 2.1 Hz, 
1H), 7.48 (d, J = 1.9 Hz, 1H), 7.20 – 6.97 (m, 5H), 4.73 (s, 2H), 4.19 (s, 2H), 4.04 (d, J = 7.0 Hz, 
2H), 3.80 (s, 2H), 2.92 (t, J = 6.1 Hz, 2H), 1.41 – 1.29 (m, 1H), 0.77 – 0.60 (m, 2H), 0.42 (qd, J = 
4.6, 2.3 Hz, 2H). 13C NMR (101 MHz, 50 °C, Methanol-d4) δ 158.58, 134.19, 132.61, 129.86, 
129.42, 128.31, 128.04, 126.52, 126.14, 121.52, 111.81, 73.45, 38.59, 9.53, 2.22. 
(S)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxo-1-((3-(pyrrolidin-1-
ylmethyl)benzyl)amino)propan-2-aminium trifluoroacetate (165): See Procedure E and F: 29 
mg (0.091 mmol) of 149, 320 µL (0.64 mmol, 7.03 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of F: 160 µL (119 mg, 0.92 mmol, 10.1 eq.) of N,N-diisopropylethylamine, 48 mg 
(0.092 mmol, 1.01 eq.) of PyBOP, 18 mg (0.11 mmol, 1.17 eq.) of 6-Cl-HOBt, 40 mg (0.098 
mmol, 1.07 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL 
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TFA and 2 mL DCM. Compound 165 (4.5 mg, Yield=10 %) was isolated as a white solid. (MS)EI: 
382.2 (M+H), Retention Time: 14.47 min. 1H NMR (500 MHz, Deuterium Oxide) δ 7.32 – 7.23 
(m, 2H), 6.96 (s, 1H), 6.87 (d, J = 6.4 Hz, 1H), 6.27 (s, 2H), 4.32 (d, J = 14.8 Hz, 1H), 4.22 (d, J 
= 13.0 Hz, 1H), 4.15 (d, J = 13.0 Hz, 1H), 3.93 – 3.77 (m, 2H), 3.41 – 3.27 (m, 2H), 3.08 – 2.87 
(m, 4H), 2.01 (dd, J = 12.5, 5.0 Hz, 2H), 1.92 (s, 6H), 1.86 – 1.73 (m, 2H). 
(S)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxo-1-((3-(piperidin-1-
ylmethyl)benzyl)amino)propan-2-aminium trifluoroacetate (166): See Procedure E and F: 16 
mg (0.048 mmol) of 150, 170 µL (0.34 mmol, 7.08 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of F: 90 µL (67 mg, 0.52 mmol, 10.7 eq.) of N,N-diisopropylethylamine, 29 mg (0.056 
mmol, 1.16 eq.) of PyBOP, 9 mg (0.053 mmol, 1.10 eq.) of 6-Cl-HOBt, 21 mg (0.051 mmol, 1.07 
eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL TFA and 2 mL 
DCM. Compound 166 (11.5 mg, Yield=47 %) was isolated as a white solid. (MS)EI: 396.3 (M+H), 
Retention Time: 15.67 min. 1H NMR (500 MHz, Deuterium Oxide) δ 7.95 (t, J = 6.0 Hz, 1H), 7.33 
– 7.18 (m, 2H), 6.96 (s, 1H), 6.90 (d, J = 7.2 Hz, 1H), 6.28 (s, 2H), 4.38 – 4.28 (m, 1H), 4.13 (d, J 
= 13.2 Hz, 1H), 4.06 (d, J = 13.2 Hz, 1H), 3.95 – 3.82 (m, 2H), 3.29 (t, J = 12.4 Hz, 2H), 3.03 (dd, 
J = 13.9, 11.8 Hz, 1H), 2.94 (dd, J = 14.0, 5.0 Hz, 1H), 2.78 (qd, J = 13.1, 3.0 Hz, 2H), 1.93 (s, 
6H), 1.78 (d, J = 12.7 Hz, 2H), 1.67 (dt, J = 13.4, 3.3 Hz, 1H), 1.60 – 1.46 (m, 2H), 1.32 (qt, J = 
12.6, 3.5 Hz, 1H). 
(S)-3-(4-hydroxy-2,6-dimethylphenyl)-1-((3-(isoindolin-2-ylmethyl)benzyl)amino)-1-
oxopropan-2-aminium trifluoroacetate (167): See Procedure E and F: 16 mg (0.044 mmol) of 
151, 150 µL (0.30 mmol, 6.82 eq.) of 2 M BH3*Me2S in THF, and 4 mL of THF. Step 1 of F: 80 
µL (59 mg, 0.46 mmol, 10.4 eq.) of N,N-diisopropylethylamine, 25 mg (0.048 mmol, 1.10 eq.) of 
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PyBOP, 11 mg (0.065 mmol, 1.48 eq.) of 6-Cl-HOBt, 20 mg (0.049 mmol, 1.12 eq.) of Boc-O-
Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL TFA and 2 mL DCM. 
Compound 167 (4.6 mg, Yield=19 %) was isolated as a white solid. (MS)EI: 430.2 (M+H), 
Retention Time: 19.30 min. 1H NMR (500 MHz, Methanol-d4) δ 8.31 (t, J = 5.7 Hz, 1H), 7.48 – 
7.36 (m, 6H), 7.18 (d, J = 2.2 Hz, 1H), 7.06 (dt, J = 7.1, 1.7 Hz, 1H), 6.44 (s, 2H), 4.65 (s, 4H), 
4.59 (d, J = 12.9 Hz, 2H), 4.54 (d, J = 12.8 Hz, 2H), 4.50 – 4.42 (m, 2H), 4.18 (dd, J = 15.2, 4.3 
Hz, 1H), 3.91 (dd, J = 11.6, 4.7 Hz, 1H), 3.24 (dd, J = 13.8, 11.6 Hz, 1H), 3.02 (dd, J = 13.8, 4.7 
Hz, 1H), 2.19 (s, 6H). 
(S)-1-((3-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)benzyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (168): See Procedure E and F: 11 
mg (0.029 mmol) of 152, 100 µL (0.20 mmol, 6.92 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of F: 50 µL (37 mg, 0.29 mmol, 9.93 eq.) of N,N-diisopropylethylamine, 17 mg (0.033 
mmol, 1.13 eq.) of PyBOP, 5 mg (0.029 mmol, 1.02 eq.) of 6-Cl-HOBt, 12 mg (0.029 mmol, 1.01 
eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL TFA and 2 mL 
DCM. Compound 168 (5.0 mg, Yield=31 %) was isolated as a white solid. (MS)EI: 444.3 (M+H), 
Retention Time: 20.66 min. 1H NMR (500 MHz, Methanol-d4) δ 8.31 (t, J = 5.7 Hz, 1H), 7.44 (d, 
J = 6.3 Hz, 2H), 7.37 – 7.25 (m, 3H), 7.20 (s, 1H), 7.16 (d, J = 7.4 Hz, 1H), 7.06 (d, J = 6.6 Hz, 
1H), 6.45 (s, 2H), 4.50 – 4.34 (m, 5H), 4.17 (dd, J = 15.1, 4.2 Hz, 1H), 3.89 (dd, J = 11.6, 4.7 Hz, 
1H), 3.76 (s, 1H), 3.42 (s, 1H), 3.25 – 3.14 (m, 3H), 3.01 (dd, J = 13.8, 4.8 Hz, 1H), 2.19 (s, 6H). 
(S)-3-(4-hydroxy-2,6-dimethylphenyl)-1-((2-methoxy-5-(pyrrolidin-1-
ylmethyl)benzyl)amino)-1-oxopropan-2-aminium trifluoroacetate (169): See Procedure E and 
F: 18 mg (0.052 mmol) of 153, 180 µL (0.36 mmol, 6.96 eq.) of 2 M BH3*Me2S in THF, and 4 
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mL of THF. Step 1 of F: 90 µL (67 mg, 0.52 mmol, 9.99 eq.) of N,N-diisopropylethylamine, 28 
mg (0.054 mmol, 1.04 eq.) of PyBOP, 10 mg (0.059 mmol, 1.14 eq.) of 6-Cl-HOBt, 23 mg (0.056 
mmol, 1.09 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL 
TFA and 2 mL DCM. Compound 169 (11.6 mg, Yield=43 %) was isolated as a white solid. 412.3 
(M+H), Retention Time: 14.69 min. 1H NMR (500 MHz, Methanol-d4) δ 7.95 (t, J = 5.9 Hz, 1H), 
7.42 (dd, J = 8.4, 2.3 Hz, 1H), 7.14 (d, J = 2.3 Hz, 1H), 6.99 (d, J = 8.4 Hz, 1H), 6.34 (s, 2H), 4.40 
– 4.32 (m, 1H), 4.29 (d, J = 13.0 Hz, 1H), 4.24 (d, J = 13.0 Hz, 1H), 4.14 (dd, J = 14.6, 4.6 Hz, 
1H), 3.90 (dd, J = 11.8, 4.3 Hz, 1H), 3.74 (s, 3H), 3.53 – 3.38 (m, 2H), 3.22 – 3.06 (m, 3H), 2.95 
(dd, J = 13.8, 4.4 Hz, 1H), 2.17 (br s, 2H), 2.06 (s, 6H), 2.04 – 1.97 (m, 2H). 
(S)-3-(4-hydroxy-2,6-dimethylphenyl)-1-((2-methoxy-5-(piperidin-1-
ylmethyl)benzyl)amino)-1-oxopropan-2-aminium trifluoroacetate (170): See Procedure E and 
F: 23 mg (0.063 mmol) of 152, 220 µL (0.44 mmol, 6.93 eq.) of 2 M BH3*Me2S in THF, and 4 
mL of THF. Step 1 of F: 110 µL (82 mg, 0.63 mmol, 9.95 eq.) of N,N-diisopropylethylamine, 33 
mg (0.063 mmol, 1.00 eq.) of PyBOP, 13 mg (0.077 mmol, 1.21 eq.) of 6-Cl-HOBt, 28 mg (0.068 
mmol, 1.08 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL 
TFA and 2 mL DCM. Compound 170 (9.1 mg, Yield=27 %) was isolated as a white solid. 426.3 
(M+H), Retention Time: 16.13 min. 1H NMR (500 MHz, Methanol-d4) δ 7.94 (t, J = 6.0 Hz, 1H), 
7.41 (dd, J = 8.4, 2.3 Hz, 1H), 7.16 (d, J = 2.3 Hz, 1H), 7.00 (d, J = 8.4 Hz, 1H), 6.33 (s, 2H), 4.35 
(dd, J = 14.5, 6.8 Hz, 1H), 4.22 – 4.12 (m, 3H), 3.89 (dd, J = 11.7, 4.4 Hz, 1H), 3.74 (s, 3H), 3.42 
(t, J = 12.3 Hz, 2H), 3.12 (dd, J = 13.7, 11.8 Hz, 1H), 2.96 – 2.84 (m, 3H), 2.04 (s, 6H), 1.93 (d, J 




methoxybenzyl)amino)-1-oxopropan-2-aminium trifluoroacetate (171): See Procedure E and 
F: 25 mg (0.063 mmol) of 155, 220 µL (0.44 mmol, 6.97 eq.) of 2 M BH3*Me2S in THF, and 4 
mL of THF. Step 1 of F: 110 µL (82 mg, 0.63 mmol, 10.0 eq.) of N,N-diisopropylethylamine, 33 
mg (0.063 mmol, 1.00 eq.) of PyBOP, 13 mg (0.077 mmol, 1.21 eq.) of 6-Cl-HOBt, 27 mg (0.066 
mmol, 1.04 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL 
TFA and 2 mL DCM. Compound 171 (8.9 mg, Yield=30 %) was isolated as a white solid. (MS)EI: 
460.3 (M+H), Retention Time: 19.61 min. 1H NMR (500 MHz, Methanol-d4) δ 7.98 (t, J = 5.9 Hz, 
1H), 7.48 (dd, J = 8.4, 2.3 Hz, 1H), 7.45 – 7.36 (m, 4H), 7.21 (d, J = 2.2 Hz, 1H), 7.03 (d, J = 8.4 
Hz, 1H), 6.32 (s, 2H), 4.65 (s, 4H), 4.52 (d, J = 2.4 Hz, 2H), 4.38 (dd, J = 14.6, 6.9 Hz, 1H), 4.16 
(dd, J = 14.6, 4.6 Hz, 1H), 3.90 (dd, J = 11.7, 4.3 Hz, 1H), 3.76 (s, 3H), 3.12 (dd, J = 13.7, 11.8 
Hz, 1H), 2.94 (dd, J = 13.8, 4.4 Hz, 1H), 2.05 (s, 6H). 
(S)-1-((5-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-2-methoxybenzyl)amino)-3-(4-
hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (172): See Procedure 
E and F: 22 mg (0.054 mmol) of 156, 190 µL (0.38 mmol, 7.09 eq.) of 2 M BH3*Me2S in THF, 
and 4 mL of THF. Step 1 of F: 100 µL (74 mg, 0.57 mmol, 10.7 eq.) of N,N-diisopropylethylamine, 
28 mg (0.054 mmol, 1.00 eq.) of PyBOP, 10 mg (0.059 mmol, 1.10 eq.) of 6-Cl-HOBt, 23 mg 
(0.056 mmol, 1.05 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 
2 mL TFA and 2 mL DCM. Compound 172 (3.4 mg, Yield=11 %) was isolated as a white solid. 
(MS)EI: 474.3 (M+H), Retention Time: 20.56 min. 1H NMR (500 MHz, Deuterium Oxide) δ 7.39 
(dd, J = 8.5, 2.3 Hz, 1H), 7.25 – 7.19 (m, 1H), 7.19 – 7.14 (m, 3H), 7.03 (d, J = 7.5 Hz, 1H), 6.90 
(d, J = 8.5 Hz, 1H), 6.11 (s, 2H), 4.32 (d, J = 13.5 Hz, 3H), 4.24 (s, 2H), 3.88 (d, J = 14.1 Hz, 1H), 
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3.84 (dd, J = 11.6, 5.1 Hz, 1H), 3.52 (s, 5H), 3.07 (t, J = 6.4 Hz, 2H), 2.96 – 2.81 (m, 2H), 1.76 (s, 
6H). 
(S)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxo-1-((2-propoxy-5-(pyrrolidin-1-
ylmethyl)benzyl)amino)propan-2-aminium trifluoroacetate (173): See Procedure E and F: 15 
mg (0.040 mmol) of 157, 140 µL (0.28 mmol, 7.02 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of F: 70 µL (52 mg, 0.40 mmol, 10.1 eq.) of N,N-diisopropylethylamine, 21 mg (0.040 
mmol, 1.01 eq.) of PyBOP, 7 mg (0.041 mmol, 1.03 eq.) of 6-Cl-HOBt, 17 mg (0.042 mmol, 1.04 
eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL TFA and 2 mL 
DCM. Compound 173 (1.6 mg, Yield=9 %) was isolated as a white solid. (MS)EI: 440.3 (M+H), 
Retention Time: 20.67 min. 1H NMR (400 MHz, Methanol-d4) δ 7.66 (t, J = 6.0 Hz, 1H), 7.40 (dd, 
J = 8.4, 2.3 Hz, 1H), 7.12 (d, J = 2.3 Hz, 1H), 6.99 (d, J = 8.4 Hz, 1H), 6.34 (s, 2H), 4.41 (dd, J = 
14.6, 6.8 Hz, 1H), 4.26 (q, J = 13.0 Hz, 2H), 4.16 (dd, J = 14.6, 4.5 Hz, 1H), 3.95 – 3.80 (m, 3H), 
3.52 – 3.36 (m, 2H), 3.24 – 3.06 (m, 3H), 2.94 (dd, J = 13.8, 4.3 Hz, 1H), 2.18 (br s, 2H), 2.03 (m, 
8H), 1.70 (h, J = 7.0 Hz, 2H), 1.00 (t, J = 7.4 Hz, 3H). 
(S)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxo-1-((5-(piperidin-1-ylmethyl)-2-
propoxybenzyl)amino)propan-2-aminium trifluoroacetate (174): See Procedure E and F: 24 
mg (0.062 mmol) of 158, 220 µL (0.44 mmol, 7.15 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of F: 110 µL (82 mg, 0.63 mmol, 10.3 eq.) of N,N-diisopropylethylamine, 28 mg 
(0.061 mmol, 1.00 eq.) of PyBOP, 11 mg (0.065 mmol, 1.05 eq.) of 6-Cl-HOBt, 26 mg (0.063 
mmol, 1.03 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL 
TFA and 2 mL DCM. Compound 174 (4 mg, Yield=12 %) was isolated as a white solid. (MS)EI: 
454.3 (M+H), Retention Time: 21.64 min. 1H NMR (500 MHz, Methanol-d4) δ 7.66 (t, J = 5.8 Hz, 
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1H), 7.39 (dd, J = 8.4, 2.3 Hz, 1H), 7.12 (d, J = 2.3 Hz, 1H), 6.99 (d, J = 8.4 Hz, 1H), 6.35 (s, 2H), 
4.39 (dd, J = 14.7, 6.8 Hz, 1H), 4.24 – 4.11 (m, 3H), 3.98 – 3.82 (m, 3H), 3.41 (d, J = 13.6 Hz, 
2H), 3.12 (dd, J = 13.7, 11.9 Hz, 1H), 2.98 – 2.83 (m, 3H), 2.04 (s, 6H), 1.94 (d, J = 10.4 Hz, 2H), 
1.84 (d, J = 13.5 Hz, 1H), 1.79 – 1.65 (m, 4H), 1.50 (qt, J = 12.6, 3.4 Hz, 1H), 1.01 (t, J = 7.4 Hz, 
3H). 
(S)-3-(4-hydroxy-2,6-dimethylphenyl)-1-((5-(isoindolin-2-ylmethyl)-2-
propoxybenzyl)amino)-1-oxopropan-2-aminium trifluoroacetate (175): See Procedure E and 
F: 23 mg (0.061 mmol) of 159, 220 µL (0.44 mmol, 7.2 eq.) of 2 M BH3*Me2S in THF, and 4 mL 
of THF. Step 1 of F: 110 µL (82 mg, 0.63 mmol, 10.3 eq.) of N,N-diisopropylethylamine, 32 mg 
(0.061 mmol, 1.01 eq.) of PyBOP, 11 mg (0.065 mmol, 1.06 eq.) of 6-Cl-HOBt, 25 mg (0.061 
mmol, 1.00 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL 
TFA and 2 mL DCM. Compound 175 (4.5 mg, Yield=14 %) was isolated as a white solid. (MS)EI: 
488.3 (M+H), Retention Time: 25.13 min. 1H NMR (400 MHz, Methanol-d4) δ 7.72 (s, 1H), 7.46 
(dd, J = 8.4, 2.3 Hz, 1H), 7.41 (d, J = 2.0 Hz, 4H), 7.17 (d, J = 2.3 Hz, 1H), 7.02 (d, J = 8.5 Hz, 
1H), 6.32 (s, 2H), 4.65 (s, 2H), 4.63 (s, 2H), 4.51 (d, J = 3.6 Hz, 2H), 4.42 (dd, J = 14.7, 4.5 Hz, 
1H), 4.19 (dd, J = 14.6, 4.3 Hz, 1H), 3.95 – 3.81 (m, 3H), 3.12 (dd, J = 13.8, 12.4 Hz, 1H), 2.94 
(dd, J = 13.8, 4.5 Hz, 1H), 2.04 (s, 6H), 1.72 (h, J = 7.0 Hz, 2H), 1.01 (t, J = 7.4 Hz, 3H). 
(S)-1-((5-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-2-propoxybenzyl)amino)-3-(4-
hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (176): See Procedure 
E and F: 33 mg (0.075 mmol) of 160, 260 µL (0.52 mmol, 6.93 eq.) of 2 M BH3*Me2S in THF, 
and 4 mL of THF. Step 1 of F: 130 µL (96 mg, 0.75 mmol, 9.95 eq.) of N,N-diisopropylethylamine, 
39 mg (0.075 mmol, 1.00 eq.) of PyBOP, 13 mg (0.077 mmol, 1.02 eq.) of 6-Cl-HOBt, 31 mg 
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(0.076 mmol, 1.01 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 
2 mL TFA and 2 mL DCM. Compound 176 (7 mg, Yield=15 %) was isolated as a white solid. 
(MS)EI: 502.3 (M+H), Retention Time: 26.01 min. 1H NMR (500 MHz, Deuterium Oxide) δ 7.51 
(q, J = 7.5 Hz, 1H), 7.39 (dt, J = 8.6, 3.1 Hz, 1H), 7.27 – 7.15 (m, 4H), 7.05 (t, J = 7.9 Hz, 1H), 
6.92 (dd, J = 8.5, 3.0 Hz, 1H), 6.17 (s, 2H), 4.39 – 4.19 (m, 6H), 3.99 – 3.84 (m, 3H), 3.75 – 3.62 
(m, 3H), 3.36 – 3.25 (m, 1H), 3.13 – 3.02 (m, 2H), 2.96 – 2.78 (m, 2H), 1.72 (s, 6H), 1.47 (dtdd, 
J = 27.3, 14.1, 6.8, 2.1 Hz, 2H), 0.81 (t, J = 7.4 Hz, 3H). 
(S)-1-((2-(cyclopropylmethoxy)-5-(pyrrolidin-1-ylmethyl)benzyl)amino)-3-(4-
hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (177): See Procedure 
E and F: 32 mg (0.082 mmol) of 161, 290 µL (0.58 mmol, 7.04 eq.) of 2 M BH3*Me2S in THF, 
and 4 mL of THF. Step 1 of F: 140 µL (104 mg, 0.80 mmol, 9.75 eq.) of N,N-
diisopropylethylamine, 43 mg (0.083 mmol, 1.00 eq.) of PyBOP, 14 mg (0.083 mmol, 1.00 eq.) of 
6-Cl-HOBt, 35 mg (0.085 mmol, 1.04 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of 
DMF. Step 2 of F: 2 mL TFA and 2 mL DCM. Compound 177 (3.0 mg, Yield=6 %) was isolated 
as a white solid. (MS)EI: 452.3 (M+H), Retention Time: 20.81 min.  1H NMR (500 MHz, 
Methanol-d4) δ 7.66 (t, J = 5.8 Hz, 1H), 7.38 (dd, J = 8.4, 2.4 Hz, 1H), 7.10 (d, J = 2.2 Hz, 1H), 
6.97 (d, J = 8.4 Hz, 1H), 6.35 (s, 2H), 4.42 (dt, J = 14.8, 3.5 Hz, 1H), 4.33 – 4.17 (m, 3H), 3.91 
(dd, J = 11.7, 4.4 Hz, 1H), 3.78 (d, J = 6.9 Hz, 2H), 3.54 – 3.37 (m, 2H), 3.14 (dd, J = 13.8, 11.8 
Hz, 3H), 2.95 (dd, J = 13.8, 4.4 Hz, 1H), 2.18 (s, 2H), 2.06 (s, 6H), 2.01 (s, 2H), 1.17 (tdd, J = 
10.2, 7.3, 3.5 Hz, 1H), 0.64 – 0.51 (m, 2H), 0.37 – 0.24 (m, 2H). 
(S)-1-((2-(cyclopropylmethoxy)-5-(piperidin-1-ylmethyl)benzyl)amino)-3-(4-
hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (178): See Procedure 
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E and F: 25 mg (0.062 mmol) of 162, 220 µL (0.44 mmol, 7.10 eq.) of 2 M BH3*Me2S in THF, 
and 4 mL of THF. Step 1 of F: 110 µL (82 mg, 0.63 mmol, 10.2 eq.) of N,N-diisopropylethylamine, 
32 mg (0.061 mmol, 0.99 eq.) of PyBOP, 12 mg (0.071 mmol, 1.14 eq.) of 6-Cl-HOBt, 25 mg 
(0.061 mmol, 0.98 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 
2 mL TFA and 2 mL DCM. Compound 178 (1.8 mg, Yield=5 %) was isolated as a white solid. 
(MS)EI: 466.3 (M+H), Retention Time: 22.01 min. 1H NMR (500 MHz, Methanol-d4) δ 7.63 (t, J 
= 5.9 Hz, 1H), 7.37 (dd, J = 8.4, 2.3 Hz, 1H), 7.12 (d, J = 2.3 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 
6.34 (s, 2H), 4.42 (dd, J = 14.7, 6.8 Hz, 1H), 4.24 – 4.13 (m, 3H), 3.90 (dd, J = 11.7, 4.4 Hz, 1H), 
3.78 (d, J = 6.9 Hz, 2H), 3.47 – 3.37 (m, 3H), 3.13 (dd, J = 13.6, 11.9 Hz, 2H), 2.95 (dd, J = 14.1, 
4.3 Hz, 2H), 2.93 – 2.82 (m, 2H), 2.05 (s, 6H), 1.97 – 1.91 (m, 2H), 1.84 (d, J = 13.6 Hz, 1H), 1.72 
(p, J = 12.7 Hz, 2H), 1.51 (dddd, J = 16.9, 13.0, 8.2, 3.7 Hz, 1H), 1.16 (dddd, J = 15.5, 12.3, 7.6, 
4.6 Hz, 1H), 0.59 (dd, J = 8.1, 1.8 Hz, 2H), 0.30 (pd, J = 4.2, 2.8 Hz, 2H). 
(S)-1-((2-(cyclopropylmethoxy)-5-(isoindolin-2-ylmethyl)benzyl)amino)-3-(4-
hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (179): See Procedure 
E and F: 18 mg (0.041 mmol) of 163, 145 µL (0.29 mmol, 7.03 eq.) of 2 M BH3*Me2S in THF, 
and 4 mL of THF. Step 1 of F: 70 µL (52 mg, 0.40 mmol, 9.75 eq.) of N,N-diisopropylethylamine, 
22 mg (0.042 mmol, 1.03 eq.) of PyBOP, 6 mg (0.035 mmol, 0.86 eq.) of 6-Cl-HOBt, 17 mg (0.042 
mmol, 1.01 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL 
TFA and 2 mL DCM. Compound 179 (2.2 mg, Yield=9 %) was isolated as a white solid. (MS)EI: 
522.3 (M+H), Retention Time: 25.38 min. 1H NMR (500 MHz, Methanol-d4) δ 7.68 (t, J = 5.9 Hz, 
1H), 7.49 – 7.36 (m, 5H), 7.17 (d, J = 2.2 Hz, 1H), 7.00 (d, J = 8.4 Hz, 1H), 6.32 (s, 2H), 4.66 (s, 
2H), 4.63 (s, 2H), 4.53 (d, J = 12.9 Hz, 1H), 4.50 (d, J = 12.9 Hz, 1H), 4.44 (dt, J = 14.8, 3.5 Hz, 
1H), 4.23 (dd, J = 14.7, 4.5 Hz, 1H), 3.92 (dd, J = 11.7, 4.4 Hz, 1H), 3.80 (d, J = 6.9 Hz, 2H), 3.13 
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(dd, J = 13.8, 11.9 Hz, 1H), 2.95 (dd, J = 13.8, 4.4 Hz, 1H), 2.05 (s, 6H), 1.22 – 1.08 (m, 1H), 0.67 
– 0.49 (m, 2H), 0.31 (dq, J = 5.2, 3.0, 2.4 Hz, 2H). 
(S)-1-((2-(cyclopropylmethoxy)-5-((3,4-dihydroisoquinolin-2(1H)-
yl)methyl)benzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium 
trifluoro-acetate (180): See Procedure E and F: 30 mg (0.067 mmol) of 164, 230 µL (0.46 mmol, 
6.91 eq.) of 2 M BH3*Me2S in THF, and 4 mL of THF. Step 1 of F: 120 µL (89 mg, 0.69 mmol, 
10.3 eq.) of N,N-diisopropylethylamine, 35 mg (0.067 mmol, 1.01 eq.) of PyBOP, 11 mg (0.065 
mmol, 0.97 eq.) of 6-Cl-HOBt, 27 mg (0.066 mmol, 0.99 eq.) of Boc-O-Boc-L-2’,6’-
dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of F: 2 mL TFA and 2 mL DCM. Compound 180 (7.0 
mg, Yield=17 %) was isolated as a white solid. (MS)EI: 514.3 (M+H), Retention Time: 26.36 min. 
1H NMR (500 MHz, Deuterium Oxide) δ 7.63 (q, J = 7.3 Hz, 1H), 7.38 (dq, J = 8.4, 3.1, 2.7 Hz, 
1H), 7.28 – 7.13 (m, 4H), 7.05 (t, J = 8.4 Hz, 1H), 6.89 (dd, J = 8.5, 2.7 Hz, 1H), 6.16 (s, 2H), 4.43 
– 4.17 (m, 5H), 4.00 (dt, J = 13.9, 4.1 Hz, 1H), 3.87 (dt, J = 10.6, 5.2 Hz, 1H), 3.71 (dd, J = 12.3, 
5.3 Hz, 1H), 3.56 (d, J = 7.1 Hz, 2H), 3.38 – 3.25 (m, 1H), 3.18 – 3.03 (m, 2H), 3.02 – 2.76 (m, 
2H), 1.72 (s, 6H), 0.99 – 0.85 (m, 1H), 0.52 – 0.36 (m, 2H), 0.27 – 0.02 (m, 2H). 
In Vitro Pharmacology 
Cell Lines and Membrane Preparations.  
All in vitro opioid assays were performed by Ashley Brinkel, Jack Twarozynski, and 
Jessica Anand. Tissue culture reagents were purchased from Gibco Life Sciences (Grand Island, 
NY, U.S.) unless otherwise noted. C6-rat glioma cells stably expressing human MOR (C6-MOR) 
or human DOR (C6-DOR) and Chinese hamster ovary (CHO) cells stably expressing human KOR 
(CHO-KOR) were used for all in vitro assays. Cells were grown to confluence at 37 °C in 5% CO2 
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in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal bovine serum and 5% 
penicillin/streptomycin. Membranes were prepared by washing confluent cells three times with ice 
cold phosphate buffered saline (0.9% NaCl, 0.61 mM Na2HPO4, 0.38 mM KH2PO4, pH 7.4). Cells 
were detached from the plates by incubation in warm harvesting buffer (20 mM HEPES, 150 mM 
NaCl, 0.68 mM EDTA, pH 7.4) and pelleted by centrifugation at 1600 rpm for 3 min. The cell 
pellet was suspended in ice-cold 50 mM Tris- HCl buffer, pH 7.4, and homogenized with a Tissue 
Tearor (Biospec Products, Inc., Bartlesville, OK, U.S.) for 20 s. The homogenate was centrifuged 
at 15,000 rpm for 20 min at 4°C. The pellet was rehomogenized in 50 mM Tris-HCl with a Tissue 
Tearor for 10 s, followed by recentrifugation. The final pellet was resuspended in 50 mM Tris-
HCl and frozen in aliquots at -80°C. Protein concentration was determined via a BCA protein assay 
(Thermo Scientific Pierce, Waltham, MA, U.S.) using bovine serum albumin as the standard.  
Radioligand Competition Binding Assays.  
Radiolabeled compounds were purchased from Perkin-Elmer (Waltham, MA, U.S.). 
Opioid ligand binding assays were performed by competitive displacement of 0.2 nM [3H]-
diprenorphine (250 μCi, 1.85 TBq/mmol) by the peptidomimetic from membrane preparations 
containing opioid receptors as described above. The assay mixture, containing membranes (20 μg 
protein/tube) in 50 mM Tris-HCl buffer (pH 7.4), 0.2 nM [3H]-diprenorphine, and various 
concentrations of test peptidomimetic, was incubated at room temperature on a shaker for 1 h to 
allow binding to reach equilibrium. The samples were rapidly filtered through Whatman GF/C 
filters using a Brandel harvester (Brandel, Gaithersburg, MD, U.S.) and washed three times with 
50 mM Tris-HCl buffer, pH 7.4. Bound radioactivity on dried filters was determined by liquid 
scintillation counting, after saturation with EcoLume liquid scintillation cocktail, in a Wallac 1450 
MicroBeta (Perkin-Elmer, Waltham, MA, U.S.). Nonspecific binding was determined using 10 
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μM naloxone. The results presented are the mean ± standard error (S.E.M.) from at least three 
separate assays performed in duplicate. Ki (nM) values were calculated using nonlinear regression 
analysis to fit a logistic equation to the competition data using GraphPad Prism, version 6.0c, 
(GraphPad Software Inc., La Jolla, CA).  
 
[35S]-GTPγS Binding Assays.  
Agonist stimulation of [35S]guanosine 5′-O-[γ- thio]triphosphate ([35S]-GTPγS, 1250 Ci, 
46.2 TBq/mmol) binding to G protein was measured as described previously.82 Briefly, membranes 
(10 μg of protein/well) were incubated for 1 h at 25°C in GTPγS buffer (50 mM Tris-HCl, 100 
mM NaCl, 5 mM MgCl2, 1 mM EDTA, pH 7.4) containing 0.1 nM [
35S]-GTPγS, 30 μM guanosine 
diphosphate (GDP), and varying concentrations of test peptidomimetic. G protein activation 
following receptor activation by peptidomimetic was compared with 10 μM of the standard 
compounds [D-Ala2,N-MePhe4,Gly-ol]enkephalin (DAMGO) at MOR, D-Pen2,5- enkephalin 
(DPDPE) at DOR, or U69,593 at KOR. The reaction was terminated by vacuum filtration through 
GF/C filters that were washed 5 times with GTPγS buffer. Bound radioactivity was measured as 
described above. The results are presented as the mean ± standard error (S.E.M.) from at least three 
separate assays performed in duplicate; potency (EC50 (nM)) and percent stimulation were 
determined using nonlinear regression analysis with GraphPad Prism, as above.  
Mouse Liver Microsome Stability Assays 
All liver microsome assays were performed by Quintara Biosciences. Metabolic stability 
of testing compounds was evaluated using mouse liver microsomes to predict intrinsic clearance. 
Mouse liver microsome tissue fractions were obtained from Corning or BioreclamationIVT. The 
assay was carried out in 96-well microtiter plates at 37°C. Reaction mixtures (25 μL) contained a 
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final concentration of 1 μM test compound, 0.1 mg/mL liver microsome protein, and 1 mM 
NADPH in 100 mM potassium phosphate, pH 7.4 buffer with 3 mM MgCl2. At each of the time 
points (0, 15, 30, and 60 minutes), 150 μL of quench solution (acetonitrile with 0.1% formic acid) 
with internal standard (bucetin) was transferred to each well. Verapamil was included as a positive 
control to verify assay performance. Plates were sealed, vortexed, and centrifuged at 4°C for 15 
minutes at 4000 rpm. The supernatant was transferred to fresh plates for LC/MS/MS analysis. All 
samples were analyzed on LC/MS/MS using an AB Sciex API 4000 instrument, coupled to a 
Shimadzu LC-20AD LC Pump system. Analytical samples were separated using a Waters Atlantis 
T3 dC18 reverse phase HPLC column (20 mm x 2.1 mm) at a flow rate of 0.5 mL/min. The mobile 
phase consists of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile 
(solvent B). The extent of metabolism was calculated as the disappearance of the test compound, 
compared to the 0-min time incubation. Initial rates were calculated for the compound 
concentration and used to determine t1/2 values and subsequently, the intrinsic clearance. 
Molecular Modeling 
All in silico experiments were performed by Irina Pogozheva. Modeling of three-
dimensional (3D) structures of receptor-ligand complexes was based on available X-ray structures 
of the mouse MOR (PDB ID: 5c1m)83 in the active conformation, human KOR (PDB IDs: 4djh)125 
in the inactive conformation, and human DOR in the inactive conformation (PDB IDs: 4rwa)126. 
Structures of peptidomimetic ligands were generated using the 3D-Builder Application of 
QUANTA (Accelrys, Inc) followed by Conformational Search included in the program package. 
Low-energy ligand conformations (within 2 kcal/mol) that demonstrated the best superposition of 
aromatic substituents of the ligand core with the pharmacophore elements (DMT and 
tetrahydroquinoline pendant) of receptor-bound conformations of peptidomimetics  were selected 
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for docking into the receptor binding pocket. Ligands were positioned inside the receptor binding 
cavity to reproduce the binding modes of peptidomimetics and co-crystalized ligands in MOR, 
DOR, and KOR X-ray structures. The docking pose of each ligand was subsequently refined using 
the solid docking module of QUANTA.  
Animals and In Vivo Solutions 
All in vivo assays were performed by Bryan Sears. Animal care and experimental 
procedures complied with the US National Research Council's Guide for the Care and Use of 
Laboratory Animals.91 Animal studies are reported in compliance with the ARRIVE 
guidelines.92,93 Mice were group‐housed with a maximum of five animals per cage in clear 
polypropylene cages with corn cob bedding and nestlets as enrichment. Mice had free access to 
food and water at all times. Animals were housed in pathogen‐free rooms maintained between 68 
and 79 °F and humidity between 30 and 70 % humidity with a 12 h light/dark cycle with lights on 
at 07:00 h. Experiments were conducted in the housing room during the light cycle. All studies 
utilize male C57BL/6 mice from Envigo laboratories. Wild type mice weighing between 20-30 g 
at 7-15 weeks old, were used for behavioral experiments. All drug solutions were injected at a 
volume of 10 ml/kg. All drugs were dissolved in 9:1 DMSO/saline solution except for morphine 
sulphate and 0.6 % acetic acid which were dissolved in saline and water, respectively. All drugs 
were given sc. except for 0.6 % acetic acid which was given ip. 
Acetic Acid Stretch Assay (AASA) 
Antinociceptive effects were evaluated in the mouse acetic acid stretch assay in which a 
noxious stimulus is administered ip. that induces a stretching behavior characterized by 
constriction of the abdomen followed by extension of the hind limbs. Mice received an injection 
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of 0.6 % acetic acid, placed individually in clear plastic observation cages (10 x 6 x 8 in) with 
bedding, and the number of stretches were recorded for 20 min. Antinociceptive effects were 
determined with a 30 min pretreatment dose of compound sc. followed by 0.6 % acetic acid ip. A 
5 min latency period after acetic acid injection was establish and total number of stretches were 





















Chapter 6: Aromatic-Amine Pharmacophore Enables Removal of Aromatic Core  
6.1 Introduction 
 In the previous chapter, we discovered that incorporation of the aromatic-amine 
pharmacophore onto our monocyclic core system produced potent and efficacious MOR-agonists 
whose activity was insensitive to functional changes to the aromatic core. In fact, a core containing 
a simple aromatic ring in conjunction with a tetrahydroisoquinoline pendant produced a potent 
superagonist. Since MOR-agonism appears thus far to not be affected negatively by elimination of 
structural elements on the core, we were interested in the scope upon which these structural 
elements may be removed (Figure 18A). We therefore decided to remove the aromatic core 
entirely, relying instead on simple alkyl, peptide, ether, or amine groups to hold the 
peptidomimetic together. This represents a radical change from our original bicyclic core 
peptidomimetics, and this further structural simplification enables shorter syntheses of novel 
analogues and more rapid diversification.  
It should be noted that this structural simplification will increase the conformational 
flexibility of these ligands. Previously, our lab reported a series of 4-substituted piperidine and 
piperazines as bifunctional MOR/DOR ligands.70 Despite good binding affinity at MOR and DOR, 
these ligands possessed poor MOR-efficacy and potency. As such, further derivatization of these 
ligands was not pursued. However, the discovery of our aromatic-amine pharmacophore has 
inspired us to return to these analogues. One of the most potent and efficacious analogues in this 
previous series possessed its aromatic core seven atoms away from the dimethyltyrosine pendant, 
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the same as that in our aromatic-amine analogues as shown in Figure 18B. Since efficacy was an 
issue with these ligands, we opted to incorporate an amine into the structure in the form of a 
tetrahydroisoquinoline pendant. This pendant was selected as it produced the most potent MOR 
analogues and yielded the highest levels of efficacy. This will briefly allow comparisons to the 
other tetrahydroisoquinoline pendants in this chapter and determine if these more rigid cores are 
viable for further derivatization. 
 
Figure 18: A) Design of analogues possessing greater simplification of core elements. These 
analogues utilized the tetrahydroisoquinoline pendant, which produced a superagonist at MOR 
using an unfunctionalized aromatic core. B) Design of more rigid analogues that use the 
tetrahydroisoquinoline pendant. These were inspired by previously described piperazine core 
analogues. 
6.2 Results 
General Chemistry: The synthesis of many of these new analogues required very few steps and 
most are described in Scheme 9. These include a simple alkyl chain, a chain possessing an ether, 
and the piperidine and piperazine core structures aimed at producing conformational restrictions. 
An amide analogue was also synthesized to confirm if the efficacy produced at MOR is a product 
of the amine and not the product of conformational restrictions induced by an amide. The only 
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amide analogues synthesized thus far are 135 and 136, of which the amide was conjugated to the 
aromatic core. The synthesis here began with peptide coupling of tetrahydroisoquinoline to an 
appropriate Boc-protected δ-amino acid. The Boc group was removed with conc. HCl, and the 
tertiary amide was reduced with BH3*Me2S at 65 °C if necessary. The primary amine was the 
coupled to Boc-protected 2’,6’-dimethyltyrosine, at which point the Boc-groups were removed 
with TFA, yielding the final peptidomimetic. 
Scheme 9: Synthesis of Analogues 193-197. 
 
A) 1. HO2C-X-Boc, NMM, PyBOP, DMF B) conc. HCl, Dioxane or TFA, DCM. C) BH3*Me2S, 
THF, 65 C° D) 1. DiBocDMT, DIEA, PyBOP, 6-Cl-HOBt, DMF. 2. TFA, DCM. 
 The analogues that contained a peptide bond or amine in the chain required a slightly 
modified procedure and are described in Scheme 10. Analogue 198, which possesses a tertiary 
amine in the chain, was synthesized using peptide coupling of tetrahydroisoquinoline to N-Boc 
sarcosine using PyBOP, at which point the Boc group was removed with conc. HCl. This was then 
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coupled to N-Boc glycine and deprotected using the same method. Both peptide bonds were then 
reduced with BH3*Me2S and the primary amine was then coupled to Boc-protected 2’,6’-
dimethyltyrosine, at which point the Boc-groups were removed with TFA, yielding 198. 
Scheme 10: Synthesis of Peptide Core Analogues 198-200. 
 
A) 1. HO2C-CH2-NXBoc, NMM, PyBOP, DMF B) conc. HCl, Dioxane or TFA, DCM. C) 
BH3*Me2S, THF, 65 C° D) 1. DiBocDMT, DIEA, PyBOP, 6-Cl-HOBt, DMF. 2. TFA, DCM. 
 Two additional analogues containing whole peptide bonds in the chain were also 
synthesized. These two analogues largely used the same steps as those for the simpler analogues 
above but used slightly different synthetic strategies. As described in Scheme 10, 
tetrahydroisoquinoline was coupled to N-Boc protected glycine or sarcosine. These intermediates 
were isolated before Boc deprotection, at which point the synthetic schemes diverged. The 
sarcosine intermediate 186 was then subject to reduction with borane before removal of the Boc 
group, yielding intermediate 191. This was coupled to glycine and deprotected. No extensive 
purification of this intermediate was performed, as this analogue had poor UV absorbance 
properties and the impurities present were peptide coupling side products, which were going to be 
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present in the subsequent coupling to DMT. As such, DMT coupling was performed on this impure 
mixture and subsequent deprotection yielded the N-methyl amide 199. For the glycine intermediate 
187, Boc deprotection was performed before reduction, as the secondary carbamate was unstable 
under these reduction conditions. This was then coupled to an additional glycine residue, yielding 
intermediate 192 with better UV absorbance properties than its sarcosine counterpart. After Boc 
deprotection, the intermediate was then coupled to DMT, yielding 200 after another deprotection. 
SAR: The binding affinities of these analogues were screened and are shown in Table 19. For 
comparison, the superagonist 168 from the previous chapter was included. With regard to MOR-
binding, each analogue in this series possessed single-digit or sub-nanomolar affinity. At DOR, 
elimination of the core aromatic ring produced well over a ten-fold drop in affinity. The exceptions 
here are the rigid piperazine 197 and the two amide analogues 199 and 200. KOR-binding does 
not change significantly from the original lead 168, the only exception here being the sarcosine 
analogue 199, which has low KOR-affinity. Finally, this series generated analogues that deviate 
from our original MOR/DOR bifunctional profile and instead appear to promote a MOR/KOR 
profile. The exception here exists again with the piperazine and amide analogues, due to their 
ability to maintain high DOR affinity and/or to reduce KOR affinity. 
The potency and efficacy of these analogues were also screened in each of these receptors 
and are shown in Table 20. Each of the amine pendant analogues possessed high MOR-efficacy, 
though were not superagonists like analogue 168. The amide analogue 195, while showing 
significantly reduced MOR-efficacy compared to its amine counterpart 194, retained upwards of 
48 % stimulation. The MOR-potency of these did not vary much compared to 168, though there 
were few exceptions. Here the exceptions consist with the rigid piperidine analogue 197, and the 
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sarcosine analogue 199, both of which expressed at least a log unit loss in potency. It should be 
noted also that conversion to the amide 195 did not affect potency. 
 
Binding Affinity, Ki (nM) Selectivity 
Name Structure MOR DOR KOR MOR:DOR:KOR 
168 
 
0.23±0.02 4.8±1.0 36.9±3.1* 1:21:160 
193 
 
1.5±0.3 142±16 44.2±5.6 1:93:29 
194 
 
0.36** 105** 45±12 1:290:125 
195 
 
7.8±6.3* 261** 20.6** 1:1373:108 
196 
 
0.98** 42.2** 30.5** 1:43:31 
197 
 
3.67** 9.55** 124±69* 1:2.6:34 
198 
 
0.39** 211** 9.51** 1:540:24 
199 
 
6.07** 25.8** 1800±1300* 1:4.3:289 
200 
 
1.32±0.38 7.3±1.5 107±35 1:5.5:81 
Table 19: Binding affinity of simple core compounds at MOR, DOR, and KOR. Binding 
affinities (Ki) were obtained by competitive displacement of radiolabeled [
3H] diprenorphine in 
membrane preparations. Included is 168 for comparison. Selectivity was calculated by dividing 
the Ki of each receptor by the Ki at MOR for a given compound. All data were from three 
separate experiments, performed in duplicate unless otherwise noted. These data are reported as 
the average ± standard error of the mean. ** N=1, * N=2 
 DOR-agonism was found to be low in this series. Analogues that did stimulate DOR were 
weak partial agonists with low potency and efficacy. The greatest efficacy at DOR occurred with 
the ether analogue 194 and the glycine analogue 200. This DOR-efficacy was eliminated with the 
piperazine 197, the alkyl chain analogue 193, and the amide analogue 195. At KOR, these  
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Table 20: Potency and efficacy of simple core compounds at MOR, DOR, and KOR. Potency 
and efficacy data were obtained using agonist induced stimulation of [35S] GTPγS binding. 
Potency is represented as EC50 (nM) and efficacy as percent maximal stimulation relative to 
standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 μM. Included is 
168 for comparison. All data were from three separate experiments, performed in duplicate 
unless otherwise noted. These data are reported as the average ± standard error of the mean. ** 
N=1, * N=2. DNS=Does Not Stimulate. 
 
Potency, EC50 (nM) Efficacy (% Stimulation) 
Name Structure MOR DOR KOR MOR DOR KOR 
168 
 
8.9±2.9 370±190 DNS 148±13 47±12 DNS 
193 
 
15.4±1.3 DNS DNS 80.8±4.5 DNS DNS 
194 
 
10.3±3.7 316±65 921±162* 95.0±7.4 32±16 20.9±4.0* 
195 
 
26±20* DNS* DNS* 47.9±3.6* DNS* DNS* 
196 
 
300±220 DNS DNS* 70±15 DNS DNS* 
197 
 
26.9** DNS* >3000** 91.3** DNS* >50** 
198 
 
24±10 1240±720* 427* 80.0±9.5 27.6±0.5* 34.5* 
199 
 
173** 567** DNS** 88.3** 23.3** DNS** 
200 
 
6.0±1.0 113.5±9.4* DNS* 86.6±3.3 40.2±1.4 DNS* 
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analogues either could not stimulate this receptor or were weak partial agonists with very low 
potency.  
Name Structure T1/2 (min) Verapamil T1/2 (min) Stability Ratio  cLogP 
168 
 
34.9±4.7 25.7±1.7 1.4±0.2 4.12 
193 
 
38.9±2.8  27.6±4.9 1.4±0.3 3.29 
194 
 
15.7±1.2 28.1±7.4 0.56±0.15 2.92 
195 
 
61.3±4.2 28.1±7.4 2.18±0.59 1.80 
196 
 
>120 28.1±7.4 >4.27 3.56 
197 
 
79±25 28.1±7.4 2.8±1.2 3.38 
198 
 
34.7±1.4 28.1±7.4 1.23±0.33 3.40 
199 
 
44±11 28.1±7.4 1.57±0.57 2.80 
200 
 
16.6±1.5  27.6±4.9 0.60±0.12 2.26 
Table 21: Metabolic stability of simple core compounds in MLM. Included are the compound 
half-life (T1/2), the half-life of the positive control verapamil, and the stability ratio between the 
compound and the positive control. The stability ratio was calculated by dividing the half-life of 
the analogue of interest by the half-life of the positive control in that assay. Included is 
compound 168 for comparison. Individual compounds were tested once, with errors representing 
the SE in the decay curve regressed onto the data collected in 15-minute intervals. Finally, the 




Metabolic Stability: The metabolic stability of these simplified analogues was also evaluated 
(Table 21). Simple elimination of the core to produce 193 yielded no improvements in stability 
when compared to 168. Curiously, incorporation of an ether into this simple alkyl chain (194) 
managed to reduce stability by nearly a factor of 3. The amide of 194 (195) subsequently improved 
the stability of 194 by a factor of 4. The most interesting data came from the piperidine (196) and 
piperazine (197) core analogues. Here, the T1/2 was greater than 2 hours for 196 and 79 minutes 
for 197. Breaking the piperazine ring to produce 198 eliminated these improvements, cutting their 
stability in half. Finally, the two peptide analogues were also analyzed, with the N-methyl analogue 
199 being 2.5 times more stable than desmethyl analogue 200 which was worse than the positive 
control. 
Molecular Modeling: Since we produce of MOR/KOR analogue with a simple alkyl core, analogue 
193 was then subject to molecular docking studies (Figure 19). This ligand was docked to MOR 
in the active state, and to DOR and KOR in the inactive state. The interactions that may be present 
at MOR are largely the same as those for analogue 168 described in Chapter 5. The amine interacts 
with Asn127 and the aromatic ring interacts with Trp133. The same is true at DOR, with the 
aromatic ring possessing interactions with Lys108 and a possible interaction with Trp114. The 
amine, likewise, interacts with the phenol of Tyr109. At KOR, a new interaction appears to emerge. 
In addition to those provided by Trp124 and Gln115 described previously, the amine also interacts 




Figure 19: Molecular docking of analogue 193 at the three opioid receptors. Shown are 
interactions of the tetrahydroisoquinoline pendant with A) MOR in the active state, B) DOR in 
the inactive state, and C) KOR in the inactive state. 
Antinociceptive Activity: In conjunction with the previous chapters, the in vivo activity of these 
analogues was elucidated in the AASA (Figure 20). The superagonist 168 is included for 
comparison and morphine was again used as the positive control. Unlike the superagonist, several 
of the analogues here were producing antinociception at a dose of 10 mg/kg, including 197-200, 
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Figure 20: Antinociceptive activity of the 168 and analogues 193-194, and 197-200 using the 
AASA. Included is morphine as positive control. Panels A-C represent dose-response curves 
with the ligands: A) 168 and the alkyl analogue 193, B) the ether analogue 134 and cyclic 
analogues 196-197 C) amine and amide analogues 198-200. * P<0.05 compared to vehicle. ** 
P<0.01 compared to vehicle. **** P<0.0001 compared to vehicle. N’s are between 1 and 6 for 
each data point. 
6.3 Discussion and Conclusions 
SAR: The data acquired here further demonstrate the in vitro capability of our aromatic-amine 
pharmacophore to produce MOR-agonists. While no MOR-superagonists were synthesized, all the 
analogues that possessed the desired amine yielded consistently high levels of MOR-efficacy, and 
this efficacy was reduced by 45 % when the amine is converted to an amide. This reinforces the 
importance of the amine for producing MOR-efficacy. When coupled with the MOR-efficacy data 
of the amide analogues from Chapter 4, these data suggest that the reduced conformational 
flexibility of the amides conjugated to the aromatic core are contributing in part to their reduced 





Potency was in general not affected, except for potency losses with the piperidine analogue 
196 and the sarcosine analogue 199. Several factors can be ruled out that could explain this trend: 
the carbonyl of the amide is tolerated as shown with analogue 200, the N-methyl is tolerated as 
shown with analogue 198, and formation of the ring is tolerated as shown with analogue 197. The 
piperidine analogue 196 is more rigid than the piperazine analogue 197, as the lone pair of the 
tertiary amine of the latter is capable of inverting across the heteroatom, whereas the piperidine 
possesses a hydride that cannot invert without rotation of the whole piperidine. This may contribute 
to the difference in potency in this case. The sarcosine analogue 199 possessed the lowest potency 
of those that express the aromatic-amine pharmacophore. While the glycine analogue 200 and the 
N-methyl amine analogue 198 both expressed improved potency, it is conceivable that a 
combination of both modifications may produce this impaired MOR-potency. 
 DOR and KOR-agonism were low in this series, though a few trends were observed. The 
greatest DOR-efficacy and potency came with the glycine analogue 200. This activity can be 
attributed to the presence of the hydrogen bond donor on the amide, as removal of this donor in 
the sarcosine analogue 199 yields losses in potency and efficacy at DOR. Residual KOR-agonism 
was observed in analogues 194, 197, and 198, each of which can be explained by a hydrogen bond 
acceptor within the simplified core. It should be noted that the amide analogue 195 did not 
stimulate KOR, even though it possessed a hydrogen bond acceptor within the core. This though, 
is consistent with the data shown in Chapters 4 and 5, where residual DOR and KOR agonism 
appear in analogues that possess the amine where none existed before. 
Metabolic Stability: An analysis of the metabolic stability of this series has produced some 
interesting trends. To begin, the conversion from an aromatic core (168) to a simple aliphatic chain 
(193) yielded no improvements in stability. This is despite the fact the aromatic ring is no longer 
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present to stabilize free radical formation and despite a drop in the cLogP by a single unit. Instead, 
this is likely a product of increased conformational flexibility in the ligand. These factors can also 
explain the reduced stability of the ether analogue 194, whereby there is great flexibility in the 
ligand and the ether can stabilize the formation of adjacent free radicals. Adding the amide (195) 
to this ether provides a 4-fold stability improvement, likely through a combination of reduced 
cLogP, reduced flexibility through conjugation, and the carbonyl blocking a possible metabolic 
site. 
 Curiously, the piperidine analogue 196 managed to significantly improve the metabolic 
stability over both the aromatic core analogue 168 and the alkyl chain analogue 193. This is most 
likely the product of cyclization, as rigidity in the ligand can deter binding to the CYP enzyme, 
and the piperidine is less capable of stabilizing metabolism in adjacent positions compared to an 
aromatic ring. This rigidity contributing to stability is supported with the piperazine analogue 197, 
whereby the stability here is 79 minutes. When the piperazine analogue 197 is compared to the N-
methyl analogue 198, in which the only difference between these two analogues is the removal of 
a single methylene group that destroys the ring system, the stability of 198 drops to less than half 
of that of 197. It should be noted that the stability of 197 is less than that of 196, likely for the 
same reasons that the ether analogue 194 is less stable than the alkyl analogue 193. 
 Finally, the two peptide analogues 199 and 200 were compared. Curiously, the desmethyl 
analogue 200 was among the least stable in our series, and N-methylation to 199 improved the 
stability by a factor of 2.5. This is consistent with peptidase activity, as N-methylation can inhibit 
the degradation of peptide bonds.127 A survey of enzymes found in the mouse liver microsomes 
determined that among many others, aminopeptidase N was present.128 This enzyme is currently 
being considered as a target for indirect opioid analgesics because of its capacity for degrading 
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opioid peptides.129 In particular, it recognizes enkephalins as substrates and produces Tyr-Gly 
fragments. It is conceivable then, that this peptidase may also recognize the DMT-Gly fragment 
of our peptidomimetic, the activity of which is consistent with attenuation by N-methylation. 
Molecular Modeling: The data revealed by docking analogue 193 to each of the opioid receptors 
reveals some interesting new trends. At MOR, no new interactions with the receptor appear to 
manifest, though the distance between the tertiary amine and Asn127 appears to increase as 
compared to 168. This may be sufficient to explain the drop in efficacy, though this interaction is 
still likely present, as 193 is still a potent MOR-agonist. 
 With regard to DOR, the cation-π interaction is still present. However, the phenol of 
Tyr109 is further away from the amine by a few Angstroms. Notably, the core aromatic ring of 
superagonist 168 is not close to any particular residue in DOR, and no interactions with the ring 
itself is lost upon the removal of this structure to produce analogue 193. If the argument described 
in Chapter 5 holds weight, then it is possible that rigidity provided by the aromatic core of 168 
helps position the tertiary amine into a favorable interaction between the Tyr109 and the tertiary 
amine. If this structural rigidity is lost, then this amine cannot adequately engage Tyr109, causing 
the loss of an important interaction that facilitates DOR-binding. 
 At KOR, the interactions between the tetrahydroisoquinoline pendant and the residues 
Gln115 and Trp124 are largely unaltered. However, a new interaction is produced, with the phenol 
of Tyr312 interacting with both the tertiary amine of the pendant and the amide of the DMT 
pharmacophore. This additional interaction may help explain the unaltered binding affinity that 
comes with the loss of the core aromatic ring. As stated in Chapter 5, some of the interactions at 
each of these receptors are at an increasingly long distance and additional in silico studies will be 
needed to verify any observed trends. 
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Antinociceptive Activity: Of particular importance to these simplified structures is the fact that 
most of them retain some antinociceptive activity in vivo. In fact, only the ether 194 and the 
piperidine 195 did not express any activity in this series. Thus far, only 193 expresses statistically 
significant antinociception at 1 mg/kg, though there are insufficient N’s acquired in this series. 
The piperazine 197 only has 2 out of the desired 6 N’s, and statistically significant antinociception 
may appear with this compound at 1 mg/kg. Ultimately, these data further establish the ability of 
this pharmacophore to produce MOR-agonists that are active in vivo. 
Conclusions: The analogues shown in this chapter demonstrate that the aromatic-amine 
pharmacophore can apply to greatly simplified core structures. Here, MOR-agonism was 
consistently high, though variable effects at DOR and KOR were observed. Conversion of the 
amine in 194 to the amide in 195 significantly reduced their efficacy at MOR. This reinforces the 
observation that the amine is a MOR-efficacy pharmacophore element. These data further suggest 
that either selective MOR-agonists, bifunctional MOR/DOR, or bifunctional MOR/KOR ligands 
may be possible depending on how the core is structurally manipulated. MOR/DOR structures 
appear to be favored with more rigid cores or cores containing an amide, whereas the MOR/KOR 
ligands favor more flexible cores. With the piperidine and piperazine analogues 196 and 197, 
metabolic stability can be greatly improved with increased rigidity of the ligand, all while 
maintaining moderate to potent MOR-agonism. The implications of this chapter expand beyond 
these peptidomimetic series and suggest that the aromatic-amine pharmacophore can be used in a 
wide variety of structures, particularly the previously studied opioid peptides to produce MOR-







General Methods: All reagents and solvents were obtained commercially and were used 
without further purification. Intermediates were purified by flash chromatography using a Biotage 
Isolera One instrument. Most purification methods utilized a hexanes/ethyl acetate solvent system 
in a Biotage SNAP KP-Sil column, with a linear gradient between 0 and 100% ethyl acetate. 
Reverse phase column chromatography using a linear gradient of 0% to 100% solvent B (0.1% 
TFA in acetonitrile) in solvent A (0.1% TFA in water) using a Biotage SNAP Ultra C18 column 
was utilized for some intermediate amine salts. Purification of final compounds was performed 
using a Waters semipreparative HPLC with a Vydac protein and peptide C18 reverse phase 
column, using a linear gradient of 0% to 100% solvent B in solvent A at a rate 1% per minute, 
monitoring UV absorbance at 230 nm. The purity of final compounds was assessed using a Waters 
Alliance 2690 analytical HPLC instrument with a Vydac protein and peptide C18 reverse phase 
column. A linear gradient (gradient A) of 0% to70% solvent B in solvent A in 70 min, measuring 
UV absorbance at 230 nm was used to determine purity. All final compounds used for testing were 
≥95% pure, as determined by analytical HPLC. 1H NMR and 13C NMR data were obtained on a 
500 or 400 MHz Varian spectrometer using CDCl3, CD3OD, DMSO-d6, or D2O as solvents. The 
identities of final compounds were verified by mass spectrometry using an Agilent 6130 LC–MS 
mass spectrometer in positive ion mode, or an Agilent 6230 TOF HPLC-MS in the positive ion 
mode. 
General Procedure for Coupling of Tetrahydroquinoline Analogues to N-Boc Protected 
Carboxylic Acids (Procedure A): To a flask containing 1 equivalent of N-Boc protected carboxylic 
acid was added 1 equivalent of PyBOP and 1 equivalent of tetrahydroisoquinoline or the 
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tetrahydroquinoline analog. The flask was flushed with argon, DMF was added as solvent, and 10 
equivalents of N-methylmorpholine was added. The reaction was stirred overnight, at which point 
it was concentrated in vacuo. The residue was then partitioned between EtOAc and sat. Na2CO3, 
extracted with EtOAc, the organic layers were combined, dried with MgSO4, filtered, and 
concentrated in vacuo. Purification by column chromatography (0-5% MeOH in DCM, or 0-66% 
EtOAc in Hexanes) yielded the coupled product. 
General Procedure for the Deprotection of Boc-Groups using Concentrated HCl 
(Procedure Ba): To the Boc protected compound was added was added 2-6 mL of Dioxane and 
0.2-0.6 mL concentrated HCl. The solution was stirred at room temperature for 1-5 minutes and 
concentrated in vacuo. The ensuing salt was suspended in solvent A and was either concentrated 
in vacuo and triturated with hexanes or purified by reverse phase chromatography (0-100% B in 
A), yielding the product as a TFA salt. 
General Procedure for the Deprotection of Boc-Groups using TFA (Procedure Bb): To the 
Boc protected compound was added was added 2 mL of TFA and 2 mL of DCM. The solution was 
stirred at room temperature for 1-5 minute and concentrated in vacuo. The ensuing salt was either 
continued without further purification or suspended in solvent A and was purified via reverse phase 
chromatography (0-100% B in A), yielding the product as a TFA salt. 
General Procedure for the Reduction of Amides (Procedure C): To a dried flask containing 
1 equivalent of the desired amide under argon was added THF and 7 equivalents of 2 M BH3*Me2S 
complex in THF. The reaction was heated at 75 °C for 3 hours, at which point the reaction was 
quenched with MeOH and heated for an additional 15 minutes. The reaction was then cooled, 
concentrated in vacuo, and was used in Procedure G without further purification. 
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General Procedure for the Coupling of 2’,6’-Dimethyltyrosine to Functionalized Amine 
Salts (Procedure D): To a dried flask containing the amine under argon was added 3 mL of DMF 
and 10 equivalents of Hunig’s base. 1 equivalent of PyBOP and 1 equivalent of 6-Cl-HOBt was 
added, followed by a 1 equivalent of Boc protected 2’,6’-Dimethyltyrosine in 1.5 mL DMF. The 
solution was stirred overnight at room temperature, concentrated in vacuo, and purified via 
semipreparative reverse phase HPLC (0.1% TFA in water: 0.1% TFA in acetonitrile). 2 mL of 
TFA and 2 mL of DCM were then added, and the solution was stirred for an additional hour. The 
reaction mixture was concentrated in vacuo and purified via an additional semipreparative reverse 
phase HPLC (0.1% TFA in water: 0.1% TFA in acetonitrile). The product was concentrated in 
vacuo and lyophilized overnight to yield the final peptidomimetic. 
5-(3,4-dihydroisoquinolin-2(1H)-yl)-5-oxopentan-1-aminium trifluoroacetate (181): 
See Procedure A: 85 mg (0.39 mmol) of 5-((tert-butoxycarbonyl)amino)pentanoic acid, 204 mg 
(0.39 mmol, 1.0 eq.) of PyBOP, 50 µL (53 mg, 0.39 mmol, 1.0 eq.) of 1,2,3,4-
tetrahydroisoquinoline, 430 µL (396 mg, 3.9 mmol, 10 eq.) of NMM, and 4 mL of DMF. The 
intermediate was purified by column chromatography (0-50 % EtOAc in Hexanes). Procedure Ba: 
5 mL of dioxane and 0.5 mL conc. HCl were added and the solution was concentrated in vacuo 
after 5 min. Compound 181 (99 mg, Yield=73 %) was isolated as a colorless oil. 1H NMR (500 
MHz, Methanol-d4) δ 7.23 – 7.09 (m, 4H), 4.69 (s, 1H), 4.68 (s, 1H), 3.78 (t, J = 6.0 Hz, 1H), 3.74 
(t, J = 6.0 Hz, 1H), 2.93 (p, J = 6.4 Hz, 3H), 2.84 (t, J = 6.0 Hz, 1H), 2.55 (q, J = 6.6 Hz, 2H), 1.76 
– 1.67 (m, 4H). 13C NMR (126 MHz, Methanol-d4) δ 172.33, 172.29, 160.32, 160.02, 134.68, 
134.26, 132.96, 132.60, 128.24, 127.98, 126.60, 126.38, 126.18, 126.08, 126.02, 125.81, 117.21, 




trifluoroacetate (182): See Procedure A: 94 mg (0.43 mmol) of 2-(2-((tert-
butoxycarbonyl)amino)ethoxy)acetic acid, 223 mg (0.43 mmol, 1.0 eq.) of PyBOP, 60 µL (63 
mg, 0.47 mmol, 1.1 eq.) of 1,2,3,4-tetrahydroisoquinoline, 470 µL (432 mg, 4.3 mmol, 10 eq.) of 
NMM, and 4 mL of DMF. The intermediate was purified by column chromatography (0-5 % 
MeOH in DCM).  Procedure Ba: 5 mL of dioxane and 0.5 mL conc. HCl were added and the 
solution was concentrated in vacuo after 5 min. Compound 182 (121 mg, Yield=81 %) was isolated 
as a colorless oil. 1H NMR (400 MHz, Methanol-d4) δ 7.21 – 7.12 (m, 4H), 4.69 (s, 1H), 4.55 (s, 
1H), 4.43 (s, 1H), 4.42 (s, 1H), 3.82 – 3.74 (m, 3H), 3.59 (t, J = 6.0 Hz, 1H), 3.15 (q, J = 4.5 Hz, 
2H), 2.91 (t, J = 6.0 Hz, 1H), 2.85 (t, J = 6.0 Hz, 1H). 13C NMR (101 MHz, Methanol-d4) δ 169.39, 
169.35, 161.16, 160.80, 160.44, 160.08, 134.54, 134.14, 132.52, 131.97, 128.26, 127.98, 126.70, 
126.50, 126.26, 126.15, 126.03, 125.87, 120.64, 117.75, 114.86, 68.20, 45.19, 43.79, 41.68, 39.89, 
39.22, 28.46, 27.74. 
4-(2-(3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl)piperidin-1-ium hydrochloride 
(183): See Procedure A: 75 mg (0.31 mmol) of 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic 
acid, 161 mg (0.31 mmol, 1.0 eq.) of PyBOP, 40 µL (42 mg, 0.32 mmol, 1.0 eq.) of 1,2,3,4-
tetrahydroisoquinoline, 340 µL (313 mg, 3.1 mmol, 10 eq.) of NMM, and 4 mL of DMF. The 
intermediate was purified by column chromatography (0-5 % MeOH in DCM). Procedure Ba: 5 
mL of dioxane and 0.5 mL conc. HCl were added and the solution was concentrated in vacuo after 
1 min. Compound 183 (86 mg, Yield=95 %) was isolated as an off white amorphous solid. 1H 
NMR (500 MHz, Methanol-d4) δ 7.22 – 7.11 (m, 4H), 4.70 (s, 1H), 4.68 (s, 1H), 3.78 (t, J = 6.0 
Hz, 1H), 3.75 (t, J = 5.9 Hz, 1H), 3.37 (ddd, J = 12.8, 6.3, 3.1 Hz, 2H), 3.05 – 2.94 (m, 2H), 2.92 
(t, J = 5.9 Hz, 1H), 2.84 (t, J = 6.0 Hz, 1H), 2.49 (t, J = 7.3 Hz, 2H), 2.14 (ddtt, J = 14.4, 10.7, 6.9, 
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3.8 Hz, 1H), 2.05 – 1.95 (m, 2H), 1.55 – 1.41 (m, 2H). 13C NMR (126 MHz, Methanol-d4) δ 170.84, 
170.78, 160.78, 160.49, 134.67, 134.24, 132.94, 132.62, 128.26, 127.99, 126.62, 126.38, 126.19, 
126.08, 126.03, 125.80, 117.46, 115.14, 43.92, 43.73, 43.71, 43.26, 39.96, 38.72, 38.52, 30.66, 
30.63, 28.87, 28.46, 28.42, 27.92. 
1-(2-(3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl)piperazine-1,4-diium 
trifluoroacetate (184): See Procedure A: 78 mg (0.32 mmol) of 2-(4-(tert-
butoxycarbonyl)piperazin-1-yl)acetic acid, 172 mg (0.33 mmol, 1.0 eq.) of PyBOP, 50 µL (53 
mg, 0.39 mmol, 1.2 eq.) of 1,2,3,4-tetrahydroisoquinoline, 350 µL (322 mg, 3.2 mmol, 10 eq.) of 
NMM, and 4 mL of DMF. The intermediate was purified by column chromatography (0-5 % 
MeOH in DCM).  Procedure Ba: 5 mL of dioxane and 0.5 mL conc. HCl were added and the 
solution was concentrated in vacuo after 5 min. Compound 184 (156 mg, Quantitative Yield) was 
isolated as a white waxy solid. 1H NMR (500 MHz, Methanol-d4) δ 7.25 – 7.09 (m, 4H), 4.70 (s, 
1H), 4.63 (s, 1H), 4.40 (s, 2H), 3.79 (t, J = 6.1 Hz, 1H), 3.69 – 3.57 (m, 9H), 2.96 (t, J = 6.0 Hz, 
1H), 2.87 (t, J = 6.1 Hz, 1H). 13C NMR (126 MHz, Methanol-d4) δ 163.34, 163.26, 161.82, 161.54, 
161.25, 134.44, 134.05, 132.07, 131.59, 128.26, 128.05, 126.90, 126.70, 126.39, 126.31, 126.07, 
125.99, 117.61, 115.29, 57.02, 56.93, 49.41, 49.38, 45.84, 44.05, 42.45, 40.69, 40.31, 28.35, 27.64. 
 2-(3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-oxoethan-1-aminium 
trifluoroacetate (185): See Procedure A: 104 mg (0.55 mmol) of N-(tert-butoxycarbonyl)-N-
methylglycine, 288 mg (0.55 mmol, 1.0 eq.) of PyBOP, 70 µL (74 mg, 0.55 mmol, 1.0 eq.) of 
1,2,3,4-tetrahydroisoquinoline, 600 µL (552 mg, 5.5 mmol, 10 eq.) of NMM, and 4 mL of DMF. 
The intermediate was purified by column chromatography (0-5 % MeOH in DCM). Procedure Ba: 
6 mL of dioxane and 0.6 mL conc. HCl were added and the solution was concentrated in vacuo 
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after 5 min. Compound 185 (132 mg, Yield=75 %) was isolated as a colorless oil that turned purple 
overtime. 1H NMR (500 MHz, Methanol-d4) δ 7.23 – 7.10 (m, 4H), 4.69 (s, 1H), 4.60 (s, 1H), 4.16 
(s, 1H), 4.15 (s, 1H), 3.79 (t, J = 6.1 Hz, 1H), 3.63 (t, J = 6.0 Hz, 1H), 2.94 (t, J = 6.0 Hz, 1H), 
2.85 (t, J = 6.0 Hz, 1H), 2.78 (s, 3H). 13C NMR (126 MHz, Methanol-d4) δ 164.05, 164.01, 161.03, 
160.74, 160.46, 160.16, 134.42, 134.00, 132.18, 131.60, 128.27, 128.05, 126.81, 126.61, 126.33, 
126.24, 126.02, 125.92, 119.71, 117.40, 115.09, 112.77, 49.10, 49.00, 45.56, 43.93, 42.14, 40.08, 
32.25, 28.34, 27.67. 
tert-butyl (2-(3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl)(methyl)carbamate (186): 
See Procedure A: 99 mg (0.52 mmol) of N-(tert-butoxycarbonyl)-N-methylglycine, 271 mg 
(0.52 mmol, 1.0 eq.) of PyBOP, 70 µL (74 mg, 0.55 mmol, 1.1 eq.) of 1,2,3,4-
tetrahydroisoquinoline, 580 µL (534 mg, 5.3 mmol, 10 eq.) of NMM, and 4 mL of DMF. The 
product was purified by column chromatography (0-50 % EtOAc in Hexanes), yielding Compound 
186 (152 mg, Yield= 95 %) as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.22 – 7.02 
(m, 4H), 4.71 (d, J = 9.6 Hz, 1H), 4.57 (s, 1H), 4.13 (d, J = 6.2 Hz, 1H), 4.05 (s, 1H), 3.84 – 3.77 
(m, 1H), 3.67 – 3.59 (m, 1H), 2.92 (d, J = 5.4 Hz, 3H), 2.85 (dt, J = 15.7, 5.5 Hz, 2H), 1.46 (s, 
6H), 1.39 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 167.55, 167.46, 156.22, 134.87, 133.97, 
133.23, 132.16, 129.01, 128.85, 128.28, 126.94, 126.62, 126.57, 126.36, 126.07, 125.96, 79.95, 
51.02, 50.56, 50.44, 46.29, 44.36, 42.43, 39.93, 35.46, 29.30, 28.36, 28.29. 
tert-butyl (2-(3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl)carbamate (187): See 
Procedure A: 91 mg (0.52 mmol) of (tert-butoxycarbonyl)glycine, 270 mg (0.52 mmol, 1.0 eq.) 
of PyBOP, 70 µL (74 mg, 0.55 mmol, 1.1 eq.) of 1,2,3,4-tetrahydroisoquinoline, 570 µL (524 mg, 
5.2 mmol, 10 eq.) of NMM, and 4 mL of DMF. The product was purified by column 
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chromatography (0-66 % EtOAc in Hexanes), yielding Compound 187 (136 mg, Yield= 90 %) as 
a yellow oil. 1H NMR (500 MHz, Chloroform-d) δ 7.22 – 7.03 (m, 4H), 5.59 (s, 1H), 4.71 (s, 1H), 
4.52 (s, 1H), 4.02 (dd, J = 8.5, 4.4 Hz, 2H), 3.81 (t, J = 6.0 Hz, 1H), 3.58 (t, J = 5.9 Hz, 1H), 2.86 
(dt, J = 22.9, 6.0 Hz, 2H), 1.43 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 167.29, 155.83, 
134.70, 133.80, 132.83, 131.68, 128.84, 128.30, 127.12, 126.75, 126.70, 126.55, 126.53, 126.11, 
79.61, 45.93, 44.38, 42.64, 42.48, 42.03, 40.06, 29.09, 28.34, 28.29. 
tert-butyl (2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)(methyl)carbamate (188): See 
Procedure C: 48 mg (0.16 mmol) of 186, 550 µL (1.1 mmol, 7.0 eq.) of 2M BH3*Me2S in THF, 
and 4 mL THF. The concentrated product was purified by column chromatography (0-33 % EtOAc 
in Hexanes), yielding Compound 188 (30 mg, Yield= 66 %) as a colorless oil. 1H NMR (500 MHz, 
Chloroform-d) δ 7.26 – 7.13 (m, 3H), 7.02 (d, J = 7.1 Hz, 1H), 4.23 (d, J = 15.6 Hz, 1H), 3.96 – 
3.58 (m, 3H), 3.35 – 2.78 (m, 9H), 1.40 (s, 4H), 1.34 (s, 5H). 13C NMR (126 MHz, Chloroform-d) 
δ 129.75, 128.59, 127.60, 127.36, 127.00, 126.78, 80.00, 79.82, 62.10, 61.03, 54.96, 54.79, 54.10, 
53.87, 44.29, 43.94, 35.01, 34.70, 28.32, 24.04. 
2-(3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethan-1-aminium trifluoroacetate (189) 
Procedure Ba: 54 mg (0.19 mmol) of 187, 5 mL of dioxane and 0.5 mL conc. HCl were added 
and the solution was concentrated in vacuo after 5 min. Compound 189 (32 mg, Yield=57 %) was 
isolated as a pinkish white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.24 – 7.10 (m, 4H), 4.69 (s, 
1H), 4.60 (s, 1H), 4.04 (s, 1H), 4.03 (s, 1H), 3.78 (t, J = 6.1 Hz, 1H), 3.64 (t, J = 6.0 Hz, 1H), 2.94 
(t, J = 6.0 Hz, 1H), 2.86 (t, J = 6.1 Hz, 1H). 13C NMR (126 MHz, Methanol-d4) δ 164.95, 164.90, 
161.74, 161.46, 161.18, 160.89, 134.48, 134.04, 132.13, 131.57, 128.28, 128.07, 126.91, 126.69, 
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126.40, 126.32, 126.08, 125.98, 119.96, 117.64, 115.32, 113.00, 45.64, 44.15, 42.23, 40.39, 28.33, 
27.66. 
2-((2-(3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl)(methyl)amino)-2-oxoethan-1-
aminium trifluroacetate (190): See Procedure A: 47 mg (0.15 mmol) of 185, 80 mg (0.15 mmol, 
1.0 eq.) of PyBOP, 29 mg (0.17 mmol, 1.1 eq.) of N-(tert-butoxycarbonyl)glycine, 170 µL (156 
mg, 1.5 mmol, 10 eq.) of NMM, and 4 mL of DMF. The intermediate was purified by column 
chromatography (0-5 % MeOH in DCM).  Procedure Ba: 5 mL of dioxane and 0.5 mL conc. HCl 
were added and the solution was concentrated in vacuo after 5 min. Compound 190 (24 mg, 
Yield=43 %) was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.23 – 7.12 (m, 
4H), 4.71 – 4.66 (m, 2H), 4.45 – 4.40 (m, 2H), 4.00 (s, 2H), 3.79 (q, J = 6.0, 5.6 Hz, 1H), 3.71 (td, 
J = 6.0, 1.8 Hz, 1H), 3.11 – 3.02 (m, 3H), 2.98 – 2.96 (m, 1H), 2.90 – 2.81 (m, 1H). 13C NMR (126 
MHz, Methanol-d4) δ 167.14, 166.71, 160.08, 159.78, 134.59, 134.22, 133.52, 132.63, 128.81, 
128.23, 127.97, 127.93, 127.26, 126.68, 126.58, 126.50, 126.30, 126.24, 126.15, 126.00, 125.89, 
117.07, 114.76, 55.11, 49.47, 49.32, 45.76, 44.24, 44.08, 42.29, 42.23, 41.87, 40.16, 39.64, 39.47, 
34.68, 34.63, 34.27, 28.49, 27.82, 27.25. 
2-(3,4-dihydroisoquinolin-2(1H)-yl)-N-methylethan-1-aminium trifluroacetate (191): 
See Procedure Ba: 30 mg (0.16 mmol) of 188, 5 mL of dioxane and 0.5 mL conc. HCl were added 
and the solution was concentrated in vacuo after 5 min. The residue was then partitioned between 
EtOAc and sat. Na2CO3, and extracted with EtOAc. The organic layers were then combined, dried 
with MgSO4, filtered, and concentrated in vacuo. The residue was suspended in solvent A, 
concentrated in vacuo, and triturated with hexanes. Compound 191 (28 mg, Yield= 89 %) was 
isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.33 – 7.25 (m, 3H), 7.22 – 7.18 
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(m, 1H), 4.53 (s, 2H), 3.71 – 3.63 (m, 4H), 3.63 – 3.53 (m, 2H), 3.24 (t, J = 6.4 Hz, 2H), 2.82 (s, 
3H). 13C NMR (126 MHz, Methanol-d4) δ 130.47, 128.46, 128.18, 128.15, 127.09, 126.93, 126.88, 
126.43, 126.38, 53.31, 53.24, 52.14, 50.94, 50.47, 50.22, 49.57, 42.85, 42.24, 32.58, 27.17, 24.88. 
2-((2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)amino)-2-oxoethan-1-aminium 
trifluroacetate (192): See Procedure C: 24 mg (0.079 mmol) of 189, 280 µL (0.56 mmol, 7.1 eq.) 
of 2M BH3*Me2S in THF, and 4 mL THF. Procedure A: 43 mg (0.083 mmol, 1.0 eq.) of PyBOP, 
14 mg (0.080 mmol, 1.0 eq.) of N-(tert-butoxycarbonyl)glycine, 90 µL (83 mg, 0.82 mmol, 10 eq.) 
of NMM, and 4 mL of DMF. Procedure Bb: 2 mL of TFA and 2 mL DCM were added, and the 
solution was concentrated in vacuo after 1 min. The residue was then purified by reverse phase 
chromatography. Compound 192 (16 mg, Yield=58 %) was isolated as a colorless oil. 1H NMR 
(500 MHz, Methanol-d4) δ 7.35 – 7.23 (m, 3H), 7.20 (d, J = 7.2 Hz, 1H), 4.55 (br s, 2H), 3.99 – 
3.68 (m, 5H), 3.65 – 3.40 (m, 3H), 3.22 (s, 2H). 13C NMR (126 MHz, Methanol-d4) δ 167.41, 
160.53, 160.24, 159.94, 130.59, 128.43, 128.09, 127.21, 126.85, 126.41, 117.24, 114.93, 55.08, 
53.22, 49.88, 40.13, 33.96, 24.78. 
(S)-1-((5-(3,4-dihydroisoquinolin-2(1H)-yl)pentyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (193): See Procedure C: 30 mg 
(0.087 mmol) of 181, 300 µL (0.60 mmol, 6.9 eq.) of 2 M BH3*Me2S in THF, and 4 mL of THF. 
Step 1 of Procedure D: 150 µL (111 mg, 0.86 mmol, 10 eq.) of N,N-diisopropylethylamine, 45 mg 
(0.086 mmol, 1.0 eq.) of PyBOP, 16 mg (0.094 mmol, 1.1 eq.) of 6-Cl-HOBt, 38 mg (0.093 mmol, 
1.1 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of Procedure D: 2 mL 
TFA and 2 mL DCM. Compound 193 (13.1 mg, Yield=29 %) was isolated as a white solid. 1H 
NMR (500 MHz, Methanol-d4) δ 7.80 (t, J = 5.7 Hz, 1H), 7.36 – 7.24 (m, 3H), 7.22 (d, J = 7.4 Hz, 
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1H), 6.51 (s, 2H), 4.60 (dd, J = 14.5, 7.7 Hz, 1H), 4.32 (t, J = 14.4 Hz, 1H), 3.90 – 3.75 (m, 2H), 
3.40 (dd, J = 25.6, 15.6 Hz, 1H), 3.31 – 3.10 (m, 9H), 3.00 (dd, J = 13.8, 4.8 Hz, 1H), 2.97 – 2.87 
(m, 1H), 2.27 (s, 6H), 1.81 – 1.65 (m, 2H), 1.35 (dp, J = 9.1, 6.5 Hz, 2H), 1.05 (dtt, J = 21.2, 13.2, 
6.7 Hz, 2H). (MS)EI: 410.3 (M+H), Retention Time: 19.34 min.  
(S)-1-((2-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethoxy)ethyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (194): See Procedure C: 41 mg 
(0.12 mmol) of 182, 420 µL (0.84 mmol, 7.1 eq.) of 2 M BH3*Me2S in THF, and 4 mL of THF. 
Step 1 of Procedure D: 210 µL (156 mg, 1.2 mmol, 10 eq.) of N,N-diisopropylethylamine, 63 mg 
(0.12 mmol, 1.0 eq.) of PyBOP, 21 mg (0.12 mmol, 1.0 eq.) of 6-Cl-HOBt, 50 mg (0.12 mmol, 
1.0 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of Procedure D: 2 mL 
TFA and 2 mL DCM. Compound 194 (11.1 mg, Yield=18 %) was isolated as a white solid. 1H 
NMR (500 MHz, Methanol-d4) δ 7.34 – 7.25 (m, 3H), 7.21 (d, J = 7.5 Hz, 1H), 6.50 (s, 2H), 4.56 
(s, 1H), 4.37 (s, 1H), 3.89 (dd, J = 11.4, 4.9 Hz, 1H), 3.83 – 3.72 (m, 2H), 3.69 (ddd, J = 11.7, 7.7, 
4.2 Hz, 1H), 3.50 – 3.34 (m, 5H), 3.29 – 3.16 (m, 4H), 3.01 (dd, J = 13.8, 4.9 Hz, 1H), 2.26 (s, 
6H). (MS)EI: 413.3 (M+H), Retention Time: 17.78 min. 
(S)-1-((2-(2-(3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethoxy)ethyl)amino)-3-(4-
hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (195): See Procedure 
D: Step 1: 36 mg (0.10 mmol) of 182, 180 µL (134 mg, 1.0 mmol, 10 eq.) of N,N-
diisopropylethylamine, 56 mg (0.11 mmol, 1.0 eq.) of PyBOP, 19 mg (0.11 mmol, 1.1 eq.) of 6-
Cl-HOBt, 44 mg (0.11 mmol, 1.0 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. 
Step 2: 2 mL TFA and 2 mL DCM. Compound 195 (15.1 mg, Yield=27 %) was isolated as a white 
solid. 1H NMR (500 MHz, Methanol-d4) δ 8.14 (dt, J = 22.7, 5.2 Hz, 1H), 7.23 – 7.11 (m, 4H), 
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6.46 (s, 1H), 6.43 (s, 1H), 4.67 (s, 1H), 4.55 (d, J = 2.7 Hz, 1H), 4.16 (qd, J = 15.0, 6.9 Hz, 2H), 
3.85 (dd, J = 11.5, 4.9 Hz, 1H), 3.83 – 3.70 (m, 1H), 3.63 – 3.54 (m, 1H), 3.54 – 3.48 (m, 1H), 
3.37 – 3.31 (m, 1H), 3.28 – 3.15 (m, 3H), 3.04 – 2.83 (m, 3H), 2.25 (s, 2H), 2.24 (s, 4H). (MS)EI: 
427.3 (M+H), Retention Time: 26.81 min. 
(S)-1-(4-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)piperidin-1-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (196): See Procedure C: 25 mg 
(0.067 mmol) of 183, 250 µL (0.50 mmol, 7.4 eq.) of 2 M BH3*Me2S in THF, and 4 mL of THF. 
Step 1 of Procedure D: 120 µL (89 mg, 0.69 mmol, 10 eq.) of N,N-diisopropylethylamine, 35 mg 
(0.067 mmol, 1.0 eq.) of PyBOP, 13 mg (0.077 mmol, 1.1 eq.) of 6-Cl-HOBt, 29 mg (0.071 mmol, 
1.1 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of Procedure D: 2 mL 
TFA and 2 mL DCM. Compound 196 (2.8 mg, Yield=8 %) was isolated as a white solid. 1H NMR 
(500 MHz, Methanol-d4) δ 7.37 – 7.15 (m, 4H), 6.56 (s, 1H), 6.49 (s, 1H), 4.66 – 4.44 (m, 3H), 
4.38 – 4.20 (m, 1H), 3.79 (s, 1H), 3.28 – 3.10 (m, 5H), 3.10 – 3.00 (m, 1H), 2.87 (td, J = 12.9, 2.6 
Hz, 1H), 2.50 (dtd, J = 44.8, 13.0, 2.4 Hz, 1H), 2.29 (s, 4H), 2.23 (s, 2H), 1.73 (dd, J = 33.7, 13.1 
Hz, 2H), 1.67 – 1.38 (m, 3H), 1.21 (d, J = 13.2 Hz, 1H), 1.17 – 1.00 (m, 1H), 0.84 (qd, J = 13.0, 
4.7 Hz, 1H), -0.30 – -0.63 (m, 1H). (MS)EI: 436.3 (M+H), Retention Time: 20.44 min. 
(S)-1-(4-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)piperazin-1-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (197): See Procedure C: 70 mg 
(0.14 mmol) of 184, 720 µL (1.4 mmol, 10 eq.) of 2 M BH3*Me2S in THF, and 5 mL of THF. Step 
1 of Procedure D: 250 µL (186 mg, 1.4 mmol, 10 eq.) of N,N-diisopropylethylamine, 76 mg (0.15 
mmol, 1.0 eq.) of PyBOP, 25 mg (0.15 mmol, 1.0 eq.) of 6-Cl-HOBt, 59 mg (0.14 mmol, 1.0 eq.) 
of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+2.5 mL of DMF. Step 2 of Procedure D: 2 mL TFA 
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and 2 mL DCM. Compound 197 (2.9 mg, Yield=3.7 %) was isolated as a white solid. 1H NMR 
(500 MHz, Methanol-d4) δ 7.35 – 7.23 (m, 3H), 7.22 – 7.12 (m, 1H), 6.52 (s, 2H), 4.53 (dd, J = 
12.1, 4.4 Hz, 1H), 4.46 (s, 2H), 3.66 (d, J = 13.4 Hz, 1H), 3.60 (t, J = 6.4 Hz, 2H), 3.54 (t, J = 10.5 
Hz, 1H), 3.39 (t, J = 6.1 Hz, 2H), 3.24 – 3.17 (m, 3H), 3.16 – 3.10 (m, 1H), 3.07 (dd, J = 13.8, 4.4 
Hz, 1H), 2.80 (q, J = 6.4 Hz, 2H), 2.69 – 2.57 (m, 2H), 2.43 – 2.33 (m, 2H), 2.26 (s, 6H), 1.64 – 
1.52 (m, 1H). (MS)EI: 437.3 (M+H), Retention Time: 17.60 min. 
(S)-1-((2-((2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)(methyl)amino)ethyl)amino)-3-
(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (198): See 
Procedure C: 24 mg (0.064 mmol) of 190, 300 µL (0.60 mmol, 9.4 eq.) of 2 M BH3*Me2S in THF, 
and 4 mL of THF. Step 1 of Procedure D: 110 µL (82 mg, 0.63 mmol, 9.9 eq.) of N,N-
diisopropylethylamine, 35 mg (0.67 mmol, 1.1 eq.) of PyBOP, 13 mg (0.077 mmol, 1.2 eq.) of 6-
Cl-HOBt, 28 mg (0.068 mmol, 1.1 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of 
DMF. Step 2 of Procedure D: 2 mL TFA and 2 mL DCM. Compound 198 (4.9 mg, Yield=14 %) 
was isolated as a white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.34 – 7.25 (m, 3H), 7.20 (d, J 
= 7.4 Hz, 1H), 6.51 (s, 2H), 4.49 (s, 2H), 3.84 (dd, J = 11.3, 5.1 Hz, 1H), 3.73 – 3.58 (m, 6H), 3.57 
– 3.47 (m, 1H), 3.29 – 3.18 (m, 4H), 3.14 (dt, J = 11.9, 5.7 Hz, 1H), 3.01 (ddd, J = 20.8, 13.6, 6.0 
Hz, 2H), 2.83 (s, 3H), 2.25 (s, 6H). (MS)EI: 425.3 (M+H), Retention Time: 16.72 min. 
(S)-1-((2-((2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)(methyl)amino)-2-
oxoethyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium 
trifluoroacetate (199): See Procedure A: 28 mg (0.092 mmol) of 191, 47 mg (0.0.90 mmol, 0.98 
eq.) of PyBOP, 18 mg (0.10 mmol, 1.1 eq.) of N-(tert-butoxycarbonyl)glycine, 100 µL (92 mg, 
0.91 mmol, 9.9 eq.) of NMM, and 4 mL of DMF. The intermediate was purified by column 
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chromatography (0-5 % MeOH in DCM), and 25 mg of intermediate was isolated as a crude 
mixture with tri(pyrrolidin-1-yl)phosphine oxide (approximately 2.5:1 phosphine 
oxide:intermediate by NMR). No repurification was performed due to poor UV absorbance.  
Procedure Bb: 25 mg (approximately 0.029 mmol) of crude, 2 mL of TFA and 2 mL DCM were 
added, and the solution was concentrated in vacuo after 5 min. No purification by reverse phase 
chromatography was performed. See Procedure D: Step 1: 50 µL (37 mg, 0.29 mmol, 1.0 eq.) of 
N,N-diisopropylethylamine, 16 mg (0.031 mmol, 1.1 eq.) of PyBOP, 7 mg (0.041 mmol, 1.4 eq.) 
of 6-Cl-HOBt, 13 mg (0.32 mmol, 1.1 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of 
DMF. Step 2: 2 mL TFA and 2 mL DCM. Compound 199 (10.1 mg, Yield=20 % over 4 steps) 
was isolated as a white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.35 – 7.22 (m, 3H), 7.19 (d, J 
= 7.4 Hz, 1H), 6.48 (s, 2H), 4.67 (s, 1H), 4.42 (s, 1H), 4.16 – 3.74 (m, 6H), 3.60 – 3.41 (m, 3H), 
3.25 – 3.14 (m, 3H), 3.05 (s, 3H), 3.01 (dd, J = 14.1, 5.3 Hz, 1H), 2.24 (s, 6H). (MS)EI: 439.3 
(M+H), Retention Time: 16.60 min. 
(S)-1-((2-((2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)amino)-2-oxoethyl)amino)-3-(4-
hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (200): See Procedure 
D: Step 1: 15 mg (0.043 mmol) of 192, 80 µL (59 mg, 0.46 mmol, 11 eq.) of N,N-
diisopropylethylamine, 23 mg (0.044 mmol, 1.0 eq.) of PyBOP, 7 mg (0.041 mmol, 0.96 eq.) of 
6-Cl-HOBt, 19 mg (0.046 mmol, 1.1 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of 
DMF. Step 2: 2 mL TFA and 2 mL DCM. Compound 200 (7.3 mg, Yield=31 %) was isolated as 
a white solid. 1H NMR (400 MHz, Methanol-d4) δ 7.38 – 7.24 (m, 3H), 7.21 (d, J = 6.6 Hz, 1H), 
6.49 (s, 2H), 4.62 (s, 1H), 4.41 (s, 1H), 4.03 – 3.83 (m, 3H), 3.69 (s, 2H), 3.56 (d, J = 16.8 Hz, 
1H), 3.41 (t, J = 5.8 Hz, 3H), 3.27 – 3.14 (m, 3H), 3.02 (dd, J = 14.0, 5.2 Hz, 1H), 2.24 (s, 6H). 
(MS)EI: 425.3 (M+H), Retention Time: 16.30 min. 
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In Vitro Pharmacology 
Cell Lines and Membrane Preparations.  
All in vitro opioid assays were performed by Ashley Brinkel, Jack Twarozynski, and 
Jessica Anand. Tissue culture reagents were purchased from Gibco Life Sciences (Grand Island, 
NY, U.S.) unless otherwise noted. C6-rat glioma cells stably expressing human MOR (C6-MOR) 
or human DOR (C6-DOR) and Chinese hamster ovary (CHO) cells stably expressing human KOR 
(CHO-KOR) were used for all in vitro assays. Cells were grown to confluence at 37 °C in 5% CO2 
in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal bovine serum and 5% 
penicillin/streptomycin. Membranes were prepared by washing confluent cells three times with ice 
cold phosphate buffered saline (0.9% NaCl, 0.61 mM Na2HPO4, 0.38 mM KH2PO4, pH 7.4). Cells 
were detached from the plates by incubation in warm harvesting buffer (20 mM HEPES, 150 mM 
NaCl, 0.68 mM EDTA, pH 7.4) and pelleted by centrifugation at 1600 rpm for 3 min. The cell 
pellet was suspended in ice-cold 50 mM Tris- HCl buffer, pH 7.4, and homogenized with a Tissue 
Tearor (Biospec Products, Inc., Bartlesville, OK, U.S.) for 20 s. The homogenate was centrifuged 
at 15,000 rpm for 20 min at 4°C. The pellet was rehomogenized in 50 mM Tris-HCl with a Tissue 
Tearor for 10 s, followed by recentrifugation. The final pellet was resuspended in 50 mM Tris-
HCl and frozen in aliquots at -80°C. Protein concentration was determined via a BCA protein assay 
(Thermo Scientific Pierce, Waltham, MA, U.S.) using bovine serum albumin as the standard.  
Radioligand Competition Binding Assays.  
Radiolabeled compounds were purchased from Perkin-Elmer (Waltham, MA, U.S.). 
Opioid ligand binding assays were performed by competitive displacement of 0.2 nM [3H]-
diprenorphine (250 μCi, 1.85 TBq/mmol) by the peptidomimetic from membrane preparations 
containing opioid receptors as described above. The assay mixture, containing membranes (20 μg 
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protein/tube) in 50 mM Tris-HCl buffer (pH 7.4), 0.2 nM [3H]-diprenorphine, and various 
concentrations of test peptidomimetic, was incubated at room temperature on a shaker for 1 h to 
allow binding to reach equilibrium. The samples were rapidly filtered through Whatman GF/C 
filters using a Brandel harvester (Brandel, Gaithersburg, MD, U.S.) and washed three times with 
50 mM Tris-HCl buffer, pH 7.4. Bound radioactivity on dried filters was determined by liquid 
scintillation counting, after saturation with EcoLume liquid scintillation cocktail, in a Wallac 1450 
MicroBeta (Perkin-Elmer, Waltham, MA, U.S.). Nonspecific binding was determined using 10 
μM naloxone. The results presented are the mean ± standard error (S.E.M.) from at least three 
separate assays performed in duplicate. Ki (nM) values were calculated using nonlinear regression 
analysis to fit a logistic equation to the competition data using GraphPad Prism, version 6.0c, 
(GraphPad Software Inc., La Jolla, CA).  
[35S]-GTPγS Binding Assays.  
Agonist stimulation of [35S]guanosine 5′-O-[γ- thio]triphosphate ([35S]-GTPγS, 1250 Ci, 
46.2 TBq/mmol) binding to G protein was measured as described previously.82 Briefly, membranes 
(10 μg of protein/well) were incubated for 1 h at 25°C in GTPγS buffer (50 mM Tris-HCl, 100 
mM NaCl, 5 mM MgCl2, 1 mM EDTA, pH 7.4) containing 0.1 nM [
35S]-GTPγS, 30 μM guanosine 
diphosphate (GDP), and varying concentrations of test peptidomimetic. G protein activation 
following receptor activation by peptidomimetic was compared with 10 μM of the standard 
compounds [D-Ala2,N-MePhe4,Gly-ol]enkephalin (DAMGO) at MOR, D-Pen2,5- enkephalin 
(DPDPE) at DOR, or U69,593 at KOR. The reaction was terminated by vacuum filtration through 
GF/C filters that were washed 5 times with GTPγS buffer. Bound radioactivity was measured as 
described above. The results are presented as the mean ± standard error (S.E.M.) from at least three 
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separate assays performed in duplicate; potency (EC50 (nM)) and percent stimulation were 
determined using nonlinear regression analysis with GraphPad Prism, as above.  
Mouse Liver Microsome Stability Assays 
All liver microsome assays were performed by Quintara Biosciences. Metabolic stability 
of testing compounds was evaluated using mouse liver microsomes to predict intrinsic clearance. 
Mouse liver microsome tissue fractions were obtained from Corning or BioreclamationIVT. The 
assay was carried out in 96-well microtiter plates at 37°C. Reaction mixtures (25 μL) contained a 
final concentration of 1 μM test compound, 0.1 mg/mL liver microsome protein, and 1 mM 
NADPH in 100 mM potassium phosphate, pH 7.4 buffer with 3 mM MgCl2. At each of the time 
points (0, 15, 30, and 60 minutes), 150 μL of quench solution (acetonitrile with 0.1% formic acid) 
with internal standard (bucetin) was transferred to each well. Verapamil was included as a positive 
control to verify assay performance. Plates were sealed, vortexed, and centrifuged at 4°C for 15 
minutes at 4000 rpm. The supernatant was transferred to fresh plates for LC/MS/MS analysis. All 
samples were analyzed on LC/MS/MS using an AB Sciex API 4000 instrument, coupled to a 
Shimadzu LC-20AD LC Pump system. Analytical samples were separated using a Waters Atlantis 
T3 dC18 reverse phase HPLC column (20 mm x 2.1 mm) at a flow rate of 0.5 mL/min. The mobile 
phase consists of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile 
(solvent B). The extent of metabolism was calculated as the disappearance of the test compound, 
compared to the 0-min time incubation. Initial rates were calculated for the compound 
concentration and used to determine T1/2 values. 
Molecular Modeling 
All in silico experiments were performed by Irina Pogozheva. Modeling of three-
dimensional (3D) structures of receptor-ligand complexes was based on available X-ray structures 
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of the mouse MOR (PDB ID: 5c1m)83 in the active state, human KOR (PDB IDs: 4djh)125 in the 
inactive conformation, and human DOR in the inactive conformation (PDB IDs: 4rwa)126. 
Structures of peptidomimetic ligands were generated using the 3D-Builder Application of 
QUANTA (Accelrys, Inc) followed by Conformational Search included in the program package. 
Low-energy ligand conformations (within 2 kcal/mol) that demonstrated the best superposition of 
aromatic substituents of the ligand core with the pharmacophore elements (DMT and 
tetrahydroquinoline pendant) of receptor-bound conformations of peptidomimetics  were selected 
for docking into the receptor binding pocket. Ligands were positioned inside the receptor binding 
cavity to reproduce the binding modes of peptidomimetics and co-crystalized ligands in MOR, 
DOR, and KOR X-ray structures. The docking pose of each ligand was subsequently refined using 
the solid docking module of QUANTA.  
Animals and In Vivo Solutions 
All in vivo assays were performed by Bryan Sears. Animal care and experimental 
procedures complied with the US National Research Council's Guide for the Care and Use of 
Laboratory Animals.91 Animal studies are reported in compliance with the ARRIVE 
guidelines.92,93 Mice were group‐housed with a maximum of five animals per cage in clear 
polypropylene cages with corn cob bedding and nestlets as enrichment. Mice had free access to 
food and water at all times. Animals were housed in pathogen‐free rooms maintained between 68 
and 79 °F and humidity between 30 and 70 % humidity with a 12 h light/dark cycle with lights on 
at 07:00 h. Experiments were conducted in the housing room during the light cycle. All studies 
utilize male C57BL/6 mice from Envigo laboratories. Wild type mice weighing between 20-30 g 
at 7-15 weeks old, were used for behavioral experiments. All drug solutions were injected at a 
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volume of 10 ml/kg. All drugs were dissolved in 9:1 DMSO/saline solution except for morphine 
sulphate and 0.6 % acetic acid which were dissolved in saline and water, respectively. All drugs 
were given sc. except for 0.6 % acetic acid which was given ip. 
Acetic Acid Stretch Assay (AASA) 
Antinociceptive effects were evaluated in the mouse acetic acid stretch assay in which a 
noxious stimulus is administered ip. that induces a stretching behavior characterized by 
constriction of the abdomen followed by extension of the hind limbs. Mice received an injection 
of 0.6 % acetic acid, placed individually in clear plastic observation cages (10 x 6 x 8 in) with 
bedding, and the number of stretches were recorded for 20 min. Antinociceptive effects were 
determined with a 30 min pretreatment dose of compound sc. followed by 0.6 % acetic acid ip. A 
5 min latency period after acetic acid injection was establish and total number of stretches were 













Chapter 7: Aliphatic Heterocycles as Novel Core Elements 
7.1 Introduction 
Before the full characterization of the aromatic-amine pendants described previously, we 
were interested in expanding the structural variability of our peptidomimetics. In short, this was a 
fallback plan if stability, in vivo, or in vitro improvements did not occur with any further 
modifications to our original monocyclic aromatic core. The direction we took was to perform a 
scaffold hop from an aromatic core to a cyclic aliphatic core (Figure 21). For these purposes, 
analogue 70 was used as the lead for this series. This scaffold hop would change the orbital 
hybridization of three important atoms (Figure 21, X, Y, Z) from sp2 to sp3. This conversion from 
aromatic to aliphatic carbons is also correlated to improved drug solubility, success during clinical 
development,130,131 and reduced likelihood of CYP3A4 inhibition.132  
These three atoms located at the “joints” of the aromatic core ligand are used to hold the 
ether, benzyl, and dimethyltyrosine pharmacophores together. In the proposed aliphatic core, if 
these joints are carbon atoms, then new stereocenters would be introduced into this system, adding 
additional synthetic and SAR complexity to the ligands. If nitrogen is used instead, the stereocenter 
problem would not exist, though atoms X and Y cannot both be nitrogen, as this would make the 
peptidomimetic unstable in aqueous acid. Therefore, a combination of carbon and nitrogen atoms 
was utilized, of which a piperazine structure was selected to fulfil this role (Figure 21). The two 
nitrogens of the piperazine are spaced far enough apart to prevent acid instability, whereas the 
number of carbons at these joints are minimized to one, producing only one new stereocenter. One 
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nitrogen will be used to attach the benzyl pendant and the other will be used to attach an n-propyl 
group, which is designed to mimic the ethyl ether in the aromatic series. The carbon, thus, will be 
used to attach the DMT pharmacophore.  By converting to this piperazine core, we also managed 
to improve some of the physiochemical properties of these ligands for BBB penetration, namely 
cLogP and tPSA,133 without significantly changing their mass. Herein, the SAR of this novel core 
structure will be discussed. It should be noted that derivatives of this series are not limited to a 
piperazine structure, merely that the piperazine core will be used as a starting point. 
 
Figure 21: Conversion of the aromatic core peptidomimetic to cyclic aliphatic core 
peptidomimetics. This conversion would improve PK properties such as cLogP and tPSA 
without significantly increasing molecular weight. 
7.2 Results 
General Chemistry: To synthesize these new aliphatic core peptidomimetics, commercially 
available nitrogen containing heterocycles were utilized that possessed a methyl ester. (Scheme 
11). The appropriate commercially available enantiomer was used as starting material, and the 
stereochemistry of these heterocycles was maintained throughout the synthesis. This synthesis 
began with the introduction of the benzyl group through one equivalent of benzyl bromide. 
Saponification then followed using LiOH, with subsequent workup using sat. NaHCO3 yields the 
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product as a sodium carboxylate. This carboxylate was converted into a primary amide using 
ammonium chloride and PyBOP, at which point the synthesis diverged depending on the analogues 
desired.  
Should alkyl chains coming off the piperazine be desired, the Boc group here would first 
be removed with TFA and DCM and the subsequent amine would be acylated using neat acyl 
anhydride. The synthesis would resume with reduction by BH3*Me2S at 65 °C followed by 
coupling to DMT. Final compounds that contained the piperidine, morpholine, or the unsubstituted 
piperazine core (227-229) were instead immediately subject to reduction by BH3*Me2S at 65 °C 
followed by PyBOP mediated coupling to Boc protected DMT. In the case of the unsubstituted 
piperazine, the reduction occurred with the Boc group still present, as this group was not reduced 
and protected the secondary amine from coupling to DMT. Finally, if amides are desired off the 
piperazine, then reduction by BH3*Me2S at 65 °C would be performed on the Boc protected 
piperazine. Here, the reduced primary amine would be protected using trifluoroacetic anhydride 
and pyridine. This orthogonal protection strategy allowed for selective deprotection of the Boc 
group and subsequent acylation of the newly liberated secondary amine. This was followed by 








Scheme 11: Synthesis of Analogues 224-231. 
 
A) BnBr, K2CO3, DMF. B) LiOH, THF, EtOH, H2O. C) NH4Cl, PyBOP, NMM, DMF. D) 2M 
BH3*Me2S, THF. E) 1. DibocDMT, DIEA, PyBOP, HOBt-Cl, DMF. 2. TFA, DCM F) TFA, 




SAR: The conversion of aromatic core analogue 70 to the aliphatic core introduced a new 
stereocenter into our aliphatic core series. As such, we first opted to determine which stereocenter, 
if any, will be the best for our ligands. Based upon the binding affinity of the R- and S-isomers 
(224 and 225 respectively) of the newly introduced stereocenter (Table 22) it appears that the S-  
Table 22: Binding affinity of cyclic aliphatic core compounds at human MOR, DOR, and KOR. 
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3H] 
diprenorphine in membrane preparations. Included is 70 for comparison. Selectivity was 
calculated by dividing the Ki of each receptor by the Ki at MOR for a given compound. All data 
were from three separate experiments, performed in duplicate unless otherwise noted. These data 
are reported as the average ± standard error of the mean. ** N=1, * N=2. 
 
Binding Affinity, Ki (nM) Selectivity 
Name R MOR DOR KOR MOR:DOR:KOR 
70 
 
3.6±0.5 4.8±0.9 1200±120 1:1.3:330 
224 
 
27±14 390±150 320** 1:14:12 
225 
 
1.6±0.3 108±15 62.5** 1:69:40 
226 
 
1.08** 44.7** 48.2±3.8* 1:41:45 
227 
 
21.6** 0.01** 2000** 1:0.00046:93 
228 
 
3.24** 147±70 335** 1:45:103 
229 
 
1.54** 112** 483** 1:73:314 
230 
 
24.6** 30.1** 585** 1:1.2:24 
231 
 
44.3** 60.0** >3000** 1:1.4:>68 
222 
 
isomer yields a log improvement in affinity at MOR, and a 4-fold improvement in affinity at DOR. 
When the potencies of these two analogues are compared (Table 23), the S-isomer again triumphs 
over the R-isomer with a 2-log improvement in potency at MOR. Therefore, the S-isomer appears 
to be the superior diastereomer. Further derivatives were then made with this stereocenter. 
Of the additional analogues synthesized in this series, most possessed similar MOR-affinity 
as piperazine 225. The only exceptions here are the unmodified piperazine 227, and the two amide 
analogues 230 and 231, which yielded a log unit loss in affinity. DOR-affinity varied little in this 
series, and most analogues had around 100 nM affinity at this receptor, akin to piperazine 225. The 
only exception here is the free piperazine 227 which possessed a 4-log improvement in binding 
affinity at DOR over the other analogues.  
KOR-affinity was found to be 20-fold higher than 70 upon conversion to the new scaffold 
with the favorable diastereomer 225. This enhanced affinity is maintained with the other N-alkyl 
analogue 226. However, conversion to the morpholine 229, free piperazine 227, or N-acyl 
piperazines 230-231 reduced binding affinity by at least a log unit.  
Notable within these analogues is a significant drop in binding affinity balance between 
MOR and DOR upon conversion to the new core. Four of these analogues possessed 40-fold 
improved MOR-binding over DOR-binding. The amide analogues 230 and 231 managed to 
maintain a roughly 1:1 binding affinity balance, whereas the free piperazine 227 massively favored 
binding to DOR over MOR based on an N of 1. Selectivity over KOR was generally diminished 
for all analogues, the only exception being the morpholine core compound 229. 
 The compounds synthesized herein yielded interesting trends in potency and efficacy at 
MOR, DOR, and KOR, and are shown in Table 23. MOR-potency was generally not significantly 
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different from the aromatic core analogue 70, though potency was diminished with the free 
piperazine and the piperidine analogues 227 and 228 respectively. Interestingly, the two amide 
analogues 230 and 231 produced no MOR-stimulation whatsoever. Of those that did stimulate 
MOR, there was little significant variation in efficacy. With regards to DOR, only analogue 230 
was capable of stimulating DOR. Even then, the potency and efficacy of this analogue was low.  
 
Table 23: Potency and efficacy of cyclic aliphatic core compounds at human MOR, DOR, and 
KOR. Potency and efficacy data were obtained using agonist induced stimulation of [35S] GTPγS 
binding. Potency is represented as EC50 (nM) and efficacy as percent maximal stimulation 
relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 μM. 
Included is 70 for comparison. All data were from three separate experiments, performed in 
duplicate unless otherwise noted. These data are reported as the average ± standard error of the 
mean. ** N=1, * N=2. DNS=Does Not Stimulate. 
 
Potency, EC50 (nM) Efficacy (% Stimulation) 
Name Structure MOR DOR KOR MOR DOR KOR 
70 
 
72±14 DNS DNS 75.5±5.8 DNS DNS 
224 
 
>2480 DNS DNS** >34.6 DNS DNS** 
225 
 
110±24 DNS* >1200** 76.0±8.5 DNS* >40** 
226 
 
139** DNS** DNS** 62.9** DNS** DNS** 
227 
 
851** DNS** DNS** 76.5** DNS** DNS** 
228 
 
420** DNS** >3000** 81.3** DNS** >45** 
229 
 
100** DNS** >1500** 84.0** DNS** >15** 
230 
 
DNS** 607** DNS** DNS** 21.0** DNS** 
231 
 
DNS** DNS** DNS** DNS** DNS** DNS** 
224 
 
Only three analogues could stimulate KOR, namely the original S-piperazine analogue 225, the 
piperidine analogue 228, and the morpholine analogue 229. However, the potency of these 
analogues was poor, with values greater than 1.2 µM. 
Metabolic Stability: A few of these analogues were also screened for their metabolic stability. 
These are shown in Table 24 and the aromatic precursor 70 was included for comparison. Here 
only the two piperazine diastereomers 224 and 225 were tested. This conversion yielded no 
significant changes in metabolic stability compared to the aromatic core analogue 70 and there 
was no difference in stability between the two diastereomers. 
Name R1 T1/2 (min) Verapamil T1/2 (min) Stability Ratio  cLogP 
70 
 










27.6±4.9 1.3±0.2 4.29 
Table 24: Metabolic stability of cyclic aliphatic core compounds in MLM. Included are the 
compound half-life (T1/2), the half-life of the positive control verapamil, and the stability ratio 
between the compound and the positive control. The stability ratio was calculated by dividing the 
half-life of the analogue of interest by the half-life of the positive control in that assay. Included 
is compound 70 for comparison. Individual compounds were tested once, with errors 
representing the SE in the decay curve regressed onto the data collected in 15-minute intervals. 
Finally, the cLogP of these analogues are included and were calculated using PerkinElmer’s 
ChemDraw® Professional Software. 
7.3 Discussion and Conclusions 
SAR: The analogues presented in this chapter grant deeper insight into factors necessary to produce 
bifunctional MOR/DOR ligands. The distinction between the two piperazine diastereomers 224 
and 225 points to the importance of the S-isomer, needed to orient the pharmacophore elements 
properly to interact with the opioid receptors. This stereochemistry is consistent with that of the 
original bicyclic peptidomimetic series, suggesting similar modes of receptor binding.  In general, 
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conversion to this new scaffold did not reduce MOR-affinity. The exceptions here are the free 
piperazine 227, and the two amide analogues 230 and 231 which each yielded a log unit loss in 
binding affinity. These data point to two different trends. MOR-affinity is reduced by the presence 
of a hydrogen bond donor in the free piperazine, or by the presence of the amide in the piperazine. 
For the amide, this loss can be attributed either to a loss of conformational flexibility, or more 
likely, due to negative interactions between the carbonyl of the ligand and MOR. DOR-affinity 
was lost upon conversion to this new core and was consistent across most analogues. This suggests 
that the conversion to the aliphatic core itself is responsible for the loss in affinity rather than any 
particular functional group. The only exception here is the free piperazine analogue 227, which 
possessed subnanomolar binding affinity at DOR. This again points to the hydrogen bond donor 
in this analogue and may be a useful pharmacophore for DOR selective ligands. 
 KOR-affinity was increased upon conversion to this aliphatic core, though in this case it 
was sensitive to changes in functional groups on the core. In general, elimination of the N-alkyl 
chains or conversion of the N-alkyl groups to N-acyl groups reduced the binding affinity of these 
analogues at KOR. This suggests that the alkyl group is picking up a specific interaction in KOR, 
an interaction that can be disrupted with removal of the alkyl chain, or by the incorporation of a 
carbonyl.  
 Conversion to the new core also yielded a greater number of MOR-agonists compared to 
their aromatic core counterparts. Whereas the aromatic core analogues reached an efficacy 
optimum in compound 70 as illustrated in Chapter 2, here most analogues possessed consistently 
high MOR-efficacy. This was true regardless of the size or presence of the N-alkyl chain, 
suggesting the amine connecting the benzyl group may be responsible for MOR activation. This 
is consistent with the amine portion of the aromatic-amine pharmacophore described in the 
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previous chapters, the difference here being the distance of that amine from the DMT residue. 
Interestingly, this efficacy was lost with the two amide analogues 230 and 231. This can be 
attributed to interactions of the newly introduced carbonyl negatively interacting with MOR and 
preventing receptor activation. This factor may also be what is affecting MOR-binding with these 
two ligands. MOR-potency appears to be retained when a hydrogen bond acceptor exists within 
the core, as the N-alkyl analogues 225 and 226, and the morpholine analogue 229 each possessed 
the highest potency at MOR. Removal of this hydrogen bond acceptor as in the piperidine 228 or 
the presence of a hydrogen bond donor at this position as in 227 results in losses in MOR-potency. 
 Consistent with their aromatic core counterparts from Chapter 2, these analogues 
consistently did not stimulate DOR and KOR with few exceptions. Only the N-propionyl analogue 
230 possessed any capability to stimulate DOR, a property that may be a product of its possession 
of both a carbonyl and a sufficiently long alkyl chain. The N-ethyl piperazine, piperidine and 
morpholine analogues 226, 228, and 229 were very weak KOR-partial agonists. Two of these 
analogues were the smallest in this series and did not possess a hydrogen bond donor in the ring. 
As such, it is possible that a hydrogen bond donor here may prevent KOR-stimulation, or that this 
can be attenuated by short alkyl chains.  
Metabolic Stability: While these new analogues managed to reduce the cLogP by half a unit, no 
significant differences in stability were observed compared to aromatic analogue 70 where tested. 
Unlike the diastereomers discussed in Chapter 3, inversion of the core stereocenter between 224 
and 225 did not yield any differences in stability. This suggests that the CYP enzyme is unable to 
target this stereocenter. Furthermore, the failure to improve stability may be a product of the 
piperazine nitrogens stabilizing free radical formation on adjacent positions. Thus far, only the 
227 
 
more lipophilic cyclic aliphatic core analogues were tested for stability. Additional screening of 
the smaller, less lipophilic analogues may yet yield stability improvements. 
Conclusions: The analogues synthesized herein reinforce the utility of our aromatic-amine 
pharmacophore. Here, the difference lies in the distance the pharmacophore is from the DMT 
pendant. While these analogues possess reduced potency compared to those of the previous 
chapters, they suggest that the aromatic-amine pharmacophore can tolerate differences in 
positioning and alternative forms of rigidification in the core of the ligand. In this case, shifting of 
the pharmacophore position makes the pharmacophore more dependent on core modifications to 
retain MOR-potency, and efficacy can only be eliminated with distal amides in this series. Notably, 
while losses in DOR affinity were observed, only one analogue could weakly stimulate DOR. 
Likewise, only a few could weakly stimulate KOR. If bifunctional MOR/DOR ligands are desired 
from this series, additional derivatization is necessary to recover the lost DOR-affinity. 
7.4 Experimental 
Chemistry 
General Methods: All reagents and solvents were obtained commercially and were used without 
further purification. Intermediates were purified by flash chromatography using a Biotage Isolera 
One instrument. Most purification methods utilized a hexanes/ethyl acetate solvent system in a 
Biotage SNAP KP-Sil column, with a linear gradient between 0 and 100% ethyl acetate. Reverse 
phase column chromatography using a linear gradient of 0% to 100% solvent B (0.1% TFA in 
acetonitrile) in solvent A (0.1% TFA in water) using a Biotage SNAP Ultra C18 column was 
utilized for some intermediate amine salts. Purification of final compounds was performed using 
a Waters semipreparative HPLC with a Vydac protein and peptide C18 reverse phase column, 
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using a linear gradient of 0% to 100% solvent B in solvent A at a rate 1% per minute, monitoring 
UV absorbance at 230 nm. The purity of final compounds was assessed using a Waters Alliance 
2690 analytical HPLC instrument with a Vydac protein and peptide C18 reverse phase column. A 
linear gradient (gradient A) of 0% to 70% solvent B in solvent A in 70 min, measuring UV 
absorbance at 230 nm was used to determine purity. All final compounds used for testing were 
≥95% pure, as determined by analytical HPLC. 1H NMR and 13C NMR data were obtained on a 
500 or 400 MHz Varian spectrometer using CDCl3, CD3OD, DMSO-d6, or D2O as solvents. The 
identities of final compounds were verified by mass spectrometry using an Agilent 6130 LC–MS 
mass spectrometer in positive ion mode, or an Agilent 6230 TOF HPLC-MS in the positive ion 
mode. 
General Procedure for N-Benzyl Attachment (Procedure A): To a flame dried flask containing 
cyclic secondary amine was added 2 equivalents of potassium carbonate and the flask was flushed 
with argon. 4 mL of DMF was added and 1.2 equivalents of benzyl bromide was added dropwise. 
The flask was stirred overnight at room temperature and concentrated in vacuo. The residue was 
partitioned between EtOAc and sat. Na2CO3 and extracted with EtOAc. The organic layers were 
combined, dried with MgSO4, and filtered. The filtrate was concentrated in vacuo and the residue 
was purified via column chromatography (0 to 20 % EtOAc in Hexanes) yielding the N-benzylated 
product. 
General Procedure for the Saponification of Esters (Procedure B): To a flask containing 1 
equivalent of the desired ester was added 7 equivalents of LiOH, 2 mL of THF, 2 mL of EtOH, 
and 2 mL of H2O. The reaction was stirred for 4-6 hours under ambient atmosphere and 
temperature. Upon completion, the solvent was quench with sat. NaHCO3 concentrated in vacuo, 
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suspended in acetone, and filtered. The precipitate was washed with additional acetone, and the 
filtrate was concentrated in vacuo, yielding the saponified product as a sodium carboxylate.  
General Procedure for Primary Amide Formation (Procedure C): To a flask containing 1 
equivalent of the sodium carboxylate was added 1 equivalent of PyBOP and 1 equivalent of 
ammonium chloride. The flask was flushed with argon, DMF was added as solvent, and 10 
equivalents of N-methylmorpholine were added. The reaction was stirred overnight, at which point 
it was partitioned between DCM and 2M NaOH. The product was then extracted with DCM and 
the organic layer was filtered and concentrated in vacuo. The residue was then purified via column 
chromatography (0-10 % methanol in DCM or EtOAc). 
General Procedure for the Reduction of Amides (Procedure D): To a dried flask containing 1 
equivalent of the desired amide under argon was added THF and 7 equivalents of 2 M BH3*Me2S 
complex in THF. The reaction was heated at 65 °C for 3 hours, at which point the reaction was 
quenched with MeOH and heated for an additional 15 minutes. The reaction was then cooled, 
concentrated in vacuo, and was used without further purification. 
General Procedure for the Coupling of 2’,6’-Dimethyltyrosine to Functionalized Amine Salt 
(Procedure E): To a dried flask containing the amine under argon was added 3 mL of DMF and 
10 equivalents of Hunig’s base. 1 equivalent of PyBOP and 1 equivalent of 6-Cl-HOBt was added, 
followed by a 1 equivalent of doubly Boc protected 2’,6’-Dimethyltyrosine in 1.5 mL DMF. The 
solution was stirred overnight at room temperature, concentrated in vacuo, and purified via 
semipreparative reverse phase HPLC (0.1% TFA in water: 0.1% TFA in acetonitrile). 2 mL of 
TFA and 2 mL of DCM were then added, and the solution was stirred for an additional hour. The 
reaction mixture was concentrated in vacuo and purified via an additional semipreparative reverse 
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phase HPLC (0.1% TFA in water: 0.1% TFA in acetonitrile). The product was concentrated in 
vacuo and lyophilized overnight to yield the final peptidomimetic. 
General procedure for the deprotection of Boc groups on intermediates using TFA and DCM 
(Procedure Fa): To a flask containing the Boc protected intermediate was added 2 mL of TFA 
and 2 mL of DCM. The solution was stirred for 1 hour under ambient atmosphere and temperature. 
The solution was then concentrated in vacuo, yielding the deprotected product as a TFA salt.  
General procedure for the deprotection of Boc groups on intermediates using conc. HCl and 
Dioxane (Procedure Fb): To a flask containing the Boc protected intermediate was added 2 mL 
of dioxane and 0.2 mL of conc. HCl. The solution was stirred for 1 minute under ambient 
atmosphere and temperature. The solution was then concentrated in vacuo and triturated with 
DCM, yielding the deprotected product as an HCl salt.  
General procedure for the acylation of the piperazine core analogues (Procedure Ga): To a dried 
flask containing the Boc deprotected piperazine under argon was added neat acyl anhydride. The 
reaction was stirred for 1 hour and concentrated in vacuo. The product was then partitioned 
between 2M NaOH and DCM. The compound was extracted with DCM, filtered, and concentrated 
in vacuo yielding the desired acylated compound. 
General procedure for the acylation of the piperazine core analogues (Procedure Gb): To a dried 
flask containing the Boc deprotected piperazine under argon was added neat acyl anhydride. The 
reaction was stirred for 1 hour and concentrated in vacuo. The product was then partitioned 
between sat. NaHCO3 and DCM. The compound was extracted with DCM, filtered, concentrated 
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in vacuo and purified via column chromatography (10% MeOH in DCM) yielding the desired 
acylated compound. 
General procedure for the trifluoroacetyl protection of reduced primary amides (Procedure H): 
To a dried flask containing a stir bar and the just reduced crude primary amine under argon was 
added 7 equivalents of trifluoroacetic anhydride and 4 mL of pyridine. The solution was stirred at 
room temperature overnight. The reaction was then concentrated in vacuo and partitioned between 
DCM and an aqueous solution of saturated NaHCO3. The product was then extracted with DCM, 
and the combined extracts were filtered and concentrated in vacuo. Purification by column 
chromatography (0 to 60 % EtOAc in Hexanes) yielded the protected amine. 
General procedure for the deprotection of trifluoroacetamides (Procedure I): To a flask equipped 
with the trifluoroacetyl protected amide and a stir bar was added 2 mL of MeOH and 2 mL of 2M 
NaOH in water. The solution was stirred for 2 hours, at which point the solution was either directly 
concentrated in vacuo, or first quenched with an aqueous solution of saturated NaHCO3 before 
being concentrated in vacuo. The residue was suspended in action and filtered, leaving the 
deprotected amine that was used without further purification. 
1-(tert-butyl) 2-methyl (S)-4-benzylpiperazine-1,2-dicarboxylate (204): See Procedure 
A: 120 mg (0.49 mmol) of 1-(tert-butyl) 2-methyl (S)-piperazine-1,2-dicarboxylate (201), 135 
mg (0.98 mmol, 2.0 eq.) of potassium carbonate, 50 µL (72 mg, 0.42 mmol, 0.86 eq.) of benzyl 
bromide, and 4 mL of DMF. Compound 204 (143 mg, Yield=87 %) was isolated as a colorless oil. 
1H NMR (400 MHz, Chloroform-d) δ 7.35 – 7.18 (m, 5H), 4.71 (s, 0.5H), 4.54 (s, 0.5H), 3.81 (dd, 
J = 38.4, 12.0 Hz, 1H), 3.73 (s, 1.5H), 3.70 (s, 1.5H), 3.57 (t, J = 13.1 Hz, 1H), 3.43 (t, J = 14.2 
Hz, 1H), 3.35 – 3.24 (m, 1.5H), 3.18 (td, J = 12.6, 3.6 Hz, 0.5H), 2.77 (dd, J = 21.2, 11.5 Hz, 1H), 
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2.18 (td, J = 11.2, 4.0 Hz, 1H), 2.09 (t, J = 11.7 Hz, 1H), 1.47 (s, 5H), 1.42 (s, 4H). 13C NMR (101 
MHz, Chloroform-d) δ 171.36, 171.09, 155.86, 155.36, 137.67, 128.74, 128.15, 127.18, 80.27, 
62.31, 55.53, 54.37, 53.49, 52.47, 52.32, 51.99, 41.99, 41.03, 28.33, 28.27. 
1-(tert-butyl) 2-methyl (R)-4-benzylpiperazine-1,2-dicarboxylate (205): See Procedure 
A: 189 mg (0.77 mmol) of 1-(tert-butyl) 2-methyl (R)-piperazine-1,2-dicarboxylate (202), 218 
mg (1.6 mmol, 2.0 eq.) of potassium carbonate, 110 µL (158 mg, 0.92 mmol, 1.2 eq.) of benzyl 
bromide, and 5 mL of DMF. Compound 205 (229 mg, Yield=89 %) was isolated as a colorless oil. 
1H NMR (500 MHz, Chloroform-d) δ 7.33 – 7.21 (m, 5H), 4.71 (s, 0.5H), 4.54 (s, 0.5H), 3.81 (dd, 
J = 48.8, 13.1 Hz, 1H), 3.73 (s, 1.5H), 3.70 (s, 1.5H), 3.56 (t, J = 14.4 Hz, 1H), 3.43 (dd, J = 18.2, 
13.3 Hz, 1H), 3.35 – 3.24 (m, 1.5H), 3.18 (td, J = 12.7, 3.7 Hz, 0.5H), 2.77 (dd, J = 26.9, 11.2 Hz, 
1H), 2.18 (td, J = 12.5, 11.7, 4.0 Hz, 1H), 2.10 (td, J = 11.5, 3.5 Hz, 1H), 1.47 (s, 5H), 1.43 (s, 
4H). 13C NMR (126 MHz, Chloroform-d) δ 171.32, 171.06, 155.85, 155.34, 137.68, 128.73, 
128.14, 127.17, 80.23, 62.33, 62.30, 55.55, 54.38, 53.50, 52.47, 52.33, 51.97, 51.93, 42.01, 41.04, 
28.33, 28.27. 
Ethyl (R)-1-benzylpiperidine-3-carboxylate (206): See Procedure A: 133 mg (0.85 
mmol) of ethyl (R)-piperidine-3-carboxylate (203), 236 mg (1.7 mmol, 2.0 eq.) of potassium 
carbonate, 120 µL (173 mg, 1.0 mmol, 1.2 eq.) of benzyl bromide, and 4 mL of DMF. Compound 
206 (129 mg, Yield=62 %) was isolated as a colorless oil. 1H NMR (400 MHz, Chloroform-d) δ 
7.38 – 7.20 (m, 5H), 4.11 (q, J = 7.2 Hz, 2H), 3.52 (q, J = 13.4 Hz, 2H), 2.95 (d, J = 11.2 Hz, 1H), 
2.72 (d, J = 11.4 Hz, 1H), 2.58 (ddd, J = 14.1, 6.9, 3.8 Hz, 1H), 2.23 (t, J = 10.5 Hz, 1H), 2.10 – 
1.98 (m, 1H), 1.92 (dt, J = 12.8, 4.1 Hz, 1H), 1.72 (dt, J = 13.0, 3.8 Hz, 1H), 1.66 – 1.42 (m, 2H), 
1.23 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 174.23, 138.24, 129.04, 128.16, 
126.97, 63.28, 60.22, 55.39, 53.59, 41.88, 26.96, 24.52, 14.21. 
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Sodium (S)-4-benzyl-1-(tert-butoxycarbonyl)piperazine-2-carboxylate (207): See 
Procedure B: 118 mg (0.35 mmol) of 204, 42.5 mg (1.77 mmol, 5.0 eq.) of LiOH, 2 mL of EtOH, 
2 mL of THF, 2 mL of H2O. Compound 207 (108 mg, Yield= 89 %) was isolated as the sodium 
salt and as a colorless oil. 1H NMR (400 MHz, Methanol-d4) δ 7.32 (d, J = 6.7 Hz, 2H), 7.26 (t, J 
= 7.3 Hz, 2H), 7.24 – 7.14 (m, 1H), 4.36 (br s, 1H), 3.74 (d, J = 13.0 Hz, 1H), 3.57 – 3.33 (m, 4H), 
2.71 (br s, 1H), 2.15 (dd, J = 11.2, 4.6 Hz, 1H), 1.94 (td, J = 11.9, 3.5 Hz, 1H), 1.43 (s, 9H). 13C 
NMR (101 MHz, Methanol-d4) δ 176.18, 137.59, 128.76, 127.75, 126.63, 79.43, 62.31, 54.80, 
52.18, 27.32. 
Sodium (R)-4-benzyl-1-(tert-butoxycarbonyl)piperazine-2-carboxylate (208): See 
Procedure B: 118 mg (0.35 mmol) of 205, 42.5 mg (1.77 mmol, 5.0 eq.) of LiOH, 2 mL of EtOH, 
2 mL of THF, 2 mL of H2O. Compound 208 (121 mg, Quantitative Yield) was isolated as the 
sodium salt and as a colorless oil. 1H NMR (400 MHz, Methanol-d4) δ 7.32 (d, J = 6.7 Hz, 2H), 
7.26 (t, J = 7.4 Hz, 3H), 7.24 – 7.14 (m, 1H), 4.37 (s, 1H), 3.74 (d, J = 13.0 Hz, 1H), 3.57 – 3.34 
(m, 6H), 2.71 (s, 1H), 2.15 (dd, J = 11.2, 4.6 Hz, 1H), 1.94 (td, J = 11.8, 3.5 Hz, 1H), 1.43 (s, 9H). 
13C NMR (101 MHz, Methanol-d4) δ 176.21, 137.56, 128.78, 127.76, 126.64, 79.45, 62.33, 54.83, 
52.18, 27.34. 
Sodium (R)-1-benzylpiperidine-3-carboxylate (209): See Procedure B: 120 mg (0.49 
mmol) of 206, 61 mg (2.5 mmol, 5.3 eq.) of LiOH, 3 mL of EtOH, 3 mL of THF, 3 mL of H2O. 
Compound 209 (121 mg, Quantitative Yield) was isolated as the sodium salt and as a white waxy 
solid. 1H NMR (400 MHz, Methanol-d4) δ 7.36 – 7.19 (m, 5H), 3.53 (d, J = 12.8 Hz, 2H), 3.49 (d, 
J = 12.8 Hz, 2H), 3.08 (ddt, J = 11.3, 3.7, 1.6 Hz, 1H), 2.84 (d, J = 11.6 Hz, 1H), 2.39 (tt, J = 11.9, 
3.8 Hz, 1H), 2.04 (t, J = 11.3 Hz, 1H), 2.00 – 1.89 (m, 2H), 1.73 – 1.64 (m, 1H), 1.58 (qt, J = 12.9, 
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3.9 Hz, 1H), 1.34 (qd, J = 12.6, 4.4 Hz, 1H). 13C NMR (101 MHz, Methanol-d4) δ 181.51, 137.00, 
129.50, 127.82, 126.92, 63.20, 56.71, 53.45, 45.02, 28.05, 24.56. 
Tert-butyl (S)-4-benzyl-2-carbamoylpiperazine-1-carboxylate (210): See Procedure C: 
126 mg (0.37 mmol) of 207, 193 mg (0.37 mmol, 1.0 eq.) of PyBOP, 21 mg (0.39 mmol, 1.1 eq.) 
of ammonium chloride, 410 µL (377 mg, 3.7 mol, 10 eq.) of NMM, and 4 mL of DMF. Compound 
210 (78 mg, Yield= 66 %) was isolated using standard phase chromatography (EtOAc) as a 
colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.33 – 7.20 (m, 5H), 6.38 (br s, 1H), 6.12 (br 
s, 1H), 4.59 (br s, 1H), 3.96 (br s, 1H), 3.58 – 3.46 (m, 2H), 3.35 (dt, J = 11.7, 2.0 Hz, 1H), 3.12 
(br s, 1H), 2.75 (d, J = 11.2 Hz, 1H), 2.17 (dd, J = 11.7, 4.3 Hz, 1H), 2.04 (td, J = 11.7, 3.5 Hz, 
1H), 1.45 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 172.77, 137.06, 129.04, 128.31, 127.33, 
80.89, 62.62, 52.90, 52.13, 28.30. 
Tert-butyl (R)-4-benzyl-2-carbamoylpiperazine-1-carboxylate (211): See Procedure C: 
231 mg (0.68 mmol) of 208, 352 mg (0.68 mmol, 1.0 eq.) of PyBOP, 39 mg (0.73 mmol, 1.1 eq.) 
of ammonium chloride, 740 µL (681 mg, 6.7 mol, 10.0 eq.) of NMM, and 5 mL of DMF. 
Compound 211 (217 mg, Quantitative Yield) was isolated using standard phase chromatography 
(10% MeOH in DCM ) as a yellow oil. 1H NMR (500 MHz, Chloroform-d) δ 7.32 – 7.18 (m, 5H), 
6.34 (br s, 1H), 6.03 (br s, 1H), 4.59 (br s, 1H), 3.96 (br s, 1H), 3.54 (d, J = 13.2 Hz, 1H), 3.49 (d, 
J = 13.3 Hz, 1H), 3.35 (dt, J = 11.6, 2.0 Hz, 1H), 3.12 (br s, 1H), 2.75 (d, J = 11.3 Hz, 1H), 2.17 
(dd, J = 11.7, 4.3 Hz, 1H), 2.03 (td, J = 11.8, 3.5 Hz, 1H), 1.46 (s, 9H). 13C NMR (126 MHz, 
Chloroform-d) δ 172.68, 137.19, 129.00, 128.29, 127.29, 80.84, 62.64, 52.93, 52.13, 28.30. 
(S)-1-benzylpiperidine-3-carboxamide (212): See Procedure C: 26 mg (0.11 mmol) of 
209, 58 mg (0.11 mmol, 1.0 eq.) of PyBOP, 6 mg (0.11 mmol, 1.0 eq.) of ammonium chloride, 
120 µL (110 mg, 1.1 mol, 10 eq.) of NMM, and 4 mL of DMF. Compound 212 (24 mg, 
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Quantitative Yield) was isolated using standard phase chromatography (10% MeOH in DCM) as 
a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.75 (br s, 1H), 7.43 – 6.70 (m, 5H), 5.68 (br 
s, 1H), 3.50 (d, J = 12.9 Hz, 1H), 3.47 (d, J = 12.9 Hz, 1H), 2.84 (br s, 1H), 2.72 (br s, 1H), 2.50 
(p, J = 4.4 Hz, 1H), 2.37 (br s, 1H), 2.19 (br s, 1H), 1.89 (br s, 1H), 1.79 – 1.68 (m, 1H), 1.67 – 
1.50 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 177.75, 137.43, 129.16, 128.43, 127.41, 
63.44, 54.91, 53.77, 41.72, 26.90. 
(R)-2-carbamoylmorpholin-4-ium chloride (219): See Procedure C and Fb: 82 mg (0.36 
mmol) of (R)-4-(tert-butoxycarbonyl)morpholine-2-carboxylic acid (218), 187 mg (0.36 
mmol, 1.0 eq.) of PyBOP, 20 mg (0.37 mmol, 1.1 eq) of ammonium chloride, 390 µL (359 mg, 
3.5 mmol, 10.0 eq.) of NMM, and 4 mL of DMF. No column chromatography was performed. 2 
mL of Dioxane and 0.2 mL of conc. HCl. Compound 219 (30 mg, Yield=51 %) was isolated as a 
colorless oil. 1H NMR (400 MHz, Methanol-d4) δ 4.33 (dd, J = 10.9, 2.9 Hz, 1H), 4.19 (ddd, J = 
13.0, 3.9, 1.9 Hz, 1H), 3.93 (td, J = 13.1, 12.3, 2.7 Hz, 1H), 3.59 (dd, J = 12.7, 1.7 Hz, 1H), 3.24 
– 3.14 (m, 2H), 3.09 (dd, J = 12.9, 11.0 Hz, 1H). 13C NMR (101 MHz, Methanol-d4) δ 170.74, 
72.20, 63.12, 44.11, 42.37. 
(S)-4-benzylmorpholine-2-carboxamide (220): See Procedure A: 30 mg (0.18 mmol) of 
219, 25 µL (36 mg, 0.21 mmol, 1.2 eq.) of BnBr, 52 mg (0.38 mmol, 2.1 eq.) of K2CO3, and 4 mL 
DMF. Compound 220 (24 mg, Yield= 61 %) was isolated as a white solid. 1H NMR (400 MHz, 
Chloroform-d) δ 7.34 – 7.22 (m, 5H), 6.51 (br s, 1H), 5.75 (br s, 1H), 4.06 (dd, J = 10.5, 2.8 Hz, 
1H), 3.90 (ddd, J = 11.3, 3.4, 1.7 Hz, 1H), 3.70 (td, J = 11.3, 2.5 Hz, 1H), 3.56 (d, J = 13.0 Hz, 
1H), 3.51 (d, J = 13.1 Hz, 1H), 3.20 (ddd, J = 11.6, 2.9, 1.9 Hz, 1H), 2.67 (dq, J = 11.7, 2.0 Hz, 
1H), 2.16 (td, J = 11.5, 3.4 Hz, 1H), 2.05 (dd, J = 11.5, 10.5 Hz, 1H). 13C NMR (101 MHz, 
Chloroform-d) δ 172.83, 137.12, 129.17, 128.33, 127.31, 75.50, 66.64, 63.03, 55.12, 52.35. 
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(3S)-1-benzyl-3-carbamoylpiperazine-1,4-diium-2-ylium trifluoroacetate (213): See 
Procedure Fa: 78 mg (0.24 mmol) of 211, 2 mL TFA, and 2 mL of DCM. Compound 213 (103 
mg, 94 % yield) was isolated as a yellow oil. 1H NMR (500 MHz, Methanol-d4) δ 7.48 – 7.31 (m, 
5H), 4.23 (dd, J = 11.1, 3.6 Hz, 1H), 4.05 (s, 2H), 3.59 (dd, J = 12.8, 2.0 Hz, 1H), 3.54 (dt, J = 
14.1, 3.2 Hz, 1H), 3.40 – 3.32 (m, 2H), 3.00 – 2.86 (m, 2H). 13C NMR (126 MHz, Methanol-d4) δ 
167.20, 132.25, 129.98, 128.75, 128.62, 61.06, 55.32, 51.23, 41.01. 
(3R)-1-benzyl-3-carbamoylpiperazine-1,4-diium-2-ylium trifluoroacetate (214): See 
Procedure Fa: 79 mg (0.25 mmol) of 211, 2 mL TFA, and 2 mL of DCM. Compound 214 (98 mg, 
89 % yield) was isolated as a yellow oil. 1H NMR (500 MHz, Methanol-d4) δ 7.49 – 7.40 (m, 5H), 
4.24 (dd, J = 11.2, 3.5 Hz, 1H), 4.13 (s, 2H), 3.65 (dd, J = 12.6, 2.9 Hz, 1H), 3.60 – 3.55 (m, 1H), 
3.43 – 3.32 (m, 2H), 3.04 – 2.94 (m, 2H). 13C NMR (126 MHz, Methanol-d4) δ 166.87, 131.35, 
130.21, 129.07, 128.75, 61.02, 55.06, 50.97, 40.73. 
  (S)-4-benzyl-1-propionylpiperazine-2-carboxamide (215): See Procedure Ga: 33 mg 
(0.074 mmol) of 213 and 1.5 mL of propionic anhydride. Compound 215 (14 mg, Yield=69 %) 
was isolated as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.40 – 7.17 (m, 5H), 5.03 (dt, 
J = 3.8, 1.6 Hz, 1H), 4.53 – 4.33 (m, 1H), 3.79 (d, J = 13.2 Hz, 1H), 3.61 – 3.46 (m, 3H), 3.39 (tt, 
J = 13.5, 2.1 Hz, 1H), δ 3.03 (td, J = 13.0, 3.7 Hz, 0.3H), 2.88 – 2.78 (m, 1H), 2.57 – 2.39 (m, 2H), 
2.35 – 2.22 (m, 0.7H), 2.15 (dd, J = 11.9, 4.4 Hz, 1H), 2.09 (td, J = 11.8, 3.5 Hz, 0.7H), 2.02 (td, 
J = 12.0, 3.6 Hz, 0.3H), 1.11 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 174.97, 
173.45, 137.30, 128.73, 128.67, 127.94, 127.89, 126.89, 61.97, 56.61, 53.61, 53.50, 52.85, 52.32, 
52.03, 43.15, 39.24, 25.95, 25.66, 8.30, 8.20. 
  (R)-4-benzyl-1-propionylpiperazine-2-carboxamide (216): See Procedure Ga: 26 mg 
(0.058 mmol) of 214 and 1.5 mL of propionic anhydride. Compound 216 (13 mg, Yield=81 %) 
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was isolated as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.45 – 7.22 (m, 5H), 6.21 (br 
s, 0.5H), 5.84 (br s, 0.5H), 5.73 (br s, 0.5H), 5.18 (br s, 0.5H), 4.59 – 4.45 (m, 0.5H), 4.35 (s, 
0.5H), 3.70 (d, J = 13.5 Hz, 0.5H), 3.56 (d, J = 8.0 Hz, 1.5H), 3.54 – 3.42 (m, 1H), 3.38 (d, J = 
11.9 Hz, 0.5H), 3.25 (d, J = 11.9 Hz, 0.5H), 3.00 – 2.82 (m, 1.5H), 2.60 (dq, J = 15.0, 7.3 Hz, 
0.5H), 2.51 – 2.32 (m, 2H), 2.25 (dd, J = 11.9, 4.0 Hz, 0.5H), 2.17 (d, J = 10.8 Hz, 0.5H), 2.13 – 
2.04 (m, 1H), 1.20 – 1.10 (m, 3H). 13C NMR (126 MHz, Chloroform-d) δ 173.77, 172.11, 171.72, 
129.11, 129.07, 128.58, 128.38, 127.74, 127.47, 62.70, 62.48, 56.47, 53.27, 52.53, 52.40, 46.26, 
43.17, 38.68, 26.64, 26.44, 26.37, 26.27, 9.26. 
 
(R)-1-acetyl-4-benzylpiperazine-2-carboxamide (217): See Procedure Ga: 21 mg (0.047 
mmol) of 214 and 2 mL of Ac2O. Compound 217 (14 mg, Quantitative Yield) was isolated as a 
colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.44 (br s, 0.5H), 7.38 – 7.24 (m, 5H), 6.20 (s, 
0.5H), 5.73 (s, 0.5H), 5.61 (s, 0.5H), 5.17 (dt, J = 3.7, 1.7 Hz, 0.5H), 4.50 (d, J = 12.9 Hz, 0.5H), 
4.29 (s, 0.5H), 3.66 (d, J = 13.2 Hz, 0.5H), 3.61 – 3.46 (m, 2.5H), 3.36 (dt, J = 11.9, 1.9 Hz, 0.5H), 
3.24 (dt, J = 12.1, 1.9 Hz, 0.5H), 2.99 – 2.87 (m, 1H), 2.84 (d, J = 12.1 Hz, 0.5H), 2.28 (dd, J = 
12.0, 4.0 Hz, 0.5H), 2.23 (s, 1.5H), 2.17 – 2.06 (m,  3H). 13C NMR (126 MHz, Chloroform-d) δ 
171.47, 170.62, 136.50, 129.11, 129.03, 128.60, 128.37, 127.77, 127.45, 62.70, 62.48, 57.41, 
53.22, 52.46, 52.32, 38.55, 21.53. 
(3S)-1-benzyl-3-((2,2,2-trifluoroacetamido)methyl)piperazine-1,4-diium 
trifluoroacetate (221): See Procedure D, H, and Fa: 44 mg (0.14 mmol) of 211, 480 µL (0.96 
mmol, 7.0 eq.) of 2M BH3*Me2S in THF, and 4 mL of THF. 40 µL (60 mg, 0.29 mmol, 2.1 eq.) 
of trifluoroacetic anhydride and 4 mL of pyridine. 2 mL of TFA and 2 mL of DCM. Compound 
221 (25 mg, Yield= 34 %) was isolated using reverse phase chromatography (0 to 60 % B in A) 
as a colorless oil. 1H NMR (500 MHz, Methanol-d4) δ 7.64 – 7.25 (m, 5H), 4.20 (d, J = 2.4 Hz, 
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2H), 3.74 (dtd, J = 11.4, 5.6, 3.1 Hz, 1H), 3.66 – 3.55 (m, 3H), 3.48 (t, J = 15.6 Hz, 2H), 3.36 (td, 
J = 13.8, 13.2, 3.3 Hz, 1H), 3.10 (td, J = 12.8, 3.4 Hz, 1H), 3.00 (dd, J = 13.1, 11.4 Hz, 1H). 13C 
NMR (126 MHz, Methanol-d4) δ 160.57, 160.26, 159.10, 158.80, 131.44, 130.18, 129.01, 128.70, 
116.93, 114.65, 60.96, 53.73, 50.91, 41.95, 39.00. 
(S)-N-((4-benzyl-1-propionylpiperazin-2-yl)methyl)-2,2,2-trifluoroacetamide (222): 
See Procedure Gb: 25 mg (0.047 mmol) of 221 and 2 mL propionic anhydride. Compound 222 (12 
mg, Yield=71 %) was isolated as a yellow oil. 1H NMR (500 MHz, Chloroform-d) δ 7.61 (s, 1H), 
7.40 – 7.25 (m, 6H), 4.83 (dt, J = 9.5, 4.0 Hz, 1H), 4.20 (ddd, J = 14.1, 10.4, 6.9 Hz, 1H), 3.62 (d, 
J = 13.1 Hz, 1H), 3.57 (d, J = 13.0 Hz, 1H), 3.53 – 3.39 (m, 2H), 3.23 (dt, J = 14.1, 3.9 Hz, 1H), 
2.89 (d, J = 10.9 Hz, 1H), 2.82 (d, J = 12.0 Hz, 1H), 2.39 – 2.24 (m, 2H), 2.20 (dd, J = 12.0, 4.2 
Hz, 1H), 2.10 (td, J = 11.8, 3.8 Hz, 1H), 1.11 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, Chloroform-
d) δ 174.68, 128.89, 128.50, 127.56, 62.63, 53.96, 52.83, 47.40, 41.58, 26.71, 9.19. 
(S)-N-((1-acetyl-4-benzylpiperazin-2-yl)methyl)-2,2,2-trifluoroacetamide (223): See 
Procedure Gb: 24 mg (0.045 mmol) of 221 and 2 mL acetic anhydride. Compound 223 (12 mg, 
Yield=77 %) was isolated as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.64 (s, 1H), 
7.40 – 7.26 (m, 5H), 4.80 (dd, J = 9.9, 4.7 Hz, 1H), 4.26 – 4.08 (m, 1H), 3.63 – 3.46 (m, 3H), 3.42 
(d, J = 13.0 Hz, 1H), 3.27 (dt, J = 14.1, 4.0 Hz, 1H), 2.88 (dp, J = 11.5, 2.1 Hz, 1H), 2.80 (dt, J = 
11.9, 1.9 Hz, 1H), 2.19 (dd, J = 12.0, 4.3 Hz, 1H), 2.12 (dd, J = 11.6, 4.1 Hz, 1H), 2.08 (s, 3H). 
13C NMR (126 MHz, Chloroform-d) δ 171.29, 137.20, 128.85, 128.49, 127.51, 62.65, 53.99, 
52.86, 47.41, 42.63, 41.70, 21.45. 
  (S)-1-((((R)-4-benzyl-1-propylpiperazin-2-yl)methyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (224): See Procedure D and E: 17 
mg (0.044 mmol) of 215, 160 µL (0.32 mmol, 7.3 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
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THF. Step 1 of E: 80 µL (59 mg, 0.46 mmol, 10.4 eq.) of N,N-diisopropylethylamine, 24 mg 
(0.046 mmol, 1.1 eq.) of PyBOP, 8 mg (0.047 mmol, 1.1 eq.) of 6-Cl-HOBt, 21 mg (0.051 mmol, 
1.2 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of E: 2 mL TFA and 
2 mL DCM. Compound 224 (3.6 mg, Yield=15 %) was isolated as a white solid. 1H NMR (499 
MHz, Deuterium Oxide) δ 7.38 – 7.28 (m, 3H), 7.28 – 7.23 (m, 2H), 6.50 (s, 2H), 3.89 (dd, J = 
11.1, 6.0 Hz, 1H), 3.77 (d, J = 13.0 Hz, 1H), 3.64 (d, J = 13.1 Hz, 1H), 3.49 (dd, J = 14.1, 2.5 Hz, 
1H), 3.22 – 3.12 (m, 2H), 3.07 – 2.61 (m, 9H), 2.53 (br s, 1H), 2.09 (s, 6H), 1.55 (ddt, J = 17.8, 
11.3, 5.8 Hz, 1H), 1.44 (tt, J = 12.7, 6.4 Hz, 1H), 0.80 (t, J = 7.3 Hz, 3H). (MS)EI: 439.3 (M+H), 
Retention Time: 20.51 min. 
(S)-1-((((S)-4-benzyl-1-propylpiperazin-2-yl)methyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (225): See Procedure D and E: 11 
mg (0.028 mmol) of 216, 100 µL (0.20 mmol, 7.1 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of E: 50 µL (37 mg, 0.29 mmol, 10.1 eq.) of N,N-diisopropylethylamine, 17 mg 
(0.033 mmol, 1.2 eq.) of PyBOP, 8 mg (0.047 mmol, 1.7 eq.) of 6-Cl-HOBt, 12 mg (0.029 mmol, 
1.0 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of E: 2 mL TFA and 
2 mL DCM. Compound 225 (1.4 mg, Yield=9 %) was isolated as a white solid. 1H NMR (500 
MHz, Deuterium Oxide) δ 7.41 – 7.32 (m, 5H), 6.50 (s, 2H), 4.27 (s, 2H), 3.90 (dd, J = 10.7, 6.0 
Hz, 1H), 3.72 (d, J = 14.1 Hz, 1H), 3.62 – 3.42 (m, 3H), 3.34 – 3.18 (m, 3H), 3.16 – 2.93 (m, 5H), 
2.56 (td, J = 11.8, 4.9 Hz, 1H), 2.09 (s, 6H), 1.57 (ddt, J = 19.2, 14.2, 6.7 Hz, 1H), 1.45 (dq, J = 
17.3, 5.7 Hz, 1H), 0.78 (t, J = 7.3 Hz, 3H). (MS)EI: 439.3 (M+H), Retention Time: 20.53 min. 
(S)-1-((((S)-4-benzyl-1-ethylpiperazin-2-yl)methyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (226): See Procedure D and E:14 
mg (0.054 mmol) of 217, 190 µL (0.38 mmol, 7.0 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
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THF. Step 1 of E: 100 µL (74 mg, 0.57 mmol, 10.7 eq.) of N,N-diisopropylethylamine, 29 mg 
(0.056 mmol, 1.0 eq.) of PyBOP, 10 mg (0.059 mmol, 1.1 eq.) of 6-Cl-HOBt, 23 mg (0.056 mmol, 
1.0 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of E: 2 mL TFA and 
2 mL DCM. Compound 226 (4.4 mg, Yield=15 %) was isolated as a white solid. 1H NMR (500 
MHz, Deuterium Oxide) δ 7.39 – 7.33 (m, 5H), 6.50 (s, 2H), 4.25 (s, 2H), 3.90 (dd, J = 10.6, 6.1 
Hz, 1H), 3.69 (d, J = 14.1 Hz, 1H), 3.57 (d, J = 13.7 Hz, 1H), 3.50 (dd, J = 15.2, 4.3 Hz, 2H), 3.33 
(dt, J = 14.1, 4.4 Hz, 1H), 3.29 – 3.15 (m, 3H), 3.15 – 2.93 (m, 4H), 2.68 (dq, J = 13.8, 6.9 Hz, 
1H), 2.08 (s, 6H), 1.10 (t, J = 7.2 Hz, 3H). (MS)EI: 425.3 (M+H), Retention Time: 19.22 min. 
(S)-1-((((S)-4-benzylpiperazin-2-yl)methyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (227): See Procedure D and E: 21 
mg (0.066 mmol) of 211, 230 µL (0.46 mmol, 7.0 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of E: 120 µL (89 mg, 0.69 mmol, 10.5 eq.) of N,N-diisopropylethylamine, 36 mg 
(0.069 mmol, 1.1 eq.) of PyBOP, 11 mg (0.065 mmol, 1.0 eq.) of 6-Cl-HOBt, 27 mg (0.066 mmol, 
1.0 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of E: 2 mL TFA and 
2 mL DCM. Compound 227 (8.9 mg, Yield=27 %) was isolated as a white solid. 1H NMR (500 
MHz, Deuterium Oxide) δ 7.41 – 7.36 (m, 3H), 7.36 – 7.29 (m, 2H), 6.51 (s, 2H), 4.16 (s, 2H), 
3.88 (dd, J = 10.4, 6.2 Hz, 1H), 3.46 (d, J = 12.6 Hz, 2H), 3.40 (dd, J = 14.6, 6.8 Hz, 1H), 3.28 (d, 
J = 12.4 Hz, 2H), 3.14 – 2.93 (m, 5H), 2.79 (dd, J = 13.7, 12.1 Hz, 1H), 2.08 (s, 6H). (MS)EI: 
397.3 (M+H), Retention Time: 17.13 min. 
(S)-1-((((S)-1-benzylpiperidin-3-yl)methyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (228): See Procedure D and E: 46 
mg (0.14 mmol) of 212, 485 µL (0.97 mmol, 7.0 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of E: 240 µL (178 mg, 1.4 mmol, 10.0 eq.) of N,N-diisopropylethylamine, 74 mg 
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(0.14 mmol, 1.0 eq.) of PyBOP, 24 mg (0.14 mmol, 1.0 eq.) of 6-Cl-HOBt, 58 mg (0.14 mmol, 
1.0 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of E: 2 mL TFA and 
2 mL DCM. Compound 228 (13.2 mg, Yield=19 %) was isolated as a white solid. 1H NMR (400 
MHz, Methanol-d4) δ 8.09 (t, J = 6.0 Hz, 1H), 7.48 (s, 5H), 6.50 (s, 2H), 4.26 (d, J = 13.0 Hz, 1H), 
4.20 (d, J = 13.0 Hz, 1H), 3.87 (dd, J = 11.6, 5.0 Hz, 1H), 3.37 (d, J = 12.5 Hz, 1H), 3.28 – 3.16 
(m, 3H), 2.99 (dd, J = 13.7, 5.0 Hz, 1H), 2.80 – 2.65 (m, 2H), 2.41 (t, J = 12.3 Hz, 1H), 2.26 (s, 
6H), 1.91 – 1.72 (m, 2H), 1.62 (qt, J = 15.0, 3.8 Hz, 1H), 1.29 (d, J = 13.3 Hz, 1H), 0.86 (qd, J = 
12.9, 3.8 Hz, 1H). (MS)EI: 396.3 (M+H), Retention Time: 16.86 min. 
(S)-1-((((S)-4-benzylmorpholin-2-yl)methyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (229): See Procedure D and E: 23 
mg (0.10 mmol) of 220, 365 µL (0.73 mmol, 7.0 eq.) of 2 M BH3*Me2S in THF, and 4 mL of 
THF. Step 1 of E: 180 µL (134 mg, 1.0 mmol, 9.9 eq.) of N,N-diisopropylethylamine, 55 mg (0.11 
mmol, 1.0 eq.) of PyBOP, 19 mg (0.11 mmol, 1.1 eq.) of 6-Cl-HOBt, 44 mg (0.11 mmol, 1.0 eq.) 
of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of E: 2 mL TFA and 2 mL 
DCM. Compound 229 (5.5 mg, Yield=10 %) was isolated as a white solid. 1H NMR (400 MHz, 
Deuterium Oxide) δ 7.43 – 7.24 (m, 5H), 6.50 (s, 2H), 4.18 (d, J = 13.0 Hz, 1H), 4.09 (d, J = 13.0 
Hz, 1H), 3.93 – 3.71 (m, 2H), 3.48 (t, J = 12.7 Hz, 1H), 3.42 – 3.29 (m, 2H), 3.24 (d, J = 12.7 Hz, 
1H), 3.05 (dd, J = 13.8, 11.9 Hz, 2H), 2.95 (dd, J = 14.1, 5.4 Hz, 1H), 2.86 (dd, J = 13.3, 4.8 Hz, 
1H), 2.74 (dd, J = 14.5, 7.0 Hz, 1H), 2.38 (t, J = 11.7 Hz, 1H), 2.07 (s, 6H). (MS)EI: 398.2 (M+H), 
Retention Time: 15.79 min. 
(S)-1-((((S)-4-benzyl-1-propionylpiperazin-2-yl)methyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (230): See Procedure I and E: 12 
mg (0.034 mmol) of 222, 2 mL of 2M NaOH, and 2 mL of MeOH. The solution was quenched 
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with saturated NaHCO3 in water before being concentrated in vacuo. Step 1 of E: 80 µL (59 mg, 
0.46 mmol, 13.7 eq.) of N,N-diisopropylethylamine, 25 mg (0.048 mmol, 1.4 eq.) of PyBOP, 6 
mg (0.035 mmol, 1.1 eq.) of 6-Cl-HOBt, 23 mg (0.049 mmol, 1.5 eq.) of Boc-O-Boc-L-2’,6’-
dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of E: 2 mL TFA and 2 mL DCM. Compound 230 
(6.7 mg, Yield=35 %) was isolated as a white solid. 1H NMR (500 MHz, Methanol-d4) δ 7.51 (s, 
5H), 6.65 (s, 2H), 4.81 – 4.70 (m, 1H), 4.53 (dd, J = 12.1, 4.6 Hz, 1H), 4.28 (d, J = 12.9 Hz, 1H), 
3.77 (d, J = 12.9 Hz, 1H), 3.64 (dd, J = 14.1, 10.2 Hz, 1H), 3.47 – 3.37 (m, 2H), 3.27 – 3.15 (m, 
2H), 3.13 (dd, J = 13.8, 4.6 Hz, 1H), 3.06 (dd, J = 14.1, 6.6 Hz, 1H), 2.77 (d, J = 12.7 Hz, 1H), 
2.54 (dd, J = 13.4, 4.4 Hz, 1H), 2.27 (s, 6H), 2.23 (q, J = 7.6 Hz, 2H), 1.12 (t, J = 7.6 Hz, 3H), 
0.92 (td, J = 12.5, 3.9 Hz, 1H). (MS)EI: 453.3 (M+H), Retention Time: 17.14 min. 
(S)-1-((((S)-1-acetyl-4-benzylpiperazin-2-yl)methyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)-1-oxopropan-2-aminium trifluoroacetate (231): See Procedure I and E:10 mg 
(0.029 mmol) of 223, 2 mL of 2M NaOH, and 2 mL of MeOH. The solution was concentrated in 
vacuo directly. Step 1 of E: 50 µL (37 mg, 0.29 mmol, 9.9 eq.) of N,N-diisopropylethylamine, 15 
mg (0.029 mmol, 1.0 eq.) of PyBOP, 7 mg (0.041 mmol, 1.4 eq.) of 6-Cl-HOBt, 12 mg (0.029 
mmol, 1.0 eq.) of Boc-O-Boc-L-2’,6’-dimethyltyrosine, 3+1.5 mL of DMF. Step 2 of E: 2 mL 
TFA and 2 mL DCM. Compound 231 (3.9 mg, Yield=24 %) was isolated as a white solid. 1H 
NMR (500 MHz, Deuterium Oxide) δ 7.44 – 7.37 (m, 3H), 7.30 – 7.25 (m, 2H), 6.57 (s, 2H), 4.50 
(dd, J = 11.5, 5.4 Hz, 1H), 4.12 (d, J = 13.0 Hz, 1H), 3.77 (d, J = 13.0 Hz, 1H), 3.49 – 3.35 (m, 
2H), 3.29 (td, J = 14.2, 13.1, 2.6 Hz, 1H), 3.08 (dd, J = 11.6, 5.6 Hz, 4H), 2.82 (d, J = 12.6 Hz, 
1H), 2.49 (dd, J = 13.5, 4.6 Hz, 1H), 2.09 (s, 6H), 1.79 (s, 3H), 0.67 (td, J = 12.3, 3.3 Hz, 1H). 




In Vitro Pharmacology 
Cell Lines and Membrane Preparations.  
All in vitro opioid assays were performed by Ashley Brinkel, Jack Twarozynski, and 
Jessica Anand. Tissue culture reagents were purchased from Gibco Life Sciences (Grand Island, 
NY, U.S.) unless otherwise noted. C6-rat glioma cells stably expressing human MOR (C6-MOR) 
or human DOR (C6-DOR) and Chinese hamster ovary (CHO) cells stably expressing human KOR 
(CHO-KOR) were used for all in vitro assays. Cells were grown to confluence at 37 °C in 5% CO2 
in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal bovine serum and 5% 
penicillin/streptomycin. Membranes were prepared by washing confluent cells three times with ice 
cold phosphate buffered saline (0.9% NaCl, 0.61 mM Na2HPO4, 0.38 mM KH2PO4, pH 7.4). Cells 
were detached from the plates by incubation in warm harvesting buffer (20 mM HEPES, 150 mM 
NaCl, 0.68 mM EDTA, pH 7.4) and pelleted by centrifugation at 1600 rpm for 3 min. The cell 
pellet was suspended in ice-cold 50 mM Tris- HCl buffer, pH 7.4, and homogenized with a Tissue 
Tearor (Biospec Products, Inc., Bartlesville, OK, U.S.) for 20 s. The homogenate was centrifuged 
at 15,000 rpm for 20 min at 4°C. The pellet was rehomogenized in 50 mM Tris-HCl with a Tissue 
Tearor for 10 s, followed by recentrifugation. The final pellet was resuspended in 50 mM Tris-
HCl and frozen in aliquots at -80°C. Protein concentration was determined via a BCA protein assay 
(Thermo Scientific Pierce, Waltham, MA, U.S.) using bovine serum albumin as the standard.  
Radioligand Competition Binding Assays.  
Radiolabeled compounds were purchased from Perkin-Elmer (Waltham, MA, U.S.). 
Opioid ligand binding assays were performed by competitive displacement of 0.2 nM [3H]-
diprenorphine (250 μCi, 1.85 TBq/mmol) by the peptidomimetic from membrane preparations 
containing opioid receptors as described above. The assay mixture, containing membranes (20 μg 
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protein/tube) in 50 mM Tris-HCl buffer (pH 7.4), 0.2 nM [3H]-diprenorphine, and various 
concentrations of test peptidomimetic, was incubated at room temperature on a shaker for 1 h to 
allow binding to reach equilibrium. The samples were rapidly filtered through Whatman GF/C 
filters using a Brandel harvester (Brandel, Gaithersburg, MD, U.S.) and washed three times with 
50 mM Tris-HCl buffer, pH 7.4. Bound radioactivity on dried filters was determined by liquid 
scintillation counting, after saturation with EcoLume liquid scintillation cocktail, in a Wallac 1450 
MicroBeta (Perkin-Elmer, Waltham, MA, U.S.). Nonspecific binding was determined using 10 
μM naloxone. The results presented are the mean ± standard error (S.E.M.) from at least three 
separate assays performed in duplicate. Ki (nM) values were calculated using nonlinear regression 
analysis to fit a logistic equation to the competition data using GraphPad Prism, version 6.0c, 
(GraphPad Software Inc., La Jolla, CA).  
[35S]-GTPγS Binding Assays.  
Agonist stimulation of [35S]guanosine 5′-O-[γ- thio]triphosphate ([35S]-GTPγS, 1250 Ci, 
46.2 TBq/mmol) binding to G protein was measured as described previously.82 Briefly, membranes 
(10 μg of protein/well) were incubated for 1 h at 25°C in GTPγS buffer (50 mM Tris-HCl, 100 
mM NaCl, 5 mM MgCl2, 1 mM EDTA, pH 7.4) containing 0.1 nM [
35S]-GTPγS, 30 μM guanosine 
diphosphate (GDP), and varying concentrations of test peptidomimetic. G protein activation 
following receptor activation by peptidomimetic was compared with 10 μM of the standard 
compounds [D-Ala2,N-MePhe4,Gly-ol]enkephalin (DAMGO) at MOR, D-Pen2,5- enkephalin 
(DPDPE) at DOR, or U69,593 at KOR. The reaction was terminated by vacuum filtration through 
GF/C filters that were washed 5 times with GTPγS buffer. Bound radioactivity was measured as 
described above. The results are presented as the mean ± standard error (S.E.M.) from at least three 
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separate assays performed in duplicate; potency (EC50 (nM)) and percent stimulation were 
determined using nonlinear regression analysis with GraphPad Prism, as above.  
Mouse Liver Microsome Stability Assays 
All liver microsome assays were performed by Quintara Biosciences. Metabolic stability 
of testing compounds was evaluated using mouse liver microsomes to predict intrinsic clearance. 
Mouse liver microsome tissue fractions were obtained from Corning or BioreclamationIVT. The 
assay was carried out in 96-well microtiter plates at 37°C. Reaction mixtures (25 μL) contained a 
final concentration of 1 μM test compound, 0.1 mg/mL liver microsome protein, and 1 mM 
NADPH in 100 mM potassium phosphate, pH 7.4 buffer with 3 mM MgCl2. At each of the time 
points (0, 15, 30, and 60 minutes), 150 μL of quench solution (acetonitrile with 0.1% formic acid) 
with internal standard (bucetin) was transferred to each well. Verapamil was included as a positive 
control to verify assay performance. Plates were sealed, vortexed, and centrifuged at 4°C for 15 
minutes at 4000 rpm. The supernatant was transferred to fresh plates for LC/MS/MS analysis. All 
samples were analyzed on LC/MS/MS using an AB Sciex API 4000 instrument, coupled to a 
Shimadzu LC-20AD LC Pump system. Analytical samples were separated using a Waters Atlantis 
T3 dC18 reverse phase HPLC column (20 mm x 2.1 mm) at a flow rate of 0.5 mL/min. The mobile 
phase consists of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile 
(solvent B). The extent of metabolism was calculated as the disappearance of the test compound, 
compared to the 0-min time incubation. Initial rates were calculated for the compound 
concentration and used to determine T1/2 values. 
Molecular Modeling 
All in silico experiments were performed by Irina Pogozheva. Modeling of three-
dimensional (3D) structures of receptor-ligand complexes was based on available X-ray structures 
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of the mouse MOR (PDB IDs: 4dkl and 5c1m)1, 2 and the human KOR (PDB IDs: 4djh and 
6b73)3, 4 in the inactive and active conformations, respectively, and the human DOR in the 
inactive conformation (PDB IDs: 4n6h, 4rwa)5, 6. Structures of peptidomimetic ligands were 
generated using the 3D-Builder Application of QUANTA (Accelrys, Inc) followed by 
Conformational Search included in the program package. Low-energy ligand conformations 
(within 2 kcal/mol) that demonstrated the best superposition of aromatic substituents of the ligand 
core with the pharmacophore elements (Tyr1 and Phe3) of receptor-bound conformations of cyclic 
tetrapeptides 7 were selected for docking into the receptor binding pocket. Ligands were positioned 
inside the receptor binding cavity to reproduce the binding modes of cyclic tetrapeptides and co-
crystalized ligands in MOR, DOR, and KOR X-ray structures. The docking pose of each ligand 


















Chapter 8: Conclusions and Future Directions 
8.1 Conclusions 
Core Modifications and Stability: The impetus for this project was to address problems in the 
metabolic stability of the original bicyclic core series. This instability was endemic to the core 
itself, and no superficial modification to either the bicyclic core or the benzyl pendant could 
eliminate this instability. Chapters 2 and 3 demonstrated that conversion of this bicyclic core into 
a monocyclic aromatic core could yield stability improvements while retaining our desired 
bifunctional MOR/DOR profile and these data are summarized in Figure 22. The main source of 
instability was found to be the benzylic position connecting the aromatic core to the DMT pendant 
(Figure 22, red circle) and was sensitive to the stereochemistry of alkyl groups on this position.  
 The conversion to the monocyclic core was initially met with losses in MOR-agonism, a 
necessary component of our desired bifunctional opioid profile. This was significantly ameliorated 
by the incorporation of short chain ethers onto the aromatic core (Figure 22, blue circle), of which 
the ethyl ether was the best. Additional modifications were pursued on the aromatic ring (Figure 
22, purple circle). These structural elements improved MOR-potency in some cases, but generally 
reduced what stability gains were made upon conversion to this new core. Overall, the conversion 
to this monocyclic core was promising in terms of both their MOR/DOR bifunctional profile and 
their stability. However, the MOR-potency and the metabolic stability of these ligands still left 




Figure 22: Summary of results from Chapters 2 and 3. Bicyclic core analogues are typically 
potent MOR-agonist/DOR-antagonists but express very poor metabolic stability in MLM. This 
instability is not affected by superficial modifications (black circles) to the ligand. Conversion to 
a monocyclic core improved stability and identified a major metabolic hotspot (red circle). 
Moderate MOR-agonism was achieved with short chain ethers (blue circle), and additional core 
modifications yielded no overall improvements (purple circle).  
Discovery of Aromatic-Amine Pharmacophore: While the improvements in the ligands thus far 
were promising, we were interested in further optimizing these peptidomimetics. A survey of 
analogues synthesized previously in our lab indicated that amine pendants were tolerated in the 
bicyclic series, and therefore might be of utility in our monocyclic series. As such, these amine 
pendants were incorporated into our monocyclic core peptidomimetic series (Figure 23). Initially, 
a series of amine pendant analogues containing an ethyl ether on the core were synthesized. This 
series suggested that simple monocyclic amines pendants improved metabolic stability while 
consistently maintaining high levels of MOR-efficacy. However, this was at the cost of MOR-
potency in some cases.  
This lost potency can not only be restored, but improved upon by the addition of an 
aromatic ring onto the cyclic amine pendant. This retains the MOR-efficacy of these analogues, 
albeit at the cost of some of the improvements in stability. Conformational flexibility of the 
pendant as illustrated by the benzyl amines does not drastically affect the MOR-agonist 
characteristics of these analogues, though this comes at a cost to metabolic stability and selectivity 
over KOR. Finally, members of this series were shown to possess in vivo activity as illustrated by 
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the acetic acid stretch assay (AASA). This activity was inhibited by the opioid antagonist naloxone 
and show that these analogues are inducing their antinociception via the opioid receptors. These 
analogues were not active in the warm water tail withdrawal (WWTW) suggesting that these 
ligands operate on peripheral opioid receptors and not central opioid receptors. 
 The in vitro and stability performance of these new amine pharmacophores warranted 
further investigation into their scope as MOR-agonists. To this end, a series of matrices were 
constructed that examined the effects of both the amine pendant and aromatic core modification 
on both the opioid profile and metabolic stability. These matrices revealed that the amine alone 
can generate high MOR-efficacy, and that the aromatic ring on the pendant can generate high 
MOR-potency, all independent of the identity of the core modification. Two MOR-superagonists  
Figure 23: Summary of results from Chapters 4 and 5, which discuss the discovery of the 
aromatic-amine pharmacophore. The initial monocyclic core analogues used a benzyl pendant 
and relied upon R-groups on the aromatic core for activity. Conversion to pendants that contain 
an amine (purple circle) managed to drastically improve stability and MOR-efficacy. If this was 
coupled with an aromatic ring (blue circle) then improvements in MOR-potency were also 
observed, though at the cost of some stability improvements. The potency and efficacy at MOR 
of the aromatic-amine pharmacophore was largely independent of the identity of the R group on 
the aromatic core (red circle) and in some cases produced MOR-superagonists. Members of this 
series were active in the acetic acid stretch assay (AASA), of which that activity was opioid 
receptor mediated. Finally, it should be noted that residual DOR-agonism was present in some of 
these analogues. 
were synthesized in this series, both containing an aromatic-amine pharmacophore. Finally, 
metabolic stability was consistently high for the monocyclic amine pendants, whereas the stability  
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of the aromatic-amine pendant analogues was dependent on the identity of the aromatic core 
modification. 
The Aromatic-Amine Pharmacophore with New Cores: As illustrated above, the aromatic-amine 
pharmacophore shows great promise in producing MOR-agonists. Since this agonism was 
insensitive to the identity of the aromatic core modifications, we sought to determine if this activity 
was retained when the aromatic core was removed. This design strategy (Figure 24) yielded 
analogues that possessed simplified structures, albeit with increased conformational flexibility. As 
such, some conformationally restricted analogues were included to supplement this series. The 
aromatic-amine pharmacophore was found to produce potent and efficacious MOR-agonists in 
these simplified structures. Only the conformationally rigid analogues exhibited reduced MOR-
potency, though MOR-efficacy was still high, indicating that positioning of the aromatic part of 
the pharmacophore in these ligands may need optimization.  
DOR and KOR effects tended to vary within this series. The cyclic analogues possessed 
high DOR-affinity with no appreciable efficacy, whereas the amides possessed high DOR-affinity 
and were partial agonists at this receptor. Conversely, the more conformationally flexible 
analogues in this series exhibited reduced DOR-affinity. The effects at KOR were largely the 
inverse of that at DOR. The amides and the piperazine analogues possess reduced KOR-affinity, 
whereas the more flexible ligands had greater binding affinity at KOR than DOR.  Finally, there 
were no initial improvements in metabolic stability with these flexible analogues, indicating that 
improvements garnered from eliminating the aromatic ring were countered by the increases in 
flexibility. Restricting this flexibility without using an aromatic ring was found to produce 
significant stability improvements. 
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Figure 24: Summary of results from Chapter 6. The tetrahydroisoquinoline pendant (which 
stands-in as the aromatic-amine pharmacophore) enabled consistently high MOR-efficacy and 
potency in these simplified analogues. DOR-affinity, efficacy and potency tended to be variable, 
as well as their metabolic stability.  
 In addition to the analogues described above, a miscellaneous set of analogues were 
synthesized that converted the aromatic core into a cyclic aliphatic core (Figure 25) using the ethyl 
ether analogue as a lead. This introduced a new stereocenter, of which the S-isomer was found to 
optimum (Figure 25, purple circle), and required an amine to attach the benzyl pendant (Figure 
25, blue circle). While these analogues were initially made as a contingency to replace the aromatic 
core, they had the effect of introducing the aromatic-amine pharmacophore in an altered structure. 
Here, the amine fulfilled its role in producing consistently high MOR-efficacy, though the MOR-
potency of these compounds was diminished. This may be attributed to the shortened distance 
between the aromatic-amine pharmacophore and the DMT pendant within the ligand. This potency 
was also dependent on the identity of the substituent that replaced the ethyl ether (Figure 25, red 
circle). Moderate potency was retained when there is only a hydrogen bond acceptor at this 
position, and all MOR-agonism was lost when this substituent was an amide. While not in an 




Figure 25: Summary of Results from Chapter 7. This series generated analogues that used an 
amine to connect the benzyl pendant (blue circle) and introduced a new stereocenter (purple 
circle). This amine managed to also induce high MOR-efficacy, though the potency and efficacy 
here was dependent on the identity of X (red circle). 
8.2 Future Directions 
General Considerations: The SAR campaigns described herein show the development of the 
aromatic-amine pharmacophore. While the aromatic part mimics phenylalanine in the endogenous 
opioids, the amine is a novel element for MOR stimulation. They show how variations within the 
core structure, be it through removal of core elements or conversion of core elements into new 
forms can maintain MOR efficacy and potency with variability in their effects at DOR and KOR. 
Though promising in terms of their novelty, size, and stability, the in vivo properties of these 
analogues need to be further elucidated and the variations in the opioid profile that have developed 
near the end of these campaigns need to be further characterized. Fortunately, these ligands can be 
diversified in a wide number of directions to achieve these goals. The scope of these analogues is 








Figure 26: General design scope upon which future analogues may be developed. Further 
derivatives can follow several different pathways. These can include modifications of the 
aromatic-amine pendant, the incorporation of alternative amino acids into the peptide core, a 
return to the aromatic core with further derivatization on the core, or the exploration of 
alternative rigid structures to hold the two pharmacophores together. 
Modify Aromatic Amine Pendant: One of the simplest means of diversifying our SAR is through 
the direct alteration of our aromatic-amine pharmacophore. This can open the door to a wide 
variety of new structures that can modulate our opioid profile, improve stability, and reduce 
potential toxicity. Some of the first modifications here can focus on improving several of these 
factors simultaneously and are shown in Figure 27. Here, the aromatic ring can be modified 
through the introduction of fluoro groups or by converting the benzene ring to a pyridine ring. In 
addition to expanding our knowledge on the effects of these substituents in our in vitro opioid 
profile, these changes can also improve the PK properties of these ligands. Both moieties are 
electron poor and can therefore prevent CYP metabolism by altering the electronics of the core, 
and in the case of fluoro groups, through steric effects as well. Care must be taken with the pyridine 
analogues, as improper positioning of the pyridine ring can produce a CYP inhibitor and facilitate 
drug-drug interactions.134 Finally, these moieties can reduce the basicity of the adjacent amine, 
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which reduces the likelihood of hERG (human ether-à-go-go-related gene) inhibition, a common 
source of drug toxicity that can result in lethal heart arrythmias.135  
Figure 27: Proposed analogues to be synthesized that modify the aromatic-amine 
pharmacophore. These analogues are aimed at preventing CYP metabolism and reducing the 
basicity of the amine. 
Incorporate Alternative Amino Acids into Chain: The peptide core analogues 199 and 200 have 
potential to produce MOR/DOR bifunctional ligands. Considering that the endogenous opioids are 
peptides, the introduction of various side chains off the peptide backbone can yield some 
interesting properties. The Tyr-D-Ala motif occurs in the deltorphins and dermorphins, as well as 
the synthetic opioid peptides [D-Ala2, D-Leu5]-enkephalin (DADLE) and biphalin. Replacement 
of Tyr with DMT in deltorphin B yielded a bifunctional MOR/DOR ligand,136 and show that D-
Ala may be useful in our series.   
DMT-Tic-OH is a dipeptide that was found to be a potent and selective DOR-antagonist.137 
This motif has found its way into a large number of other opioid peptides, many of which are 
described in the introduction to Chapter 6. Therefore, the incorporation of our aromatic-amine 
pharmacophore into these peptides can greatly modulate the opioid activity of these ligands, and 
further our understanding of the opioid peptides (Figure 28). 
 
Figure 28: Proposed peptide derivatives of analogues 199 and 200. These derivatives 




Return to the Aromatic Core: While the simplified core analogues described in Chapter 6 opened 
many possibilities for further derivatization and demonstrated the potential of the aromatic-amine 
pharmacophore to activate MOR, this by no means rules out further modifications to analogues 
described in previous chapters. The aromatic core preserved our mixed MOR/DOR efficacy 
profile, many of which were MOR-agonist/DOR-antagonists. Furthermore, the MOR-
superagonists synthesized herein all possessed an aromatic core. Here, the aromatic core can be 
altered by incorporating functional groups akin to those described above with the aromatic-amine 
pendant (Figure 29).  
These may have additional beneficial effects, namely that these compounds may reduce 
KOR affinity, and therefore improve selectivity. The peptide analogues 199 and 200 displayed 
reduced binding affinity at KOR compared to both their aromatic and simple alkyl core analogues. 
This is unlikely to be an effect of core rigidity from the amide bond, as the aromatic analogues 
132, 168, and 172 had greater rigidity than 199 and 200. Instead, it is more likely an effect of the 
carbonyl acting as a hydrogen bond acceptor, a trend further suggested by the morpholino analogue 
229. As such, incorporation of hydrogen bond acceptors within the ring, in the form of a pyridine 
core for example, may mimic this interaction and reduce KOR binding without affecting MOR 
and DOR. 
Figure 29: Proposed analogues that modify the aromatic core. These analogues are aimed at 
preventing CYP metabolism, reducing the basicity of the amine, and may be able to reduce KOR 
binding affinity. 
Vary Structural Rigidity: Part of the guiding philosophy for the synthesis of the piperidine and 
piperazine analogues 196 and 197 was to reintroduce structural rigidity into our analogues after 
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the elimination of the aromatic core. The complete elimination of the original metabolically labile 
bicyclic core yielded benefits in terms of stability, simplicity in structure, and shortened synthesis. 
This came at the cost of high conformational flexibility in the ligand. 196 and 197 eliminated some 
of this flexibility and improved metabolic stability. It is possible that the structural orientation that 
was introduced by these ring systems may not be optimal. Therefore, the introduction of alternative 
conformationally rigid core systems may be of great benefit to our opioid and PK profile (Figure 
30). One is the cyclohexane core structure, which can yield cis and trans isomers that orientate the 
pharmacophore elements in different directions. Furthermore, tying down the aromatic core into a 
tetrahydroisoquinoline core can yield even greater levels of structural rigidity if desired. Similar 
analogues that possess this tetrahydroisoquinoline core have been synthesized in this lab and show 
promising opioid profiles.138 
 
Figure 30: Rigid cyclic core derivatives akin to analogues 196-197. These analogues are aimed 
at reducing the conformational flexibility of our ligands and may further improve our opioid and 
PK profiles. 
Cyclic Aliphatic Core Derivatives: In addition to those analogues described above, the cyclic 
aliphatic core analogues described in Chapter 7 may still be of some value. These compounds have 
been shown to have good MOR binding affinity and efficacy, though their MOR potency and DOR 
binding affinity leave room for improvement. Here, the morpholine core analogue 229 will be 
used, due to its opioid properties and ease of synthesis (Figure 31). Previously reported (see 
Chapter 1) and unpublished data suggest that a 2-napthyl pendant instead of a benzyl pendant was 
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of value in the bicyclic series. This may translate into this series as well and may improve the 
MOR-potency of these ligands. 
Furthermore, the incorporation of something akin to our aromatic-amine pharmacophore 
described in Chapters 4-6 may yield some interesting properties. In this case, the amine portion of 
this pharmacophore will have to be moved, as using it as a joint to connect it to the rest of the 
peptidomimetic will introduce instability to aqueous acid on this scaffold. Since a carbon atom 
will be at this position, a new stereocenter will be introduced and can easily be synthesized using 
commercially available tetrahydroisoquinoline carboxylate (Tic) amino acids and our established 
reduction chemistry.  
 
Figure 31: Proposed derivatives of the cyclic aliphatic analogue 229. These analogues are aimed 
at improving MOR potency and DOR binding affinity, or by incorporating an aromatic-amine 
pharmacophore. 
Final Conclusions: The data collected in this dissertation may have wide implications in the 
development of future opioid ligands and in their pharmacology. While the initial aims of this 
project were to improve the metabolic stability of our peptidomimetic series, the direction this 
series took allowed us to discover the aromatic-amine pharmacophore. Classically, opioid peptides 
required relatively large peptide chains that needed cyclization in order to activate their respective 
opioid receptors. This required multiple steps from starting material to synthesize and was limited 
by the availability of chiral amino acids. Our aromatic-amine pharmacophore allowed us to greatly 
simplify structure of our original peptidomimetic, to the point where no ring systems were needed 
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to yield potent and efficacious MOR-agonists. These analogues required relatively few steps to 
synthesize, and the variability of their effects at DOR at KOR suggest that these analogues may be 
developed into either selective MOR-agonists, or bifunctional MOR/DOR or MOR/KOR ligands.  
 Of particular value within these analogues was the possibility of developing MOR-
superagonists. DAMGO is frequently used as the standard MOR-agonist for studying MOR-
potency and efficacy. A ligand then that has an efficacy 48 % higher than the standard agonist may 
have pharmacological effects in vivo beyond that of the known MOR-agonists. Future research 
will therefore be needed to understand the pharmacological scope of these ligands. 
 In the end, our original goal of improving the metabolic stability of our peptidomimetic 
series while retaining our opioid profile was met. This included simplified synthetic schemes and 
opened the door for a whole host of new derivatives that are more readily accessible. Furthermore, 
these analogues were active in the AASA, and their activity was shown to be mediated by action 
on the opioid receptors. The work provided here not only pushes the development of our ligands 
to become opioid analgesics with reduced side-effects, but also expands our understanding of how 
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